
<!DOCTYPE html>
<html lang="en" >
    <head >

        <meta charset="UTF-8" />
        <meta http-equiv="X-UA-Compatible" content="IE=edge" />
        <meta name="HandheldFriendly" content="True" />
        <meta name="MobileOptimized" content="320" />
        <meta name="viewport" content="width=device-width, initial-scale=1.0" />

        
        

        
        
  <link rel="stylesheet" href="/static/assets/style-8258669d.css" />
<script type="module" crossorigin="" src="/static/assets/base_style-f4a99799.js"></script>

  <link rel="stylesheet" href="/static/assets/style-ef962842.css" />
<link rel="stylesheet" href="/static/assets/style-3ade8b5c.css" />
<script type="module" crossorigin="" src="/static/assets/article_style-d757a0dd.js"></script>

  
  
    <style>
  
  
  @media screen and (min-width: 64em) {
    div.pmc-wm {
      background: repeat-y;
      background-image: url("data:image/svg+xml,%3Csvg xmlns='http://www.w3.org/2000/svg' width='20' height='350' xmlns:xlink='http://www.w3.org/1999/xlink'%3E%3Cdefs%3E%3Cfilter x='-.02' y='0' width='1.05' height='1' id='c'%3E%3CfeFlood flood-color='%23FFF'/%3E%3CfeComposite in='SourceGraphic'/%3E%3C/filter%3E%3Ctext id='b' font-family='Helvetica' font-size='11pt' style='opacity:1;fill:%23005ea2;stroke:none;text-anchor:middle' x='175' y='14'%3E%3C/text%3E%3Cpath id='a' style='fill:%23005ea2' d='M0 8h350v3H0z'/%3E%3C/defs%3E%3Cuse xlink:href='%23a' transform='rotate(90 10 10)'/%3E%3Cuse xlink:href='%23b' transform='rotate(90 10 10)' filter='url(%23c)'/%3E%3C/svg%3E");
      padding-left: 3rem;
    }
  }
</style>

  



        
            <link rel="apple-touch-icon"
                  sizes="180x180"
                  href="/static/img/favicons/apple-touch-icon.png" />
            <link rel="icon"
                  type="image/png"
                  sizes="48x48"
                  href="/static/img/favicons/favicon-48x48.png" />
            <link rel="icon"
                  type="image/png"
                  sizes="32x32"
                  href="/static/img/favicons/favicon-32x32.png" />
            <link rel="icon"
                  type="image/png"
                  sizes="16x16"
                  href="/static/img/favicons/favicon-16x16.png" />
            <link rel="manifest" href="/static/img/favicons/site.webmanifest" />
            <link rel="mask-icon"
                  href="/static/img/favicons/safari-pinned-tab.svg"
                  color="#0071bc" />
            <meta name="msapplication-config"
                  content="/static/img/favicons/browserconfig.xml" />
            <meta name="theme-color" content="#ffffff" />
        

        <title>
            The assessment of breast cancer biomarkers in diagnosis, prognosis and treatment monitoring: integrated analysis - PMC
        </title>

        
        
  
  <!-- Logging params: Pinger defaults -->
<meta name="ncbi_app" content="cloudpmc-viewer" />
<meta name="ncbi_db" content="pmc" />
<meta name="ncbi_phid" content="AE5329878AF194C3052987007C139333.m_1" />
<meta name="ncbi_pinger_stat_url" content="https://pmc.ncbi.nlm.nih.gov/stat" />
<!-- Logging params: Pinger custom -->
<meta name="ncbi_pdid" content="article" />
  
    <link rel="preconnect" href="https://www.google-analytics.com" />

    
        <link rel="preconnect" href="https://cdn.ncbi.nlm.nih.gov" />
    

    <!-- Include USWDS Init Script -->
    <script src="/static/assets/uswds-init.js"></script>


    <meta name="ncbi_domain" content="jcrco">
<meta name="ncbi_type" content="fulltext">
<meta name="ncbi_pcid" content="journal">
<meta name="ncbi_feature" content="associated_data">
<link rel="canonical" href="https://pmc.ncbi.nlm.nih.gov/articles/PMC12373631/">
<meta name="robots" content="INDEX,NOFOLLOW,NOARCHIVE">
<meta name="citation_journal_title" content="Journal of Cancer Research and Clinical Oncology">
<meta name="citation_title" content="The assessment of breast cancer biomarkers in diagnosis, prognosis and treatment monitoring: integrated analysis">
<meta name="citation_author" content="Patrycja Królewska-Daszczyńska">
<meta name="citation_author_institution" content="Department of Immunology and Serology, Faculty of Pharmaceutical Sciences in Sosnowiec, Medical University of Silesia, 40-055 Katowice, Poland">
<meta name="citation_author" content="Aleksandra Englisz">
<meta name="citation_author_institution" content="Department of Immunology and Serology, Faculty of Pharmaceutical Sciences in Sosnowiec, Medical University of Silesia, 40-055 Katowice, Poland">
<meta name="citation_author" content="Maria-Laura Morawiec">
<meta name="citation_author_institution" content="Department of Immunology and Serology, Faculty of Pharmaceutical Sciences in Sosnowiec, Medical University of Silesia, 40-055 Katowice, Poland">
<meta name="citation_author" content="Joanna Miśkiewicz">
<meta name="citation_author_institution" content="Department of Immunology and Serology, Faculty of Pharmaceutical Sciences in Sosnowiec, Medical University of Silesia, 40-055 Katowice, Poland">
<meta name="citation_author" content="Maciej Gołębski">
<meta name="citation_author_institution" content="Department of Immunology and Serology, Faculty of Pharmaceutical Sciences in Sosnowiec, Medical University of Silesia, 40-055 Katowice, Poland">
<meta name="citation_author" content="Aleksandra Mielczarek-Palacz">
<meta name="citation_author_institution" content="Department of Immunology and Serology, Faculty of Pharmaceutical Sciences in Sosnowiec, Medical University of Silesia, 40-055 Katowice, Poland">
<meta name="citation_publication_date" content="2025 Aug 22">
<meta name="citation_volume" content="151">
<meta name="citation_issue" content="8">
<meta name="citation_firstpage" content="233">
<meta name="citation_doi" content="10.1007/s00432-025-06271-1">
<meta name="citation_pmid" content="40844552">
<meta name="citation_abstract_html_url" content="https://pmc.ncbi.nlm.nih.gov/articles/PMC12373631/">
<meta name="citation_fulltext_html_url" content="https://pmc.ncbi.nlm.nih.gov/articles/PMC12373631/">
<meta name="citation_pdf_url" content="https://pmc.ncbi.nlm.nih.gov/articles/PMC12373631/pdf/432_2025_Article_6271.pdf">
<meta name="description" content="Breast cancer is a heterogeneous disease, which is still a challenge for modern cancer diagnostics. Despite significant progress in diagnosis, monitoring and treatment of breast cancer, it remains the leading cause of cancer-related death in women. ...">
<meta name="og:title" content="The assessment of breast cancer biomarkers in diagnosis, prognosis and treatment monitoring: integrated analysis">
<meta name="og:type" content="article">
<meta name="og:site_name" content="PubMed Central (PMC)">
<meta name="og:description" content="Breast cancer is a heterogeneous disease, which is still a challenge for modern cancer diagnostics. Despite significant progress in diagnosis, monitoring and treatment of breast cancer, it remains the leading cause of cancer-related death in women. ...">
<meta name="og:url" content="https://pmc.ncbi.nlm.nih.gov/articles/PMC12373631/">
<meta name="og:image" content="https://cdn.ncbi.nlm.nih.gov/pmc/cms/images/pmc-card-share.jpg?_=0">
<meta name="twitter:card" content="summary_large_image">
<meta name="twitter:site" content="@ncbi">
    
    

    </head>
    <body >
        
    <a class="usa-skipnav " href="#main-content">
      Skip to main content
    </a>


        
            

<section class="usa-banner " aria-label="Official website of the United States government" >
    <div class="usa-accordion">
        <header class="usa-banner__header">
            <div class="usa-banner__inner">
                <div class="grid-col-auto">
                    <img aria-hidden="true"
                         class="usa-banner__header-flag"
                         src="/static/img/us_flag.svg"
                         alt="" />
                </div>

                <div class="grid-col-fill tablet:grid-col-auto" aria-hidden="true">
                    <p class="usa-banner__header-text">
                        An official website of the United States government
                    </p>
                    <span class="usa-banner__header-action">Here's how you know</span>
                </div>

                



















    
        <button
            type="button"
        
    
    class="usa-accordion__button usa-banner__button
           

           
               
               
               
               
            

           
           
           
           "
    aria-expanded="false"
    aria-controls="gov-banner-default"
    
    data-testid="storybook-django-banner"
    
    >
    
        

        
                    <span class="usa-banner__button-text">Here's how you know</span>
                

        
    
        
            </button>
        


            </div>
        </header>

        <div class="usa-banner__content usa-accordion__content"
             id="gov-banner-default"
             hidden>
            <div class="grid-row grid-gap-lg">
                <div class="usa-banner__guidance tablet:grid-col-6">
                    <img class="usa-banner__icon usa-media-block__img"
                         src="/static/img/icon-dot-gov.svg"
                         alt=""
                         aria-hidden="true" />
                    <div class="usa-media-block__body">
                        <p>
                            <strong>Official websites use .gov</strong>
                            <br />
                            A
                            <strong>.gov</strong> website belongs to an official
                            government organization in the United States.
                        </p>
                    </div>
                </div>

                <div class="usa-banner__guidance tablet:grid-col-6">
                    <img class="usa-banner__icon usa-media-block__img"
                         src="/static/img/icon-https.svg"
                         alt=""
                         aria-hidden="true" />

                    <div class="usa-media-block__body">
                        <p>
                            <strong>Secure .gov websites use HTTPS</strong>
                            <br />
                            A <strong>lock</strong> (
                            <span class="icon-lock">
                                <svg xmlns="http://www.w3.org/2000/svg"
                                     width="52"
                                     height="64"
                                     viewBox="0 0 52 64"
                                     class="usa-banner__lock-image"
                                     role="graphics-symbol"
                                     aria-labelledby="banner-lock-description"
                                     focusable="false">
                                    <title id="banner-lock-title">Lock</title>
                                    <desc id="banner-lock-description">
                                    Locked padlock icon
                                    </desc>
                                    <path fill="#000000"
                                          fill-rule="evenodd"
                                          d="M26 0c10.493 0 19 8.507 19 19v9h3a4 4 0 0 1 4 4v28a4 4 0 0 1-4 4H4a4 4 0 0 1-4-4V32a4 4 0 0 1 4-4h3v-9C7 8.507 15.507 0 26 0zm0 8c-5.979 0-10.843 4.77-10.996 10.712L15 19v9h22v-9c0-6.075-4.925-11-11-11z" />
                                </svg>
</span>) or <strong>https://</strong> means you've safely
                                connected to the .gov website. Share sensitive
                                information only on official, secure websites.
                            </p>
                        </div>
                    </div>
                </div>
            </div>
        </div>
    </section>

        

        
    
    
    

<div class="usa-overlay">
</div>



<header class="usa-header usa-header--extended usa-header--wide" data-header data-testid="header"    >
    <div class="ncbi-header">
        <div class="ncbi-header__container">
            <a class="ncbi-header__logo-container"
               href="https://www.ncbi.nlm.nih.gov/">
                <img alt="NCBI home page"
                     class="ncbi-header__logo-image"
                     src="/static/img/ncbi-logos/nih-nlm-ncbi--white.svg"
                     width="410"
                     height="100" />
            </a>

            <!-- Mobile menu hamburger button -->
            



















    
        <button
            type="button"
        
    
    class="usa-menu-btn ncbi-header__hamburger-button
           

           
               
               
               
               
            

           
           
           
           "
    
    
    aria-label="Show menu"
    data-testid="navMenuButton"
    
    >
    
        

        
                <svg aria-hidden="true"
                     class="ncbi-hamburger-icon"
                     fill="none"
                     focusable="false"
                     height="21"
                     viewBox="0 0 31 21"
                     width="31"
                     xmlns="http://www.w3.org/2000/svg">
                    <path clip-rule="evenodd"
                          d="M0.125 20.75H30.875V17.3333H0.125V20.75ZM0.125 12.2083H30.875V8.79167H0.125V12.2083ZM0.125 0.25V3.66667H30.875V0.25H0.125Z"
                          fill="#F1F1F1"
                          fill-rule="evenodd" />
                </svg>
            

        
    
        
            </button>
        



            
                <!-- Desktop buttons-->
                <div class="ncbi-header__desktop-buttons">
                    
                        <!-- Desktop search button -->
                        



















    
        <button
            type="button"
        
    
    class="usa-button
           

           
               
               
               
               
            

           
           
           usa-button--unstyled ncbi-header__desktop-button
           "
    aria-expanded="false"
    aria-controls="search-field-desktop-navigation"
    aria-label="Show search overlay"
    data-testid="toggleSearchPanelButton"
    data-toggle-search-panel-button
    >
    
        

        
                            



    <svg class="usa-icon " role="graphics-symbol" aria-hidden="true" >
        
        <use xlink:href="/static/img/sprite.svg#search" />
    </svg>


                            Search
                        

        
    
        
            </button>
        


                    

                    <!-- Desktop login dropdown -->
                    
                        <div class="ncbi-header__login-dropdown">
                            



















    
        <button
            type="button"
        
    
    class="usa-button
           

           
               
               
               
               
            

           
           
           usa-button--unstyled ncbi-header__desktop-button ncbi-header__login-dropdown-button
           "
    aria-expanded="false"
    aria-controls="login-dropdown-menu"
    aria-label="Show login menu"
    data-testid="toggleLoginMenuDropdown"
    data-desktop-login-button
    >
    
        

        
                                



    <svg class="usa-icon " role="graphics-symbol" aria-hidden="true" >
        
        <use xlink:href="/static/img/sprite.svg#person" />
    </svg>



                                <span data-login-dropdown-text>Log in</span>

                                <!-- Dropdown icon pointing up -->
                                



    <svg class="usa-icon ncbi-header__login-dropdown-icon ncbi-header__login-dropdown-icon--expand-less ncbi-header__login-dropdown-icon--hidden" role="graphics-symbol" aria-hidden="true" data-login-dropdown-up-arrow>
        
        <use xlink:href="/static/img/sprite.svg#expand_less" />
    </svg>



                                <!-- Dropdown icon pointing down -->
                                



    <svg class="usa-icon ncbi-header__login-dropdown-icon ncbi-header__login-dropdown-icon--expand-more ncbi-header__login-dropdown-icon--hidden" role="graphics-symbol" aria-hidden="true" data-login-dropdown-down-arrow>
        
        <use xlink:href="/static/img/sprite.svg#expand_more" />
    </svg>


                            

        
    
        
            </button>
        



                            <!-- Login dropdown menu -->
                            <ul class="usa-nav__submenu ncbi-header__login-dropdown-menu"
                                id="login-dropdown-menu"
                                data-desktop-login-menu-dropdown
                                hidden>
                                
                                    <li class="usa-nav__submenu-item">
                                        <!-- Uses custom style overrides to render external and document links. -->
                                        









    <a href="https://www.ncbi.nlm.nih.gov/myncbi/" class="usa-link  "  >
        

        
            Dashboard
        

        
    </a>


                                    </li>
                                
                                    <li class="usa-nav__submenu-item">
                                        <!-- Uses custom style overrides to render external and document links. -->
                                        









    <a href="https://www.ncbi.nlm.nih.gov/myncbi/collections/bibliography/" class="usa-link  "  >
        

        
            Publications
        

        
    </a>


                                    </li>
                                
                                    <li class="usa-nav__submenu-item">
                                        <!-- Uses custom style overrides to render external and document links. -->
                                        









    <a href="https://www.ncbi.nlm.nih.gov/account/settings/" class="usa-link  "  >
        

        
            Account settings
        

        
    </a>


                                    </li>
                                
                                <li class="usa-nav__submenu-item">
                                    



















    
        <button
            type="button"
        
    
    class="usa-button
           

           
               
               
               
               
            

           
           
           usa-button--outline ncbi-header__login-dropdown-logout-button
           "
    
    
    
    data-testid="desktopLogoutButton"
    data-desktop-logout-button
    >
    
        

        Log out

        
    
        
            </button>
        


                                </li>
                            </ul>
                        </div>
                    
                </div>
            
        </div>
    </div>

    <!-- Search panel -->
    
        <div class="ncbi-search-panel ncbi--show-only-at-desktop"
             data-header-search-panel
             hidden>
            <div class="ncbi-search-panel__container">
                <form action="https://www.ncbi.nlm.nih.gov/search/all/"
                      
                      autocomplete="off"
                      class="usa-search usa-search--big ncbi-search-panel__form"
                      data-testid="desktop-navigation-search-form"
                      method="GET"
                      role="search">
                    <label class="usa-sr-only" for="search-field-desktop-navigation">
                        Search…
                    </label>
                    <input class="usa-input"
                           id="search-field-desktop-navigation"
                           name="term"
                           
                               placeholder="Search NCBI"
                           
                           type="search"
                           value="" />
                    



















    
        <button
            type="submit"
        
    
    class="usa-button
           

           
               
               
               
               
            

           
           
           
           "
    
    
    
    
    
    >
    
        

        
                        <span class="usa-search__submit-text">
                            Search NCBI
                        </span>
                    

        
    
        
            </button>
        


                </form>

                
            </div>
        </div>
    

    <nav aria-label="Primary navigation" class="usa-nav">
        <p class="usa-sr-only" id="primary-navigation-sr-only-title">
            Primary site navigation
        </p>

        <!-- Mobile menu close button -->
        



















    
        <button
            type="button"
        
    
    class="usa-nav__close ncbi-nav__close-button
           

           
               
               
               
               
            

           
           
           
           "
    
    
    aria-label="Close navigation menu"
    data-testid="navCloseButton"
    
    >
    
        

        
            <img src="/static/img/usa-icons/close.svg" alt="Close" />
        

        
    
        
            </button>
        



        
            <!-- Mobile search component -->
            <form class="usa-search usa-search--small ncbi--hide-at-desktop margin-top-6"
                  action="https://www.ncbi.nlm.nih.gov/search/all/"
                  
                  autocomplete="off"
                  data-testid="mobile-navigation-search-form"
                  method="GET"
                  role="search">
                <label class="usa-sr-only" for="search-field-mobile-navigation">
                    Search
                </label>

                <input class="usa-input"
                       id="search-field-mobile-navigation"
                       type="search"
                       
                           placeholder="Search NCBI"
                       
                       name="term" />

                



















    
        <button
            type="submit"
        
    
    class="usa-button
           

           
               
               
               
               
            

           
           
           
           "
    
    
    
    
    
    >
    
        

        
                    <!-- This SVG should be kept inline and not replaced with a link to the icon as otherwise it will render in the wrong color -->
                    <img src="data:image/svg+xml;base64,PHN2ZyB4bWxucz0iaHR0cDovL3d3dy53My5vcmcvMjAwMC9zdmciIGhlaWdodD0iMjQiIHZpZXdCb3g9IjAgMCAyNCAyNCIgd2lkdGg9IjI0Ij48cGF0aCBkPSJNMCAwaDI0djI0SDB6IiBmaWxsPSJub25lIi8+PHBhdGggZmlsbD0iI2ZmZiIgZD0iTTE1LjUgMTRoLS43OWwtLjI4LS4yN0E2LjQ3MSA2LjQ3MSAwIDAgMCAxNiA5LjUgNi41IDYuNSAwIDEgMCA5LjUgMTZjMS42MSAwIDMuMDktLjU5IDQuMjMtMS41N2wuMjcuMjh2Ljc5bDUgNC45OUwyMC40OSAxOWwtNC45OS01em0tNiAwQzcuMDEgMTQgNSAxMS45OSA1IDkuNVM3LjAxIDUgOS41IDUgMTQgNy4wMSAxNCA5LjUgMTEuOTkgMTQgOS41IDE0eiIvPjwvc3ZnPg=="
                         class="usa-search__submit-icon"
                         alt="Search" />
                

        
    
        
            </button>
        


            </form>

            
        

        <!-- Primary navigation menu items -->
        <!-- This usa-nav__inner wrapper is required to correctly style the navigation items on Desktop -->
        

        
            <div class="ncbi-nav__mobile-login-menu ncbi--hide-at-desktop"
                 data-mobile-login-menu
                 hidden>
                <p class="ncbi-nav__mobile-login-menu-status">
                    Logged in as:
                    <strong class="ncbi-nav__mobile-login-menu-email"
                            data-mobile-login-email-text></strong>
                </p>
                <ul class="usa-nav__primary usa-accordion">
                    
                        <li class="usa-nav__primary-item">
                            









    <a href="https://www.ncbi.nlm.nih.gov/myncbi/" class="usa-link  "  >
        

        
            Dashboard
        

        
    </a>


                        </li>
                    
                        <li class="usa-nav__primary-item">
                            









    <a href="https://www.ncbi.nlm.nih.gov/myncbi/collections/bibliography/" class="usa-link  "  >
        

        
            Publications
        

        
    </a>


                        </li>
                    
                        <li class="usa-nav__primary-item">
                            









    <a href="https://www.ncbi.nlm.nih.gov/account/settings/" class="usa-link  "  >
        

        
            Account settings
        

        
    </a>


                        </li>
                    
                </ul>
            </div>
        

        



















    
        <button
            type="button"
        
    
    class="usa-button
           

           
               
               
               
               
            

           
           
           ncbi-nav__mobile-login-button ncbi--hide-at-desktop
           "
    
    
    
    data-testid="mobileLoginButton"
    data-mobile-login-button
    >
    
        

        Log in

        
    
        
            </button>
        


    </nav>
</header>

    
    
        

<section class="pmc-header pmc-header--basic" aria-label="PMC Header with search box">
    <div class="pmc-nav-container">
        <div class="pmc-header__bar">
           <div class="pmc-header__logo">
               <a href="/" title="Home" aria-label="PMC Home"></a>
           </div>
            <button
                    type="button"
                    class="usa-button usa-button--unstyled pmc-header__search__button"
                    aria-label="Open search"
                    data-ga-category="search"
                    data-ga-action="PMC"
                    data-ga-label="pmc_search_panel_mobile"
            >
                <svg class="usa-icon width-4 height-4 pmc-icon__open" aria-hidden="true" focusable="false" role="img">
                    <use xlink:href="/static/img/sprite.svg#search"></use>
                </svg>
                <svg class="usa-icon width-4 height-4 pmc-icon__close" aria-hidden="true" focusable="false" role="img">
                    <use xlink:href="/static/img/sprite.svg#close"></use>
                </svg>
            </button>
        </div>
        <div class="pmc-header__search">
            


<form class="usa-search usa-search--extra usa-search--article-right-column  pmc-header__search__form" id="pmc-search-form" autocomplete="off" role="search">
<label class="usa-sr-only" for="pmc-search">Search PMC Full-Text Archive</label>
<span class="autoComplete_wrapper flex-1">
<input class="usa-input width-full maxw-none" required="required" placeholder="Search PMC Full-Text Archive" id="pmc-search"  type="search" name="term" data-autocomplete-url="https://pmc.ncbi.nlm.nih.gov/autocomp/search/autocomp/"/>
</span>
<button
class="usa-button"
type="submit"
formaction="https://www.ncbi.nlm.nih.gov/pmc/"
data-ga-category="search"
data-ga-action="PMC"
data-ga-label="PMC_search_button"
>
<span class="usa-search__submit-text">Search in PMC</span>
<img
src="/static/img/usa-icons-bg/search--white.svg"
class="usa-search__submit-icon"
alt="Search"
/>
</button>
</form>
            <div class="display-flex flex-column tablet:flex-row tablet:flex-justify flex-justify-center flex-align-center width-full desktop:maxw-44">
                <ul class="pmc-header__search__menu">
                    <li>
                        
                            <a class="usa-link" href="/journals/" data-ga-action="featured_link" data-ga-label="journal list">
                                Journal List
                            </a>
                        
                    </li>
                    <li>
                        
                            <a class="usa-link" href="/about/userguide/" data-ga-action="featured_link"
                            data-ga-label="user guide">
                                User Guide
                            </a>
                        
                    </li>
                </ul>
                
                    <button form="pmc-search-form" formaction="https://pmc.ncbi.nlm.nih.gov/search/" type="submit" class="usa-button usa-button--unstyled hover:text-no-underline text-no-underline width-auto margin-top-1 tablet:margin-top-0">
     <span class="bg-green-label padding-05 text-white">New</span><span class="text-underline text-primary">Try this search in PMC Beta Search</span>
</button>
                
            </div>
        </div>
    </div>
</section>

    


        
        

       
  <div class="usa-section padding-top-0 desktop:padding-top-6 pmc-article-section" data-article-db="pmc" data-article-id="12373631">

    

   



<div class="grid-container pmc-actions-bar" aria-label="Actions bar" role="complementary">
    <div class="grid-row">
        <div class="grid-col-fill display-flex">
             <div class="display-flex">
                <ul class="usa-list usa-list--unstyled usa-list--horizontal">
                    <li class="margin-right-2 mobile-lg:margin-right-4 display-flex mob">
                        <button
                                type="button"
                                class="usa-button pmc-sidenav__container__open usa-button--unstyled width-auto display-flex"
                                aria-label="Open resources"
                                data-extra-class="is-visible-resources"
                                data-ga-category="resources_accordion"
                                data-ga-action="click"
                                data-ga-label="mobile_icon"
                        >
                            <svg class="usa-icon width-4 height-4" aria-hidden="true" focusable="false" role="img">
                                <use xlink:href="/static/img/sprite.svg#more_vert"></use>
                            </svg>
                        </button>
                    </li>
                    
                    <li class="margin-right-2 mobile-lg:margin-right-4 display-flex mob">
                        <a
                                href="https://doi.org/10.1007/s00432-025-06271-1"
                                class="usa-link display-flex usa-tooltip"
                                role="button"
                                target="_blank"
                                rel="noreferrer noopener"
                                title="View on publisher site"
                                data-position="bottom"
                                aria-label="View on publisher site"
                                data-ga-category="actions"
                                data-ga-action="click"
                                data-ga-label="publisher_link_mobile"
                        >
                                <svg class="usa-icon width-4 height-4" aria-hidden="true" focusable="false" role="img">
                                    <use xlink:href="/static/img/sprite.svg#launch"></use>
                                </svg>
                        </a>
                    </li>
                    
                    
                        <li class="margin-right-2 mobile-lg:margin-right-4 display-flex">
                             <a
                                     href="pdf/432_2025_Article_6271.pdf"
                                     class="usa-link display-flex usa-tooltip"
                                     role="button"
                                     title="Download PDF"
                                     data-position="bottom"
                                     aria-label="Download PDF"
                                     data-ga-category="actions"
                                     data-ga-action="click"
                                     data-ga-label="pdf_download_mobile"
                             >
                                <svg class="usa-icon width-4 height-4" aria-hidden="true" focusable="false" role="img">
                                    <use xlink:href="/static/img/sprite.svg#file_download"></use>
                                </svg>
                            </a>
                        </li>
                    
                    <li class="margin-right-2 mobile-lg:margin-right-4 display-flex">
                        <button
                            class="usa-button usa-button--unstyled  usa-tooltip collections-dialog-trigger collections-button display-flex collections-button-empty"
                            title="Add to Collections"
                            data-position="bottom"
                            aria-label="Save article in MyNCBI collections."
                            data-ga-category="actions"
                            data-ga-action="click"
                            data-ga-label="collections_button_mobile"
                            data-collections-open-dialog-enabled="false"
                            data-collections-open-dialog-url="https://account.ncbi.nlm.nih.gov/?back_url=https%3A%2F%2Fpmc.ncbi.nlm.nih.gov%2Farticles%2FPMC12373631%2F%3Freport%3Dclassic%23open-collections-dialog"
                            data-in-collections="false"
                        >
                            <svg class="usa-icon width-4 height-4 usa-icon--bookmark-full" aria-hidden="true" focusable="false" role="img" hidden>
                                <use xlink:href="/static/img/action-bookmark-full.svg#icon"></use>
                            </svg>
                            <svg class="usa-icon width-4 height-4 usa-icon--bookmark-empty" aria-hidden="true" focusable="false" role="img" hidden>
                                <use xlink:href="/static/img/action-bookmark-empty.svg#icon"></use>
                            </svg>
                        </button>
                    </li>
                    
                    <li class="margin-right-2 mobile-lg:margin-right-4 display-flex">
                        <button role="button" class="usa-button usa-button--unstyled usa-tooltip citation-dialog-trigger display-flex"
                            aria-label="Open dialog with citation text in different styles"
                            title="Cite"
                            data-position="bottom"
                            data-ga-category="actions"
                            data-ga-action="open"
                            data-ga-label="cite_mobile"
                            data-all-citations-url="/resources/citations/12373631/"
                            data-citation-style="nlm"
                            data-download-format-link="/resources/citations/12373631/export/"
                        >
                            <svg class="usa-icon width-4 height-4 usa-icon--bookmark-empty" aria-hidden="true" focusable="false" role="img" hidden>
                                <use xlink:href="/static/img/sprite.svg#format_quote"></use>
                            </svg>
                        </button>
                    </li>
                    
                    <li class="pmc-permalink display-flex" >
                         <button
                                 type="button"
                                 title="Permalink"
                                 data-position="bottom"
                                 class="usa-button usa-button--unstyled display-flex usa-tooltip"
                                 aria-label="Show article permalink"
                                 aria-expanded="false"
                                 aria-haspopup="true"
                                 data-ga-category="actions"
                                 data-ga-action="open"
                                 data-ga-label="permalink_mobile"
                         >
                            <svg class="usa-icon width-4 height-4" aria-hidden="true" focusable="false" role="img">
                                <use xlink:href="/static/img/sprite.svg#share"></use>
                            </svg>
                        </button>
                        

<div class="pmc-permalink__dropdown" hidden>
    <div class="pmc-permalink__dropdown__container">
          <h2 class="usa-modal__heading margin-top-0 margin-bottom-2 text-uppercase font-sans-xs">PERMALINK</h2>
          <div class="pmc-permalink__dropdown__content">
              <input type="text" class="usa-input" value="https://pmc.ncbi.nlm.nih.gov/articles/PMC12373631/" aria-label="Article permalink">
              <button class="usa-button display-inline-flex pmc-permalink__dropdown__copy__btn margin-right-0" title="Copy article permalink" data-ga-category="save_share" data-ga-action="link" data-ga-label="copy_link">
                  <svg class="usa-icon" aria-hidden="true" focusable="false" role="img">
                    <use xlink:href="/static/img/sprite.svg#content_copy"></use>
                  </svg>
                  <span class="margin-left-1">Copy</span>
              </button>
          </div>
    </div>
</div>
                    </li>
                </ul>
            </div>
            <button
                    type="button"
                    class="usa-button pmc-sidenav__container__open usa-button--unstyled width-auto display-flex"
                    aria-label="Open article navigation"
                    data-extra-class="is-visible-in-page"
                    data-ga-category="actions"
                    data-ga-action="open"
                    data-ga-label="article_nav_mobile"
            >
                <svg class="usa-icon width-4 height-4" aria-hidden="true" focusable="false" role="img">
                    <use xlink:href="/static/img/sprite.svg#list"></use>
                </svg>
            </button>
        </div>
    </div>
</div>
    <div class="grid-container desktop:padding-left-6">
      <div id="article-container" class="grid-row grid-gap">
        <div class="grid-col-12 desktop:grid-col-8 order-2 pmc-layout__content">
            <div class="grid-container padding-left-0 padding-right-0">
                <div class="grid-row desktop:margin-left-neg-6">
                    <div class="grid-col-12">
                        <div class="pmc-layout__disclaimer" role="complementary" aria-label="Disclaimer note">
    As a library, NLM provides access to scientific literature. Inclusion in an NLM database does not imply endorsement of, or agreement with,
    the contents by NLM or the National Institutes of Health.<br/>
    Learn more:
    <a class="usa-link" data-ga-category="Link click" data-ga-action="Disclaimer" data-ga-label="New disclaimer box" href="/about/disclaimer/">PMC Disclaimer</a>
    |
    <a class="usa-link" data-ga-category="Link click" data-ga-action="PMC Copyright Notice" data-ga-label="New disclaimer box" href="/about/copyright/">
        PMC Copyright Notice
    </a>
</div>
                    </div>
                </div>
                <div class="grid-row pmc-wm desktop:margin-left-neg-6">
                    <!-- Main content -->
                    <main
                      id="main-content"
                      class="usa-layout-docs__main usa-layout-docs grid-col-12 pmc-layout pmc-prose padding-0"
                    >

                      
                        <section class="pmc-journal-banner text-center line-height-none" aria-label="Journal banner"><img src="https://cdn.ncbi.nlm.nih.gov/pmc/banners/logo-jcrco.png" alt="Journal of Cancer Research and Clinical Oncology logo" usemap="#pmc-banner-imagemap" width="500" height="75"><map name="pmc-banner-imagemap"><area alt="Link to Journal of Cancer Research and Clinical Oncology" title="Link to Journal of Cancer Research and Clinical Oncology" shape="default" href="https://doi.org/10.1007/s00432-025-06271-1" target="_blank" rel="noopener noreferrer"></map></section><article lang="en"><section aria-label="Article citation and metadata"><section class="pmc-layout__citation font-secondary font-xs"><div>
<div class="display-inline-block"><button type="button" class="cursor-pointer text-no-underline bg-transparent border-0 padding-0 text-left margin-0 text-normal text-primary" aria-controls="journal_context_menu">J Cancer Res Clin Oncol</button></div>. 2025 Aug 22;151(8):233. doi: <a href="https://doi.org/10.1007/s00432-025-06271-1" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">10.1007/s00432-025-06271-1</a>
</div>
<nav id="journal_context_menu" hidden="hidden"><ul class="menu-list font-family-ui" role="menu">
<li role="presentation"><a href="https://www.ncbi.nlm.nih.gov/pmc/?term=%22J%20Cancer%20Res%20Clin%20Oncol%22%5Bjour%5D" class="usa-link" role="menuitem">Search in PMC</a></li>
<li role="presentation"><a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22J%20Cancer%20Res%20Clin%20Oncol%22%5Bjour%5D" lang="en" class="usa-link" role="menuitem">Search in PubMed</a></li>
<li role="presentation"><a href="https://www.ncbi.nlm.nih.gov/nlmcatalog?term=%22J%20Cancer%20Res%20Clin%20Oncol%22%5BTitle%20Abbreviation%5D" class="usa-link" role="menuitem">View in NLM Catalog</a></li>
<li role="presentation"><a href="?term=%22J%20Cancer%20Res%20Clin%20Oncol%22%5Bjour%5D" class="usa-link" role="menuitem" data-add-to-search="true">Add to search</a></li>
</ul></nav></section><section class="front-matter"><div class="ameta p font-secondary font-xs">
<hgroup><h1>The assessment of breast cancer biomarkers in diagnosis, prognosis and treatment monitoring: integrated analysis</h1></hgroup><div class="cg p">
<a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Kr%C3%B3lewska-Daszczy%C5%84ska%20P%22%5BAuthor%5D" class="usa-link" aria-describedby="id1"><span class="name western">Patrycja Królewska-Daszczyńska</span></a><div hidden="hidden" id="id1">
<h3><span class="name western">Patrycja Królewska-Daszczyńska</span></h3>
<div class="p">
<sup>1</sup>Department of Immunology and Serology, Faculty of Pharmaceutical Sciences in Sosnowiec, Medical University of Silesia, 40-055 Katowice, Poland </div>
<div class="p">Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Kr%C3%B3lewska-Daszczy%C5%84ska%20P%22%5BAuthor%5D" class="usa-link"><span class="name western">Patrycja Królewska-Daszczyńska</span></a>
</div>
</div>
<sup>1,</sup><sup>✉</sup>, <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Englisz%20A%22%5BAuthor%5D" class="usa-link" aria-describedby="id2"><span class="name western">Aleksandra Englisz</span></a><div hidden="hidden" id="id2">
<h3><span class="name western">Aleksandra Englisz</span></h3>
<div class="p">
<sup>1</sup>Department of Immunology and Serology, Faculty of Pharmaceutical Sciences in Sosnowiec, Medical University of Silesia, 40-055 Katowice, Poland </div>
<div class="p">Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Englisz%20A%22%5BAuthor%5D" class="usa-link"><span class="name western">Aleksandra Englisz</span></a>
</div>
</div>
<sup>1</sup>, <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Morawiec%20ML%22%5BAuthor%5D" class="usa-link" aria-describedby="id3"><span class="name western">Maria-Laura Morawiec</span></a><div hidden="hidden" id="id3">
<h3><span class="name western">Maria-Laura Morawiec</span></h3>
<div class="p">
<sup>1</sup>Department of Immunology and Serology, Faculty of Pharmaceutical Sciences in Sosnowiec, Medical University of Silesia, 40-055 Katowice, Poland </div>
<div class="p">Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Morawiec%20ML%22%5BAuthor%5D" class="usa-link"><span class="name western">Maria-Laura Morawiec</span></a>
</div>
</div>
<sup>1</sup>, <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Mi%C5%9Bkiewicz%20J%22%5BAuthor%5D" class="usa-link" aria-describedby="id4"><span class="name western">Joanna Miśkiewicz</span></a><div hidden="hidden" id="id4">
<h3><span class="name western">Joanna Miśkiewicz</span></h3>
<div class="p">
<sup>1</sup>Department of Immunology and Serology, Faculty of Pharmaceutical Sciences in Sosnowiec, Medical University of Silesia, 40-055 Katowice, Poland </div>
<div class="p">Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Mi%C5%9Bkiewicz%20J%22%5BAuthor%5D" class="usa-link"><span class="name western">Joanna Miśkiewicz</span></a>
</div>
</div>
<sup>1</sup>, <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Go%C5%82%C4%99bski%20M%22%5BAuthor%5D" class="usa-link" aria-describedby="id5"><span class="name western">Maciej Gołębski</span></a><div hidden="hidden" id="id5">
<h3><span class="name western">Maciej Gołębski</span></h3>
<div class="p">
<sup>1</sup>Department of Immunology and Serology, Faculty of Pharmaceutical Sciences in Sosnowiec, Medical University of Silesia, 40-055 Katowice, Poland </div>
<div class="p">Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Go%C5%82%C4%99bski%20M%22%5BAuthor%5D" class="usa-link"><span class="name western">Maciej Gołębski</span></a>
</div>
</div>
<sup>1</sup>, <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Mielczarek-Palacz%20A%22%5BAuthor%5D" class="usa-link" aria-describedby="id6"><span class="name western">Aleksandra Mielczarek-Palacz</span></a><div hidden="hidden" id="id6">
<h3><span class="name western">Aleksandra Mielczarek-Palacz</span></h3>
<div class="p">
<sup>1</sup>Department of Immunology and Serology, Faculty of Pharmaceutical Sciences in Sosnowiec, Medical University of Silesia, 40-055 Katowice, Poland </div>
<div class="p">Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Mielczarek-Palacz%20A%22%5BAuthor%5D" class="usa-link"><span class="name western">Aleksandra Mielczarek-Palacz</span></a>
</div>
</div>
<sup>1</sup>
</div>
<ul class="d-buttons inline-list">
<li><button class="d-button" aria-controls="aip_a" aria-expanded="false">Author information</button></li>
<li><button class="d-button" aria-controls="anp_a" aria-expanded="false">Article notes</button></li>
<li><button class="d-button" aria-controls="clp_a" aria-expanded="false">Copyright and License information</button></li>
</ul>
<div class="d-panels font-secondary-light">
<div id="aip_a" class="d-panel p" style="display: none">
<div class="p" id="Aff1">
<sup>1</sup>Department of Immunology and Serology, Faculty of Pharmaceutical Sciences in Sosnowiec, Medical University of Silesia, 40-055 Katowice, Poland </div>
<div class="author-notes p"><div class="fn" id="_fncrsp93pmc__">
<sup>✉</sup><p class="display-inline">Corresponding author.</p>
</div></div>
</div>
<div id="anp_a" class="d-panel p" style="display: none"><div class="notes p"><section id="historyarticle-meta1" class="history"><p>Received 2025 Jun 5; Accepted 2025 Jul 12; Collection date 2025 Aug.</p></section></div></div>
<div id="clp_a" class="d-panel p" style="display: none">
<div>© The Author(s) 2025</div>
<p><strong>Open Access</strong> This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <a href="https://creativecommons.org/licenses/by/4.0/" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">http://creativecommons.org/licenses/by/4.0/</a>.</p>
<div class="p"><a href="/about/copyright/" class="usa-link">PMC Copyright notice</a></div>
</div>
</div>
<div>PMCID: PMC12373631  PMID: <a href="https://pubmed.ncbi.nlm.nih.gov/40844552/" class="usa-link">40844552</a>
</div>
</div></section></section><section aria-label="Article content"><section class="body main-article-body"><section class="abstract" id="Abs1"><h2>Abstract</h2>
<p id="Par1">Breast cancer is a heterogeneous disease, which is still a challenge for modern cancer diagnostics. Despite significant progress in diagnosis, monitoring and treatment of breast cancer, it remains the leading cause of cancer-related death in women. Effective screening methods, which enable early diagnosis of the disease and rapid personalised treatment are crucial to improving survival of women with breast cancer. In recent years, increasing attention has been paid to the clinical utility of circulating biomarkers, such as proteins, autoantibodies, miRNAs, circRNAs, ctDNA or CTCs, which have the potential to supplement traditional methods of BC diagnosis. Despite much research, no sufficiently sensitive and minimally invasive marker has been identified to aid in the early diagnosis, monitoring of disease progression and response to therapy in women with breast cancer. Combinatorial analysis of circulating biomarkers is novel and promising approach, which may overcome the limitations of single biomarker assays.</p>
<section id="kwd-group1" lang="en" class="kwd-group"><p><strong>Keywords:</strong> Breast cancer, Biomarkers, Molecular markers, Biomarkers combination, Personalised treatment</p></section></section><section id="Sec1"><h2 class="pmc_sec_title">Introduction</h2>
<p id="Par41">Female breast cancer (BC) was the second most commonly diagnosed cancer (2.3 million new cases; 11.6% of all cancer patients) and the fourth leading cause of cancer mortality ( 665 684 deaths) worldwide in 2022 (Bray et al. <a href="#CR27" class="usa-link" aria-describedby="CR27">2024</a>). Most of BC cases occur in transitioned countries, however mortality rates are higher in transitioning versus transitioned countries (Bray et al. <a href="#CR27" class="usa-link" aria-describedby="CR27">2024</a>; Arnold et al. <a href="#CR12" class="usa-link" aria-describedby="CR12">2022</a>). In European countries, BC was estimated to be the most frequently diagnosed cancer in female population and the first cause of cancer mortality in women for 2020 (Dyba et al. <a href="#CR74" class="usa-link" aria-describedby="CR74">2020</a>). Moreover, differences in the five-year survival rates for BC are very wide among countries. For women diagnosed during 2010–2014, the five-year net survival approached 90% in United States, while in India it was 66% (Allemani et al. <a href="#CR4" class="usa-link" aria-describedby="CR4">2018</a>).</p>
<p id="Par42">The global differences in BC incidence are associated with human development and various risk factors for the disease (Wilkinson and Gathani <a href="#CR257" class="usa-link" aria-describedby="CR257">2022</a>). Younger age of menarche or late menopause age, having fewer children and not breastfeeding or breastfeeding only for a short period of time are among risk factors for BC development (Wilkinson and Gathani <a href="#CR257" class="usa-link" aria-describedby="CR257">2022</a>; Collaborative Group on Hormonal Factors in Breast Cancer <a href="#CR50" class="usa-link" aria-describedby="CR50">2012</a>, <a href="#CR49" class="usa-link" aria-describedby="CR49">2002</a>). Moreover, other BC risk factors include obesity, alcohol consumption, increasing life expectancy and changes in female reproductive patterns (Wilkinson and Gathani <a href="#CR257" class="usa-link" aria-describedby="CR257">2022</a>). For less developed countries, however, the reasons that may correlate with the lower BC incidence and higher mortality include low BC awareness and limited healthcare resources reflecting lack of screening programs, late diagnosis at an advanced stage and decreased access to proper treatment (Wilkinson and Gathani <a href="#CR257" class="usa-link" aria-describedby="CR257">2022</a>; Tfayli et al. <a href="#CR239" class="usa-link" aria-describedby="CR239">2010</a>; Costa Vieira et al. <a href="#CR56" class="usa-link" aria-describedby="CR56">2017</a>).</p>
<p id="Par43">Breast cancer is a histopathologically and genetically heterogeneous disease which is reflected by histopathologic and molecular classifications and staging system. Breast cancers differ among different patients as well as within an individual tumour, due to the presence of heterogeneous cell populations (Turashvili and Brogi <a href="#CR245" class="usa-link" aria-describedby="CR245">2017</a>). Moreover, breast tumours are diverse in terms of growth intensity, aggressiveness, metastatic imprint and response to therapy (Barba et al. <a href="#CR19" class="usa-link" aria-describedby="CR19">2021</a>; Beňačka et al. <a href="#CR23" class="usa-link" aria-describedby="CR23">2022</a>).</p>
<p id="Par44">Early diagnosis of BC and adequate screening are crucial for improving the survival of patients and effective treatment. Currently, the diagnosis of BC is mostly based on imaging techniques, among which mammography is the primary screening method, and, histopathological confirmation on tissue biopsy samples (Barba et al. <a href="#CR19" class="usa-link" aria-describedby="CR19">2021</a>; Wang <a href="#CR251" class="usa-link" aria-describedby="CR251">2017</a>; Jafari et al. <a href="#CR114" class="usa-link" aria-describedby="CR114">2018</a>; Pesapane et al. <a href="#CR201" class="usa-link" aria-describedby="CR201">2020</a>). However, despite evidence that screening mammography reduces BC mortality (Broeders et al. <a href="#CR28" class="usa-link" aria-describedby="CR28">2012</a>; Nickson et al. <a href="#CR183" class="usa-link" aria-describedby="CR183">2012</a>) this method has also some limitations (Gegios et al. <a href="#CR90" class="usa-link" aria-describedby="CR90">2023</a>), such as reduced sensitivity of the mammography examination in women with dense breast tissue (McLean and Stone <a href="#CR170" class="usa-link" aria-describedby="CR170">2018</a>; Checka et al. <a href="#CR38" class="usa-link" aria-describedby="CR38">2012</a>; Destounis et al. <a href="#CR68" class="usa-link" aria-describedby="CR68">2017</a>; Gils et al. <a href="#CR248" class="usa-link" aria-describedby="CR248">1998</a>). Moreover, tissue biopsy, which is required after the detection of a suspected lesion in the breast, is an invasive and time-consuming procedure that may not reveal the complete heterogeneity of cancer (Eigeliene et al. <a href="#CR76" class="usa-link" aria-describedby="CR76">2019</a>; Zubor et al. <a href="#CR288" class="usa-link" aria-describedby="CR288">2019</a>).</p>
<p id="Par45">In recent years, multiple molecular test have been developed to supplement traditional clinicopathological prognostic factors for BC, such as lymph node metastasis, tumour size and tumour grade (Nicolini et al. <a href="#CR185" class="usa-link" aria-describedby="CR185">2018</a>). Currently, the aim of many studies is to search for novel minimally invasive biomarkers useful for the diagnosis of early-stage BC, prognosis, monitoring response to treatment and prediction of tumour progression (Pesapane et al. <a href="#CR201" class="usa-link" aria-describedby="CR201">2020</a>; Ozawa et al. <a href="#CR192" class="usa-link" aria-describedby="CR192">2020</a>).</p>
<p id="Par46">This review critically evaluates recent advances in BC biomarkers, with special emphasis on circulating biomarkers. Particular attention was paid to the combinatorial analysis of biomarkers, which may be a modern approach to overcome the limitations of single biomarker assays.</p></section><section id="Sec2"><h2 class="pmc_sec_title">Classical markers in breast cancer diagnosis</h2>
<section id="Sec3"><h3 class="pmc_sec_title">Molecular markers defining molecular subtypes of breast cancer</h3>
<p id="Par47">The molecular classification of breast cancer reflects differences in the clinicopathological features and response to treatment of tumour subtypes (Roy et al. <a href="#CR211" class="usa-link" aria-describedby="CR211">2023</a>). Classical molecular biomarkers, detected from tumour cells by immunohistochemistry, that define molecular subtypes include oestrogen receptor (ER), progesterone receptor (PR) and human epidermal growth factor receptor 2 (HER2) (Barba et al. <a href="#CR19" class="usa-link" aria-describedby="CR19">2021</a>; Beňačka et al. <a href="#CR23" class="usa-link" aria-describedby="CR23">2022</a>; Dai et al. <a href="#CR57" class="usa-link" aria-describedby="CR57">2016</a>). The expression of these biomarkers should be assessed routinely in all newly diagnosed breast carcinomas as they are established prognostic and predictive factors critical in guiding appropriate patient treatment (Turashvili and Brogi <a href="#CR245" class="usa-link" aria-describedby="CR245">2017</a>; Wolff et al. <a href="#CR259" class="usa-link" aria-describedby="CR259">2023</a>; Allison et al. <a href="#CR5" class="usa-link" aria-describedby="CR5">2020</a>; Grogan Fleege and Cobain <a href="#CR92" class="usa-link" aria-describedby="CR92">2021</a>; Jorns <a href="#CR122" class="usa-link" aria-describedby="CR122">2019</a>).</p>
<section id="Sec4"><h4 class="pmc_sec_title">Estrogen and progesterone receptors</h4>
<p id="Par48">ER and PR are nuclear receptors belong to the steroid/nuclear receptor family of ligand-activated transcription factors (Jameera Begam et al. <a href="#CR115" class="usa-link" aria-describedby="CR115">2017</a>; Hilton et al. <a href="#CR106" class="usa-link" aria-describedby="CR106">2018</a>). There are two isoforms of ER encoded by independent genes located on different chromosomes: ERα (<em>ESR1</em> at 6q24-27) and ERβ (<em>ESR2</em> at 14q22-24) (Xia and Lin <a href="#CR262" class="usa-link" aria-describedby="CR262">2022</a>; Khan et al. <a href="#CR125" class="usa-link" aria-describedby="CR125">2022</a>; Clusan et al. <a href="#CR48" class="usa-link" aria-describedby="CR48">2021</a>). In BC cells ERα shows higher expression than ERβ and, being involved in the regulation of endocrine function, is responsible for growth, survival and proliferation of breast epithelial cells, leading to tumour development (Almeida <a href="#CR7" class="usa-link" aria-describedby="CR7">2020</a>). PR has two isoforms: PR-A and PR-B encoded by <em>PGR</em> gene located on chromosome 11 (Krystel-Whittemore et al. <a href="#CR131" class="usa-link" aria-describedby="CR131">2024</a>; Boonyaratanakornkit et al. <a href="#CR26" class="usa-link" aria-describedby="CR26">2018</a>; Tarighati et al. <a href="#CR237" class="usa-link" aria-describedby="CR237">2023</a>; Wu et al. <a href="#CR260" class="usa-link" aria-describedby="CR260">2020</a>). The expression of PR is regulated by ERα and the presence of PR indicates that ER pathway is functional (Allred <a href="#CR6" class="usa-link" aria-describedby="CR6">2010</a>; Rakha et al. <a href="#CR206" class="usa-link" aria-describedby="CR206">2022</a>) indicating the potential sensitivity to endocrine therapy (Tarighati et al. <a href="#CR237" class="usa-link" aria-describedby="CR237">2023</a>; Neves Rebello Alves et al. <a href="#CR182" class="usa-link" aria-describedby="CR182">2023</a>).</p>
<p id="Par49">ER is a well-established predictive marker in BC used for consideration of endocrine therapy (Rakha et al. <a href="#CR206" class="usa-link" aria-describedby="CR206">2022</a>) that for ER-positive patients include aromatase inhibitors (AI), which inhibit the estrogens synthesis and anti-estrogens: selective ER modulators (SERMs; e.g., tamoxifen) and selective ER downregulators (SERDs; e.g., fulvestrant), which interfere with estrogen-dependent pathways (Nicolini et al. <a href="#CR185" class="usa-link" aria-describedby="CR185">2018</a>; Almeida <a href="#CR7" class="usa-link" aria-describedby="CR7">2020</a>; Awan and Esfahani <a href="#CR16" class="usa-link" aria-describedby="CR16">2018</a>; Hanker et al. <a href="#CR100" class="usa-link" aria-describedby="CR100">2020</a>).</p>
<p id="Par50">It was demonstrated that patients with ER-positive/PR-positive BCs were more likely to benefit from endocrine therapy than those with ER-positive/PR-negative tumours (Nordenskjöld et al. <a href="#CR188" class="usa-link" aria-describedby="CR188">2016</a>; Bardou et al. <a href="#CR20" class="usa-link" aria-describedby="CR20">2003</a>). Meta-analysis by Zhong et al. (<a href="#CR285" class="usa-link" aria-describedby="CR285">2022</a>) showed that patients with high expression of these hormone receptors have better prognosis. However, meta-analysis of randomized trials revealed that PR measurements did not seem to be predictive of endocrine therapy efficacy (Early Breast Cancer Trialists’ Collaborative Group <a href="#CR75" class="usa-link" aria-describedby="CR75">2011</a>). Thus, the predictive role of PR independent of ER is debatable.</p>
<p id="Par51">However, the Expert Panel recommends routine PR testing in invasive BCs and points to the prognostic role of PR (Allison et al. <a href="#CR5" class="usa-link" aria-describedby="CR5">2020</a>). ER-positive/PR-negative tumours were found to have more aggressive features than ER-positive/PR-positive BCs (Arpino et al. <a href="#CR13" class="usa-link" aria-describedby="CR13">2005</a>) Moreover, meta-analysis by Shiino et al. (<a href="#CR226" class="usa-link" aria-describedby="CR226">2022</a>) revealed that in recurrent tumours the loss of ER or PR is associated with shorter overall survival compared with receptor-positive concordant groups.</p>
<p id="Par52">Distant metastases and resistance to therapy are the main causes of mortality in BC patients (Szostakowska et al. <a href="#CR234" class="usa-link" aria-describedby="CR234">2019</a>). ER+ BCs may develop recurrences in distant organs, which can be detected years after the primary tumour diagnosis and adjuvant therapy, what suggest the dormancy of ER+ cancer cells (Zhang et al. <a href="#CR275" class="usa-link" aria-describedby="CR275">2013</a>; Clarke et al. <a href="#CR47" class="usa-link" aria-describedby="CR47">2015</a>). Moreover, it was shown that during the five years after primary BC diagnosis patients with ER-negative tumours have a higher risk of second BC (Lowry et al. <a href="#CR154" class="usa-link" aria-describedby="CR154">2023</a>), whereas, for patients with ER-positive tumours the risk of recurrence is higher beyond five years in comparison with ER-negative cancers (Colleoni et al. <a href="#CR51" class="usa-link" aria-describedby="CR51">2016</a>).</p></section><section id="Sec5"><h4 class="pmc_sec_title">Human<em> epidermal growth factor receptor 2</em>
</h4>
<p id="Par53">HER2 (HER2/<em>neu</em>, ErbB2) is a member of human epidermal growth factor receptor family. The HER2 protooncogene (<em>neu</em>, c-erbB-2) is located on chromosome 17q21 and encodes the transmembrane HER2 protein (Yarden <a href="#CR267" class="usa-link" aria-describedby="CR267">2001</a>; Moasser <a href="#CR176" class="usa-link" aria-describedby="CR176">2007</a>). HER2 testing should be performed in all newly diagnosed and metastatic BC patients. The techniques used to determine HER2 status (positive, equivocal, negative) include immunohistochemistry (IHC) for protein overexpression and/or in situ hybridization (ISH) for gene amplification (Wolff et al. <a href="#CR259" class="usa-link" aria-describedby="CR259">2023</a>; Wolff et al. <a href="#CR258" class="usa-link" aria-describedby="CR258">2018</a>; Rakha et al. <a href="#CR206" class="usa-link" aria-describedby="CR206">2022</a>).</p>
<p id="Par54">HER2 gene is amplified or the protein is overexpressed in approximately 15% of BC patients (Rakha et al. <a href="#CR206" class="usa-link" aria-describedby="CR206">2022</a>; Taucher et al. <a href="#CR238" class="usa-link" aria-describedby="CR238">2004</a>; Wf et al. <a href="#CR9" class="usa-link" aria-describedby="CR9">2014</a>). HER2 overexpression promotes tumour growth by activating MAPK and PI3K/AKT signalling pathways leading to enhanced cell proliferation, invasion and metastasis (Beňačka et al. <a href="#CR23" class="usa-link" aria-describedby="CR23">2022</a>; Nicolini et al. <a href="#CR185" class="usa-link" aria-describedby="CR185">2018</a>; Pan et al. <a href="#CR196" class="usa-link" aria-describedby="CR196">2024</a>). In BCs patients, HER2 amplification/overexpression is associated with poor prognosis (Ménard et al. <a href="#CR171" class="usa-link" aria-describedby="CR171">2001</a>). HER2/neu positive expression was reported to be associated with decreased survival in BC patients (Cao et al. <a href="#CR33" class="usa-link" aria-describedby="CR33">2007</a>).</p>
<p id="Par55">HER2-targeted therapy significantly improved the outcome for HER2-positive BC patients (Harbeck <a href="#CR102" class="usa-link" aria-describedby="CR102">2022</a>; Martínez-Sáez and Prat <a href="#CR161" class="usa-link" aria-describedby="CR161">2021</a>). HER2-targeted therapies include monoclonal antibodies (trastuzumab, pertuzumab), tyrosine kinase inhibitors (lapatinib, tucatinib, neratinib, pyrotinib) and antibody–drug conjugates (ADC) (Stanowicka-Grada and Senkus <a href="#CR232" class="usa-link" aria-describedby="CR232">2023</a>; Dempsey et al. <a href="#CR65" class="usa-link" aria-describedby="CR65">2023</a>).</p></section></section><section id="Sec6"><h3 class="pmc_sec_title">Additional biomarkers</h3>
<p id="Par56">Ki67 (encoded by <em>MKI67</em>) is a nuclear antigen that is a marker associated with cell proliferation (Zhang et al. <a href="#CR279" class="usa-link" aria-describedby="CR279">2021a</a>; Schlüter et al. <a href="#CR220" class="usa-link" aria-describedby="CR220">1993</a>) and is usually detected by IHC and reported as Ki67 index (Penault-Llorca and Radosevic-Robin <a href="#CR199" class="usa-link" aria-describedby="CR199">2017</a>). It is mainly used in ER+/HER2- BC to differentiate luminal A from luminal B tumours (Penault-Llorca and Radosevic-Robin <a href="#CR199" class="usa-link" aria-describedby="CR199">2017</a>). Despite evidence of the prognostic and predictive importance of Ki67 (Zhang et al. <a href="#CR279" class="usa-link" aria-describedby="CR279">2021a</a>; Petrelli et al. <a href="#CR202" class="usa-link" aria-describedby="CR202">2015</a>; Nielsen et al. <a href="#CR186" class="usa-link" aria-describedby="CR186">2021</a>), the analytical validity of this marker is still questionable due to the lack of a standardised procedure of Ki67 assessment and the actual clinical utility (Rakha et al. <a href="#CR206" class="usa-link" aria-describedby="CR206">2022</a>; Penault-Llorca and Radosevic-Robin <a href="#CR199" class="usa-link" aria-describedby="CR199">2017</a>).</p>
<p id="Par57">Cytokeratins belong to intermediate filament proteins of epithelial cells (McGinn et al. <a href="#CR169" class="usa-link" aria-describedby="CR169">2022</a>; Moar et al. <a href="#CR175" class="usa-link" aria-describedby="CR175">2023</a>). In BC, the most commonly used assays include CYFRA 21.1—for CK19, tissue polypeptide antigen (TPA)—for CK8, CK18, CK19 and tissue polypeptide-specific antigen (TPS)—for CK8 and CK18 (Moar et al. <a href="#CR175" class="usa-link" aria-describedby="CR175">2023</a>; Mirabelli and Incornoto <a href="#CR173" class="usa-link" aria-describedby="CR173">2013</a>; Nicolini et al. <a href="#CR184" class="usa-link" aria-describedby="CR184">2015</a>).</p>
<p id="Par58">p53 is a transcription factor and tumour suppressor, encoded by <em>TP53</em> gene, involved in the regulation of several cell functions such as cell cycle regulation, apoptosis, senescence and DNA repair (Neves Rebello Alves et al. <a href="#CR182" class="usa-link" aria-describedby="CR182">2023</a>; Marvalim et al. <a href="#CR162" class="usa-link" aria-describedby="CR162">2023</a>). In BC, the <em>TP53</em> gene is the most frequently mutated gene, being mutated in nearly 30% of all BC cases (Shahbandi et al. <a href="#CR223" class="usa-link" aria-describedby="CR223">2020</a>). Mutated p53 may serve as a potential biomarker and therapeutic target for BC patients, particularly in triple negative subtype as about 80% of those patients have mutation in p53 (Duffy et al. <a href="#CR72" class="usa-link" aria-describedby="CR72">2018</a>).</p>
<p id="Par59">BRCA1 and BRCA2 are two tumour suppressor genes that play a role in DNA repair processes (Neves Rebello Alves et al. <a href="#CR182" class="usa-link" aria-describedby="CR182">2023</a>; Lee et al. <a href="#CR135" class="usa-link" aria-describedby="CR135">2020</a>). The pathogenic variants of these genes are associated with hereditary BC that accounts for 5–10% of all BC cases (Lee et al. <a href="#CR135" class="usa-link" aria-describedby="CR135">2020</a>). Patients with BRCA1 mutation carrier status mainly have triple negative BCs, whereas tumours arising in BRCA2 carriers are more likely to be ER-positive (Talhouet et al. <a href="#CR62" class="usa-link" aria-describedby="CR62">2020</a>; Mavaddat, et al. <a href="#CR166" class="usa-link" aria-describedby="CR166">2012</a>). There are evidence of the prognostic role of BRCA1/BRCA2 in BC and the therapeutic target for this disease (Jin et al. <a href="#CR120" class="usa-link" aria-describedby="CR120">2022</a>). However, there are conflicting data on the predictive and prognostic significance of BRCA mutations on the survival of patients with non-metastatic BC (Neves Rebello Alves et al. <a href="#CR182" class="usa-link" aria-describedby="CR182">2023</a>; Talhouet et al. <a href="#CR62" class="usa-link" aria-describedby="CR62">2020</a>).</p></section><section id="Sec7"><h3 class="pmc_sec_title">Serum biomarkers in clinical use</h3>
<p id="Par60">Serum tumour markers in BC include cancer antigen 15–3 (CA 15–3), carcinoembryonic antigen (CEA), cancer antigen 27–29 (CA27-29) and cancer antigen 125 (CA 125) (Tarighati et al. <a href="#CR237" class="usa-link" aria-describedby="CR237">2023</a>; Moar et al. <a href="#CR175" class="usa-link" aria-describedby="CR175">2023</a>; Seale and Tkaczuk <a href="#CR221" class="usa-link" aria-describedby="CR221">2022</a>). In the clinical fields, the most widely used serum markers in BC are CA 15–3 and CEA (Shao et al. <a href="#CR224" class="usa-link" aria-describedby="CR224">2015</a>). It was shown that BC patients with elevated preoperative CA 15–3 and CEA levels had worse prognosis (Shao et al. <a href="#CR224" class="usa-link" aria-describedby="CR224">2015</a>; Uehara et al. <a href="#CR246" class="usa-link" aria-describedby="CR246">2008</a>; S. Lee et al. <a href="#CR213" class="usa-link" aria-describedby="CR213">2013</a>). Moreover, serial measurement of CEA and CA15-3 was shown to be useful for early detection of BC recurrence (Molina et al. <a href="#CR177" class="usa-link" aria-describedby="CR177">1995</a>). CA15-3, CEA and CA27.29 was found to have increased sensitivity in metastatic BC (Hou et al. <a href="#CR108" class="usa-link" aria-describedby="CR108">1999</a>) and to be useful in monitoring response to therapy with serial measurements (Seale and Tkaczuk <a href="#CR221" class="usa-link" aria-describedby="CR221">2022</a>). Fang et al. (<a href="#CR82" class="usa-link" aria-describedby="CR82">2017a</a>) demonstrated that high preoperative CA125 levels may predict poor outcome and prognosis in BC patients.</p>
<p id="Par61">These circulating biomarkers are useful in the management of metastatic BC. In early BC they have prognostic significance but, due to low sensitivity in early disease and lack of specificity, most expert panels do not recommend these markers for screening (Seale and Tkaczuk <a href="#CR221" class="usa-link" aria-describedby="CR221">2022</a>; Duque et al. <a href="#CR73" class="usa-link" aria-describedby="CR73">2022</a>).</p></section></section><section id="Sec8"><h2 class="pmc_sec_title">Potential markers in breast cancer diagnosis, prognosis and treatment monitoring</h2>
<section id="Sec9"><h3 class="pmc_sec_title">Proteins</h3>
<section id="Sec10"><h4 class="pmc_sec_title">Galectins</h4>
<p id="Par62">Galectins are a family of lectins, that have an affinity for β-galactoside structures. These proteins are involved in multiple processes such as cell cycle, apoptosis, cell differentiation or RNA transcription as well as cancerogenesis (Delacour et al. <a href="#CR63" class="usa-link" aria-describedby="CR63">2009</a>).</p>
<p id="Par63">In BC tissues increased galectin-1 expression was observed in stromal cells of invasive carcinoma compared to carcinoma in situ and the association between expression of galectin-1 in cancer-associated stromal cells and different clinicopathologic parameters, including tumour invasiveness, was demonstrated (Jung et al. <a href="#CR123" class="usa-link" aria-describedby="CR123">2007</a>). Overexpression of galectin-1 was found in claudin-low BC (Balestrieri et al. <a href="#CR18" class="usa-link" aria-describedby="CR18">2021</a>). The potential of galectin-1 as a therapeutic target to overcome immunosuppression associated with BC was also studied (Dalotto-Moreno et al. <a href="#CR59" class="usa-link" aria-describedby="CR59">2013</a>; Chung et al. <a href="#CR46" class="usa-link" aria-describedby="CR46">2024</a>). Chetry et al. (<a href="#CR43" class="usa-link" aria-describedby="CR43">2022</a>) demonstrated that high mRNA expression of galectin-1 (LGALS1) was associated with a poor prognosis in BC patients, while overexpression of galectin—2 (LGALS2) was related to a better prognosis. Decreased expression of galectin-3 was found to be associated with aggressiveness and poor prognosis in BC (Castronovo et al. <a href="#CR35" class="usa-link" aria-describedby="CR35">1996</a>; Ilmer et al. <a href="#CR111" class="usa-link" aria-describedby="CR111">2016</a>; Shafiq et al. <a href="#CR222" class="usa-link" aria-describedby="CR222">2020</a>). Ilmer et al. (<a href="#CR111" class="usa-link" aria-describedby="CR111">2016</a>) showed that decreased galectin-3 expression was associated with poor survival and advanced locoregional invasion in BC patients. Shafiq et al. (<a href="#CR222" class="usa-link" aria-describedby="CR222">2020</a>) found that elevated galectin-3 levels in stroma are associated with response to chemotherapy in BC. Elevated expression of galectin-7 was found to be restricted to high-grade BCs (Demers et al. <a href="#CR64" class="usa-link" aria-describedby="CR64">2010</a>). Moreover, overexpression of galectin-7 was shown to increase BC cells ability to metastasise to lungs and bones in mouse models (Demers et al. <a href="#CR64" class="usa-link" aria-describedby="CR64">2010</a>). Trebo et al. (<a href="#CR243" class="usa-link" aria-describedby="CR243">2020</a>) found that in primary BC patients high expression of galectin-7 in the cytoplasm was correlated with a worse outcome, whereas high expression of galectin-8 was associated with an improved patients outcome. The antimetastatic potential of galectin-9 in BC was revealed by Irie et al. (<a href="#CR112" class="usa-link" aria-describedby="CR112">2005</a>), as the authors found that patients with galectin-9—positive tumours had a lower frequency of distant metastasis and more favourable disease-free survival in comparison with galectin-9—negative tumours, suggesting prognostic potential of galectin-9.</p>
<p id="Par64">Several studies evaluated serum concentrations of galectins in BC patients. Barrow et al. (<a href="#CR21" class="usa-link" aria-describedby="CR21">2011</a>) showed significantly increased serum concentrations of galectin-2, -3, -4 and -8 and significantly lower concentration of galectin-1 in patients with BC. However, Gurel Cayir et al. (Gurel Cayir et al. <a href="#CR98" class="usa-link" aria-describedby="CR98">2020</a>) found higher serum levels of galectin-1 in preoperative BC patients compared to the group of healthy controls. Moreover, higher serum galectin-1 level in preoperative patients compared to postoperative patients was shown, what may suggest that serum levels of galectin-1 positively corelate with tumour presence. According to these findings, galectin-1 may have importance in breast carcinogenesis as well as in evaluation response to treatment (Gurel Cayir et al. <a href="#CR98" class="usa-link" aria-describedby="CR98">2020</a>). Increased serum levels of galectin-1 were also shown in BC patients who received systemic therapy (hormone therapy, immunotherapy or chemotherapy) compared to patients, who were not exposed to treatment (Funkhouser et al. <a href="#CR88" class="usa-link" aria-describedby="CR88">2023</a>). Blair et al. (<a href="#CR25" class="usa-link" aria-describedby="CR25">2021</a>) found increased circulating concentrations of galectin-1, -3 and -7 in BC patients. However, statistically significant increase in concentration of galectin-3 was observed in all stages, whereas galectin-1 was elevated in stages I and III and galectin-7 only in stage I (Blair et al. <a href="#CR25" class="usa-link" aria-describedby="CR25">2021</a>). Shafiq et al. (<a href="#CR222" class="usa-link" aria-describedby="CR222">2020</a>) showed that plasma levels of galectin-3 had an inverse correlation with increasing grade of BC. Moreover, the authors found a relationship between elevated levels of galectin-3 and response to chemotherapy. Higher serum levels of galectin-3 in BC patients were also found by Topcu et al. (<a href="#CR242" class="usa-link" aria-describedby="CR242">2018</a>). Additionally, the study showed that between patients with and without metastasis there was no difference in serum levels of galectin-3 (Topcu et al. <a href="#CR242" class="usa-link" aria-describedby="CR242">2018</a>). In a study by Funkhouser et al. (<a href="#CR88" class="usa-link" aria-describedby="CR88">2023</a>), serum concentrations of galectin-9 was found to be increased in HER2-amplified tissues and decreased in samples with positive hormone receptor markers. In another study, Funkhouser et al. (Funkhouser et al. <a href="#CR87" class="usa-link" aria-describedby="CR87">2022</a>) showed higher levels of galectins-1, -3, -8, and -9 in serum of BC patients with a mutation in the <em>KIT</em> gene. Markalunas et al. (<a href="#CR160" class="usa-link" aria-describedby="CR160">2024</a>) found correlations between <em>KIT</em> mutations and elevated serum levels of galectin-9 in BC patients, <em>FLT3</em> mutations and lower serum levels of galectin-1 and -9 as well as <em>TP53</em> mutations and higher serum levels of galectin-3 in luminal A subtype. Moreover, higher serum galectin-3 levels were shown in patients with invasive ductal carcinoma in comparison with patients with ductal carcinoma in situ. Additionally, elevated serum galectin-3 levels were found in patients with both <em>TP53</em> and <em>PIK3CA</em> mutations, while there was no difference in galectin-3 levels in patients with one or neither mutation (Markalunas et al. <a href="#CR160" class="usa-link" aria-describedby="CR160">2024</a>). Summarised information of selected galectins in BC presents Table <a href="#Tab1" class="usa-link">1</a>.</p>
<section class="tw xbox font-sm" id="Tab1"><h5 class="obj_head">Table 1.</h5>
<div class="caption p"><p>Significance of galectins in tissue and serum in BC</p></div>
<div class="tbl-box p" tabindex="0"><table class="content" frame="hsides" rules="groups">
<thead><tr>
<th align="left" colspan="1" rowspan="1">Galectin</th>
<th align="left" colspan="1" rowspan="1">Expression in tissue/cell line</th>
<th align="left" colspan="1" rowspan="1">Serum/plasma concentration</th>
<th align="left" colspan="1" rowspan="1">Proposed clinical utility</th>
</tr></thead>
<tbody>
<tr>
<td align="left" colspan="1" rowspan="1">Galectin-1</td>
<td align="left" colspan="1" rowspan="1">
<p>↑ in stromal cells of invasive BC and correlate with tumour invasiveness (Jung et al. <a href="#CR123" class="usa-link" aria-describedby="CR123">2007</a>)</p>
<p>↑ in claudin-low BC (Balestrieri et al. <a href="#CR18" class="usa-link" aria-describedby="CR18">2021</a>)</p>
<p>↑association with a poor prognosis (Chetry et al. <a href="#CR43" class="usa-link" aria-describedby="CR43">2022</a>)</p>
</td>
<td align="left" colspan="1" rowspan="1">
<p>↓ (Barrow et al. <a href="#CR21" class="usa-link" aria-describedby="CR21">2011</a>)</p>
<p>↑ in preoperative patients (Gurel Cayir et al. <a href="#CR98" class="usa-link" aria-describedby="CR98">2020</a>)</p>
<p>↑ in patients exposed to treatment (Funkhouser et al. <a href="#CR88" class="usa-link" aria-describedby="CR88">2023</a>)</p>
<p>↑ (in stage I and III) (Blair et al. <a href="#CR25" class="usa-link" aria-describedby="CR25">2021</a>)</p>
<p>↑ in patients with <em>KIT</em> mutation (Funkhouser et al. <a href="#CR87" class="usa-link" aria-describedby="CR87">2022</a>)</p>
<p>↓ in patients with <em>FLT3</em> mutation in luminal A subtype (Markalunas et al. <a href="#CR160" class="usa-link" aria-describedby="CR160">2024</a>)</p>
</td>
<td align="left" colspan="1" rowspan="1">
<p>Therapeutic target (Dalotto-Moreno et al. <a href="#CR59" class="usa-link" aria-describedby="CR59">2013</a>; Chung et al. <a href="#CR46" class="usa-link" aria-describedby="CR46">2024</a>)</p>
<p>Treatment evaluation (Gurel Cayir et al. <a href="#CR98" class="usa-link" aria-describedby="CR98">2020</a>)</p>
</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">Galectin-2</td>
<td align="left" colspan="1" rowspan="1">↑ associated with a better prognosis (Chetry et al. <a href="#CR43" class="usa-link" aria-describedby="CR43">2022</a>)</td>
<td align="left" colspan="1" rowspan="1">↑ (Barrow et al. <a href="#CR21" class="usa-link" aria-describedby="CR21">2011</a>)</td>
<td align="left" colspan="1" rowspan="1">
<p>Potential immunotherapy target in TNBC (Ji et al. <a href="#CR119" class="usa-link" aria-describedby="CR119">2022</a>)</p>
<p>Immunotherapy response, drug resistance (He et al. <a href="#CR105" class="usa-link" aria-describedby="CR105">2023</a>)</p>
<p>Immunotherapeutic biomarker, potential therapeutic target (Li et al. <a href="#CR144" class="usa-link" aria-describedby="CR144">2024</a>)</p>
</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">Galectin-3</td>
<td align="left" colspan="1" rowspan="1">
<p>↓ associated with aggressiveness and poor prognosis (Castronovo et al. <a href="#CR35" class="usa-link" aria-describedby="CR35">1996</a>; Ilmer et al. <a href="#CR111" class="usa-link" aria-describedby="CR111">2016</a>; Shafiq et al. <a href="#CR222" class="usa-link" aria-describedby="CR222">2020</a>)</p>
<p>↓ associated with advanced locoregional invasion and poor survival (Ilmer et al. <a href="#CR111" class="usa-link" aria-describedby="CR111">2016</a>)</p>
<p>↑ levels in stroma in relationship with response to chemotherapy (Shafiq et al. <a href="#CR222" class="usa-link" aria-describedby="CR222">2020</a>)</p>
</td>
<td align="left" colspan="1" rowspan="1">
<p>↑ (Barrow, et al. <a href="#CR21" class="usa-link" aria-describedby="CR21">2011</a>; Blair et al. <a href="#CR25" class="usa-link" aria-describedby="CR25">2021</a>; Topcu et al. Sep. <a href="#CR242" class="usa-link" aria-describedby="CR242">2018</a>)</p>
<p>inverse relationship with increasing grade (Shafiq et al. Mar. <a href="#CR222" class="usa-link" aria-describedby="CR222">2020</a>)</p>
<p>↑ in relationship with chemotherapy response (Shafiq et al. Mar. <a href="#CR222" class="usa-link" aria-describedby="CR222">2020</a>)</p>
<p>↑ in patients with <em>KIT</em> mutation (Funkhouser et al. <a href="#CR87" class="usa-link" aria-describedby="CR87">2022</a>)</p>
<p>↑ in patients with both <em>TP53</em> and <em>PIK3CA</em> mutations (Markalunas et al. <a href="#CR160" class="usa-link" aria-describedby="CR160">2024</a>)</p>
<p>↑ in patients with invasive ductal carcinoma (Markalunas et al. <a href="#CR160" class="usa-link" aria-describedby="CR160">2024</a>)</p>
</td>
<td align="left" colspan="1" rowspan="1">Chemotherapy response.(Shafiq et al. <a href="#CR222" class="usa-link" aria-describedby="CR222">2020</a>)</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">Galectin-7</td>
<td align="left" colspan="1" rowspan="1">
<p>↑ increase metastasise ability of BC cells (Demers et al. <a href="#CR64" class="usa-link" aria-describedby="CR64">2010</a>)</p>
<p>↑ in the cytoplasm—worse outcome (Trebo et al. <a href="#CR243" class="usa-link" aria-describedby="CR243">2020</a>)</p>
</td>
<td align="left" colspan="1" rowspan="1">↑ (in stage I) (Blair et al. <a href="#CR25" class="usa-link" aria-describedby="CR25">2021</a>)</td>
<td align="left" colspan="1" rowspan="1">Targeted therapy (cell lines) (Grosset et al. <a href="#CR93" class="usa-link" aria-describedby="CR93">2014</a>)</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">Galectin-8</td>
<td align="left" colspan="1" rowspan="1">↑ in the cytoplasm—improved outcome (Trebo et al. <a href="#CR243" class="usa-link" aria-describedby="CR243">2020</a>)</td>
<td align="left" colspan="1" rowspan="1">
<p>↑ (Barrow, et al. <a href="#CR21" class="usa-link" aria-describedby="CR21">2011</a>)</p>
<p>↑ in patients with <em>KIT</em> mutation (Funkhouser et al. <a href="#CR87" class="usa-link" aria-describedby="CR87">2022</a>)</p>
</td>
<td align="left" colspan="1" rowspan="1">Therapeutic potential (Chien et al. <a href="#CR44" class="usa-link" aria-describedby="CR44">2025</a>)</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">Galectin-9</td>
<td align="left" colspan="1" rowspan="1">Antimetastatic and prognostic potential (Irie, et al. <a href="#CR112" class="usa-link" aria-describedby="CR112">2005</a>)</td>
<td align="left" colspan="1" rowspan="1">
<p>↑ in HER2-amplified tissues (Funkhouser et al. <a href="#CR88" class="usa-link" aria-describedby="CR88">2023</a>)</p>
<p>↓ in samples with positive hormone receptor markers (Funkhouser et al. <a href="#CR88" class="usa-link" aria-describedby="CR88">2023</a>)</p>
<p>↑ in patients with <em>KIT</em> mutation (Funkhouser et al. <a href="#CR87" class="usa-link" aria-describedby="CR87">2022</a>; Markalunas et al. <a href="#CR160" class="usa-link" aria-describedby="CR160">2024</a>)</p>
<p>↓ in patients with <em>FLT3</em> mutation in luminal A subtype (Markalunas et al. <a href="#CR160" class="usa-link" aria-describedby="CR160">2024</a>)</p>
</td>
<td align="left" colspan="1" rowspan="1">Dynamic biomarker after radiotherapy for TNBC, therapeutic implications (Lerévérend et al. <a href="#CR138" class="usa-link" aria-describedby="CR138">2025</a>)</td>
</tr>
</tbody>
</table></div>
<div class="p text-right font-secondary"><a href="table/Tab1/" class="usa-link" target="_blank" rel="noopener noreferrer">Open in a new tab</a></div>
<div class="tw-foot p"><div class="fn" id="_fn_p58"><p>↑—high expression/concentration, ↓—low expression/concentration</p></div></div></section></section></section><section id="Sec11"><h3 class="pmc_sec_title">Adipokines</h3>
<p id="Par65">Adipokines (or adipocytokines) are cytokines (cell signalling proteins) secreted by adipose tissue that consists of adipocytes, immune cells and an extracellular matrix (Kothari et al. <a href="#CR130" class="usa-link" aria-describedby="CR130">2020</a>; Hoy et al. <a href="#CR109" class="usa-link" aria-describedby="CR109">2017</a>). Adipocytes constitute the predominant cell population in the breast stroma and participate in the crosstalk with BC cells contributing to proliferation and invasion of BC cells as well as resistance to therapy (Hoy et al. <a href="#CR109" class="usa-link" aria-describedby="CR109">2017</a>; Christodoulatos et al. <a href="#CR45" class="usa-link" aria-describedby="CR45">2019</a>; Samuel et al. <a href="#CR215" class="usa-link" aria-describedby="CR215">2018</a>). Adipocytokines are produced mainly by adipocytes and are associated with obesity, insulin resistance, lipid disorders, endothelial dysfunction, tumour pathogenesis etc., therefore they are involved in the pathogenesis of many diseases affecting different body systems (e.g. diabetes mellitus, gynaecological diseases, rheumatologic disorders or cancers) (Maximus et al. <a href="#CR167" class="usa-link" aria-describedby="CR167">2020</a>).</p>
<p id="Par66">Among adipocytokines, the increased levels of leptin and resistin as well as decreased levels of adiponectin are associated with BC development (Li and Han <a href="#CR139" class="usa-link" aria-describedby="CR139">2018</a>). Another adipokines, such as visfatin, apelin, lipocalin 2, osteopontin or oncostatin M were also linked to BC (Christodoulatos et al. <a href="#CR45" class="usa-link" aria-describedby="CR45">2019</a>). In this review, we describe the importance of adiponectin, leptin and resistin in BC.</p>
<section id="Sec12"><h4 class="pmc_sec_title">Adiponectin</h4>
<p id="Par67">Adiponectin is a glycoprotein that exhibits pleiotropic protective effects, including insulin sensitizing, antiapoptotic, antioxidant, anti-inflammatory and anti-atherogenic properties (Andò et al. <a href="#CR11" class="usa-link" aria-describedby="CR11">2020</a>; Nehme et al. <a href="#CR181" class="usa-link" aria-describedby="CR181">2022</a>; Nagaraju et al. <a href="#CR180" class="usa-link" aria-describedby="CR180">2016</a>). The effects of adiponectin are mediated through its binding to membrane receptors, such as adiponectin receptors 1 (AdipoR1) and 2 (AdipoR2) and T-cadherin in target tissues and organs (Li and Han <a href="#CR139" class="usa-link" aria-describedby="CR139">2018</a>; Andò et al. <a href="#CR11" class="usa-link" aria-describedby="CR11">2020</a>).</p>
<p id="Par68">Adiponectin is considered to have an inhibitory effect on BC development (Nehme et al. <a href="#CR181" class="usa-link" aria-describedby="CR181">2022</a>). Meta- analysis found the association of decreased serum levels of adiponectin with an increased BC risk in premenopausal and postmenopausal women (Gu et al. Jul. <a href="#CR95" class="usa-link" aria-describedby="CR95">2018</a>; Yu et al. <a href="#CR272" class="usa-link" aria-describedby="CR272">2019</a>), while others found an association only between adiponectin and postmenopausal BC (Ye, et al. <a href="#CR268" class="usa-link" aria-describedby="CR268">2014</a>; Liu et al. <a href="#CR147" class="usa-link" aria-describedby="CR147">2013</a>). Moreover, BC women with the low serum levels of adiponectin were found to be more likely to present an aggressive phenotype (large tumours, high histological grade) (Miyoshi, et al. <a href="#CR174" class="usa-link" aria-describedby="CR174">2003</a>). Oh et al. (<a href="#CR190" class="usa-link" aria-describedby="CR190">2011</a>) showed that serum adiponectin levels were higher in ER/PR-positive BC patients. Moreover, in the ER/PR-negative patients serum adiponectin levels showed an inverse association with the risk of BC recurrence. The authors suggest that assessing the concentrations of adiponectin may be useful in establishing prognosis in ER/PR-negative BC and that actions aimed at increasing serum adiponectin levels may protect against recurrence in ER/PR-negative cancers (Oh et al. <a href="#CR190" class="usa-link" aria-describedby="CR190">2011</a>). Higher expression of adiponectin and lower expression of its receptor ADIPOR1 were found in BC tissue of postmenopausal women with normal BMI in comparison to women with overweight or obesity (Orozco-Arguelles et al. <a href="#CR191" class="usa-link" aria-describedby="CR191">2021</a>). Jeong et al. (<a href="#CR118" class="usa-link" aria-describedby="CR118">2011</a>) showed that positive expression rates of adiponectin and AdipoR were significantly higher in invasive BC than in patients with ductal carcinoma in situ (DCIS). Moreover, in invasive BC, high expression of adiponectin was associated with lower T-stage, while the expression of AdipoR was associated with high Ki-67 expression. The authors suggest that high expressions of adiponectin and AdipoR may be related to BC invasiveness (Jeong et al. <a href="#CR118" class="usa-link" aria-describedby="CR118">2011</a>). Several studies demonstrated that in ER-negative BC cells adiponectin inhibits cell growth, induces apoptosis and inhibits cell proliferation (Kang et al. <a href="#CR124" class="usa-link" aria-describedby="CR124">2005</a>; Grossmann et al. <a href="#CR94" class="usa-link" aria-describedby="CR94">2008</a>; Santos et al. <a href="#CR71" class="usa-link" aria-describedby="CR71">2008</a>; Andò et al. <a href="#CR10" class="usa-link" aria-describedby="CR10">2019</a>). However, it was shown that adiponectin stimulates growth in ER-positive BC cells (Mauro et al. <a href="#CR164" class="usa-link" aria-describedby="CR164">2014</a>). It was also found that adiponectin may differentially regulate cyclin D1 (CD1) expression in BC cells depend on ER-α expression, what results in the divergent effects of adiponectin on cell growth (Mauro et al. <a href="#CR165" class="usa-link" aria-describedby="CR165">2015</a>).</p></section><section id="Sec13"><h4 class="pmc_sec_title">Leptin</h4>
<p id="Par69">Leptin is a peptide hormone (encoded by the <em>LEP</em> gene) produced mainly by adipocytes and secreted in proportion to the mass of adipose tissue. The main known functions of leptin include regulation of appetite and energy homeostasis (Ramos-Lobo and Donato <a href="#CR207" class="usa-link" aria-describedby="CR207">2017</a>; Buonaiuto et al. <a href="#CR29" class="usa-link" aria-describedby="CR29">2022</a>; Skoracka et al. <a href="#CR229" class="usa-link" aria-describedby="CR229">2025</a>). Leptin participate in many physiological functions, such as glucose homeostasis, neuronal development and plasticity, memory or reproduction (Ramos-Lobo and Donato <a href="#CR207" class="usa-link" aria-describedby="CR207">2017</a>). Binding of leptin with the long isoform of its transmembrane receptor (ObR) activates signalling pathways, such as JAK2/STAT3, MAPK and PI3K/Akt involved in the processes of cell proliferation, differentiation, migration and invasion (Andò et al. <a href="#CR10" class="usa-link" aria-describedby="CR10">2019</a>).</p>
<p id="Par70">Wang et al. (<a href="#CR255" class="usa-link" aria-describedby="CR255">2023a</a>) showed high expression of leptin and leptin receptor (LEPR) in BC tissues, while the expression in benign breast tissues was low. Moreover, leptin expression was significantly higher in patients with lymph node metastases than in patients without such metastases, whereas the expression of LEPR was associated with higher Ki-67 rate. Additionally, the authors found that neither leptin nor LEPR had an impact on survival (Wang et al. <a href="#CR255" class="usa-link" aria-describedby="CR255">2023a</a>). A meta-analysis by Gu et al. (<a href="#CR96" class="usa-link" aria-describedby="CR96">2019</a>) showed significantly higher serum leptin levels in BC patients compared to the healthy controls. Moreover, patients with lymph node metastases had significantly higher serum levels of leptin than cases without those metastases (Gu et al. <a href="#CR96" class="usa-link" aria-describedby="CR96">2019</a>). The results of another meta-analysis by Niu et al. (<a href="#CR187" class="usa-link" aria-describedby="CR187">2013</a>) revealed that serum leptin levels increased (from low to high) among groups in the following order: healthy people, breast benign cases, BC patients and BC patients with lymph node metastasis. This may suggests leptin’s role in BC development and prognosis (Niu et al. <a href="#CR187" class="usa-link" aria-describedby="CR187">2013</a>). Pan et al. (<a href="#CR194" class="usa-link" aria-describedby="CR194">2018</a>) showed in their meta-analysis the association between serum leptin levels and BC risk in postmenopausal women and overweight or obese patients (Pan et al. <a href="#CR194" class="usa-link" aria-describedby="CR194">2018</a>). A study by Koprivčić et al. (<a href="#CR128" class="usa-link" aria-describedby="CR128">2022</a>) demonstrated significantly higher leptin levels in postmenopausal women with either benign or malignant breast tumour compared to premenopausal group. Additionally, the highest leptin levels had postmenopausal obese women in comparison to other postmenopausal women and premenopausal patients (Koprivčić et al. <a href="#CR128" class="usa-link" aria-describedby="CR128">2022</a>). In premenopausal BC cases, several studies noticed an inverse association between leptin levels and BC risk (Harris et al. <a href="#CR103" class="usa-link" aria-describedby="CR103">2011</a>; Petridou et al. <a href="#CR203" class="usa-link" aria-describedby="CR203">2000</a>; Falk et al. <a href="#CR80" class="usa-link" aria-describedby="CR80">2006</a>), but some studies did not found such an association (Mantzoros et al. <a href="#CR158" class="usa-link" aria-describedby="CR158">1999</a>; Sauter et al. <a href="#CR219" class="usa-link" aria-describedby="CR219">2004</a>).</p></section><section id="Sec14"><h4 class="pmc_sec_title">Resistin</h4>
<p id="Par71">Resistin is an inflammatory cytokine that belongs to the resistin-like molecule family (RELMs) and is expressed mostly by the macrophages. Binding of resistin to its receptors, such as the transmembrane Toll-like receptor 4 (TLR4) and adenylyl cyclase-associated protein 1 (CAP1) induces activation of diverse signalling pathways leading, for example, to cancer cell proliferation and invasion, inhibition of apoptosis or resistance to therapy (Sudan et al. <a href="#CR233" class="usa-link" aria-describedby="CR233">2020</a>). Resistin has pro-inflammatory properties and plays a role in the pathogenesis of different malignancies (Sudan et al. <a href="#CR233" class="usa-link" aria-describedby="CR233">2020</a>). A study on BC cell lines demonstrated that resistin induces epithelial to mesenchymal transition (EMT) and stemness of BC cells leading to the promotion of metastatic potential of BC cells. (Avtanski et al. <a href="#CR15" class="usa-link" aria-describedby="CR15">2019</a>). In another study resistin was shown to stimulate invasion and migration of BC cells through phosphorylation of ezrin, radixin and moesin (ERM) proteins (Lee et al. <a href="#CR134" class="usa-link" aria-describedby="CR134">2016</a>). Moreover, resistin was found to induce migration and invasion of BC cells and promote their aggressive phenotype through the activation of STAT3 (Deshmukh et al. <a href="#CR66" class="usa-link" aria-describedby="CR66">2015</a>).</p>
<p id="Par72">BC patients exhibit higher concentrations of resistin compared to healthy controls as was shown in a recent meta analysis (Zoroddu et al. <a href="#CR286" class="usa-link" aria-describedby="CR286">2024</a>). In premenopausal women serum levels of resistin were shown to be inversely related to BC risk as was found by Georgiou et al. (Georgiou et al. <a href="#CR91" class="usa-link" aria-describedby="CR91">2016</a>). In BC tissue high resistin expression was found to be associated with a more malignant clinicopathological status and worse prognosis (Lee et al. <a href="#CR133" class="usa-link" aria-describedby="CR133">2012</a>). Similarly, serum resistin was shown to be significantly associated with cancer stage, grade, tumour size, and lymph node invasion in postmenopausal BC (Dalamaga et al. <a href="#CR58" class="usa-link" aria-describedby="CR58">2013</a>). Coskun et al. (<a href="#CR53" class="usa-link" aria-describedby="CR53">2016</a>) investigated that BC patients with stage II and III had increased levels of resistin after completion of the oncological treatment compared to pre-treatment resistin levels. Moreover, the studies demonstrated that resistin may play a role in promoting chemoresistance in BC cell lines (Liu et al. <a href="#CR149" class="usa-link" aria-describedby="CR149">2017</a>; Deshmukh et al. <a href="#CR67" class="usa-link" aria-describedby="CR67">2017</a>).</p></section></section><section id="Sec15"><h3 class="pmc_sec_title">Autoantibodies</h3>
<p id="Par73">The production of autoantibodies is triggered when tumour-associated antigens are no longer recognised by immune system as self-antigens (Rauf et al. <a href="#CR208" class="usa-link" aria-describedby="CR208">2020</a>). As this response to cancer occurs early in tumorigenesis, the detection of tumour autoantibodies should enable earlier cancer diagnosis even before the appearing of clinical symptoms (Rauf et al. <a href="#CR208" class="usa-link" aria-describedby="CR208">2020</a>; Montero-Calle et al. <a href="#CR178" class="usa-link" aria-describedby="CR178">2024</a>; Yang et al. <a href="#CR266" class="usa-link" aria-describedby="CR266">2022</a>).</p>
<p id="Par74">Among autoantibodies described in BC (reviewed (Rauf et al. <a href="#CR208" class="usa-link" aria-describedby="CR208">2020</a>; Montero-Calle et al. <a href="#CR178" class="usa-link" aria-describedby="CR178">2024</a>; Yang et al. <a href="#CR266" class="usa-link" aria-describedby="CR266">2022</a>)), one of the best diagnostic ability to distinguish between early stage BC patients and benign breast disease or healthy controls possess autoantibodies against TOPO48 (SN 76%, SP 100%, AUC = 0.801) described by He et al. (<a href="#CR104" class="usa-link" aria-describedby="CR104">2020</a>). Moreover, the authors showed improved survival rates for early stage BC patients with positive detection of the anti-TOPO48 autoantibody compared to those with a negative detection of this autoantibody (He et al. <a href="#CR104" class="usa-link" aria-describedby="CR104">2020</a>). Dong et al. (<a href="#CR69" class="usa-link" aria-describedby="CR69">2013</a>), using phage display, identified another autoantibodies, heterogeneous nuclear ribonucleoproteins F (hnRNPF) (SN 84.2%, SP 60.8%, AUC = 0.725) and ferritin heavy chain (FTH1) (SN 81.2%, SP 56.1%, AUC = 0.686). Many other individual autoantibodies have been studied in BC, such as p53, MUC1, Her2/Neu, c-MYC, NY-ESO-1, IMP2/p62, HSP60, survivin, CDKN2A (p16), BRCA1, BRCA2 or cyclin B1 autoantibody. However, most of the studied autoantibodies possess low sensitivities and their individual assessment is not useful for BC screening (Rauf et al. <a href="#CR208" class="usa-link" aria-describedby="CR208">2020</a>; Montero-Calle et al. <a href="#CR178" class="usa-link" aria-describedby="CR178">2024</a>; Yang et al. <a href="#CR266" class="usa-link" aria-describedby="CR266">2022</a>). Thus, many studies focused on combining autoantibodies into a panel. Selected panels of autoantibodies are presented in Table <a href="#Tab2" class="usa-link">2</a>.</p>
<section class="tw xbox font-sm" id="Tab2"><h4 class="obj_head">Table 2.</h4>
<div class="caption p"><p>Comparison of the diagnostic utility of autoantibody panels in BC</p></div>
<div class="tbl-box p" tabindex="0"><table class="content" frame="hsides" rules="groups">
<thead><tr>
<th align="left" colspan="1" rowspan="1"> Autoantibody panels</th>
<th align="left" colspan="1" rowspan="1">SN [%]/SP [%]/AUC</th>
<th align="left" colspan="1" rowspan="1">References</th>
</tr></thead>
<tbody>
<tr>
<td align="left" colspan="1" rowspan="1">GAL3+PAK2+PHB2+RACK1+RUVBL1</td>
<td align="left" colspan="1" rowspan="1">66/84/0.81</td>
<td align="left" colspan="1" rowspan="1">Lacombe et al. (<a href="#CR132" class="usa-link" aria-describedby="CR132">2013</a>)</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">p-53+c-myc+HER2+NY-ESO-1+BRCA1+BRCA2+MUC1</td>
<td align="left" colspan="1" rowspan="1">64/85/-</td>
<td align="left" colspan="1" rowspan="1">Chapman et al. (<a href="#CR36" class="usa-link" aria-describedby="CR36">2007</a>)</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">ANGPTL4+DKK1+GAL1+MUC1+GFRA1+GRN+LRRC15 (+ age, BMI, race, current smoking status)</td>
<td align="left" colspan="1" rowspan="1">72.9/76/0.82</td>
<td align="left" colspan="1" rowspan="1">Evans et al. (<a href="#CR78" class="usa-link" aria-describedby="CR78">2014</a>)</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">BMI-1+HSP70+NY-ESO-1+p53</td>
<td align="left" colspan="1" rowspan="1">63.4/90.2/0.819</td>
<td align="left" colspan="1" rowspan="1">Hong et al. (<a href="#CR107" class="usa-link" aria-describedby="CR107">2021</a>)</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">RAD50+PARD3+SPP1+SAP30BP+NY-BR-62+NY-CO-58</td>
<td align="left" colspan="1" rowspan="1">70/91/0.808</td>
<td align="left" colspan="1" rowspan="1">Kostianets et al. (<a href="#CR129" class="usa-link" aria-describedby="CR129">2017</a>)</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">CyclinB1+Imp1+Koc+survivin+p16+c-myc</td>
<td align="left" colspan="1" rowspan="1">67.3/92.2/-</td>
<td align="left" colspan="1" rowspan="1">Liu et al. (<a href="#CR148" class="usa-link" aria-describedby="CR148">2015</a>)</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">
<p>CTAG1B+CTAG2+TP53+RNF216+PPHLN1+</p>
<p>PIP4K2C+ZBTB16+TAS2R8+WBP2NL+DOK2+</p>
<p>PSRC1+MN1+TRIM21</p>
</td>
<td align="left" colspan="1" rowspan="1">33/98/0.68</td>
<td align="left" colspan="1" rowspan="1">Wang, et al. (<a href="#CR253" class="usa-link" aria-describedby="CR253">2015</a>)</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">
<p>ATP6AP1+PDCD6IP+DBT+CSNK1E+FRS3+RAC3+</p>
<p>HOXD1+SF3A1+CTBP1+C15orf48+MYOZ2+EIF3E+</p>
<p>BAT4+ATF3+BMX+RAB5A+UBAP1+SOX2+GPR157+</p>
<p>BDNF+ZMYM6+SLC33A1+TRIM32+ALG10+TFCP2+</p>
<p>SERPINH1+SELL+ZNF510</p>
</td>
<td align="left" colspan="1" rowspan="1">80.8/61.6/0.756</td>
<td align="left" colspan="1" rowspan="1">Anderson et al. (<a href="#CR8" class="usa-link" aria-describedby="CR8">2011</a>)</td>
</tr>
</tbody>
</table></div>
<div class="p text-right font-secondary"><a href="table/Tab2/" class="usa-link" target="_blank" rel="noopener noreferrer">Open in a new tab</a></div></section></section><section id="Sec16"><h3 class="pmc_sec_title">MicroRNAs (miRNAs)</h3>
<p id="Par75">MicroRNAs (miRNAs) are a major class of non-coding RNAs that regulate gene expression at the mRNA level (Saliminejad et al. <a href="#CR214" class="usa-link" aria-describedby="CR214">2019</a>; Bartel <a href="#CR22" class="usa-link" aria-describedby="CR22">2004</a>). It is known that miRNAs play a key role in the carcinogenic process. In BC, miRNA dysregulation may occur through genetic and epigenetic mechanisms (Mulrane et al. <a href="#CR179" class="usa-link" aria-describedby="CR179">2013</a>).</p>
<p id="Par76">A recent study by Chekhun et al. (<a href="#CR39" class="usa-link" aria-describedby="CR39">2024</a>) presents miRNA that can constitute potential prognostic and diagnostic BC biomarkers. The study showed that an increase in the expressions of miR-182, miR-21, miR-29b and miR-34a and a decrease in the miR-27a expression in the tumour tissue is associated with high malignancy degree of BC in young women. Moreover, it was shown that the expression of miRNAs was associated with BC molecular subtypes. Higher expression of miR-182 and lower levels of miR-21 and miR-27a were revealed in luminal A cases than those in luminal B tumours. Additionally, the authors showed lower miR-145 and higher miR-29b expression in receptor-negative BC compared to the luminal A subtype and lower expression of miR-27a compared to the luminal B cases. Overexpression of miR-182 and miR-21 was demonstrated in both luminal A and B subtypes (Chekhun et al. <a href="#CR39" class="usa-link" aria-describedby="CR39">2024</a>).</p>
<p id="Par77">In another study, blood plasma levels of miR-25, miR-155, miR-27, miR-335, miR-200 and miR-497 were analysed (Harashchenko <a href="#CR101" class="usa-link" aria-describedby="CR101">2024</a>). The study showed significantly increased levels of miR-27 and miR-335 in postmenopause BC patients. In addition, it was found a trend toward an increase in the miR-155 and miR-200 molecules levels. Moreover, the expression levels of miR-27 and miR-497 were significantly lower in premenopausal patients after adjuvant polychemotherapy, whereas in menopausal patients after neoadjuvant polychemotherapy miR-27 level decreased and miR-497 increased (Harashchenko <a href="#CR101" class="usa-link" aria-describedby="CR101">2024</a>). Canatan et al. (<a href="#CR31" class="usa-link" aria-describedby="CR31">2021</a>) found that miR-21, miR-155 and miR-125 molecules may be promising circulating biomarker useful in the diagnosis of early-stage BC. The potential utility of serum circulating mi RNAs: miR-21 and miR-155 as BC biomarkers was also demonstrated in another study (Fan et al. <a href="#CR81" class="usa-link" aria-describedby="CR81">2018</a>). Among other circulating miRNAs studied in BC are, for example, miR-10b, miR-17, miR-30b, miR-103a or miR-200c (Liu et al. <a href="#CR152" class="usa-link" aria-describedby="CR152">2022</a>).</p>
<p id="Par78">Elhelbawy et al. (<a href="#CR77" class="usa-link" aria-describedby="CR77">2021</a>) showed that miR-148a and miR-30c expressions were down regulated in BC patients. Moreover, the expression levels of both miRNAs were negatively correlated with CEA and CA15-3 (Elhelbawy et al. <a href="#CR77" class="usa-link" aria-describedby="CR77">2021</a>). Ahmed et al. (<a href="#CR2" class="usa-link" aria-describedby="CR2">2022</a>) investigated that the diagnostic efficacy for miR-29a and miR-335 were superior to the classic tumour markers CEA and CA15-3 for early detection of BC. In a systematic review by Duque et al. (<a href="#CR73" class="usa-link" aria-describedby="CR73">2022</a>), which analysed biomarkers obtained in liquid biopsy (LB) for early BC diagnosis, it was observed that the analysis of miRNA predominates among LB methods. Table <a href="#Tab3" class="usa-link">3</a> shows selected miRNAs with altered expression in different BC subtypes..</p>
<section class="tw xbox font-sm" id="Tab3"><h4 class="obj_head">Table 3.</h4>
<div class="caption p"><p>miRNAs with altered expression in BC subtypes</p></div>
<div class="tbl-box p" tabindex="0"><table class="content" frame="hsides" rules="groups">
<thead><tr>
<th align="left" colspan="1" rowspan="1">BC subtype</th>
<th align="left" colspan="2" rowspan="1">miRNA<br>Downregulated</th>
<th align="left" colspan="1" rowspan="1">miRNA<br>upregulated</th>
<th align="left" colspan="1" rowspan="1">References</th>
</tr></thead>
<tbody>
<tr>
<td align="left" rowspan="3" colspan="1">Luminal A</td>
<td align="left" colspan="2" rowspan="1">
<p>miR-29a</p>
<p>miR-652</p>
<p>miR-181a</p>
</td>
<td align="left" colspan="1" rowspan="1"></td>
<td align="left" colspan="1" rowspan="1">McDermott et al. (<a href="#CR168" class="usa-link" aria-describedby="CR168">2014</a>)</td>
</tr>
<tr>
<td align="left" colspan="2" rowspan="1">
<p>miR-23b</p>
<p>miR-181c</p>
<p>miR-29a</p>
<p>miR-29b</p>
<p>miR-181d</p>
</td>
<td align="left" colspan="1" rowspan="1">
<p>miR-142</p>
<p>miR-155</p>
<p>miR-16</p>
</td>
<td align="left" colspan="1" rowspan="1">Triantafyllou et al. (<a href="#CR244" class="usa-link" aria-describedby="CR244">2022</a>)</td>
</tr>
<tr>
<td align="left" colspan="2" rowspan="1">
<p>hsa-miR-18b-5p</p>
<p>hsa-miR-487b-5p</p>
<p>hsa-miR-526b-5p</p>
<p>hsa-miR-543</p>
<p>hsa-miR-627-5p</p>
<p>hsa-miR-3614-5p</p>
<p>hsa-miR-6503-5p</p>
</td>
<td align="left" colspan="1" rowspan="1">
<p>hsa-miR-23a-3p</p>
<p>hsa-miR-122-5p</p>
<p>hsa-miR-196a-5p</p>
<p>hsa-miR-301b-5p</p>
<p>hsa-miR-376a-3p</p>
<p>hsa-miR-873-3p</p>
</td>
<td align="left" colspan="1" rowspan="1">Souza et al. (<a href="#CR231" class="usa-link" aria-describedby="CR231">2019</a>)</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">Luminal B</td>
<td align="left" colspan="2" rowspan="1">hsa-miR-128-1-5p</td>
<td align="left" colspan="1" rowspan="1">
<p>hsa-miR-203a-5p</p>
<p>hsa-miR-502-5p</p>
<p>hsa-miR-548ar-5p</p>
</td>
<td align="left" colspan="1" rowspan="1">Souza et al. (<a href="#CR231" class="usa-link" aria-describedby="CR231">2019</a>)</td>
</tr>
<tr>
<td align="left" rowspan="2" colspan="1">HER2+</td>
<td align="left" colspan="2" rowspan="1">miR-101-5p</td>
<td align="left" colspan="1" rowspan="1"></td>
<td align="left" colspan="1" rowspan="1">Normann et al. (<a href="#CR189" class="usa-link" aria-describedby="CR189">2022</a>)</td>
</tr>
<tr>
<td align="left" colspan="2" rowspan="1">
<p>hsa-miR-584-3p</p>
<p>hsa-miR-615-3p</p>
</td>
<td align="left" colspan="1" rowspan="1">hsa-miR-548ar-5p</td>
<td align="left" colspan="1" rowspan="1">Souza et al. (<a href="#CR231" class="usa-link" aria-describedby="CR231">2019</a>)</td>
</tr>
<tr>
<td align="left" rowspan="4" colspan="1">TNBC</td>
<td align="left" colspan="2" rowspan="1"></td>
<td align="left" colspan="1" rowspan="1">miR-21</td>
<td align="left" colspan="1" rowspan="1">Fang et al. (<a href="#CR83" class="usa-link" aria-describedby="CR83">2017b</a>)</td>
</tr>
<tr>
<td align="left" colspan="2" rowspan="1"></td>
<td align="left" colspan="1" rowspan="1">miR-93</td>
<td align="left" colspan="1" rowspan="1">Hu et al. (<a href="#CR110" class="usa-link" aria-describedby="CR110">2015</a>)</td>
</tr>
<tr>
<td align="left" colspan="2" rowspan="1">
<p>miR-145</p>
<p>miR-195</p>
</td>
<td align="left" colspan="1" rowspan="1">
<p>miR-221</p>
<p>miR-21</p>
<p>miR-210</p>
<p>let-7a</p>
</td>
<td align="left" colspan="1" rowspan="1">Thakur et al. (<a href="#CR240" class="usa-link" aria-describedby="CR240">2016</a>)</td>
</tr>
<tr>
<td align="left" colspan="2" rowspan="1"></td>
<td align="left" colspan="1" rowspan="1">miR-17-92 cluster</td>
<td align="left" colspan="1" rowspan="1">Farazi et al. (<a href="#CR85" class="usa-link" aria-describedby="CR85">2011</a>)</td>
</tr>
</tbody>
</table></div>
<div class="p text-right font-secondary"><a href="table/Tab3/" class="usa-link" target="_blank" rel="noopener noreferrer">Open in a new tab</a></div></section><p id="Par79">Circular RNAs (circRNAs) are noncoding, single-stranded RNAs formed in a circular structure (Chen and Shan <a href="#CR40" class="usa-link" aria-describedby="CR40">2021</a>). CircRNA has the ability to serve as miRNA sponge by binding circRNA with miRNA and thus inhibit miRNA activity. This results in the regulation of target genes expression (Chen and Shan <a href="#CR40" class="usa-link" aria-describedby="CR40">2021</a>). The circRNA-miRNA-mRNA regulatory network can participate in the processes associated with promotion and inhibition of BC, such as proliferation, migration, invasion and chemotherapy resistance (Zhang et al. <a href="#CR280" class="usa-link" aria-describedby="CR280">2021b</a>). Thus, circRNA-miRNA-mRNA axis is considered to be a promising biomarker in the diagnosis and prognosis of BC (Zhang et al. <a href="#CR280" class="usa-link" aria-describedby="CR280">2021b</a>). Table <a href="#Tab4" class="usa-link">4</a> presents selected circRNAs, miRNAs and target mRNAs that play a role in BC promotion and inhibition.</p>
<section class="tw xbox font-sm" id="Tab4"><h4 class="obj_head">Table 4.</h4>
<div class="caption p"><p>CircRNA, miRNAs and targeted mRNAs in BC</p></div>
<div class="tbl-box p" tabindex="0"><table class="content" frame="hsides" rules="groups">
<thead><tr>
<th align="left" colspan="1" rowspan="1">CircRNA</th>
<th align="left" colspan="1" rowspan="1">miRNA</th>
<th align="left" colspan="1" rowspan="1">mRNA</th>
<th align="left" colspan="1" rowspan="1">References</th>
</tr></thead>
<tbody>
<tr><td align="left" colspan="4" rowspan="1"><em>Promoting cancer development</em></td></tr>
<tr>
<td align="left" colspan="1" rowspan="1">hsa_circ_0007255</td>
<td align="left" colspan="1" rowspan="1">miR-375</td>
<td align="left" colspan="1" rowspan="1">KIF4A</td>
<td align="left" colspan="1" rowspan="1">Tang et al. (<a href="#CR236" class="usa-link" aria-describedby="CR236">2019</a>)</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">hsa_circ_0000515</td>
<td align="left" colspan="1" rowspan="1">miR-296-5p</td>
<td align="left" colspan="1" rowspan="1">CXCL10</td>
<td align="left" colspan="1" rowspan="1">Cai et al. (<a href="#CR30" class="usa-link" aria-describedby="CR30">2021</a>)</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">hsa_circ_0072088</td>
<td align="left" colspan="1" rowspan="1">miR-578</td>
<td align="left" colspan="1" rowspan="1">HIF1A</td>
<td align="left" colspan="1" rowspan="1">Chen et al. (<a href="#CR41" class="usa-link" aria-describedby="CR41">2020a</a>)</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">hsa_circ_0061825</td>
<td align="left" colspan="1" rowspan="1">miR-326</td>
<td align="left" colspan="1" rowspan="1">TFF1</td>
<td align="left" colspan="1" rowspan="1">Pan et al. (<a href="#CR195" class="usa-link" aria-describedby="CR195">2020</a>)</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">hsa_circ_0007534</td>
<td align="left" colspan="1" rowspan="1">miR-593</td>
<td align="left" colspan="1" rowspan="1">MUC19</td>
<td align="left" colspan="1" rowspan="1">Song and Xiao (<a href="#CR230" class="usa-link" aria-describedby="CR230">2018</a>)</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">circ_0000511</td>
<td align="left" colspan="1" rowspan="1">miR-326</td>
<td align="left" colspan="1" rowspan="1">TAZ</td>
<td align="left" colspan="1" rowspan="1">Wu et al. (<a href="#CR261" class="usa-link" aria-describedby="CR261">2021</a>)</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">hsa_circ_002178</td>
<td align="left" colspan="1" rowspan="1">miR-328-3p</td>
<td align="left" colspan="1" rowspan="1">COL1A1</td>
<td align="left" colspan="1" rowspan="1">Liu et al. (<a href="#CR151" class="usa-link" aria-describedby="CR151">2020</a>)</td>
</tr>
<tr><td align="left" colspan="4" rowspan="1"><em>Inhibiting cancer development</em></td></tr>
<tr>
<td align="left" colspan="1" rowspan="1">circRNA_000554</td>
<td align="left" colspan="1" rowspan="1">miR-182</td>
<td align="left" colspan="1" rowspan="1">ZFP36</td>
<td align="left" colspan="1" rowspan="1">Mao et al. (<a href="#CR159" class="usa-link" aria-describedby="CR159">2020</a>)</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">hsa_circ_0002018</td>
<td align="left" colspan="1" rowspan="1">miR-658</td>
<td align="left" colspan="1" rowspan="1">UPK1A</td>
<td align="left" colspan="1" rowspan="1">Xu et al. (<a href="#CR264" class="usa-link" aria-describedby="CR264">2020</a>)</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">hsa_circ_0000320</td>
<td align="left" colspan="1" rowspan="1">miR-421</td>
<td align="left" colspan="1" rowspan="1">RASA1</td>
<td align="left" colspan="1" rowspan="1">Xiao et al. (<a href="#CR263" class="usa-link" aria-describedby="CR263">2019</a>)</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">hsa_circ_0001785</td>
<td align="left" colspan="1" rowspan="1">miR-942</td>
<td align="left" colspan="1" rowspan="1">SOCS3</td>
<td align="left" colspan="1" rowspan="1">Li et al. (<a href="#CR142" class="usa-link" aria-describedby="CR142">2020a</a>)</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">circ_0001368</td>
<td align="left" colspan="1" rowspan="1">miR-1204</td>
<td align="left" colspan="1" rowspan="1">ALX4</td>
<td align="left" colspan="1" rowspan="1">Yi et al. (<a href="#CR270" class="usa-link" aria-describedby="CR270">2022</a>)</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">hsa_circ_0001098</td>
<td align="left" colspan="1" rowspan="1">miR-3942-3p</td>
<td align="left" colspan="1" rowspan="1">BARD1</td>
<td align="left" colspan="1" rowspan="1">Zhao et al. (<a href="#CR284" class="usa-link" aria-describedby="CR284">2018</a>)</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">hsa_circ_0001451</td>
<td align="left" colspan="1" rowspan="1">miR-197-3p</td>
<td align="left" colspan="1" rowspan="1">FBXW7</td>
<td align="left" colspan="1" rowspan="1">Ye et al. (<a href="#CR269" class="usa-link" aria-describedby="CR269">2019</a>)</td>
</tr>
</tbody>
</table></div>
<div class="p text-right font-secondary"><a href="table/Tab4/" class="usa-link" target="_blank" rel="noopener noreferrer">Open in a new tab</a></div></section><p id="Par80">Despite the great interest and progress in the detection of circRNA, its analysis remains a challenge due to its characteristics, such as circular structure or low abundance. Northern blotting, that is considered the gold standard method for validating circRNA, is limited because of its low sensitivity, involvement of multiple and time-consuming steps or low throughput (Mi et al. <a href="#CR172" class="usa-link" aria-describedby="CR172">2022</a>; Feng et al. <a href="#CR86" class="usa-link" aria-describedby="CR86">2023</a>). The establishment of standard detection methods is a need to use circRNAs for diagnosis and treatment (Ali et al. <a href="#CR3" class="usa-link" aria-describedby="CR3">2025</a>).</p></section><section id="Sec17"><h3 class="pmc_sec_title">ctDNA</h3>
<p id="Par81">Circulating tumour DNA (ctDNA) occurs mostly as160–200 base pairs in length fragments and constitutes a distinctive subset of cell-free DNA (cfDNA) (Wang et al. <a href="#CR256" class="usa-link" aria-describedby="CR256">2023b</a>). It is thought that ctDNA originates from tumour cells through apoptosis, necrosis and active secretion from cellular structures, but it could also arise from circulating tumour cells (CTCs) (Dao et al. <a href="#CR60" class="usa-link" aria-describedby="CR60">2023</a>; Sant et al. <a href="#CR217" class="usa-link" aria-describedby="CR217">2022</a>). Thus, ctDNA can reflect BC heterogeneity and its analysis may be useful in early diagnosis, the detection of minimal residual disease (MRD) and early relapse as well as monitor tumour evolution and selection of treatment (Sant et al. <a href="#CR217" class="usa-link" aria-describedby="CR217">2022</a>).</p>
<p id="Par82">Promising results were obtained by Zhang et al. (<a href="#CR277" class="usa-link" aria-describedby="CR277">2019</a>), who showed in early-stage BC patients who need chemotherapy that ctDNA may serve as a sensitive and specific biomarker for BC diagnosis. Additionally, positive ctDNA in patients after surgery may suggest possible recurrence and metastasis (Zhang et al. <a href="#CR277" class="usa-link" aria-describedby="CR277">2019</a>). Similarly, Rodriguez et al. (Rodriguez et al. <a href="#CR209" class="usa-link" aria-describedby="CR209">2019</a>), comparing PIK3CA and TP53 mutations between breast tumour tissues and ctDNA in blood samples collected before biopsy, demonstrated that analysis of ctDNA may be useful in early BC diagnosis. Moreover, the authors showed the association between the presence of ctDNA mutations and more aggressive clinicopathological features (Rodriguez et al. <a href="#CR209" class="usa-link" aria-describedby="CR209">2019</a>). The usefulness of ctDNA in detection of recurrence in BC was also performed. Coombes et al. (Coombes et al. <a href="#CR52" class="usa-link" aria-describedby="CR52">2019</a>) revealed the ability of ctDNA assay to predict BC recurrence earlier than CT imaging, CA 15–3 measurements and liver function tests (Coombes et al. <a href="#CR52" class="usa-link" aria-describedby="CR52">2019</a>). Moreover, the association of elevated plasma ctDNA with a poor outcomes in early and metastatic BC patients and high risk of relapse was shown in a meta-analysis (Cullinane et al. <a href="#CR55" class="usa-link" aria-describedby="CR55">2020</a>). Papakonstantinou et al. (<a href="#CR197" class="usa-link" aria-describedby="CR197">2022</a>) in a systematic review and meta-analysis found that the presence of ctDNA at baseline and after completion of neoadjuvant therapy was associated with a worse survival and a higher risk of relapse. Moreover, ctDNA analysis is a promising and minimally invasive method, in comparison with tissue-based testing, for identifying estrogen receptor alpha gene (ESR1) mutations, which drive endocrine therapy resistance in patients with HR+/HER2- metastatic BC (Venetis et al. <a href="#CR250" class="usa-link" aria-describedby="CR250">2023</a>). Li et al. (<a href="#CR143" class="usa-link" aria-describedby="CR143">2020b</a>) showed that using ctDNA to dynamic monitoring of ESR1 mutations could be a biomarker in prediction of endocrine resistance in ER+ MBC patients.</p>
<p id="Par83">Some studies analysed ctDNA in other specimens, such as urine, cerebrospinal fluid (CSF) or breast milk (BM). Guan et al. (<a href="#CR97" class="usa-link" aria-describedby="CR97">2020</a>) observed higher urinary DNA in early BC patients compared to healthy individuals. Moreover, urinary DNA showed clinical relevance in BC (Guan et al. <a href="#CR97" class="usa-link" aria-describedby="CR97">2020</a>). Liu and Liu (<a href="#CR146" class="usa-link" aria-describedby="CR146">2018</a>) demonstrated that urinary DNA may be useful in predicting relapse in BC patients. Siravegna et al. (<a href="#CR228" class="usa-link" aria-describedby="CR228">2017</a>) found that in HER2-positive MBC patients with brain metastases paired plasma and CSF ctDNA analysis may be useful in the management of these women. Saura et al. (<a href="#CR218" class="usa-link" aria-describedby="CR218">2023</a>) demonstrated the presence of ctDNA in BM collected from patients with early BC occurring during pregnancy and postpartum. Additionally, the authors showed that in early BC a superior source of ctDNA is BM compared to plasma (Saura et al. <a href="#CR218" class="usa-link" aria-describedby="CR218">2023</a>).</p>
<p id="Par84">The analysis of ctDNA in clinical use has several limitations. Degradation of DNA fragments during sampling and storage may result in its low levels for ctDNA analysis in the circulation. Thus, the detection of ctDNA requires high sensitive methods. Moreover, there is a lack of established standardization for sample collection and analysis of ctDNA (Parums <a href="#CR198" class="usa-link" aria-describedby="CR198">2025</a>). The analytical methods used for ctDNA analysis include, for example, polymerase chain reaction (PCR) or next-generation sequencing (NGS) methods (Parums <a href="#CR198" class="usa-link" aria-describedby="CR198">2025</a>). The emerge ultrasensitive method for ctDNA analysis in BC patients is whole genome sequencing (WGS) (Parums <a href="#CR198" class="usa-link" aria-describedby="CR198">2025</a>; Garcia-Murillas et al. <a href="#CR89" class="usa-link" aria-describedby="CR89">2025</a>; Vavoulis et al. <a href="#CR249" class="usa-link" aria-describedby="CR249">2025</a>).</p></section><section id="Sec18"><h3 class="pmc_sec_title">Circulating tumour cells (CTCs)</h3>
<p id="Par85">CTCs are cancer cells disseminated from the primary tumour that enter the bloodstream and appear as single CTC or CTC clusters possessing enhanced metastatic potential (Cani and Hayes <a href="#CR32" class="usa-link" aria-describedby="CR32">2024</a>; Chauhan et al. <a href="#CR37" class="usa-link" aria-describedby="CR37">2021</a>; Zhang et al. <a href="#CR283" class="usa-link" aria-describedby="CR283">2023</a>; Zhang et al. <a href="#CR281" class="usa-link" aria-describedby="CR281">2021c</a>; Lin et al. <a href="#CR145" class="usa-link" aria-describedby="CR145">2021</a>). Their isolation is challenging, as CTCs are heterogeneous and very rare in the blood (Cani and Hayes <a href="#CR32" class="usa-link" aria-describedby="CR32">2024</a>; Chauhan et al. <a href="#CR37" class="usa-link" aria-describedby="CR37">2021</a>; Zhang et al. <a href="#CR283" class="usa-link" aria-describedby="CR283">2023</a>; Lin et al. <a href="#CR145" class="usa-link" aria-describedby="CR145">2021</a>). As the proportion of these cells is extremely low in comparison with other cells present in the blood, the enrichment of CTCs is required for their isolation (Chauhan et al. <a href="#CR37" class="usa-link" aria-describedby="CR37">2021</a>). Various methods developed for the isolation of CTCs are based on their physical (e.g. size, density) and biological (marker depended) properties (Chauhan et al. <a href="#CR37" class="usa-link" aria-describedby="CR37">2021</a>; Zhang et al. <a href="#CR283" class="usa-link" aria-describedby="CR283">2023</a>; Lin et al. <a href="#CR145" class="usa-link" aria-describedby="CR145">2021</a>). The techniques that are used predominantly are based on the isolation of CTCs expressing epithelial cell adhesion molecule (EpCAM) (Lin et al. <a href="#CR145" class="usa-link" aria-describedby="CR145">2021</a>; Perelmuter et al. <a href="#CR200" class="usa-link" aria-describedby="CR200">2024</a>). However, the use of combination techniques may improve CTCs isolation (Rzhevskiy et al. <a href="#CR212" class="usa-link" aria-describedby="CR212">2025</a>).</p>
<p id="Par86">In early BC, CTCs are detected in approximately 20–30% of patients and about 60% of advanced BC cases (Perelmuter et al. <a href="#CR200" class="usa-link" aria-describedby="CR200">2024</a>; Fabisiewicz et al. <a href="#CR79" class="usa-link" aria-describedby="CR79">2020</a>). Numerous studies investigated the potential prognostic significance of CTCs in both early as well as metastatic BC. In early BC, the presence of CTCs in the blood is rare, thus their use as a biomarker is limited in that population (Fabisiewicz et al. <a href="#CR79" class="usa-link" aria-describedby="CR79">2020</a>; Thomas-Bonafos et al. <a href="#CR241" class="usa-link" aria-describedby="CR241">2024</a>). Nevertheless, a meta-analysis by Bai et al. (<a href="#CR17" class="usa-link" aria-describedby="CR17">2023</a>) showed that CTCs have diagnostic value in BC. Moreover, the prognostic potential of CTCs were investigated in neoadjuvant and adjuvant studies, which found association between the presence of CTCs and worse prognosis in early BC (Cani and Hayes <a href="#CR32" class="usa-link" aria-describedby="CR32">2024</a>; Matikas et al. <a href="#CR163" class="usa-link" aria-describedby="CR163">2022</a>; Bidard et al. <a href="#CR24" class="usa-link" aria-describedby="CR24">2018</a>).</p>
<p id="Par87">In MBC, it was found that using a CTC threshold of 5 cells per 7.5 ml allows stratification of patients into two subgroups: Stage IV indolent group (&lt; 5 CTCs/7.5 ml) having a favourable prognosis and Stage IV aggressive group (≥ 5 CTCs/7.5 ml) having a poor prognosis (Thomas-Bonafos et al. <a href="#CR241" class="usa-link" aria-describedby="CR241">2024</a>; Cristofanilli et al. <a href="#CR54" class="usa-link" aria-describedby="CR54">2019</a>). In longitudinal analysis of CTCs in MBC patients by Szostakowska-Rodzos et al. (<a href="#CR235" class="usa-link" aria-describedby="CR235">2024</a>) confirmed the prognostic value of high CTC count (≥ 5 CTCs) and presented that the dynamics of CTCs during treatment may predict cancer progression. The clinical utility of CTCs in MBC has been investigated in phase II and phase III randomized trials (Thomas-Bonafos et al. <a href="#CR241" class="usa-link" aria-describedby="CR241">2024</a>).</p></section><section id="Sec19"><h3 class="pmc_sec_title">Extracellular vesicles (EVs)</h3>
<p id="Par88">EVs are nano-sized membrane-enclosed vesicles that contain various biomolecules, including proteins, lipids and nucleic acids and play a significant role in intracellular communications (Lee et al. <a href="#CR137" class="usa-link" aria-describedby="CR137">2023a</a>). EVs are differentiated as: exosomes (small EVs; 50–150 nm in diameter), microvesicles (large EVs; 100–1000 nm) and apoptotic bodies (500–5000 nm) (Lee et al. <a href="#CR136" class="usa-link" aria-describedby="CR136">2023b</a>). Exosomes are secreted by all cell types and carry biomolecules (proteins, lipids, messenger RNAs, microRNAs, long noncoding RNAs, DNAs) from their cell of origin, having potential to be a great source of tumour biomarkers (Maia et al. <a href="#CR157" class="usa-link" aria-describedby="CR157">2018</a>; Urabe et al. <a href="#CR247" class="usa-link" aria-describedby="CR247">2020</a>). The presence of EVs was demonstrated in biofluids, such as blood, urine, saliva, breast milk, cerebrospinal fluid and ascites (Lee et al. <a href="#CR136" class="usa-link" aria-describedby="CR136">2023</a>b).</p>
<p id="Par89">EVs were found to have the potential to differentiate molecular subtypes of BC by analysing subtype-specific EV protein signatures or molecular features of cancer exosomes (Lee et al. <a href="#CR137" class="usa-link" aria-describedby="CR137">2023</a>a; Rontogianni et al. <a href="#CR210" class="usa-link" aria-describedby="CR210">2019</a>; Cao et al. <a href="#CR34" class="usa-link" aria-describedby="CR34">2022</a>). Xu et al. (<a href="#CR265" class="usa-link" aria-describedby="CR265">2024</a>) investigated that the protein analysis of serum EVs in BC patients may serve as a minimally invasive tool for early detection of BC and the assessment of lymph node metastasis. Moreover, it was found that TALDO1 may serve as an EV serum biomarker for MBC (Xu et al. <a href="#CR265" class="usa-link" aria-describedby="CR265">2024</a>). Additionally, Dorado et al. (Dorado et al. <a href="#CR70" class="usa-link" aria-describedby="CR70">2024</a>) showed that the lipid composition of blood plasma EVs have the potential for BC detection. EVs were also found to have the roles in mediating BC therapy resistance (Samuels et al. <a href="#CR216" class="usa-link" aria-describedby="CR216">2022</a>).</p></section></section><section id="Sec2000"><h2 class="pmc_sec_title">Combination of biomarkers in BC</h2>
<p id="Par91">Markers with higher sensitivity and specificity, useful in BC diagnosis and management are still being sought. Several studies combined commonly used biomarkers with new, potential biomarkers to achieve better clinical utility.</p>
<p id="Par92">Several studies investigated the usefulness of different combinations of classical tumour markers, such as CA15-3 and CEA, with selected parameters in early diagnosis of BC. Chen et al. (<a href="#CR42" class="usa-link" aria-describedby="CR42">2020b</a>) compared the sensitivities and specificities of single tests: CEA, CA 15–3, CA125 (SN 4.89%, SP 95.02%) and tumour abnormal protein (TAP) (SN 4.89%, SP 99.62%), and in combinations for the detection of BC. The Authors found that the combination of those four tests, TAP+CEA+CA125+CA15-3, achieved the highest sensitivity (21.84%) for the diagnosis of BC. However, the high specificities had TAP+CEA+CA15-3 (SP 97.70%) combination and it might be helpful for confirming BC. Among the combinations without TAP, the highest sensitivity had CEA+CA125+CA15-3 combination (SN 16.95%) and the highest specificity had CEA+CA15-3 (SP 98.08%) (Chen et al. <a href="#CR42" class="usa-link" aria-describedby="CR42">2020b</a>). Luo et al. (<a href="#CR156" class="usa-link" aria-describedby="CR156">2022</a>) assessed the diagnostic value of different combinations of common tumour markers: alpha fetoprotein (AFP), carbohydrate antigen 19–9 (CA19-9), CEA, CA15-3 and CA125. The Authors found that among combinations of three parallel detections of BC tumour markers, AFP+CEA+CA15-3 had the highest sensitivity (SN 83.46%) and CEA+CA125+CA19-9 had the highest AUC (AUC = 0.922). Moreover, AFP+CEA+CA15-3 and AFP+CA15-3+CA125 had the highest accuracy (80.25%) (Luo et al. <a href="#CR156" class="usa-link" aria-describedby="CR156">2022</a>). Wang et al. (Wang et al. <a href="#CR252" class="usa-link" aria-describedby="CR252">2014</a>) analysed a panel of four potential serum/nipple discharge biomarkers: CEA, CA15-3, CA125 and tumour-specific growth factor (TSGF) in the diagnosis and prognosis of BC. The study showed that the combination of those four serum/nipple-discharge markers had significantly higher AUC value and diagnostic sensitivity in comparison to the four markers in serum, in nipple discharge or individual markers (Wang et al. <a href="#CR252" class="usa-link" aria-describedby="CR252">2014</a>).</p>
<p id="Par93">Zou et al. (<a href="#CR287" class="usa-link" aria-describedby="CR287">2022</a>) analysed routine tests indicators: neutrophil-to-lymphocyte ratio (NLR), red cell distribution width (RDW) and serum tumour markers (CEA, CA15-3, CA125, CA19-9) in BC and breast fibroadenoma (FA). NLR, CEA and CA19-9 values showed statistically significant differences between BC and FA patients and the study revealed significantly higher diagnostic efficiency of combined indicators than of the single parameters: CEA (SN 81.8%, SP 69.4%, AUC = 0.799), NLR (SN 74.2%, SP 69.4%, AUC = 0.747), CA19-9 (SN 70.0%, SP 61.1%, AUC = 0.711). The combination of three parameters: NLR+CEA+CA19-9 (SN 76.5%, SP 88.9%, AUC = 0.886; 95% confidence interval: 0.838–0.933, <em>P</em> = 0.000) showed the best diagnostic efficacy and the authors concluded that this combination may be used to screen and diagnose BC (Zou et al. <a href="#CR287" class="usa-link" aria-describedby="CR287">2022</a>). Zuo et al. (<a href="#CR289" class="usa-link" aria-describedby="CR289">2016</a>) screened complex autoantigens in the serum of BC patients using serological analysis of recombinant cDNA expression libraries (SEREX) and phage display technology. The authors identified a panel of autoantigens, including lectin, galactoside-binding, soluble 3 (LGALS3; SN 63%, AUC = 0.687), prohibitin 2 (PHB2; SN 43%, AUC = 0.583), mucin 1 (MUC1; SN 46%, AUC = 0.563) and glycerol kinase 2 (GK2; SN 46%, AUC = 0.608) that in combination with CA15-3 improved sensitivity, specificity and overall survival in the diagnosis of BC (stage T<sub>1</sub>N<sub>0</sub>M<sub>0</sub>). SP of each individual antigen were not less than 60% and AUCs were less than 0.8 (Zuo et al. <a href="#CR289" class="usa-link" aria-describedby="CR289">2016</a>). Dong et al. (<a href="#CR69" class="usa-link" aria-describedby="CR69">2013</a>) identified two novel autoantibody biomarkers, hnRNPF and FTH1. The authors showed that the analysis of these two autoantibody biomarkers: hnRNPF (SN 84.2%, SP 60.8%, AUC = 0.725) and FTH1 (SN 81.2%, SP 56.1%, AUC = 0.686) in combination with CA15-3 improved sensitivity and specificity (Dong et al. <a href="#CR69" class="usa-link" aria-describedby="CR69">2013</a>). Liu et al. (<a href="#CR150" class="usa-link" aria-describedby="CR150">2018</a>) demonstrated that the panel containing programmed cell death protein 1 (PD-1), interleukin-10 (IL-10), interleukin-2 receptor alpha (IL-2Rα) and CA15-3 can discriminate BC from benign breast disease. Moreover, this panel showed the highest AUC (0.811) for early-stage BC discrimination, while a panel of PD-1, IL-10 and CA15-3 had the highest AUC (0.896) for advanced BC discrimination (Liu et al. <a href="#CR150" class="usa-link" aria-describedby="CR150">2018</a>). Zajkowska et al. (<a href="#CR273" class="usa-link" aria-describedby="CR273">2019</a>) analysed the members of vascular endothelial growth factor receptor (VEGF) family: VEGF-A, VEGF-C, VEGF-D and their receptor VEGFR-2 individually and in combination with CA 15–3. The study showed that among all tested parameters in the total BC group VEGF-C had the highest AUC (0.7672) as well as in stage I (AUC = 0.7684) and stage II (AUC = 0.7772) of BC. Moreover, the combination of CA 15–3 and VEGF-C was the most favourable in total BC group (Zajkowska et al. <a href="#CR273" class="usa-link" aria-describedby="CR273">2019</a>). The diagnostic utility of single CEA and CA15-3 assays and their selected combinations with other parameters in diagnosis of BC are shown in Table <a href="#Tab5" class="usa-link">5</a>.</p>
<section class="tw xbox font-sm" id="Tab5"><h3 class="obj_head">Table 5.</h3>
<div class="caption p"><p>Comparison of the diagnostic utility of single CA15-3 and CEA assays and selected combinations of these markers with other parameters in the diagnosis of BC patients</p></div>
<div class="tbl-box p" tabindex="0"><table class="content" frame="hsides" rules="groups">
<thead><tr>
<th align="left" colspan="1" rowspan="1">Parameter</th>
<th align="left" colspan="1" rowspan="1">SN [%]</th>
<th align="left" colspan="1" rowspan="1">SP [%]</th>
<th align="left" colspan="1" rowspan="1">AUC</th>
<th align="left" colspan="1" rowspan="1">References</th>
</tr></thead>
<tbody>
<tr>
<td align="left" colspan="1" rowspan="1">CEA</td>
<td align="left" colspan="1" rowspan="1">7.18</td>
<td align="left" colspan="1" rowspan="1">98.85</td>
<td align="left" colspan="1" rowspan="1">–</td>
<td align="left" rowspan="7" colspan="1">Chen et al. (<a href="#CR42" class="usa-link" aria-describedby="CR42">2020b</a>)</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">CA15-3</td>
<td align="left" colspan="1" rowspan="1">7.47</td>
<td align="left" colspan="1" rowspan="1">99.23</td>
<td align="left" colspan="1" rowspan="1">–</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">CA125</td>
<td align="left" colspan="1" rowspan="1">4.89</td>
<td align="left" colspan="1" rowspan="1">95.02</td>
<td align="left" colspan="1" rowspan="1">–</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">CEA+CA15-3</td>
<td align="left" colspan="1" rowspan="1">12.93</td>
<td align="left" colspan="1" rowspan="1">98.08</td>
<td align="left" colspan="1" rowspan="1">–</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">CEA+CA125+CA15-3</td>
<td align="left" colspan="1" rowspan="1">16.95</td>
<td align="left" colspan="1" rowspan="1">93.10</td>
<td align="left" colspan="1" rowspan="1">–</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">TAP+CEA+CA15-3</td>
<td align="left" colspan="1" rowspan="1">17.82</td>
<td align="left" colspan="1" rowspan="1">97.70</td>
<td align="left" colspan="1" rowspan="1">–</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">TAP+CEA+CA125+CA15-3</td>
<td align="left" colspan="1" rowspan="1">21.84</td>
<td align="left" colspan="1" rowspan="1">92.72</td>
<td align="left" colspan="1" rowspan="1">–</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">CEA</td>
<td align="left" colspan="1" rowspan="1">23.94</td>
<td align="left" colspan="1" rowspan="1">67.44</td>
<td align="left" colspan="1" rowspan="1">0.679</td>
<td align="left" rowspan="6" colspan="1">Luo et al. (<a href="#CR156" class="usa-link" aria-describedby="CR156">2022</a>)</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">CA15-3</td>
<td align="left" colspan="1" rowspan="1">15.00</td>
<td align="left" colspan="1" rowspan="1">96.43</td>
<td align="left" colspan="1" rowspan="1">0.727</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">CA125</td>
<td align="left" colspan="1" rowspan="1">16.54</td>
<td align="left" colspan="1" rowspan="1">93.57</td>
<td align="left" colspan="1" rowspan="1">0.695</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">AFP+CEA+CA15-3</td>
<td align="left" colspan="1" rowspan="1">83.46</td>
<td align="left" colspan="1" rowspan="1">74.29</td>
<td align="left" colspan="1" rowspan="1">0.913</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">CEA+CA125+CA19-9</td>
<td align="left" colspan="1" rowspan="1">83.08</td>
<td align="left" colspan="1" rowspan="1">73.57</td>
<td align="left" colspan="1" rowspan="1">0.922</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">AFP+CA15-3+CA125 (accuracy 80.25%)</td>
<td align="left" colspan="1" rowspan="1">82.31</td>
<td align="left" colspan="1" rowspan="1">77.14</td>
<td align="left" colspan="1" rowspan="1">0.905</td>
</tr>
<tr>
<td align="left" colspan="4" rowspan="1"><em>Nipple discharge (ND)</em></td>
<td align="left" rowspan="9" colspan="1">Wang et al. (<a href="#CR252" class="usa-link" aria-describedby="CR252">2014</a>)</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">CEA</td>
<td align="left" colspan="1" rowspan="1">69.8</td>
<td align="left" colspan="1" rowspan="1">86.0</td>
<td align="left" colspan="1" rowspan="1">0.779</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">CA15-3</td>
<td align="left" colspan="1" rowspan="1">74.4</td>
<td align="left" colspan="1" rowspan="1">82.4</td>
<td align="left" colspan="1" rowspan="1">0.784</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">CA125</td>
<td align="left" colspan="1" rowspan="1">72.1</td>
<td align="left" colspan="1" rowspan="1">83.8</td>
<td align="left" colspan="1" rowspan="1">0.780</td>
</tr>
<tr><td align="left" colspan="4" rowspan="1"><em>Serum</em></td></tr>
<tr>
<td align="left" colspan="1" rowspan="1">CEA</td>
<td align="left" colspan="1" rowspan="1">53.5</td>
<td align="left" colspan="1" rowspan="1">89.0</td>
<td align="left" colspan="1" rowspan="1">0.712</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">CA15-3</td>
<td align="left" colspan="1" rowspan="1">60.5</td>
<td align="left" colspan="1" rowspan="1">91.9</td>
<td align="left" colspan="1" rowspan="1">0.762</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">CA125</td>
<td align="left" colspan="1" rowspan="1">55.8</td>
<td align="left" colspan="1" rowspan="1">90.4</td>
<td align="left" colspan="1" rowspan="1">0.732</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">(ND+serum) CEA+CA15-3+CA125+TSGF</td>
<td align="left" colspan="1" rowspan="1">97.7</td>
<td align="left" colspan="1" rowspan="1">75.0</td>
<td align="left" colspan="1" rowspan="1">0.863</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">CEA</td>
<td align="left" colspan="1" rowspan="1">81.8</td>
<td align="left" colspan="1" rowspan="1">69.4</td>
<td align="left" colspan="1" rowspan="1">0.799</td>
<td align="left" rowspan="2" colspan="1">Zou et al. (<a href="#CR287" class="usa-link" aria-describedby="CR287">2022</a>)</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">NLR+CEA+CA19-9</td>
<td align="left" colspan="1" rowspan="1">76.5</td>
<td align="left" colspan="1" rowspan="1">88.9</td>
<td align="left" colspan="1" rowspan="1">0.886</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">CA15-3</td>
<td align="left" colspan="1" rowspan="1">58</td>
<td align="left" colspan="1" rowspan="1">-</td>
<td align="left" colspan="1" rowspan="1">0.634</td>
<td align="left" rowspan="2" colspan="1">Zuo et al. (<a href="#CR289" class="usa-link" aria-describedby="CR289">2016</a>)</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">CA15-3+LGALS3+PHB2+MUC1+GK2</td>
<td align="left" colspan="1" rowspan="1">87</td>
<td align="left" colspan="1" rowspan="1">76</td>
<td align="left" colspan="1" rowspan="1">0.872</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">CA15-3</td>
<td align="left" colspan="1" rowspan="1">69.1</td>
<td align="left" colspan="1" rowspan="1">89.4</td>
<td align="left" colspan="1" rowspan="1">0.792</td>
<td align="left" rowspan="4" colspan="1">Dong et al. (<a href="#CR69" class="usa-link" aria-describedby="CR69">2013</a>)</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">FTH1+CA15-3</td>
<td align="left" colspan="1" rowspan="1">85.1</td>
<td align="left" colspan="1" rowspan="1">92.7</td>
<td align="left" colspan="1" rowspan="1">0.834</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">hnRNPF+CA15-3</td>
<td align="left" colspan="1" rowspan="1">87.4</td>
<td align="left" colspan="1" rowspan="1">91.0</td>
<td align="left" colspan="1" rowspan="1">0.862</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">FTH1+hnRNPF+CA15-3</td>
<td align="left" colspan="1" rowspan="1">89.3</td>
<td align="left" colspan="1" rowspan="1">93.8</td>
<td align="left" colspan="1" rowspan="1">0.931</td>
</tr>
<tr>
<td align="left" colspan="4" rowspan="1"><em>early-stage BC</em></td>
<td align="left" rowspan="9" colspan="1">Liu et al. (<a href="#CR150" class="usa-link" aria-describedby="CR150">2018</a>)</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">CA15-3</td>
<td align="left" colspan="1" rowspan="1">52.3</td>
<td align="left" colspan="1" rowspan="1">73.3</td>
<td align="left" colspan="1" rowspan="1">0.607</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">PD-1+IL-10+IL-2Rα+CA15-3</td>
<td align="left" colspan="1" rowspan="1">93.3</td>
<td align="left" colspan="1" rowspan="1">61.4</td>
<td align="left" colspan="1" rowspan="1">0.811</td>
</tr>
<tr><td align="left" colspan="4" rowspan="1"><em>advanced BC</em></td></tr>
<tr>
<td align="left" colspan="1" rowspan="1">CA15-3</td>
<td align="left" colspan="1" rowspan="1">65.2</td>
<td align="left" colspan="1" rowspan="1">100</td>
<td align="left" colspan="1" rowspan="1">0.791</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">PD-1+IL-10+CA15-3</td>
<td align="left" colspan="1" rowspan="1">93.3</td>
<td align="left" colspan="1" rowspan="1">78.3</td>
<td align="left" colspan="1" rowspan="1">0.896</td>
</tr>
<tr><td align="left" colspan="4" rowspan="1"><em>BC (total)</em></td></tr>
<tr>
<td align="left" colspan="1" rowspan="1">CA15-3</td>
<td align="left" colspan="1" rowspan="1">64.4</td>
<td align="left" colspan="1" rowspan="1">73.3</td>
<td align="left" colspan="1" rowspan="1">0.707</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">PD-1+IL-10+IL-2Rα+CA15-3</td>
<td align="left" colspan="1" rowspan="1">93.3</td>
<td align="left" colspan="1" rowspan="1">72.4</td>
<td align="left" colspan="1" rowspan="1">0.862</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">CA15-3</td>
<td align="left" colspan="1" rowspan="1">58.33</td>
<td align="left" colspan="1" rowspan="1">95.00</td>
<td align="left" colspan="1" rowspan="1">0.7573</td>
<td align="left" rowspan="2" colspan="1">Zajkowska et al. (<a href="#CR273" class="usa-link" aria-describedby="CR273">2019</a>)</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">VEGF-C+CA15-3</td>
<td align="left" colspan="1" rowspan="1">86.67</td>
<td align="left" colspan="1" rowspan="1">70.00</td>
<td align="left" colspan="1" rowspan="1">0.8476</td>
</tr>
</tbody>
</table></div>
<div class="p text-right font-secondary"><a href="table/Tab5/" class="usa-link" target="_blank" rel="noopener noreferrer">Open in a new tab</a></div></section><p id="Par94">Different combinations of biomarkers have also been studied in metastatic breast cancer (MBC). Diagnostic utility of selected combinations of CEA and CA15-3 with other biomarkers in MBC is shown in Table <a href="#Tab6" class="usa-link">6</a>.</p>
<section class="tw xbox font-sm" id="Tab6"><h3 class="obj_head">Table 6.</h3>
<div class="caption p"><p>Comparison of the diagnostic utility of single CA15-3 and CEA assays and combinations of these markers in the diagnosis of metastatic BC (MBC)</p></div>
<div class="tbl-box p" tabindex="0"><table class="content" frame="hsides" rules="groups">
<thead><tr>
<th align="left" colspan="1" rowspan="1">Biomarker</th>
<th align="left" colspan="1" rowspan="1">SN [%]</th>
<th align="left" colspan="1" rowspan="1">SP [%]</th>
<th align="left" colspan="1" rowspan="1">AUC</th>
<th align="left" colspan="1" rowspan="1">References</th>
</tr></thead>
<tbody>
<tr>
<td align="left" colspan="4" rowspan="1"><em>(MBC vs. BC without mestastases)</em></td>
<td align="left" rowspan="6" colspan="1">Wang et al. (<a href="#CR254" class="usa-link" aria-describedby="CR254">2017</a>)</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">CEA</td>
<td align="left" colspan="1" rowspan="1">56.7</td>
<td align="center" colspan="1" rowspan="1">92.0</td>
<td align="center" colspan="1" rowspan="1">0.806</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">CA15-3</td>
<td align="left" colspan="1" rowspan="1">44.5</td>
<td align="center" colspan="1" rowspan="1">84.5</td>
<td align="center" colspan="1" rowspan="1">0.743</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">CEA+CA 15–3</td>
<td align="left" colspan="1" rowspan="1">68.9</td>
<td align="center" colspan="1" rowspan="1">88.0</td>
<td align="center" colspan="1" rowspan="1">0.817</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">CEA+TPS</td>
<td align="left" colspan="1" rowspan="1">78.7</td>
<td align="center" colspan="1" rowspan="1">82.0</td>
<td align="center" colspan="1" rowspan="1">0.863</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">CA15-3+CA125</td>
<td align="left" colspan="1" rowspan="1">52.4</td>
<td align="center" colspan="1" rowspan="1">91.5</td>
<td align="center" colspan="1" rowspan="1">0.708</td>
</tr>
<tr>
<td align="left" colspan="4" rowspan="1"><em>(Patients with distant metastasis)</em></td>
<td align="left" rowspan="14" colspan="1">Zhang et al. (<a href="#CR282" class="usa-link" aria-describedby="CR282">2021d</a>)</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">CEA</td>
<td align="left" colspan="1" rowspan="1">57.1</td>
<td align="center" colspan="1" rowspan="1">87.4</td>
<td align="center" colspan="1" rowspan="1">0.755</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">CA15-3</td>
<td align="left" colspan="1" rowspan="1">59.2</td>
<td align="center" colspan="1" rowspan="1">94.1</td>
<td align="center" colspan="1" rowspan="1">0.821</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">CEA+CA15-3</td>
<td align="left" colspan="1" rowspan="1">81.6</td>
<td align="center" colspan="1" rowspan="1">83.8</td>
<td align="center" colspan="1" rowspan="1">0.855</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">CEA+CA 15–3+TPS</td>
<td align="left" colspan="1" rowspan="1">83.7</td>
<td align="center" colspan="1" rowspan="1">79.4</td>
<td align="center" colspan="1" rowspan="1">0.866</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">TPS+CA15-3+CEA+CA125</td>
<td align="left" colspan="1" rowspan="1">85.7</td>
<td align="center" colspan="1" rowspan="1">78.2</td>
<td align="center" colspan="1" rowspan="1">0.846</td>
</tr>
<tr><td align="left" colspan="4" rowspan="1"><em>(patients with occult metastasis in three years)</em></td></tr>
<tr>
<td align="left" colspan="1" rowspan="1">CEA</td>
<td align="left" colspan="1" rowspan="1">39.7</td>
<td align="center" colspan="1" rowspan="1">94.8</td>
<td align="center" colspan="1" rowspan="1">0.725</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">CA15-3</td>
<td align="left" colspan="1" rowspan="1">47.9</td>
<td align="center" colspan="1" rowspan="1">94.0</td>
<td align="center" colspan="1" rowspan="1">0.744</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">CEA+CA15-3</td>
<td align="left" colspan="1" rowspan="1">60.3</td>
<td align="center" colspan="1" rowspan="1">83.9</td>
<td align="center" colspan="1" rowspan="1">0.764</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">CA 15–3+TPS</td>
<td align="left" colspan="1" rowspan="1">57.5</td>
<td align="center" colspan="1" rowspan="1">91.0</td>
<td align="center" colspan="1" rowspan="1">0.799</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">CEA+CA 15–3+TAP</td>
<td align="left" colspan="1" rowspan="1">57.5</td>
<td align="center" colspan="1" rowspan="1">91.0</td>
<td align="center" colspan="1" rowspan="1">0.799</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">CA 15–3+CA 125+TAP</td>
<td align="left" colspan="1" rowspan="1">57.5</td>
<td align="center" colspan="1" rowspan="1">91.0</td>
<td align="center" colspan="1" rowspan="1">0.799</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">TPS+CA15-3+CEA+CA125</td>
<td align="left" colspan="1" rowspan="1">57.5</td>
<td align="center" colspan="1" rowspan="1">91.0</td>
<td align="center" colspan="1" rowspan="1">0.799</td>
</tr>
</tbody>
</table></div>
<div class="p text-right font-secondary"><a href="table/Tab6/" class="usa-link" target="_blank" rel="noopener noreferrer">Open in a new tab</a></div>
<div class="tw-foot p"><div class="fn" id="_fn_p136"><p>TPS, tissue polypeptide specific antigen</p></div></div></section><p id="Par95">Classic tumour markers were also studied in combinations with miRNA. Zaleski et al. (<a href="#CR274" class="usa-link" aria-describedby="CR274">2018</a>) in the comparison of BC and healthy controls found that the combination of miR-34a (SN 36.2% and 34.0% at 90% and 95% SP, AUC = 0.722) with CEA or CA15-3 improved the performance with AUCs of 0.844 and 0.800 respectively. The combination of CEA and CA15-3 reached only slightly higher performance (AUC = 0.741, SN of 38.5% at 90% and 95% SP). When BC was compared with benign breast diseases, the combination of miR-34a (SN 36.2% and 34.0% at 90% and 95% SP, AUC = 0.719) with CEA or CA15-3 also resulted in improved performance (AUCs 0.794 and 0.741 respectively) (Zaleski et al. <a href="#CR274" class="usa-link" aria-describedby="CR274">2018</a>). Similarly, Raheem et al. (Raheem et al. <a href="#CR205" class="usa-link" aria-describedby="CR205">2019</a>) found that in the differentiation between BC and healthy control group, combination of miRNA-34a and CA15-3 showed a very good discriminative value for BC patients. Qiao et al. (<a href="#CR204" class="usa-link" aria-describedby="CR204">2024</a>) investigated that serum exosomal miR-200c (SN 86.27%, SP 74.47%, AUC = 0.854) can distinguish patients with and without BC. Moreover, combination of miR-200c with traditional serum markers (CEA, CA15-3, CA125) may improve diagnostic efficacy for BC (Qiao et al. <a href="#CR204" class="usa-link" aria-describedby="CR204">2024</a>) (Table <a href="#Tab7" class="usa-link">7</a>).</p>
<section class="tw xbox font-sm" id="Tab7"><h3 class="obj_head">Table 7.</h3>
<div class="caption p"><p>Comparison of the diagnostic utility of single CA15-3 and CEA assays and selected combinations of these markers with miRNAs in diagnosis of BC patients</p></div>
<div class="tbl-box p" tabindex="0"><table class="content" frame="hsides" rules="groups">
<thead><tr>
<th align="left" colspan="1" rowspan="1">Parameter</th>
<th align="left" colspan="1" rowspan="1">SN [%]</th>
<th align="left" colspan="1" rowspan="1">SP [%]</th>
<th align="left" colspan="1" rowspan="1">AUC</th>
<th align="left" colspan="1" rowspan="1">References</th>
</tr></thead>
<tbody>
<tr>
<td align="left" colspan="4" rowspan="1">(<em>healthy controls vs BC)</em>
</td>
<td align="left" rowspan="10" colspan="1">Zaleski et al. (<a href="#CR274" class="usa-link" aria-describedby="CR274">2018</a>)</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">CEA</td>
<td align="left" colspan="1" rowspan="1">26.0/18.0</td>
<td align="left" colspan="1" rowspan="1">90.0/95.0</td>
<td align="center" colspan="1" rowspan="1">0.717</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">CA15-3</td>
<td align="left" colspan="1" rowspan="1">36.2/31.9</td>
<td align="left" colspan="1" rowspan="1">90.0/95.0</td>
<td align="center" colspan="1" rowspan="1">0.721</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">miR-34a+CEA</td>
<td align="left" colspan="1" rowspan="1">59.1/34.1</td>
<td align="left" colspan="1" rowspan="1">90.0/95.0</td>
<td align="center" colspan="1" rowspan="1">0.844</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">miR-34a+CA15-3</td>
<td align="left" colspan="1" rowspan="1">56.1/56.1</td>
<td align="left" colspan="1" rowspan="1">90.0/95.0</td>
<td align="center" colspan="1" rowspan="1">0.800</td>
</tr>
<tr><td align="left" colspan="4" rowspan="1"><em>(benign breast diseases vs BC)</em></td></tr>
<tr>
<td align="left" colspan="1" rowspan="1">CEA</td>
<td align="left" colspan="1" rowspan="1">20.0/20.0</td>
<td align="left" colspan="1" rowspan="1">90.0/95.0</td>
<td align="center" colspan="1" rowspan="1">0.623</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">CA15-3</td>
<td align="left" colspan="1" rowspan="1">25.5/23.4</td>
<td align="left" colspan="1" rowspan="1">90.0/95.0</td>
<td align="center" colspan="1" rowspan="1">0.619</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">miR34a+CEA</td>
<td align="left" colspan="1" rowspan="1">54.5/31.8</td>
<td align="left" colspan="1" rowspan="1">90.0/95.0</td>
<td align="center" colspan="1" rowspan="1">0.794</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">miR34a+CA15-3</td>
<td align="left" colspan="1" rowspan="1">53.7/53.7</td>
<td align="left" colspan="1" rowspan="1">90.0/95.0</td>
<td align="center" colspan="1" rowspan="1">0.741</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">CA15-3</td>
<td align="left" colspan="1" rowspan="1">80</td>
<td align="left" colspan="1" rowspan="1">73.3</td>
<td align="center" colspan="1" rowspan="1">0.829</td>
<td align="left" rowspan="2" colspan="1">Raheem et al. (<a href="#CR205" class="usa-link" aria-describedby="CR205">2019</a>)</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">miRNA-34a+CA15-3</td>
<td align="left" colspan="1" rowspan="1">83.3</td>
<td align="left" colspan="1" rowspan="1">77.7</td>
<td align="center" colspan="1" rowspan="1">0.842</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">CEA</td>
<td align="left" colspan="1" rowspan="1">32</td>
<td align="left" colspan="1" rowspan="1">100</td>
<td align="center" colspan="1" rowspan="1">0.615</td>
<td align="left" rowspan="3" colspan="1">Qiao et al. (<a href="#CR204" class="usa-link" aria-describedby="CR204">2024</a>)</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">CA15-3</td>
<td align="left" colspan="1" rowspan="1">53.19</td>
<td align="left" colspan="1" rowspan="1">91.49</td>
<td align="center" colspan="1" rowspan="1">0.727</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">miR-200c+CEA+CA15-3+CA125</td>
<td align="left" colspan="1" rowspan="1">91.49</td>
<td align="left" colspan="1" rowspan="1">76.6</td>
<td align="center" colspan="1" rowspan="1">0.9140</td>
</tr>
</tbody>
</table></div>
<div class="p text-right font-secondary"><a href="table/Tab7/" class="usa-link" target="_blank" rel="noopener noreferrer">Open in a new tab</a></div></section><p id="Par96">In addition, many combinations of miRNAs were investigated in the diagnosis of BC. Selected studies were summarised in Table <a href="#Tab8" class="usa-link">8</a>.</p>
<section class="tw xbox font-sm" id="Tab8"><h3 class="obj_head">Table 8.</h3>
<div class="caption p"><p>Combinations of miRNAs in the diagnosis of BC</p></div>
<div class="tbl-box p" tabindex="0"><table class="content" frame="hsides" rules="groups">
<thead><tr>
<th align="left" colspan="1" rowspan="1">Combinations of miRNA</th>
<th align="left" colspan="1" rowspan="1">SN [%]</th>
<th align="left" colspan="1" rowspan="1">SP [%]</th>
<th align="left" colspan="1" rowspan="1">AUC</th>
<th align="left" colspan="1" rowspan="1">References</th>
</tr></thead>
<tbody>
<tr>
<td align="left" colspan="1" rowspan="1">miR-1246+miR-206+miR-24+miR-373</td>
<td align="left" colspan="1" rowspan="1">98.0</td>
<td align="left" colspan="1" rowspan="1">96.0</td>
<td align="center" colspan="1" rowspan="1">0.992</td>
<td align="left" colspan="1" rowspan="1">Jang et al. (<a href="#CR117" class="usa-link" aria-describedby="CR117">2021</a>)</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">miR-145-5p+miR-191-5p (miR-222-3p normalization)</td>
<td align="left" colspan="1" rowspan="1">94.3</td>
<td align="left" colspan="1" rowspan="1">100</td>
<td align="center" colspan="1" rowspan="1">0.984</td>
<td align="left" colspan="1" rowspan="1">Ashirbekov et al. (<a href="#CR14" class="usa-link" aria-describedby="CR14">2020</a>)</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">let-7b-5p+miR-122-5p+miR-146b-5p+miR-210-3p+miR-215-5p (external validation set)</td>
<td align="left" colspan="1" rowspan="1">94.4</td>
<td align="left" colspan="1" rowspan="1">88.9</td>
<td align="center" colspan="1" rowspan="1">0.978</td>
<td align="left" colspan="1" rowspan="1">Li et al. (<a href="#CR140" class="usa-link" aria-describedby="CR140">2019</a>)</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">miR-92a-3p+miR-23b-3p+miR-191-5p</td>
<td align="left" colspan="1" rowspan="1">89.2</td>
<td align="left" colspan="1" rowspan="1">96</td>
<td align="center" colspan="1" rowspan="1">0.977</td>
<td align="left" colspan="1" rowspan="1">Sharifi et al. (<a href="#CR225" class="usa-link" aria-describedby="CR225">2022</a>)</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">miR-1246+miR-1307-3p+miR-4634+miR-6861-5p+miR-6875-5p (in the test cohort)</td>
<td align="left" colspan="1" rowspan="1">97.3</td>
<td align="left" colspan="1" rowspan="1">82.9</td>
<td align="center" colspan="1" rowspan="1">0.971</td>
<td align="left" colspan="1" rowspan="1">Shimomura et al. (<a href="#CR227" class="usa-link" aria-describedby="CR227">2016</a>)</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">miR-145+miR-425-5p+miR-139-5p+miR-130a</td>
<td align="left" colspan="1" rowspan="1">97</td>
<td align="left" colspan="1" rowspan="1">91</td>
<td align="center" colspan="1" rowspan="1">0.97</td>
<td align="left" colspan="1" rowspan="1">Itani et al. (<a href="#CR113" class="usa-link" aria-describedby="CR113">2021</a>)</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">miR-1246+miR-202+miR-21+miR-219B (patients under the age of 50)</td>
<td align="left" colspan="1" rowspan="1">85.29</td>
<td align="left" colspan="1" rowspan="1">93.33</td>
<td align="center" colspan="1" rowspan="1">0.961</td>
<td align="left" colspan="1" rowspan="1">Jang et al. (<a href="#CR116" class="usa-link" aria-describedby="CR116">2021</a>)</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">miR-185-5p+miR-362-5p</td>
<td align="left" colspan="1" rowspan="1">92.65</td>
<td align="left" colspan="1" rowspan="1">92.31</td>
<td align="center" colspan="1" rowspan="1">0.957</td>
<td align="left" colspan="1" rowspan="1">Zhang et al. (<a href="#CR278" class="usa-link" aria-describedby="CR278">2021</a>)</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">miR-451+miR-148a+miR-27a+miR-30b</td>
<td align="left" colspan="1" rowspan="1">94.7</td>
<td align="left" colspan="1" rowspan="1">82.8</td>
<td align="center" colspan="1" rowspan="1">0.953</td>
<td align="left" colspan="1" rowspan="1">Luo et al. (<a href="#CR155" class="usa-link" aria-describedby="CR155">2014</a>)</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">miR-10b-5p+miR-133a-3p+miR-155-3p+miR-195-5p+miR-195-3p</td>
<td align="left" colspan="1" rowspan="1">79</td>
<td align="left" colspan="1" rowspan="1">100</td>
<td align="center" colspan="1" rowspan="1">0.948</td>
<td align="left" colspan="1" rowspan="1">Jing et al. (<a href="#CR121" class="usa-link" aria-describedby="CR121">2024</a>)</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">c-miR-16+c-miR-21+c-miR-155+c-miR-195</td>
<td align="left" colspan="1" rowspan="1">88.89</td>
<td align="left" colspan="1" rowspan="1">86.67</td>
<td align="center" colspan="1" rowspan="1">0.936</td>
<td align="left" colspan="1" rowspan="1">Fan et al. (<a href="#CR81" class="usa-link" aria-describedby="CR81">2018</a>)</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">miR-21+miR-155+miR-365</td>
<td align="left" colspan="1" rowspan="1">85.71</td>
<td align="left" colspan="1" rowspan="1">85.72</td>
<td align="center" colspan="1" rowspan="1">0.918</td>
<td align="left" colspan="1" rowspan="1">Han et al. (<a href="#CR99" class="usa-link" aria-describedby="CR99">2017</a>)</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">miR-199a+miR-29c+miR-424</td>
<td align="left" colspan="1" rowspan="1">77.2</td>
<td align="left" colspan="1" rowspan="1">88.9</td>
<td align="center" colspan="1" rowspan="1">0.905</td>
<td align="left" colspan="1" rowspan="1">Zhang et al. (<a href="#CR276" class="usa-link" aria-describedby="CR276">2015</a>)</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">BC vs normal hsa-miR-324-3p/hsa-miR-382-5p, hsa-miR-21-3p/hsa-miR-324-3p, hsa-miR-30a-5p/hsa-miR-30e-5p, hsa-miR-221-3p/hsa-miR-324-3p</td>
<td align="left" colspan="1" rowspan="1">89.0</td>
<td align="left" colspan="1" rowspan="1">92.5</td>
<td align="center" colspan="1" rowspan="1">0.901</td>
<td align="left" rowspan="3" colspan="1">Fang et al. <a href="#CR84" class="usa-link" aria-describedby="CR84">2018</a>)</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">BC vs benign hsa-miR-30a-5p/hsa-miR-382-5p, hsa-miR-192-5p/hsa-miR-382-5p, hsa-miR-192-5p/hsa-miR-574-5p, hsa-miR-21-3p/hsa-miR-221-3p, hsa-miR-221-3p/hsa-miR-30a-5p</td>
<td align="left" colspan="1" rowspan="1">88.1</td>
<td align="left" colspan="1" rowspan="1">77.5</td>
<td align="center" colspan="1" rowspan="1">0.901</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">BC vs control (normal+benign) hsa-miR-30e-5p/hsa-miR-382-5p, hsa-miR-221-3p/hsa-miR-324-3p, hsa-miR-30a-5p/hsa-miR-382-5p, hsa-miR-152/hsa-miR-382-5p, hsa-miR-192-5p/hsa-miR-382-5p</td>
<td align="left" colspan="1" rowspan="1">71.7</td>
<td align="left" colspan="1" rowspan="1">78.2</td>
<td align="center" colspan="1" rowspan="1">0.820</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">miR-195+miR-210+miR-21+miR-16</td>
<td align="left" colspan="1" rowspan="1">71.4</td>
<td align="left" colspan="1" rowspan="1">100</td>
<td align="center" colspan="1" rowspan="1">0.898</td>
<td align="left" colspan="1" rowspan="1">Miranda et al. (<a href="#CR61" class="usa-link" aria-describedby="CR61">2024</a>)</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">miR-21-3p+miR-21-5p+miR-99a-5p</td>
<td align="left" colspan="1" rowspan="1">97.9</td>
<td align="left" colspan="1" rowspan="1">73.5</td>
<td align="center" colspan="1" rowspan="1">0.895</td>
<td align="left" colspan="1" rowspan="1">Yu et al. (<a href="#CR271" class="usa-link" aria-describedby="CR271">2018</a>)</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">EV-miRNAs: miR-9+miR-16+miR-21+miR-429</td>
<td align="left" colspan="1" rowspan="1">96.8</td>
<td align="left" colspan="1" rowspan="1">80</td>
<td align="center" colspan="1" rowspan="1">0.88</td>
<td align="left" colspan="1" rowspan="1">Kim et al. (<a href="#CR126" class="usa-link" aria-describedby="CR126">2021</a>)</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">EV-miRNAs: miR-142-5p+miR-320a+miR-4433b-5p (BC patients vs healthy controls)</td>
<td align="left" colspan="1" rowspan="1">93.33</td>
<td align="left" colspan="1" rowspan="1">68.75</td>
<td align="center" colspan="1" rowspan="1">0.8387</td>
<td align="left" rowspan="2" colspan="1">Ozawa et al. (<a href="#CR193" class="usa-link" aria-describedby="CR193">2020</a>)</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">(luminal A vs healthy controls)</td>
<td align="left" colspan="1" rowspan="1">100</td>
<td align="left" colspan="1" rowspan="1">93.8</td>
<td align="center" colspan="1" rowspan="1">0.9410</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">miR-30b-5p+miR-99a-5p</td>
<td align="left" colspan="1" rowspan="1">57.4</td>
<td align="left" colspan="1" rowspan="1">87.54</td>
<td align="center" colspan="1" rowspan="1">0.77</td>
<td align="left" rowspan="2" colspan="1">Adam-Artigues et al. (<a href="#CR1" class="usa-link" aria-describedby="CR1">2021</a>)</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">in stage I BC</td>
<td align="left" colspan="1" rowspan="1">82.35</td>
<td align="left" colspan="1" rowspan="1">87.54</td>
<td align="center" colspan="1" rowspan="1">0.9273</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">miR-210+miR-152</td>
<td align="left" colspan="1" rowspan="1">83.33</td>
<td align="left" colspan="1" rowspan="1">68.0</td>
<td align="center" colspan="1" rowspan="1">0.754</td>
<td align="left" colspan="1" rowspan="1">Lopes et al. (<a href="#CR153" class="usa-link" aria-describedby="CR153">2021</a>)</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">miR-23a-3p+miR-130a-5p+miR-144-3p+miR-148a-3p+miR-152-3p</td>
<td align="left" colspan="1" rowspan="1">86.5</td>
<td align="left" colspan="1" rowspan="1">45.9</td>
<td align="center" colspan="1" rowspan="1">0.699</td>
<td align="left" colspan="1" rowspan="1">Li et al. (<a href="#CR141" class="usa-link" aria-describedby="CR141">2020</a>)</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">miR-15a+miR-18a+miR-107+miR-133a+miR-139-5p+miR-143+miR-145+miR-365+miR-425</td>
<td align="left" colspan="1" rowspan="1">83.3</td>
<td align="left" colspan="1" rowspan="1">41.2</td>
<td align="center" colspan="1" rowspan="1">0.665</td>
<td align="left" colspan="1" rowspan="1">Kodahl et al. (<a href="#CR127" class="usa-link" aria-describedby="CR127">2014</a>)</td>
</tr>
</tbody>
</table></div>
<div class="p text-right font-secondary"><a href="table/Tab8/" class="usa-link" target="_blank" rel="noopener noreferrer">Open in a new tab</a></div></section></section><section id="Sec22"><h2 class="pmc_sec_title">Conclusions</h2>
<p id="Par97">High incidence and mortality rates of breast cancer are prompting researchers to search for new markers that could be of significant diagnostic and prognostic value in breast cancer. Combining traditional diagnostic methods with new markers could improve the effectiveness of diagnosis and monitoring of breast cancer patients and contribute to the implementation of personalised treatment. Ongoing research points to the potential importance of both immunological and molecular markers in breast cancer, as well as the creation of panels of new and traditional markers. Perhaps this approach will prove to be the future of modern breast cancer diagnosis and treatment. However, standardisation for samples collection and methods of novel circulating biomarkers detection is required. Multicentre cohort studies should be prioritised to validate novel biomarkers and their application in clinical practice. Moreover, there is a great need for longitudinal studies to assess the dynamics of biomarkers during therapy.</p></section><section id="ack1" class="ack"><h2 class="pmc_sec_title">Acknowledgements</h2>
<p>Not applicable.</p></section><section id="glossary1" class="glossary"><h2 class="pmc_sec_title">Abbreviations</h2>
<dl class="def-list">
<dt>BC</dt>
<dd><p id="Par2">Breast cancer</p></dd>
<dt>ER</dt>
<dd><p id="Par3">Oestrogen receptor</p></dd>
<dt>PR</dt>
<dd><p id="Par4">Progesterone receptor</p></dd>
<dt>HER2</dt>
<dd><p id="Par5">Human epidermal growth factor receptor 2</p></dd>
<dt>AI</dt>
<dd><p id="Par6">Aromatase inhibitors</p></dd>
<dt>SERMs</dt>
<dd><p id="Par7">Selective ER modulators</p></dd>
<dt>SERDs</dt>
<dd><p id="Par8">Selective ER downregulators</p></dd>
<dt>IHC</dt>
<dd><p id="Par9">Immunohistochemistry</p></dd>
<dt>ISH</dt>
<dd><p id="Par10">In situ hybridization</p></dd>
<dt>ADC</dt>
<dd><p id="Par11">Antibody-drug conjugates</p></dd>
<dt>CK</dt>
<dd><p id="Par12">Cytokeratin</p></dd>
<dt>TPA</dt>
<dd><p id="Par13">Tissue polypeptide antigen</p></dd>
<dt>TPS</dt>
<dd><p id="Par14">Tissue polypeptide-specific antigen</p></dd>
<dt>AdipoR1</dt>
<dd><p id="Par15">Adiponectin receptor 1</p></dd>
<dt>AdipoR2</dt>
<dd><p id="Par16">Adiponectin receptor 2</p></dd>
<dt>CA 15-3</dt>
<dd><p id="Par17">Cancer antigen 15–3</p></dd>
<dt>CEA</dt>
<dd><p id="Par18">Carcinoembryonic antigen</p></dd>
<dt>CA 27-29</dt>
<dd><p id="Par19">Cancer antigen 27–29</p></dd>
<dt>CA 125</dt>
<dd><p id="Par20">Cancer antigen 125</p></dd>
<dt>DCIS</dt>
<dd><p id="Par21">Ductal carcinoma in situ</p></dd>
<dt>LEPR</dt>
<dd><p id="Par22">Leptin receptor</p></dd>
<dt>SN</dt>
<dd><p id="Par23">Sensitivity</p></dd>
<dt>SP</dt>
<dd><p id="Par24">Specificity</p></dd>
<dt>AUC</dt>
<dd><p id="Par25">The area under the curve</p></dd>
<dt>miRNA</dt>
<dd><p id="Par26">MicroRNA</p></dd>
<dt>circ-RNA</dt>
<dd><p id="Par27">Circular RNA</p></dd>
<dt>ctDNA</dt>
<dd><p id="Par28">Circulating tumour DNA</p></dd>
<dt>cfDNA</dt>
<dd><p id="Par29">Cell-free DNA</p></dd>
<dt>CTCs</dt>
<dd><p id="Par30">Circulating tumour cells</p></dd>
<dt>MRD</dt>
<dd><p id="Par31">Minimal residual disease</p></dd>
<dt>CSF</dt>
<dd><p id="Par32">Cerebrospinal fluid</p></dd>
<dt>BM</dt>
<dd><p id="Par33">Breast milk</p></dd>
<dt>TAP</dt>
<dd><p id="Par34">Tumour abnormal protein</p></dd>
<dt>AFP</dt>
<dd><p id="Par35">Alpha fetoprotein</p></dd>
<dt>CA 19-9</dt>
<dd><p id="Par36">Carbohydrate antigen 19–9</p></dd>
<dt>TSGF</dt>
<dd><p id="Par37">Tumour-specific growth factor</p></dd>
<dt>NLR</dt>
<dd><p id="Par38">Neutrophil-to-lymphocyte ratio</p></dd>
<dt>RDW</dt>
<dd><p id="Par39">Red cell distribution width</p></dd>
<dt>MBC</dt>
<dd><p id="Par40">Metastatic breast cancer</p></dd>
</dl></section><section id="notes1"><h2 class="pmc_sec_title">Author contributions</h2>
<p>A.M.P and P.K.D conceptualised this review. A.M.P and P.K.D prepared and review the original draft. P.K.D, A.E, ML.M, J.M, M.G searched and selected literature. A.M.P supervised and revised the manuscript. All authors read and approved the final manuscript.</p></section><section id="notes2"><h2 class="pmc_sec_title">Funding</h2>
<p>The present review was funded by the Medical University of Silesia in Katowice, Poland, grant number BNW-1-012/K/4/O </p></section><section id="notes3"><h2 class="pmc_sec_title">Data availability</h2>
<p>No datasets were generated or analysed during the current study.</p></section><section id="notes4"><h2 class="pmc_sec_title">Declarations</h2>
<section id="FPar1"><h3 class="pmc_sec_title">Conflict of interest</h3>
<p id="Par98">The authors declare no competing interests.</p></section><section id="FPar3"><h3 class="pmc_sec_title">Ethical approval and consent to participate</h3>
<p id="Par99">Not applicable.</p></section><section id="FPar2"><h3 class="pmc_sec_title">Consent for publication</h3>
<p id="Par100">Not applicable.</p></section></section><section id="fn-group1" class="fn-group"><h2 class="pmc_sec_title">Footnotes</h2>
<div class="fn-group p font-secondary-light font-sm"><div class="fn p" id="fn1">
<p><strong>Publisher's Note</strong></p>
<p>Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.</p>
</div></div></section><section id="Bib1" class="ref-list"><h2 class="pmc_sec_title">References</h2>
<section id="Bib1_sec2"><ol class="ref-list font-sm">
<li id="CR1">
<cite>Adam-Artigues A et al (2021) Identification of a two-MicroRNA signature in plasma as a novel biomarker for very early diagnosis of breast cancer. Cancers 13(11):2848. 10.3390/cancers13112848
</cite> [<a href="https://doi.org/10.3390/cancers13112848" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC8201361/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/34200463/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Adam-Artigues%20A%20et%20al%20(2021)%20Identification%20of%20a%20two-MicroRNA%20signature%20in%20plasma%20as%20a%20novel%20biomarker%20for%20very%20early%20diagnosis%20of%20breast%20cancer.%20Cancers%2013(11):2848.%2010.3390/cancers13112848" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR2">
<cite>Ahmed EA, Abd El-Basit SA, Mohamed MA, Swellam M (2022) Clinical role of miRNA 29a and miRNA 335 on breast cancer management: their relevance to MMP2 protein level. Arch Physiol Biochem 128(4):1058–1065. 10.1080/13813455.2020.1749085
</cite> [<a href="https://doi.org/10.1080/13813455.2020.1749085" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/32267166/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Ahmed%20EA,%20Abd%20El-Basit%20SA,%20Mohamed%20MA,%20Swellam%20M%20(2022)%20Clinical%20role%20of%20miRNA%2029a%20and%20miRNA%20335%20on%20breast%20cancer%20management:%20their%20relevance%20to%20MMP2%20protein%20level.%20Arch%20Physiol%20Biochem%20128(4):1058%E2%80%931065.%2010.1080/13813455.2020.1749085" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR3">
<cite>Ali H et al (2025) Non-coding RNA biomarkers in basal-like breast cancer. Clin Chim Acta Int J Clin Chem 576:120408. 10.1016/j.cca.2025.120408</cite> [<a href="https://doi.org/10.1016/j.cca.2025.120408" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/40456356/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Ali%20H%20et%20al%20(2025)%20Non-coding%20RNA%20biomarkers%20in%20basal-like%20breast%20cancer.%20Clin%20Chim%20Acta%20Int%20J%20Clin%20Chem%20576:120408.%2010.1016/j.cca.2025.120408" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR4">
<cite>Allemani C et al (2018) Global surveillance of trends in cancer survival 2000–14 (CONCORD-3): analysis of individual records for 37 513 025 patients diagnosed with one of 18 cancers from 322 population-based registries in 71 countries. Lancet Lond Engl 391(10125):1023–1075. 10.1016/S0140-6736(17)33326-3</cite> [<a href="https://doi.org/10.1016/S0140-6736(17)33326-3" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC5879496/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/29395269/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Allemani%20C%20et%20al%20(2018)%20Global%20surveillance%20of%20trends%20in%20cancer%20survival%202000%E2%80%9314%20(CONCORD-3):%20analysis%20of%20individual%20records%20for%2037%20513%20025%20patients%20diagnosed%20with%20one%20of%2018%20cancers%20from%20322%20population-based%20registries%20in%2071%20countries.%20Lancet%20Lond%20Engl%20391(10125):1023%E2%80%931075.%2010.1016/S0140-6736(17)33326-3" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR5">
<cite>Allison KH et al (2020) Estrogen and progesterone receptor testing in breast cancer: ASCO/CAP guideline update. J Clin Oncol off J Am Soc Clin Oncol 38(12):1346–1366. 10.1200/JCO.19.02309</cite> [<a href="https://doi.org/10.1200/JCO.19.02309" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/31928404/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Allison%20KH%20et%20al%20(2020)%20Estrogen%20and%20progesterone%20receptor%20testing%20in%20breast%20cancer:%20ASCO/CAP%20guideline%20update.%20J%20Clin%20Oncol%20off%20J%20Am%20Soc%20Clin%20Oncol%2038(12):1346%E2%80%931366.%2010.1200/JCO.19.02309" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR6">
<cite>Allred DC (2010) Issues and updates: evaluating estrogen receptor-alpha, progesterone receptor, and HER2 in breast cancer. Mod Pathol off J US Can Acad Pathol Inc 23(Suppl 2):S52-59. 10.1038/modpathol.2010.55</cite> [<a href="https://doi.org/10.1038/modpathol.2010.55" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/20436503/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Allred%20DC%20(2010)%20Issues%20and%20updates:%20evaluating%20estrogen%20receptor-alpha,%20progesterone%20receptor,%20and%20HER2%20in%20breast%20cancer.%20Mod%20Pathol%20off%20J%20US%20Can%20Acad%20Pathol%20Inc%2023(Suppl%202):S52-59.%2010.1038/modpathol.2010.55" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR7">
<cite>Almeida CF, Oliveira A, Ramos MJ, Fernandes PA, Teixeira N, Amaral C (2020) Estrogen receptor-positive (ER+) breast cancer treatment: Are multi-target compounds the next promising approach? Biochem Pharmacol 177:113989. 10.1016/j.bcp.2020.113989
</cite> [<a href="https://doi.org/10.1016/j.bcp.2020.113989" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/32330493/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Almeida%20CF,%20Oliveira%20A,%20Ramos%20MJ,%20Fernandes%20PA,%20Teixeira%20N,%20Amaral%20C%20(2020)%20Estrogen%20receptor-positive%20(ER+)%20breast%20cancer%20treatment:%20Are%20multi-target%20compounds%20the%20next%20promising%20approach?%20Biochem%20Pharmacol%20177:113989.%2010.1016/j.bcp.2020.113989" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR8">
<cite>Anderson KS et al (2011) Protein microarray signature of autoantibody biomarkers for the early detection of breast cancer. J Proteome Res 10(1):85–96. 10.1021/pr100686b
</cite> [<a href="https://doi.org/10.1021/pr100686b" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC3158028/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/20977275/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Anderson%20KS%20et%20al%20(2011)%20Protein%20microarray%20signature%20of%20autoantibody%20biomarkers%20for%20the%20early%20detection%20of%20breast%20cancer.%20J%20Proteome%20Res%2010(1):85%E2%80%9396.%2010.1021/pr100686b" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR9">
<cite>Anderson WF, Rosenberg PS, Katki HA (2014) Tracking and evaluating molecular tumor markers with cancer registry data: HER2 and breast cancer. J Natl Cancer Inst 106(5):10. 10.1093/jnci/dju093</cite> [<a href="https://doi.org/10.1093/jnci/dju093" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC4677264/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/24777110/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Anderson%20WF,%20Rosenberg%20PS,%20Katki%20HA%20(2014)%20Tracking%20and%20evaluating%20molecular%20tumor%20markers%20with%20cancer%20registry%20data:%20HER2%20and%20breast%20cancer.%20J%20Natl%20Cancer%20Inst%20106(5):10.%2010.1093/jnci/dju093" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR10">
<cite>Andò S et al (2019) Obesity, leptin and breast cancer: epidemiological evidence and proposed mechanisms. Cancers (Basel) 11(1):62. 10.3390/cancers11010062
</cite> [<a href="https://doi.org/10.3390/cancers11010062" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC6356310/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/30634494/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?And%C3%B2%20S%20et%20al%20(2019)%20Obesity,%20leptin%20and%20breast%20cancer:%20epidemiological%20evidence%20and%20proposed%20mechanisms.%20Cancers%20(Basel)%2011(1):62.%2010.3390/cancers11010062" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR11">
<cite>Andò S, Naimo GD, Gelsomino L, Catalano S, Mauro L (2020) Novel insights into adiponectin action in breast cancer: Evidence of its mechanistic effects mediated by ERα expression. Obes Rev off J Int Assoc Study Obes 21(5):e13004. 10.1111/obr.13004</cite> [<a href="https://doi.org/10.1111/obr.13004" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/32067339/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?And%C3%B2%20S,%20Naimo%20GD,%20Gelsomino%20L,%20Catalano%20S,%20Mauro%20L%20(2020)%20Novel%20insights%20into%20adiponectin%20action%20in%20breast%20cancer:%20Evidence%20of%20its%20mechanistic%20effects%20mediated%20by%20ER%CE%B1%20expression.%20Obes%20Rev%20off%20J%20Int%20Assoc%20Study%20Obes%2021(5):e13004.%2010.1111/obr.13004" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR12">
<cite>Arnold M et al (2022) Current and future burden of breast cancer: global statistics for 2020 and 2040. Breast Edinb Scotl 66:15–23. 10.1016/j.breast.2022.08.010</cite> [<a href="https://doi.org/10.1016/j.breast.2022.08.010" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC9465273/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/36084384/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Arnold%20M%20et%20al%20(2022)%20Current%20and%20future%20burden%20of%20breast%20cancer:%20global%20statistics%20for%202020%20and%202040.%20Breast%20Edinb%20Scotl%2066:15%E2%80%9323.%2010.1016/j.breast.2022.08.010" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR13">
<cite>Arpino G et al (2005) Estrogen receptor-positive, progesterone receptor-negative breast cancer: association with growth factor receptor expression and tamoxifen resistance. J Natl Cancer Inst 97(17):1254–1261. 10.1093/jnci/dji249
</cite> [<a href="https://doi.org/10.1093/jnci/dji249" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/16145046/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Arpino%20G%20et%20al%20(2005)%20Estrogen%20receptor-positive,%20progesterone%20receptor-negative%20breast%20cancer:%20association%20with%20growth%20factor%20receptor%20expression%20and%20tamoxifen%20resistance.%20J%20Natl%20Cancer%20Inst%2097(17):1254%E2%80%931261.%2010.1093/jnci/dji249" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR14">
<cite>Ashirbekov Y et al (2020) Combination of circulating miR-145-5p/miR-191-5p as biomarker for breast cancer detection. PeerJ 8:e10494. 10.7717/peerj.10494
</cite> [<a href="https://doi.org/10.7717/peerj.10494" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC7749656/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/33362968/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Ashirbekov%20Y%20et%20al%20(2020)%20Combination%20of%20circulating%20miR-145-5p/miR-191-5p%20as%20biomarker%20for%20breast%20cancer%20detection.%20PeerJ%208:e10494.%2010.7717/peerj.10494" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR15">
<cite>Avtanski D et al (2019) Resistin induces breast cancer cells epithelial to mesenchymal transition (EMT) and stemness through both adenylyl cyclase-associated protein 1 (CAP1)-dependent and CAP1-independent mechanisms. Cytokine 120:155–164. 10.1016/j.cyto.2019.04.016
</cite> [<a href="https://doi.org/10.1016/j.cyto.2019.04.016" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/31085453/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Avtanski%20D%20et%20al%20(2019)%20Resistin%20induces%20breast%20cancer%20cells%20epithelial%20to%20mesenchymal%20transition%20(EMT)%20and%20stemness%20through%20both%20adenylyl%20cyclase-associated%20protein%201%20(CAP1)-dependent%20and%20CAP1-independent%20mechanisms.%20Cytokine%20120:155%E2%80%93164.%2010.1016/j.cyto.2019.04.016" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR16">
<cite>Awan A, Esfahani KJCO (2018) Endocrine therapy for breast cancer in the primary care setting. Curr Oncol Tor Ont 25(4):285. 10.3747/co.25.4139</cite> [<a href="https://doi.org/10.3747/co.25.4139" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC6092062/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/30111969/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Awan%20A,%20Esfahani%20KJCO%20(2018)%20Endocrine%20therapy%20for%20breast%20cancer%20in%20the%20primary%20care%20setting.%20Curr%20Oncol%20Tor%20Ont%2025(4):285.%2010.3747/co.25.4139" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR17">
<cite>Bai S et al (2023) Clinical diagnostic biomarker “circulating tumor cells” in breast cancer—a meta-analysis. Front Oncol 13:1137519. 10.3389/fonc.2023.1137519
</cite> [<a href="https://doi.org/10.3389/fonc.2023.1137519" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC10313226/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/37397397/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Bai%20S%20et%20al%20(2023)%20Clinical%20diagnostic%20biomarker%20%E2%80%9Ccirculating%20tumor%20cells%E2%80%9D%20in%20breast%20cancer%E2%80%94a%20meta-analysis.%20Front%20Oncol%2013:1137519.%2010.3389/fonc.2023.1137519" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR18">
<cite>Balestrieri K et al (2021) Proteomic identification of tumor- and metastasis-associated galectin-1 in claudin-low breast cancer. Biochim Biophys Acta Gen Subj 1865(2):129784. 10.1016/j.bbagen.2020.129784
</cite> [<a href="https://doi.org/10.1016/j.bbagen.2020.129784" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/33166603/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Balestrieri%20K%20et%20al%20(2021)%20Proteomic%20identification%20of%20tumor-%20and%20metastasis-associated%20galectin-1%20in%20claudin-low%20breast%20cancer.%20Biochim%20Biophys%20Acta%20Gen%20Subj%201865(2):129784.%2010.1016/j.bbagen.2020.129784" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR19">
<cite>Barba D et al (2021) Breast cancer, screening and diagnostic tools: all you need to know. Crit Rev Oncol Hematol 157:103174. 10.1016/j.critrevonc.2020.103174
</cite> [<a href="https://doi.org/10.1016/j.critrevonc.2020.103174" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/33249359/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Barba%20D%20et%20al%20(2021)%20Breast%20cancer,%20screening%20and%20diagnostic%20tools:%20all%20you%20need%20to%20know.%20Crit%20Rev%20Oncol%20Hematol%20157:103174.%2010.1016/j.critrevonc.2020.103174" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR20">
<cite>Bardou V-J, Arpino G, Elledge RM, Osborne CK, Clark GM (2003) Progesterone receptor status significantly improves outcome prediction over estrogen receptor status alone for adjuvant endocrine therapy in two large breast cancer databases. J Clin Oncol off J Am Soc Clin Oncol 21(10):1973–1979. 10.1200/JCO.2003.09.099</cite> [<a href="https://doi.org/10.1200/JCO.2003.09.099" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/12743151/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Bardou%20V-J,%20Arpino%20G,%20Elledge%20RM,%20Osborne%20CK,%20Clark%20GM%20(2003)%20Progesterone%20receptor%20status%20significantly%20improves%20outcome%20prediction%20over%20estrogen%20receptor%20status%20alone%20for%20adjuvant%20endocrine%20therapy%20in%20two%20large%20breast%20cancer%20databases.%20J%20Clin%20Oncol%20off%20J%20Am%20Soc%20Clin%20Oncol%2021(10):1973%E2%80%931979.%2010.1200/JCO.2003.09.099" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR21">
<cite>Barrow H et al (2011) Serum galectin-2, -4, and -8 are greatly increased in colon and breast cancer patients and promote cancer cell adhesion to blood vascular endothelium. Clin Cancer Res off J Am Assoc Cancer Res 17(22):7035–7046. 10.1158/1078-0432.CCR-11-1462</cite> [<a href="https://doi.org/10.1158/1078-0432.CCR-11-1462" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/21933892/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Barrow%20H%20et%20al%20(2011)%20Serum%20galectin-2,%20-4,%20and%20-8%20are%20greatly%20increased%20in%20colon%20and%20breast%20cancer%20patients%20and%20promote%20cancer%20cell%20adhesion%20to%20blood%20vascular%20endothelium.%20Clin%20Cancer%20Res%20off%20J%20Am%20Assoc%20Cancer%20Res%2017(22):7035%E2%80%937046.%2010.1158/1078-0432.CCR-11-1462" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR22">
<cite>Bartel DP (2004) MicroRNAs: genomics, biogenesis, mechanism, and function. Cell 116(2):281–297. 10.1016/S0092-8674(04)00045-5
</cite> [<a href="https://doi.org/10.1016/s0092-8674(04)00045-5" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/14744438/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Bartel%20DP%20(2004)%20MicroRNAs:%20genomics,%20biogenesis,%20mechanism,%20and%20function.%20Cell%20116(2):281%E2%80%93297.%2010.1016/S0092-8674(04)00045-5" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR23">
<cite>Beňačka R, Szabóová D, Guľašová Z, Hertelyová Z, Radoňák J (2022) Classic and new markers in diagnostics and classification of breast cancer. Cancers 14(21):5444. 10.3390/cancers14215444
</cite> [<a href="https://doi.org/10.3390/cancers14215444" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC9654192/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/36358862/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Be%C5%88a%C4%8Dka%20R,%20Szab%C3%B3ov%C3%A1%20D,%20Gu%C4%BEa%C5%A1ov%C3%A1%20Z,%20Hertelyov%C3%A1%20Z,%20Rado%C5%88%C3%A1k%20J%20(2022)%20Classic%20and%20new%20markers%20in%20diagnostics%20and%20classification%20of%20breast%20cancer.%20Cancers%2014(21):5444.%2010.3390/cancers14215444" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR24">
<cite>Bidard F-C et al (2018) Circulating tumor cells in breast cancer patients treated by neoadjuvant chemotherapy: a meta-analysis. J Natl Cancer Inst 110(6):560–567. 10.1093/jnci/djy018
</cite> [<a href="https://doi.org/10.1093/jnci/djy018" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/29659933/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Bidard%20F-C%20et%20al%20(2018)%20Circulating%20tumor%20cells%20in%20breast%20cancer%20patients%20treated%20by%20neoadjuvant%20chemotherapy:%20a%20meta-analysis.%20J%20Natl%20Cancer%20Inst%20110(6):560%E2%80%93567.%2010.1093/jnci/djy018" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR25">
<cite>Blair BB et al (2021) Increased circulating levels of galectin proteins in patients with breast, colon, and lung cancer. Cancers (Basel) 13(19):4819. 10.3390/cancers13194819
</cite> [<a href="https://doi.org/10.3390/cancers13194819" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC8508020/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/34638303/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Blair%20BB%20et%20al%20(2021)%20Increased%20circulating%20levels%20of%20galectin%20proteins%20in%20patients%20with%20breast,%20colon,%20and%20lung%20cancer.%20Cancers%20(Basel)%2013(19):4819.%2010.3390/cancers13194819" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR26">
<cite>Boonyaratanakornkit V, Hamilton N, Márquez-Garbán DC, Pateetin P, McGowan EM, Pietras RJ (2018) Extranuclear signaling by sex steroid receptors and clinical implications in breast cancer. Mol Cell Endocrinol 466:51–72. 10.1016/j.mce.2017.11.010
</cite> [<a href="https://doi.org/10.1016/j.mce.2017.11.010" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC5878997/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/29146555/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Boonyaratanakornkit%20V,%20Hamilton%20N,%20M%C3%A1rquez-Garb%C3%A1n%20DC,%20Pateetin%20P,%20McGowan%20EM,%20Pietras%20RJ%20(2018)%20Extranuclear%20signaling%20by%20sex%20steroid%20receptors%20and%20clinical%20implications%20in%20breast%20cancer.%20Mol%20Cell%20Endocrinol%20466:51%E2%80%9372.%2010.1016/j.mce.2017.11.010" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR27">
<cite>Bray F et al (2024) Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 74(3):229–263. 10.3322/caac.21834
</cite> [<a href="https://doi.org/10.3322/caac.21834" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/38572751/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Bray%20F%20et%20al%20(2024)%20Global%20cancer%20statistics%202022:%20GLOBOCAN%20estimates%20of%20incidence%20and%20mortality%20worldwide%20for%2036%20cancers%20in%20185%20countries.%20CA%20Cancer%20J%20Clin%2074(3):229%E2%80%93263.%2010.3322/caac.21834" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR28">
<cite>Broeders M et al (2012) The impact of mammographic screening on breast cancer mortality in Europe: a review of observational studies. J Med Screen 19(Suppl 1):14–25. 10.1258/jms.2012.012078
</cite> [<a href="https://doi.org/10.1258/jms.2012.012078" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/22972807/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Broeders%20M%20et%20al%20(2012)%20The%20impact%20of%20mammographic%20screening%20on%20breast%20cancer%20mortality%20in%20Europe:%20a%20review%20of%20observational%20studies.%20J%20Med%20Screen%2019(Suppl%201):14%E2%80%9325.%2010.1258/jms.2012.012078" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR29">
<cite>Buonaiuto R et al (2022) Insight on the role of leptin: a bridge from obesity to breast cancer. Biomolecules 12(10):1394. 10.3390/biom12101394
</cite> [<a href="https://doi.org/10.3390/biom12101394" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC9599120/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/36291602/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Buonaiuto%20R%20et%20al%20(2022)%20Insight%20on%20the%20role%20of%20leptin:%20a%20bridge%20from%20obesity%20to%20breast%20cancer.%20Biomolecules%2012(10):1394.%2010.3390/biom12101394" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR30">
<cite>Cai F et al (2021) Hsa_circ_0000515 is a novel circular RNA implicated in the development of breast cancer through its regulation of the microRNA-296-5p/CXCL10 axis. FEBS J 288(3):861–883. 10.1111/febs.15373
</cite> [<a href="https://doi.org/10.1111/febs.15373" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/32446265/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Cai%20F%20et%20al%20(2021)%20Hsa_circ_0000515%20is%20a%20novel%20circular%20RNA%20implicated%20in%20the%20development%20of%20breast%20cancer%20through%20its%20regulation%20of%20the%20microRNA-296-5p/CXCL10%20axis.%20FEBS%20J%20288(3):861%E2%80%93883.%2010.1111/febs.15373" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR31">
<cite>Canatan D et al (2021) Circulating microRNAs as potential non-invasive biomarkers for breast cancer detection. Acta Bio Medica Atenei Parm 92(2):e2021028. 10.23750/abm.v92i2.9678</cite> [<a href="https://doi.org/10.23750/abm.v92i2.9678" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC8182592/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/33988168/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Canatan%20D%20et%20al%20(2021)%20Circulating%20microRNAs%20as%20potential%20non-invasive%20biomarkers%20for%20breast%20cancer%20detection.%20Acta%20Bio%20Medica%20Atenei%20Parm%2092(2):e2021028.%2010.23750/abm.v92i2.9678" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR32">
<cite>Cani AK, Hayes DF (2024) Breast cancer circulating tumor cells: current clinical applications and future prospects. Clin Chem 70(1):68–80. 10.1093/clinchem/hvad191
</cite> [<a href="https://doi.org/10.1093/clinchem/hvad191" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/38175590/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Cani%20AK,%20Hayes%20DF%20(2024)%20Breast%20cancer%20circulating%20tumor%20cells:%20current%20clinical%20applications%20and%20future%20prospects.%20Clin%20Chem%2070(1):68%E2%80%9380.%2010.1093/clinchem/hvad191" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR33">
<cite>Cao W et al (2007) High-level SLP-2 expression and HER-2/neu protein expression are associated with decreased breast cancer patient survival. Am J Clin Pathol 128(3):430–436. 10.1309/C6X54HRB580EP2NQ
</cite> [<a href="https://doi.org/10.1309/C6X54HRB580EP2NQ" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/17709317/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Cao%20W%20et%20al%20(2007)%20High-level%20SLP-2%20expression%20and%20HER-2/neu%20protein%20expression%20are%20associated%20with%20decreased%20breast%20cancer%20patient%20survival.%20Am%20J%20Clin%20Pathol%20128(3):430%E2%80%93436.%2010.1309/C6X54HRB580EP2NQ" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR34">
<cite>Cao Y et al (2022) Molecular characterization of exosomes for subtype-based diagnosis of breast cancer. J Am Chem Soc 144(30):13475–13486. 10.1021/jacs.2c00119
</cite> [<a href="https://doi.org/10.1021/jacs.2c00119" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/35802880/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Cao%20Y%20et%20al%20(2022)%20Molecular%20characterization%20of%20exosomes%20for%20subtype-based%20diagnosis%20of%20breast%20cancer.%20J%20Am%20Chem%20Soc%20144(30):13475%E2%80%9313486.%2010.1021/jacs.2c00119" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR35">
<cite>Castronovo V et al (1996) Decreased expression of galectin-3 is associated with progression of human breast cancer. J Pathol 179(1):43–48. 10.1002/(SICI)1096-9896(199605)179:1%3c43::AID-PATH541%3e3.0.CO;2-N
</cite> [<a href="https://doi.org/10.1002/(SICI)1096-9896(199605)179:1&lt;43::AID-PATH541&gt;3.0.CO;2-N" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/8691344/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Castronovo%20V%20et%20al%20(1996)%20Decreased%20expression%20of%20galectin-3%20is%20associated%20with%20progression%20of%20human%20breast%20cancer.%20J%20Pathol%20179(1):43%E2%80%9348.%2010.1002/(SICI)1096-9896(199605)179:1%3c43::AID-PATH541%3e3.0.CO;2-N" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR36">
<cite>Chapman C et al (2007) Autoantibodies in breast cancer: their use as an aid to early diagnosis. Ann Oncol off J Eur Soc Med Oncol 18(5):868–873. 10.1093/annonc/mdm007</cite> [<a href="https://doi.org/10.1093/annonc/mdm007" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/17347129/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Chapman%20C%20et%20al%20(2007)%20Autoantibodies%20in%20breast%20cancer:%20their%20use%20as%20an%20aid%20to%20early%20diagnosis.%20Ann%20Oncol%20off%20J%20Eur%20Soc%20Med%20Oncol%2018(5):868%E2%80%93873.%2010.1093/annonc/mdm007" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR37">
<cite>Chauhan A, Kaur R, Ghoshal S, Pal A (2021) Exploration of circulating tumour cell (CTC) biology: a paradigm shift in liquid biopsy. Indian J Clin Biochem IJCB 36(2):131–142. 10.1007/s12291-020-00923-4
</cite> [<a href="https://doi.org/10.1007/s12291-020-00923-4" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC7994460/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/33867703/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Chauhan%20A,%20Kaur%20R,%20Ghoshal%20S,%20Pal%20A%20(2021)%20Exploration%20of%20circulating%20tumour%20cell%20(CTC)%20biology:%20a%20paradigm%20shift%20in%20liquid%20biopsy.%20Indian%20J%20Clin%20Biochem%20IJCB%2036(2):131%E2%80%93142.%2010.1007/s12291-020-00923-4" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR38">
<cite>Checka CM, Chun JE, Schnabel FR, Lee J, Toth H (2012) The relationship of mammographic density and age: implications for breast cancer screening. AJR Am J Roentgenol 198(3):W292-295. 10.2214/AJR.10.6049
</cite> [<a href="https://doi.org/10.2214/AJR.10.6049" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/22358028/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Checka%20CM,%20Chun%20JE,%20Schnabel%20FR,%20Lee%20J,%20Toth%20H%20(2012)%20The%20relationship%20of%20mammographic%20density%20and%20age:%20implications%20for%20breast%20cancer%20screening.%20AJR%20Am%20J%20Roentgenol%20198(3):W292-295.%2010.2214/AJR.10.6049" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR39">
<cite>Chekhun V et al (2024) Expression profile of miR-145, -182, -21, -27a, -29b, and -34a in breast cancer patients of young age. Exp Oncol 45(4):421–431. 10.15407/exp-oncology.2023.04.421
</cite> [<a href="https://doi.org/10.15407/exp-oncology.2023.04.421" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/38328848/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Chekhun%20V%20et%20al%20(2024)%20Expression%20profile%20of%20miR-145,%20-182,%20-21,%20-27a,%20-29b,%20and%20-34a%20in%20breast%20cancer%20patients%20of%20young%20age.%20Exp%20Oncol%2045(4):421%E2%80%93431.%2010.15407/exp-oncology.2023.04.421" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR40">
<cite>Chen L, Shan G (2021) CircRNA in cancer: fundamental mechanism and clinical potential. Cancer Lett 505:49–57. 10.1016/j.canlet.2021.02.004
</cite> [<a href="https://doi.org/10.1016/j.canlet.2021.02.004" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/33609610/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Chen%20L,%20Shan%20G%20(2021)%20CircRNA%20in%20cancer:%20fundamental%20mechanism%20and%20clinical%20potential.%20Cancer%20Lett%20505:49%E2%80%9357.%2010.1016/j.canlet.2021.02.004" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR41">
<cite>Chen Z, Wang F, Xiong Y, Wang N, Gu Y, Qiu X (2020a) CircZFR functions as a sponge of miR-578 to promote breast cancer progression by regulating HIF1A expression. Cancer Cell Int 20:400. 10.1186/s12935-020-01492-5
</cite> [<a href="https://doi.org/10.1186/s12935-020-01492-5" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC7437024/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/32831653/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Chen%20Z,%20Wang%20F,%20Xiong%20Y,%20Wang%20N,%20Gu%20Y,%20Qiu%20X%20(2020a)%20CircZFR%20functions%20as%20a%20sponge%20of%20miR-578%20to%20promote%20breast%20cancer%20progression%20by%20regulating%20HIF1A%20expression.%20Cancer%20Cell%20Int%2020:400.%2010.1186/s12935-020-01492-5" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR42">
<cite>Chen R et al (2020b) Combining the tumor abnormal protein test with tests for carcinoembryonic antigens, cancer antigen 15–3, and/or cancer antigen 125 significantly increased their diagnostic sensitivity for breast cancer. Medicine (Baltimore) 99(29):e21231. 10.1097/MD.0000000000021231
</cite> [<a href="https://doi.org/10.1097/MD.0000000000021231" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC7373588/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/32702897/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Chen%20R%20et%20al%20(2020b)%20Combining%20the%20tumor%20abnormal%20protein%20test%20with%20tests%20for%20carcinoembryonic%20antigens,%20cancer%20antigen%2015%E2%80%933,%20and/or%20cancer%20antigen%20125%20significantly%20increased%20their%20diagnostic%20sensitivity%20for%20breast%20cancer.%20Medicine%20(Baltimore)%2099(29):e21231.%2010.1097/MD.0000000000021231" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR43">
<cite>Chetry M, Bhandari A, Feng R, Song X, Wang P, Lin J (2022) Overexpression of galectin2 (LGALS2) predicts a better prognosis in human breast cancer. Am J Transl Res 14(4):2301–2316
</cite> [<a href="/articles/PMC9091085/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/35559406/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Chetry%20M,%20Bhandari%20A,%20Feng%20R,%20Song%20X,%20Wang%20P,%20Lin%20J%20(2022)%20Overexpression%20of%20galectin2%20(LGALS2)%20predicts%20a%20better%20prognosis%20in%20human%20breast%20cancer.%20Am%20J%20Transl%20Res%2014(4):2301%E2%80%932316" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR44">
<cite>Chien Y-C, Wu J-Y, Pang C-C, Chou R-H, Yu Y-L (2025) The clinical impact of galectin-8 in drug resistant breast cancer. J Cancer 16(4):1296–1309. 10.7150/jca.104000
</cite> [<a href="https://doi.org/10.7150/jca.104000" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC11786030/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/39895791/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Chien%20Y-C,%20Wu%20J-Y,%20Pang%20C-C,%20Chou%20R-H,%20Yu%20Y-L%20(2025)%20The%20clinical%20impact%20of%20galectin-8%20in%20drug%20resistant%20breast%20cancer.%20J%20Cancer%2016(4):1296%E2%80%931309.%2010.7150/jca.104000" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR45">
<cite>Christodoulatos GS, Spyrou N, Kadillari J, Psallida S, Dalamaga M (2019) The role of adipokines in breast cancer: current evidence and perspectives. Curr Obes Rep 8(4):413–433. 10.1007/s13679-019-00364-y
</cite> [<a href="https://doi.org/10.1007/s13679-019-00364-y" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/31637624/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Christodoulatos%20GS,%20Spyrou%20N,%20Kadillari%20J,%20Psallida%20S,%20Dalamaga%20M%20(2019)%20The%20role%20of%20adipokines%20in%20breast%20cancer:%20current%20evidence%20and%20perspectives.%20Curr%20Obes%20Rep%208(4):413%E2%80%93433.%2010.1007/s13679-019-00364-y" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR46">
<cite>Chung H, Gyu-Mi P, Na YR, Lee Y-S, Choi H, Seok SH (2024) Comprehensive characterization of early-programmed tumor microenvironment by tumor-associated macrophages reveals galectin-1 as an immune modulatory target in breast cancer. Theranostics 14(2):843–860. 10.7150/thno.88917
</cite> [<a href="https://doi.org/10.7150/thno.88917" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC10758049/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/38169569/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Chung%20H,%20Gyu-Mi%20P,%20Na%20YR,%20Lee%20Y-S,%20Choi%20H,%20Seok%20SH%20(2024)%20Comprehensive%20characterization%20of%20early-programmed%20tumor%20microenvironment%20by%20tumor-associated%20macrophages%20reveals%20galectin-1%20as%20an%20immune%20modulatory%20target%20in%20breast%20cancer.%20Theranostics%2014(2):843%E2%80%93860.%2010.7150/thno.88917" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR47">
<cite>Clarke R, Tyson JJ, Dixon JM (2015) Endocrine resistance in breast cancer–an overview and update. Mol Cell Endocrinol 418(3):220–234. 10.1016/j.mce.2015.09.035
</cite> [<a href="https://doi.org/10.1016/j.mce.2015.09.035" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC4684757/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/26455641/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Clarke%20R,%20Tyson%20JJ,%20Dixon%20JM%20(2015)%20Endocrine%20resistance%20in%20breast%20cancer%E2%80%93an%20overview%20and%20update.%20Mol%20Cell%20Endocrinol%20418(3):220%E2%80%93234.%2010.1016/j.mce.2015.09.035" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR48">
<cite>Clusan L, Le Goff P, Flouriot G, Pakdel F (2021) A closer look at estrogen receptor mutations in breast cancer and their implications for estrogen and antiestrogen responses. Int J Mol Sci 22(2):756. 10.3390/ijms22020756
</cite> [<a href="https://doi.org/10.3390/ijms22020756" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC7828590/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/33451133/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Clusan%20L,%20Le%20Goff%20P,%20Flouriot%20G,%20Pakdel%20F%20(2021)%20A%20closer%20look%20at%20estrogen%20receptor%20mutations%20in%20breast%20cancer%20and%20their%20implications%20for%20estrogen%20and%20antiestrogen%20responses.%20Int%20J%20Mol%20Sci%2022(2):756.%2010.3390/ijms22020756" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR49">
<cite>Collaborative Group on Hormonal Factors in Breast Cancer (2002) Breast cancer and breastfeeding: collaborative reanalysis of individual data from 47 epidemiological studies in 30 countries, including 50 302 women with breast cancer and 96 973 women without the disease. Lancet 360(9328):187–195. 10.1016/S0140-6736(02)09454-0
</cite> [<a href="https://doi.org/10.1016/S0140-6736(02)09454-0" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/12133652/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Collaborative%20Group%20on%20Hormonal%20Factors%20in%20Breast%20Cancer%20(2002)%20Breast%20cancer%20and%20breastfeeding:%20collaborative%20reanalysis%20of%20individual%20data%20from%2047%20epidemiological%20studies%20in%2030%20countries,%20including%2050%20302%20women%20with%20breast%20cancer%20and%2096%20973%20women%20without%20the%20disease.%20Lancet%20360(9328):187%E2%80%93195.%2010.1016/S0140-6736(02)09454-0" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR50">
<cite>Collaborative Group on Hormonal Factors in Breast Cancer (2012) Menarche, menopause, and breast cancer risk: individual participant meta-analysis, including 118 964 women with breast cancer from 117 epidemiological studies. Lancet Oncol 13(11):1141–1151. 10.1016/S1470-2045(12)70425-4
</cite> [<a href="https://doi.org/10.1016/S1470-2045(12)70425-4" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC3488186/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/23084519/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Collaborative%20Group%20on%20Hormonal%20Factors%20in%20Breast%20Cancer%20(2012)%20Menarche,%20menopause,%20and%20breast%20cancer%20risk:%20individual%20participant%20meta-analysis,%20including%20118%20964%20women%20with%20breast%20cancer%20from%20117%20epidemiological%20studies.%20Lancet%20Oncol%2013(11):1141%E2%80%931151.%2010.1016/S1470-2045(12)70425-4" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR51">
<cite>Colleoni M et al (2016) Annual hazard rates of recurrence for breast cancer during 24 years of follow-up: results from the International Breast Cancer Study Group trials I to V. J Clin Oncol 34(9):927–935. 10.1200/JCO.2015.62.3504
</cite> [<a href="https://doi.org/10.1200/JCO.2015.62.3504" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC4933127/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/26786933/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Colleoni%20M%20et%20al%20(2016)%20Annual%20hazard%20rates%20of%20recurrence%20for%20breast%20cancer%20during%2024%20years%20of%20follow-up:%20results%20from%20the%20International%20Breast%20Cancer%20Study%20Group%20trials%20I%20to%20V.%20J%20Clin%20Oncol%2034(9):927%E2%80%93935.%2010.1200/JCO.2015.62.3504" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR52">
<cite>Coombes RC et al (2019) Personalized detection of circulating tumor DNA antedates breast cancer metastatic recurrence. Clin Cancer Res off J Am Assoc Cancer Res 25(14):4255–4263. 10.1158/1078-0432.CCR-18-3663</cite> [<a href="https://doi.org/10.1158/1078-0432.CCR-18-3663" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/30992300/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Coombes%20RC%20et%20al%20(2019)%20Personalized%20detection%20of%20circulating%20tumor%20DNA%20antedates%20breast%20cancer%20metastatic%20recurrence.%20Clin%20Cancer%20Res%20off%20J%20Am%20Assoc%20Cancer%20Res%2025(14):4255%E2%80%934263.%2010.1158/1078-0432.CCR-18-3663" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR53">
<cite>Coskun T, Kosova F, Ari Z, Sakarya A, Kaya Y (2016) Effect of oncological treatment on serum adipocytokine levels in patients with stage II-III breast cancer. Mol Clin Oncol 4(5):893–897. 10.3892/mco.2016.815
</cite> [<a href="https://doi.org/10.3892/mco.2016.815" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC4840827/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/27123303/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Coskun%20T,%20Kosova%20F,%20Ari%20Z,%20Sakarya%20A,%20Kaya%20Y%20(2016)%20Effect%20of%20oncological%20treatment%20on%20serum%20adipocytokine%20levels%20in%20patients%20with%20stage%20II-III%20breast%20cancer.%20Mol%20Clin%20Oncol%204(5):893%E2%80%93897.%2010.3892/mco.2016.815" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR54">
<cite>Cristofanilli M et al (2019) The clinical use of circulating tumor cells (CTCs) enumeration for staging of metastatic breast cancer (MBC): international expert consensus paper. Crit Rev Oncol Hematol 134:39–45. 10.1016/j.critrevonc.2018.12.004
</cite> [<a href="https://doi.org/10.1016/j.critrevonc.2018.12.004" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/30771872/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Cristofanilli%20M%20et%20al%20(2019)%20The%20clinical%20use%20of%20circulating%20tumor%20cells%20(CTCs)%20enumeration%20for%20staging%20of%20metastatic%20breast%20cancer%20(MBC):%20international%20expert%20consensus%20paper.%20Crit%20Rev%20Oncol%20Hematol%20134:39%E2%80%9345.%2010.1016/j.critrevonc.2018.12.004" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR55">
<cite>Cullinane C et al (2020) Association of circulating tumor DNA with disease-free survival in breast cancer: a systematic review and meta-analysis. JAMA Netw Open 3(11):e2026921. 10.1001/jamanetworkopen.2020.26921
</cite> [<a href="https://doi.org/10.1001/jamanetworkopen.2020.26921" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC7677763/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/33211112/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Cullinane%20C%20et%20al%20(2020)%20Association%20of%20circulating%20tumor%20DNA%20with%20disease-free%20survival%20in%20breast%20cancer:%20a%20systematic%20review%20and%20meta-analysis.%20JAMA%20Netw%20Open%203(11):e2026921.%2010.1001/jamanetworkopen.2020.26921" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR56">
<cite>da Costa Vieira RA, Biller G, Uemura G, Ruiz CA, Curado MP (2017) Breast cancer screening in developing countries. Clinics 72(4):244–253. 10.6061/clinics/2017(04)09
</cite> [<a href="https://doi.org/10.6061/clinics/2017(04)09" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC5401614/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/28492725/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?da%20Costa%20Vieira%20RA,%20Biller%20G,%20Uemura%20G,%20Ruiz%20CA,%20Curado%20MP%20(2017)%20Breast%20cancer%20screening%20in%20developing%20countries.%20Clinics%2072(4):244%E2%80%93253.%2010.6061/clinics/2017(04)09" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR57">
<cite>Dai X, Xiang L, Li T, Bai Z (2016) Cancer hallmarks, biomarkers and breast cancer molecular subtypes. J Cancer 7(10):1281–1294. 10.7150/jca.13141
</cite> [<a href="https://doi.org/10.7150/jca.13141" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC4934037/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/27390604/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Dai%20X,%20Xiang%20L,%20Li%20T,%20Bai%20Z%20(2016)%20Cancer%20hallmarks,%20biomarkers%20and%20breast%20cancer%20molecular%20subtypes.%20J%20Cancer%207(10):1281%E2%80%931294.%2010.7150/jca.13141" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR58">
<cite>Dalamaga M, Sotiropoulos G, Karmaniolas K, Pelekanos N, Papadavid E, Lekka A (2013) Serum resistin: a biomarker of breast cancer in postmenopausal women? Association with clinicopathological characteristics, tumor markers, inflammatory and metabolic parameters. Clin Biochem 46(7–8):584–590. 10.1016/j.clinbiochem.2013.01.001
</cite> [<a href="https://doi.org/10.1016/j.clinbiochem.2013.01.001" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/23321342/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Dalamaga%20M,%20Sotiropoulos%20G,%20Karmaniolas%20K,%20Pelekanos%20N,%20Papadavid%20E,%20Lekka%20A%20(2013)%20Serum%20resistin:%20a%20biomarker%20of%20breast%20cancer%20in%20postmenopausal%20women?%20Association%20with%20clinicopathological%20characteristics,%20tumor%20markers,%20inflammatory%20and%20metabolic%20parameters.%20Clin%20Biochem%2046(7%E2%80%938):584%E2%80%93590.%2010.1016/j.clinbiochem.2013.01.001" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR59">
<cite>Dalotto-Moreno T et al (2013) Targeting galectin-1 overcomes breast cancer-associated immunosuppression and prevents metastatic disease. Cancer Res 73(3):1107–1117. 10.1158/0008-5472.CAN-12-2418
</cite> [<a href="https://doi.org/10.1158/0008-5472.CAN-12-2418" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/23204230/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Dalotto-Moreno%20T%20et%20al%20(2013)%20Targeting%20galectin-1%20overcomes%20breast%20cancer-associated%20immunosuppression%20and%20prevents%20metastatic%20disease.%20Cancer%20Res%2073(3):1107%E2%80%931117.%2010.1158/0008-5472.CAN-12-2418" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR60">
<cite>Dao J, Conway PJ, Subramani B, Meyyappan D, Russell S, Mahadevan D (2023) Using cfDNA and ctDNA as oncologic markers: a path to clinical validation. Int J Mol Sci 24(17):13219. 10.3390/ijms241713219
</cite> [<a href="https://doi.org/10.3390/ijms241713219" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC10487653/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/37686024/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Dao%20J,%20Conway%20PJ,%20Subramani%20B,%20Meyyappan%20D,%20Russell%20S,%20Mahadevan%20D%20(2023)%20Using%20cfDNA%20and%20ctDNA%20as%20oncologic%20markers:%20a%20path%20to%20clinical%20validation.%20Int%20J%20Mol%20Sci%2024(17):13219.%2010.3390/ijms241713219" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR61">
<cite>de Miranda FS et al (2024) MicroRNA as a promising molecular biomarker in the diagnosis of breast cancer. Front Mol Biosci 11:1337706. 10.3389/fmolb.2024.1337706
</cite> [<a href="https://doi.org/10.3389/fmolb.2024.1337706" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC11134088/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/38813102/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?de%20Miranda%20FS%20et%20al%20(2024)%20MicroRNA%20as%20a%20promising%20molecular%20biomarker%20in%20the%20diagnosis%20of%20breast%20cancer.%20Front%20Mol%20Biosci%2011:1337706.%2010.3389/fmolb.2024.1337706" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR62">
<cite>De Talhouet S et al (2020) Clinical outcome of breast cancer in carriers of BRCA1 and BRCA2 mutations according to molecular subtypes. Sci Rep 10(1):7073. 10.1038/s41598-020-63759-1
</cite> [<a href="https://doi.org/10.1038/s41598-020-63759-1" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC7184602/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/32341426/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?De%20Talhouet%20S%20et%20al%20(2020)%20Clinical%20outcome%20of%20breast%20cancer%20in%20carriers%20of%20BRCA1%20and%20BRCA2%20mutations%20according%20to%20molecular%20subtypes.%20Sci%20Rep%2010(1):7073.%2010.1038/s41598-020-63759-1" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR63">
<cite>Delacour D, Koch A, Jacob R (2009) The role of galectins in protein trafficking. Traffic Cph Den 10(10):1405–1413. 10.1111/j.1600-0854.2009.00960.x</cite> [<a href="https://doi.org/10.1111/j.1600-0854.2009.00960.x" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/19650851/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Delacour%20D,%20Koch%20A,%20Jacob%20R%20(2009)%20The%20role%20of%20galectins%20in%20protein%20trafficking.%20Traffic%20Cph%20Den%2010(10):1405%E2%80%931413.%2010.1111/j.1600-0854.2009.00960.x" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR64">
<cite>Demers M et al (2010) Overexpression of galectin-7, a myoepithelial cell marker, enhances spontaneous metastasis of breast cancer cells. Am J Pathol 176(6):3023–3031. 10.2353/ajpath.2010.090876
</cite> [<a href="https://doi.org/10.2353/ajpath.2010.090876" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC2877862/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/20382700/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Demers%20M%20et%20al%20(2010)%20Overexpression%20of%20galectin-7,%20a%20myoepithelial%20cell%20marker,%20enhances%20spontaneous%20metastasis%20of%20breast%20cancer%20cells.%20Am%20J%20Pathol%20176(6):3023%E2%80%933031.%2010.2353/ajpath.2010.090876" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR65">
<cite>Dempsey N, Sandoval A, Mahtani R (2023) Metastatic HER2-positive breast cancer: Is there an optimal sequence of therapy? Curr Treat Options Oncol 24(9):1120–1137. 10.1007/s11864-023-01108-w
</cite> [<a href="https://doi.org/10.1007/s11864-023-01108-w" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/37428332/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Dempsey%20N,%20Sandoval%20A,%20Mahtani%20R%20(2023)%20Metastatic%20HER2-positive%20breast%20cancer:%20Is%20there%20an%20optimal%20sequence%20of%20therapy?%20Curr%20Treat%20Options%20Oncol%2024(9):1120%E2%80%931137.%2010.1007/s11864-023-01108-w" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR66">
<cite>Deshmukh SK et al (2015) Resistin and interleukin-6 exhibit racially-disparate expression in breast cancer patients, display molecular association and promote growth and aggressiveness of tumor cells through STAT3 activation. Oncotarget 6(13):11231–11241. 10.18632/oncotarget.3591
</cite> [<a href="https://doi.org/10.18632/oncotarget.3591" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC4484452/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/25868978/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Deshmukh%20SK%20et%20al%20(2015)%20Resistin%20and%20interleukin-6%20exhibit%20racially-disparate%20expression%20in%20breast%20cancer%20patients,%20display%20molecular%20association%20and%20promote%20growth%20and%20aggressiveness%20of%20tumor%20cells%20through%20STAT3%20activation.%20Oncotarget%206(13):11231%E2%80%9311241.%2010.18632/oncotarget.3591" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR67">
<cite>Deshmukh SK et al (2017) Resistin potentiates chemoresistance and stemness of breast cancer cells: implications for racially disparate therapeutic outcomes. Cancer Lett 396:21–29. 10.1016/j.canlet.2017.03.010
</cite> [<a href="https://doi.org/10.1016/j.canlet.2017.03.010" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC5437742/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/28302531/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Deshmukh%20SK%20et%20al%20(2017)%20Resistin%20potentiates%20chemoresistance%20and%20stemness%20of%20breast%20cancer%20cells:%20implications%20for%20racially%20disparate%20therapeutic%20outcomes.%20Cancer%20Lett%20396:21%E2%80%9329.%2010.1016/j.canlet.2017.03.010" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR68">
<cite>Destounis S, Johnston L, Highnam R, Arieno A, Morgan R, Chan A (2017) Using volumetric breast density to quantify the potential masking risk of mammographic density. AJR Am J Roentgenol 208(1):222–227. 10.2214/AJR.16.16489
</cite> [<a href="https://doi.org/10.2214/AJR.16.16489" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/27824483/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Destounis%20S,%20Johnston%20L,%20Highnam%20R,%20Arieno%20A,%20Morgan%20R,%20Chan%20A%20(2017)%20Using%20volumetric%20breast%20density%20to%20quantify%20the%20potential%20masking%20risk%20of%20mammographic%20density.%20AJR%20Am%20J%20Roentgenol%20208(1):222%E2%80%93227.%2010.2214/AJR.16.16489" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR69">
<cite>Dong X et al (2013) Combined measurement of CA 15–3 with novel autoantibodies improves diagnostic accuracy for breast cancer. OncoTargets Ther 6:273–279. 10.2147/OTT.S43122</cite> [<a href="https://doi.org/10.2147/OTT.S43122" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC3615893/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/23569391/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Dong%20X%20et%20al%20(2013)%20Combined%20measurement%20of%20CA%2015%E2%80%933%20with%20novel%20autoantibodies%20improves%20diagnostic%20accuracy%20for%20breast%20cancer.%20OncoTargets%20Ther%206:273%E2%80%93279.%2010.2147/OTT.S43122" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR70">
<cite>Dorado E et al (2024) Extracellular vesicles as a promising source of lipid biomarkers for breast cancer detection in blood plasma. J Extracell Vesicles 13(3):e12419. 10.1002/jev2.12419
</cite> [<a href="https://doi.org/10.1002/jev2.12419" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC10914699/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/38443328/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Dorado%20E%20et%20al%20(2024)%20Extracellular%20vesicles%20as%20a%20promising%20source%20of%20lipid%20biomarkers%20for%20breast%20cancer%20detection%20in%20blood%20plasma.%20J%20Extracell%20Vesicles%2013(3):e12419.%2010.1002/jev2.12419" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR71">
<cite>Dos Santos E et al (2008) Adiponectin mediates an antiproliferative response in human MDA-MB 231 breast cancer cells. Oncol Rep 20(4):971–977
</cite> [<a href="https://pubmed.ncbi.nlm.nih.gov/18813842/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Dos%20Santos%20E%20et%20al%20(2008)%20Adiponectin%20mediates%20an%20antiproliferative%20response%20in%20human%20MDA-MB%20231%20breast%20cancer%20cells.%20Oncol%20Rep%2020(4):971%E2%80%93977" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR72">
<cite>Duffy MJ, Synnott NC, Crown J (2018) Mutant p53 in breast cancer: potential as a therapeutic target and biomarker. Breast Cancer Res Treat 170(2):213–219. 10.1007/s10549-018-4753-7
</cite> [<a href="https://doi.org/10.1007/s10549-018-4753-7" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/29564741/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Duffy%20MJ,%20Synnott%20NC,%20Crown%20J%20(2018)%20Mutant%20p53%20in%20breast%20cancer:%20potential%20as%20a%20therapeutic%20target%20and%20biomarker.%20Breast%20Cancer%20Res%20Treat%20170(2):213%E2%80%93219.%2010.1007/s10549-018-4753-7" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR73">
<cite>Duque G et al (2022) Cancer biomarkers in liquid biopsy for early detection of breast cancer: a systematic review. Clin Med Insights Oncol 16:11795549221134832. 10.1177/11795549221134831
</cite> [<a href="https://doi.org/10.1177/11795549221134831" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC9634213/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/36338263/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Duque%20G%20et%20al%20(2022)%20Cancer%20biomarkers%20in%20liquid%20biopsy%20for%20early%20detection%20of%20breast%20cancer:%20a%20systematic%20review.%20Clin%20Med%20Insights%20Oncol%2016:11795549221134832.%2010.1177/11795549221134831" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR74">
<cite>Dyba T et al (2021) The European cancer burden in 2020: incidence and mortality estimates for 40 countries and 25 major cancers. Eur J Cancer Oxf Engl 1990(157):308–347. 10.1016/j.ejca.2021.07.039</cite> [<a href="https://doi.org/10.1016/j.ejca.2021.07.039" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC8568058/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/34560371/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Dyba%20T%20et%20al%20(2021)%20The%20European%20cancer%20burden%20in%202020:%20incidence%20and%20mortality%20estimates%20for%2040%20countries%20and%2025%20major%20cancers.%20Eur%20J%20Cancer%20Oxf%20Engl%201990(157):308%E2%80%93347.%2010.1016/j.ejca.2021.07.039" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR75">
<cite>Early Breast Cancer Trialists Collaborative Group (EBCTCG) (2011) Relevance of breast cancer hormone receptors and other factors to the efficacy of adjuvant tamoxifen: patient-level meta-analysis of randomised trials. Lancet Lond Engl 378(9793):771–784. 10.1016/S0140-6736(11)60993-8</cite> [<a href="https://doi.org/10.1016/S0140-6736(11)60993-8" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC3163848/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/21802721/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Early%20Breast%20Cancer%20Trialists%20Collaborative%20Group%20(EBCTCG)%20(2011)%20Relevance%20of%20breast%20cancer%20hormone%20receptors%20and%20other%20factors%20to%20the%20efficacy%20of%20adjuvant%20tamoxifen:%20patient-level%20meta-analysis%20of%20randomised%20trials.%20Lancet%20Lond%20Engl%20378(9793):771%E2%80%93784.%2010.1016/S0140-6736(11)60993-8" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR76">
<cite>Eigeliene N, Saarenheimo J, Jekunen A (2019) Potential of liquid biopsies for breast cancer screening, diagnosis, and response to treatment. Oncology 96(3):115–124. 10.1159/000495615
</cite> [<a href="https://doi.org/10.1159/000495615" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/30654364/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Eigeliene%20N,%20Saarenheimo%20J,%20Jekunen%20A%20(2019)%20Potential%20of%20liquid%20biopsies%20for%20breast%20cancer%20screening,%20diagnosis,%20and%20response%20to%20treatment.%20Oncology%2096(3):115%E2%80%93124.%2010.1159/000495615" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR77">
<cite>Elhelbawy NG, Zaid IF, Khalifa AA, Gohar SF, Fouda EA (2021) miRNA-148a and miRNA-30c expressions as potential biomarkers in breast cancer patients. Biochem Biophys Rep 27:101060. 10.1016/j.bbrep.2021.101060
</cite> [<a href="https://doi.org/10.1016/j.bbrep.2021.101060" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC8239439/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/34195390/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Elhelbawy%20NG,%20Zaid%20IF,%20Khalifa%20AA,%20Gohar%20SF,%20Fouda%20EA%20(2021)%20miRNA-148a%20and%20miRNA-30c%20expressions%20as%20potential%20biomarkers%20in%20breast%20cancer%20patients.%20Biochem%20Biophys%20Rep%2027:101060.%2010.1016/j.bbrep.2021.101060" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR78">
<cite>Evans RL, Pottala JV, Egland KA (2014) Classifying patients for breast cancer by detection of autoantibodies against a panel of conformation-carrying antigens. Cancer Prev Res Phila Pa 7(5):545. 10.1158/1940-6207.CAPR-13-0416</cite> [<a href="https://doi.org/10.1158/1940-6207.CAPR-13-0416" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC4437507/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/24641868/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Evans%20RL,%20Pottala%20JV,%20Egland%20KA%20(2014)%20Classifying%20patients%20for%20breast%20cancer%20by%20detection%20of%20autoantibodies%20against%20a%20panel%20of%20conformation-carrying%20antigens.%20Cancer%20Prev%20Res%20Phila%20Pa%207(5):545.%2010.1158/1940-6207.CAPR-13-0416" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR79">
<cite>Fabisiewicz A, Szostakowska-Rodzos M, Zaczek AJ, Grzybowska EA (2020) Circulating tumor cells in early and advanced breast cancer; biology and prognostic value. Int J Mol Sci 21(5):1671. 10.3390/ijms21051671
</cite> [<a href="https://doi.org/10.3390/ijms21051671" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC7084781/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/32121386/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Fabisiewicz%20A,%20Szostakowska-Rodzos%20M,%20Zaczek%20AJ,%20Grzybowska%20EA%20(2020)%20Circulating%20tumor%20cells%20in%20early%20and%20advanced%20breast%20cancer;%20biology%20and%20prognostic%20value.%20Int%20J%20Mol%20Sci%2021(5):1671.%2010.3390/ijms21051671" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR80">
<cite>Falk RT et al (2006) Interrelationships between serum leptin, IGF-1, IGFBP3, C-peptide and prolactin and breast cancer risk in young women. Breast Cancer Res Treat 98(2):157–165. 10.1007/s10549-005-9144-1
</cite> [<a href="https://doi.org/10.1007/s10549-005-9144-1" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/16502016/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Falk%20RT%20et%20al%20(2006)%20Interrelationships%20between%20serum%20leptin,%20IGF-1,%20IGFBP3,%20C-peptide%20and%20prolactin%20and%20breast%20cancer%20risk%20in%20young%20women.%20Breast%20Cancer%20Res%20Treat%2098(2):157%E2%80%93165.%2010.1007/s10549-005-9144-1" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR81">
<cite>Fan T et al (2018) Branched rolling circle amplification method for measuring serum circulating microRNA levels for early breast cancer detection. Cancer Sci 109(9):2897–2906. 10.1111/cas.13725
</cite> [<a href="https://doi.org/10.1111/cas.13725" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC6125458/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/29981251/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Fan%20T%20et%20al%20(2018)%20Branched%20rolling%20circle%20amplification%20method%20for%20measuring%20serum%20circulating%20microRNA%20levels%20for%20early%20breast%20cancer%20detection.%20Cancer%20Sci%20109(9):2897%E2%80%932906.%2010.1111/cas.13725" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR82">
<cite>Fang C, Cao Y, Liu X, Zeng X-T, Li Y (2017a) Serum CA125 is a predictive marker for breast cancer outcomes and correlates with molecular subtypes. Oncotarget 8(38):63963–63970. 10.18632/oncotarget.19246
</cite> [<a href="https://doi.org/10.18632/oncotarget.19246" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC5609976/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/28969044/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Fang%20C,%20Cao%20Y,%20Liu%20X,%20Zeng%20X-T,%20Li%20Y%20(2017a)%20Serum%20CA125%20is%20a%20predictive%20marker%20for%20breast%20cancer%20outcomes%20and%20correlates%20with%20molecular%20subtypes.%20Oncotarget%208(38):63963%E2%80%9363970.%2010.18632/oncotarget.19246" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR83">
<cite>Fang H, Xie J, Zhang M, Zhao Z, Wan Y, Yao Y (2017b) miRNA-21 promotes proliferation and invasion of triple-negative breast cancer cells through targeting PTEN. Am J Transl Res 9(3):953–961
</cite> [<a href="/articles/PMC5375989/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/28386324/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Fang%20H,%20Xie%20J,%20Zhang%20M,%20Zhao%20Z,%20Wan%20Y,%20Yao%20Y%20(2017b)%20miRNA-21%20promotes%20proliferation%20and%20invasion%20of%20triple-negative%20breast%20cancer%20cells%20through%20targeting%20PTEN.%20Am%20J%20Transl%20Res%209(3):953%E2%80%93961" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR84">
<cite>Fang R et al (2018) Plasma MicroRNA pair panels as novel biomarkers for detection of early stage breast cancer. Front Physiol 9:1879. 10.3389/fphys.2018.01879
</cite> [<a href="https://doi.org/10.3389/fphys.2018.01879" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC6331533/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/30670982/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Fang%20R%20et%20al%20(2018)%20Plasma%20MicroRNA%20pair%20panels%20as%20novel%20biomarkers%20for%20detection%20of%20early%20stage%20breast%20cancer.%20Front%20Physiol%209:1879.%2010.3389/fphys.2018.01879" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR85">
<cite>Farazi TA et al (2011) Microrna sequence and expression analysis in breast tumors by deep sequencing. Cancer Res 71(13):4443–4453. 10.1158/0008-5472.CAN-11-0608
</cite> [<a href="https://doi.org/10.1158/0008-5472.CAN-11-0608" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC3129492/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/21586611/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Farazi%20TA%20et%20al%20(2011)%20Microrna%20sequence%20and%20expression%20analysis%20in%20breast%20tumors%20by%20deep%20sequencing.%20Cancer%20Res%2071(13):4443%E2%80%934453.%2010.1158/0008-5472.CAN-11-0608" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR86">
<cite>Feng X-Y, Zhu S-X, Pu K-J, Huang H-J, Chen Y-Q, Wang W-T (2023) New insight into circRNAs: characterization, strategies, and biomedical applications. Exp Hematol Oncol 12(1):91. 10.1186/s40164-023-00451-w
</cite> [<a href="https://doi.org/10.1186/s40164-023-00451-w" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC10568798/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/37828589/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Feng%20X-Y,%20Zhu%20S-X,%20Pu%20K-J,%20Huang%20H-J,%20Chen%20Y-Q,%20Wang%20W-T%20(2023)%20New%20insight%20into%20circRNAs:%20characterization,%20strategies,%20and%20biomedical%20applications.%20Exp%20Hematol%20Oncol%2012(1):91.%2010.1186/s40164-023-00451-w" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR87">
<cite>Funkhouser AT et al (2022) KIT mutations correlate with higher galectin levels and brain metastasis in breast and non-small cell lung cancer. Cancers (Basel) 14(11):2781. 10.3390/cancers14112781
</cite> [<a href="https://doi.org/10.3390/cancers14112781" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC9179545/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/35681762/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Funkhouser%20AT%20et%20al%20(2022)%20KIT%20mutations%20correlate%20with%20higher%20galectin%20levels%20and%20brain%20metastasis%20in%20breast%20and%20non-small%20cell%20lung%20cancer.%20Cancers%20(Basel)%2014(11):2781.%2010.3390/cancers14112781" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR88">
<cite>Funkhouser A, Shuster H, Martin JC, Edenfield WJ, Blenda AV (2023) Pattern analysis of serum galectins-1, -3, and -9 in breast cancer. Cancers (Basel) 15(15):3809. 10.3390/cancers15153809
</cite> [<a href="https://doi.org/10.3390/cancers15153809" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC10417135/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/37568625/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Funkhouser%20A,%20Shuster%20H,%20Martin%20JC,%20Edenfield%20WJ,%20Blenda%20AV%20(2023)%20Pattern%20analysis%20of%20serum%20galectins-1,%20-3,%20and%20-9%20in%20breast%20cancer.%20Cancers%20(Basel)%2015(15):3809.%2010.3390/cancers15153809" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR89">
<cite>Garcia-Murillas I et al (2025) Whole genome sequencing-powered ctDNA sequencing for breast cancer detection. Ann Oncol off J Eur Soc Med Oncol 36(6):673–681. 10.1016/j.annonc.2025.01.021</cite> [<a href="https://doi.org/10.1016/j.annonc.2025.01.021" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/39914664/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Garcia-Murillas%20I%20et%20al%20(2025)%20Whole%20genome%20sequencing-powered%20ctDNA%20sequencing%20for%20breast%20cancer%20detection.%20Ann%20Oncol%20off%20J%20Eur%20Soc%20Med%20Oncol%2036(6):673%E2%80%93681.%2010.1016/j.annonc.2025.01.021" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR90">
<cite>Gegios AR, Peterson MS, Fowler AM (2023) Breast cancer screening and diagnosis: recent advances in imaging and current limitations. PET Clin 18(4):459–471. 10.1016/j.cpet.2023.04.003
</cite> [<a href="https://doi.org/10.1016/j.cpet.2023.04.003" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/37296043/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Gegios%20AR,%20Peterson%20MS,%20Fowler%20AM%20(2023)%20Breast%20cancer%20screening%20and%20diagnosis:%20recent%20advances%20in%20imaging%20and%20current%20limitations.%20PET%20Clin%2018(4):459%E2%80%93471.%2010.1016/j.cpet.2023.04.003" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR91">
<cite>Georgiou GP et al (2016) Serum resistin is inversely related to breast cancer risk in premenopausal women. Breast Edinb Scotl 29:163–169. 10.1016/j.breast.2016.07.025</cite> [<a href="https://doi.org/10.1016/j.breast.2016.07.025" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/27521488/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Georgiou%20GP%20et%20al%20(2016)%20Serum%20resistin%20is%20inversely%20related%20to%20breast%20cancer%20risk%20in%20premenopausal%20women.%20Breast%20Edinb%20Scotl%2029:163%E2%80%93169.%2010.1016/j.breast.2016.07.025" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR92">
<cite>Grogan Fleege NM, Cobain EF (2022) Breast cancer management in 2021: A primer for the obstetrics and gynecology. Best Pract Res Clin Obstet Gynaecol 82:30–45. 10.1016/j.bpobgyn.2022.02.004
</cite> [<a href="https://doi.org/10.1016/j.bpobgyn.2022.02.004" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/35307285/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Grogan%20Fleege%20NM,%20Cobain%20EF%20(2022)%20Breast%20cancer%20management%20in%202021:%20A%20primer%20for%20the%20obstetrics%20and%20gynecology.%20Best%20Pract%20Res%20Clin%20Obstet%20Gynaecol%2082:30%E2%80%9345.%2010.1016/j.bpobgyn.2022.02.004" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR93">
<cite>Grosset A-A et al (2014) Cytosolic galectin-7 impairs p53 functions and induces chemoresistance in breast cancer cells. BMC Cancer 14:801. 10.1186/1471-2407-14-801
</cite> [<a href="https://doi.org/10.1186/1471-2407-14-801" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC4228062/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/25367122/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Grosset%20A-A%20et%20al%20(2014)%20Cytosolic%20galectin-7%20impairs%20p53%20functions%20and%20induces%20chemoresistance%20in%20breast%20cancer%20cells.%20BMC%20Cancer%2014:801.%2010.1186/1471-2407-14-801" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR94">
<cite>Grossmann ME, Nkhata KJ, Mizuno NK, Ray A, Cleary MP (2008) Effects of adiponectin on breast cancer cell growth and signaling. Br J Cancer 98(2):370–379. 10.1038/sj.bjc.6604166
</cite> [<a href="https://doi.org/10.1038/sj.bjc.6604166" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC2361440/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/18182989/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Grossmann%20ME,%20Nkhata%20KJ,%20Mizuno%20NK,%20Ray%20A,%20Cleary%20MP%20(2008)%20Effects%20of%20adiponectin%20on%20breast%20cancer%20cell%20growth%20and%20signaling.%20Br%20J%20Cancer%2098(2):370%E2%80%93379.%2010.1038/sj.bjc.6604166" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR95">
<cite>Gu L, Cao C, Fu J, Li Q, Li D-H, Chen M-Y (2018) Serum adiponectin in breast cancer: a meta-analysis. Medicine (Baltimore) 97(29):e11433. 10.1097/MD.0000000000011433
</cite> [<a href="https://doi.org/10.1097/MD.0000000000011433" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC6086546/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/30024516/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Gu%20L,%20Cao%20C,%20Fu%20J,%20Li%20Q,%20Li%20D-H,%20Chen%20M-Y%20(2018)%20Serum%20adiponectin%20in%20breast%20cancer:%20a%20meta-analysis.%20Medicine%20(Baltimore)%2097(29):e11433.%2010.1097/MD.0000000000011433" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR96">
<cite>Gu L, Wang C-D, Cao C, Cai L-R, Li D-H, Zheng Y-Z (2019) Association of serum leptin with breast cancer: a meta-analysis. Medicine (Baltimore) 98(5):e14094. 10.1097/MD.0000000000014094
</cite> [<a href="https://doi.org/10.1097/MD.0000000000014094" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC6380739/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/30702563/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Gu%20L,%20Wang%20C-D,%20Cao%20C,%20Cai%20L-R,%20Li%20D-H,%20Zheng%20Y-Z%20(2019)%20Association%20of%20serum%20leptin%20with%20breast%20cancer:%20a%20meta-analysis.%20Medicine%20(Baltimore)%2098(5):e14094.%2010.1097/MD.0000000000014094" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR97">
<cite>Guan G et al (2020) Utility of urinary ctDNA to monitoring minimal residual disease in early breast cancer patients. Cancer Biomark Sect Dis Markers 28(1):111–119. 10.3233/CBM-190523</cite> [<a href="https://doi.org/10.3233/CBM-190523" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/32176625/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Guan%20G%20et%20al%20(2020)%20Utility%20of%20urinary%20ctDNA%20to%20monitoring%20minimal%20residual%20disease%20in%20early%20breast%20cancer%20patients.%20Cancer%20Biomark%20Sect%20Dis%20Markers%2028(1):111%E2%80%93119.%2010.3233/CBM-190523" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR98">
<cite>Gurel Cayir E et al (2020) Preliminary study of serum Galectin-1 in breast cancer carcinogenesis [Izmir Oncology Group (IZOG) study]. J BUON off J Balk Union Oncol 25(2):675–680</cite> [<a href="https://pubmed.ncbi.nlm.nih.gov/32521852/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Gurel%20Cayir%20E%20et%20al%20(2020)%20Preliminary%20study%20of%20serum%20Galectin-1%20in%20breast%20cancer%20carcinogenesis%20%5BIzmir%20Oncology%20Group%20(IZOG)%20study%5D.%20J%20BUON%20off%20J%20Balk%20Union%20Oncol%2025(2):675%E2%80%93680" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR99">
<cite>Han J-G et al (2017) A novel panel of serum miR-21/miR-155/miR-365 as a potential diagnostic biomarker for breast cancer. Ann Surg Treat Res 92(2):55–66. 10.4174/astr.2017.92.2.55
</cite> [<a href="https://doi.org/10.4174/astr.2017.92.2.55" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC5309178/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/28203552/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Han%20J-G%20et%20al%20(2017)%20A%20novel%20panel%20of%20serum%20miR-21/miR-155/miR-365%20as%20a%20potential%20diagnostic%20biomarker%20for%20breast%20cancer.%20Ann%20Surg%20Treat%20Res%2092(2):55%E2%80%9366.%2010.4174/astr.2017.92.2.55" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR100">
<cite>Hanker AB, Sudhan DR, Arteaga CL (2020) Overcoming endocrine resistance in breast cancer. Cancer Cell 37(4):496–513. 10.1016/j.ccell.2020.03.009
</cite> [<a href="https://doi.org/10.1016/j.ccell.2020.03.009" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC7169993/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/32289273/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Hanker%20AB,%20Sudhan%20DR,%20Arteaga%20CL%20(2020)%20Overcoming%20endocrine%20resistance%20in%20breast%20cancer.%20Cancer%20Cell%2037(4):496%E2%80%93513.%2010.1016/j.ccell.2020.03.009" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR101">
<cite>Harashchenko O (2024) Assessment of circulating miRNA levels in breast cancer patients depending on clinical characteristics and chemotherapy. Exp Oncol 45(4):451–456. 10.15407/exp-oncology.2023.04.451
</cite> [<a href="https://doi.org/10.15407/exp-oncology.2023.04.451" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/38328845/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Harashchenko%20O%20(2024)%20Assessment%20of%20circulating%20miRNA%20levels%20in%20breast%20cancer%20patients%20depending%20on%20clinical%20characteristics%20and%20chemotherapy.%20Exp%20Oncol%2045(4):451%E2%80%93456.%2010.15407/exp-oncology.2023.04.451" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR102">
<cite>Harbeck N (2022) Neoadjuvant and adjuvant treatment of patients with HER2-positive early breast cancer. Breast Edinb. Scotl. 62(Suppl 1):S12–S16. 10.1016/j.breast.2022.01.006</cite> [<a href="https://doi.org/10.1016/j.breast.2022.01.006" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC9097807/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/35148934/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Harbeck%20N%20(2022)%20Neoadjuvant%20and%20adjuvant%20treatment%20of%20patients%20with%20HER2-positive%20early%20breast%20cancer.%20Breast%20Edinb.%20Scotl.%2062(Suppl%201):S12%E2%80%93S16.%2010.1016/j.breast.2022.01.006" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR103">
<cite>Harris HR, Tworoger SS, Hankinson SE, Rosner BA, Michels KB (2011) Plasma leptin levels and risk of breast cancer in premenopausal women. Cancer Prev Res Phila Pa 4(9):1449–1456. 10.1158/1940-6207.CAPR-11-0125</cite> [<a href="https://doi.org/10.1158/1940-6207.CAPR-11-0125" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC3168067/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/21680707/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Harris%20HR,%20Tworoger%20SS,%20Hankinson%20SE,%20Rosner%20BA,%20Michels%20KB%20(2011)%20Plasma%20leptin%20levels%20and%20risk%20of%20breast%20cancer%20in%20premenopausal%20women.%20Cancer%20Prev%20Res%20Phila%20Pa%204(9):1449%E2%80%931456.%2010.1158/1940-6207.CAPR-11-0125" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR104">
<cite>He X, Jiang X-H, Yie KY-X, Chen J, Zhang J-B, Yie S-M (2020) An autoantibody against a 48-Kd fragment of human DNA-topoiomerase I in breast cancer: implication for diagnosis and prognosis, and antibody-dependent cellular cytotoxicity <em>in vitro</em>. Cell Immunol 347:104007. 10.1016/j.cellimm.2019.104007
</cite> [<a href="https://doi.org/10.1016/j.cellimm.2019.104007" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/31732123/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?He%20X,%20Jiang%20X-H,%20Yie%20KY-X,%20Chen%20J,%20Zhang%20J-B,%20Yie%20S-M%20(2020)%20An%20autoantibody%20against%20a%2048-Kd%20fragment%20of%20human%20DNA-topoiomerase%20I%20in%20breast%20cancer:%20implication%20for%20diagnosis%20and%20prognosis,%20and%20antibody-dependent%20cellular%20cytotoxicity%20in%20vitro.%20Cell%20Immunol%20347:104007.%2010.1016/j.cellimm.2019.104007" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR105">
<cite>He S et al (2023) Investigation of LGALS2 expression in the TCGA database reveals its clinical relevance in breast cancer immunotherapy and drug resistance. Sci Rep 13(1):17445. 10.1038/s41598-023-44777-1
</cite> [<a href="https://doi.org/10.1038/s41598-023-44777-1" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC10576795/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/37838802/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?He%20S%20et%20al%20(2023)%20Investigation%20of%20LGALS2%20expression%20in%20the%20TCGA%20database%20reveals%20its%20clinical%20relevance%20in%20breast%20cancer%20immunotherapy%20and%20drug%20resistance.%20Sci%20Rep%2013(1):17445.%2010.1038/s41598-023-44777-1" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR106">
<cite>Hilton HN, Clarke CL, Graham JD (2018) Estrogen and progesterone signalling in the normal breast and its implications for cancer development. Mol Cell Endocrinol 466:2–14. 10.1016/j.mce.2017.08.011
</cite> [<a href="https://doi.org/10.1016/j.mce.2017.08.011" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/28851667/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Hilton%20HN,%20Clarke%20CL,%20Graham%20JD%20(2018)%20Estrogen%20and%20progesterone%20signalling%20in%20the%20normal%20breast%20and%20its%20implications%20for%20cancer%20development.%20Mol%20Cell%20Endocrinol%20466:2%E2%80%9314.%2010.1016/j.mce.2017.08.011" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR107">
<cite>Hong C-Q et al (2021) A panel of tumor-associated autoantibodies for the detection of early-stage breast cancer. J Cancer 12(9):2747–2755. 10.7150/jca.57019
</cite> [<a href="https://doi.org/10.7150/jca.57019" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC8040727/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/33854634/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Hong%20C-Q%20et%20al%20(2021)%20A%20panel%20of%20tumor-associated%20autoantibodies%20for%20the%20detection%20of%20early-stage%20breast%20cancer.%20J%20Cancer%2012(9):2747%E2%80%932755.%2010.7150/jca.57019" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR108">
<cite>Hou MF et al (1999) Evaluation of serum CA27.29, CA15-3 and CEA in patients with breast cancer. Kaohsiung J Med Sci 15(9):520–528
</cite> [<a href="https://pubmed.ncbi.nlm.nih.gov/10561976/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Hou%20MF%20et%20al%20(1999)%20Evaluation%20of%20serum%20CA27.29,%20CA15-3%20and%20CEA%20in%20patients%20with%20breast%20cancer.%20Kaohsiung%20J%20Med%20Sci%2015(9):520%E2%80%93528" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR109">
<cite>Hoy AJ, Balaban S, Saunders DN (2017) Adipocyte-tumor cell metabolic crosstalk in breast cancer. Trends Mol Med 23(5):381–392. 10.1016/j.molmed.2017.02.009
</cite> [<a href="https://doi.org/10.1016/j.molmed.2017.02.009" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/28330687/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Hoy%20AJ,%20Balaban%20S,%20Saunders%20DN%20(2017)%20Adipocyte-tumor%20cell%20metabolic%20crosstalk%20in%20breast%20cancer.%20Trends%20Mol%20Med%2023(5):381%E2%80%93392.%2010.1016/j.molmed.2017.02.009" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR110">
<cite>Hu J et al (2015) Identification of microRNA-93 as a functional dysregulated miRNA in triple-negative breast cancer. Tumour Biol J Int Soc Oncodevelopmental Biol Med 36(1):251–258. 10.1007/s13277-014-2611-8</cite> [<a href="https://doi.org/10.1007/s13277-014-2611-8" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/25238878/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Hu%20J%20et%20al%20(2015)%20Identification%20of%20microRNA-93%20as%20a%20functional%20dysregulated%20miRNA%20in%20triple-negative%20breast%20cancer.%20Tumour%20Biol%20J%20Int%20Soc%20Oncodevelopmental%20Biol%20Med%2036(1):251%E2%80%93258.%2010.1007/s13277-014-2611-8" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR111">
<cite>Ilmer M et al (2016) Low expression of galectin-3 is associated with poor survival in node-positive breast cancers and mesenchymal phenotype in breast cancer stem cells. Breast Cancer Res BCR 18(1):97. 10.1186/s13058-016-0757-6
</cite> [<a href="https://doi.org/10.1186/s13058-016-0757-6" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC5043623/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/27687248/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Ilmer%20M%20et%20al%20(2016)%20Low%20expression%20of%20galectin-3%20is%20associated%20with%20poor%20survival%20in%20node-positive%20breast%20cancers%20and%20mesenchymal%20phenotype%20in%20breast%20cancer%20stem%20cells.%20Breast%20Cancer%20Res%20BCR%2018(1):97.%2010.1186/s13058-016-0757-6" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR112">
<cite>Irie A et al (2005) Galectin-9 as a prognostic factor with antimetastatic potential in breast cancer. Clin Cancer Res off J Am Assoc Cancer Res 11(8):2962–2968. 10.1158/1078-0432.CCR-04-0861</cite> [<a href="https://doi.org/10.1158/1078-0432.CCR-04-0861" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/15837748/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Irie%20A%20et%20al%20(2005)%20Galectin-9%20as%20a%20prognostic%20factor%20with%20antimetastatic%20potential%20in%20breast%20cancer.%20Clin%20Cancer%20Res%20off%20J%20Am%20Assoc%20Cancer%20Res%2011(8):2962%E2%80%932968.%2010.1158/1078-0432.CCR-04-0861" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR113">
<cite>Itani MM et al (2021) A signature of four circulating microRNAs as potential biomarkers for diagnosing early-stage breast cancer. Int J Mol Sci 22(11):6121. 10.3390/ijms22116121
</cite> [<a href="https://doi.org/10.3390/ijms22116121" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC8200990/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/34204158/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Itani%20MM%20et%20al%20(2021)%20A%20signature%20of%20four%20circulating%20microRNAs%20as%20potential%20biomarkers%20for%20diagnosing%20early-stage%20breast%20cancer.%20Int%20J%20Mol%20Sci%2022(11):6121.%2010.3390/ijms22116121" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR114">
<cite>Jafari SH et al (2018) Breast cancer diagnosis: Imaging techniques and biochemical markers. J Cell Physiol 233(7):5200–5213. 10.1002/jcp.26379
</cite> [<a href="https://doi.org/10.1002/jcp.26379" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/29219189/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Jafari%20SH%20et%20al%20(2018)%20Breast%20cancer%20diagnosis:%20Imaging%20techniques%20and%20biochemical%20markers.%20J%20Cell%20Physiol%20233(7):5200%E2%80%935213.%2010.1002/jcp.26379" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR115">
<cite>Jameera Begam A, Jubie S, Nanjan MJ (2017) Estrogen receptor agonists/antagonists in breast cancer therapy: a critical review. Bioorganic Chem 71:257–274. 10.1016/j.bioorg.2017.02.011</cite> [<a href="https://doi.org/10.1016/j.bioorg.2017.02.011" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/28274582/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Jameera%20Begam%20A,%20Jubie%20S,%20Nanjan%20MJ%20(2017)%20Estrogen%20receptor%20agonists/antagonists%20in%20breast%20cancer%20therapy:%20a%20critical%20review.%20Bioorganic%20Chem%2071:257%E2%80%93274.%2010.1016/j.bioorg.2017.02.011" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR116">
<cite>Jang JY, Ko EY, Jung JS, Kang KN, Kim YS, Kim CW (2021) Evaluation of the value of multiplex MicroRNA analysis as a breast cancer screening in Korean women under 50 years of age with a high proportion of dense breasts. J Cancer Prev 26(4):258–265. 10.15430/JCP.2021.26.4.258
</cite> [<a href="https://doi.org/10.15430/JCP.2021.26.4.258" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC8749312/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/35047452/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Jang%20JY,%20Ko%20EY,%20Jung%20JS,%20Kang%20KN,%20Kim%20YS,%20Kim%20CW%20(2021)%20Evaluation%20of%20the%20value%20of%20multiplex%20MicroRNA%20analysis%20as%20a%20breast%20cancer%20screening%20in%20Korean%20women%20under%2050%20years%20of%20age%20with%20a%20high%20proportion%20of%20dense%20breasts.%20J%20Cancer%20Prev%2026(4):258%E2%80%93265.%2010.15430/JCP.2021.26.4.258" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR117">
<cite>Jang JY, Kim YS, Kang KN, Kim KH, Park YJ, Kim CW (2021) Multiple microRNAs as biomarkers for early breast cancer diagnosis. Mol Clin Oncol 14(2):31. 10.3892/mco.2020.2193
</cite> [<a href="https://doi.org/10.3892/mco.2020.2193" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC7783718/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/33414912/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Jang%20JY,%20Kim%20YS,%20Kang%20KN,%20Kim%20KH,%20Park%20YJ,%20Kim%20CW%20(2021)%20Multiple%20microRNAs%20as%20biomarkers%20for%20early%20breast%20cancer%20diagnosis.%20Mol%20Clin%20Oncol%2014(2):31.%2010.3892/mco.2020.2193" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR118">
<cite>Jeong Y-J, Bong J-G, Park S-H, Choi J-H, Oh H-K (2011) Expression of leptin, leptin receptor, adiponectin, and adiponectin receptor in ductal carcinoma in situ and invasive breast cancer. J Breast Cancer 14(2):96–103. 10.4048/jbc.2011.14.2.96
</cite> [<a href="https://doi.org/10.4048/jbc.2011.14.2.96" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC3148540/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/21847403/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Jeong%20Y-J,%20Bong%20J-G,%20Park%20S-H,%20Choi%20J-H,%20Oh%20H-K%20(2011)%20Expression%20of%20leptin,%20leptin%20receptor,%20adiponectin,%20and%20adiponectin%20receptor%20in%20ductal%20carcinoma%20in%20situ%20and%20invasive%20breast%20cancer.%20J%20Breast%20Cancer%2014(2):96%E2%80%93103.%2010.4048/jbc.2011.14.2.96" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR119">
<cite>Ji P et al (2022) In vivo multidimensional CRISPR screens identify Lgals2 as an immunotherapy target in triple-negative breast cancer. Sci Adv 8(26):eabl8247. 10.1126/sciadv.abl8247
</cite> [<a href="https://doi.org/10.1126/sciadv.abl8247" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC9242595/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/35767614/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Ji%20P%20et%20al%20(2022)%20In%20vivo%20multidimensional%20CRISPR%20screens%20identify%20Lgals2%20as%20an%20immunotherapy%20target%20in%20triple-negative%20breast%20cancer.%20Sci%20Adv%208(26):eabl8247.%2010.1126/sciadv.abl8247" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR120">
<cite>Jin TY, Park KS, Nam SE, Yoo YB, Park WS, Yun IJ (2022) <em>BRCA1/2</em> serves as a biomarker for poor prognosis in breast carcinoma. Int J Mol Sci 23(7):3754. 10.3390/ijms23073754
</cite> [<a href="https://doi.org/10.3390/ijms23073754" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC8998777/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/35409110/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Jin%20TY,%20Park%20KS,%20Nam%20SE,%20Yoo%20YB,%20Park%20WS,%20Yun%20IJ%20(2022)%20BRCA1/2%20serves%20as%20a%20biomarker%20for%20poor%20prognosis%20in%20breast%20carcinoma.%20Int%20J%20Mol%20Sci%2023(7):3754.%2010.3390/ijms23073754" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR121">
<cite>Jing Y et al (2024) Diagnostic value of 5 miRNAs combined detection for breast cancer. Front Genet 15:1482927. 10.3389/fgene.2024.1482927
</cite> [<a href="https://doi.org/10.3389/fgene.2024.1482927" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC11625769/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/39655225/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Jing%20Y%20et%20al%20(2024)%20Diagnostic%20value%20of%205%20miRNAs%20combined%20detection%20for%20breast%20cancer.%20Front%20Genet%2015:1482927.%2010.3389/fgene.2024.1482927" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR122">
<cite>Jorns JM (2019) Breast cancer biomarkers: challenges in routine Estrogen receptor, progesterone receptor, and HER2/neu evaluation. Arch Pathol Lab Med 143(12):1444–1449. 10.5858/arpa.2019-0205-RA
</cite> [<a href="https://doi.org/10.5858/arpa.2019-0205-RA" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/31373514/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Jorns%20JM%20(2019)%20Breast%20cancer%20biomarkers:%20challenges%20in%20routine%20Estrogen%20receptor,%20progesterone%20receptor,%20and%20HER2/neu%20evaluation.%20Arch%20Pathol%20Lab%20Med%20143(12):1444%E2%80%931449.%2010.5858/arpa.2019-0205-RA" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR123">
<cite>Jung E-J et al (2007) Galectin-1 expression in cancer-associated stromal cells correlates tumor invasiveness and tumor progression in breast cancer. Int J Cancer 120(11):2331–2338. 10.1002/ijc.22434
</cite> [<a href="https://doi.org/10.1002/ijc.22434" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/17304502/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Jung%20E-J%20et%20al%20(2007)%20Galectin-1%20expression%20in%20cancer-associated%20stromal%20cells%20correlates%20tumor%20invasiveness%20and%20tumor%20progression%20in%20breast%20cancer.%20Int%20J%20Cancer%20120(11):2331%E2%80%932338.%2010.1002/ijc.22434" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR124">
<cite>Kang JH et al (2005) Adiponectin induces growth arrest and apoptosis of MDA-MB-231 breast cancer cell. Arch Pharm Res 28(11):1263–1269. 10.1007/BF02978210
</cite> [<a href="https://doi.org/10.1007/BF02978210" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/16350853/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Kang%20JH%20et%20al%20(2005)%20Adiponectin%20induces%20growth%20arrest%20and%20apoptosis%20of%20MDA-MB-231%20breast%20cancer%20cell.%20Arch%20Pharm%20Res%2028(11):1263%E2%80%931269.%2010.1007/BF02978210" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR125">
<cite>Khan MZI, Uzair M, Nazli A, Chen J-Z (2022) An overview on estrogen receptors signaling and its ligands in breast cancer. Eur J Med Chem 241:114658. 10.1016/j.ejmech.2022.114658
</cite> [<a href="https://doi.org/10.1016/j.ejmech.2022.114658" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/35964426/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Khan%20MZI,%20Uzair%20M,%20Nazli%20A,%20Chen%20J-Z%20(2022)%20An%20overview%20on%20estrogen%20receptors%20signaling%20and%20its%20ligands%20in%20breast%20cancer.%20Eur%20J%20Med%20Chem%20241:114658.%2010.1016/j.ejmech.2022.114658" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR126">
<cite>Kim MW et al (2021) Multi-miRNA panel of tumor-derived extracellular vesicles as promising diagnostic biomarkers of early-stage breast cancer. Cancer Sci 112(12):5078–5087. 10.1111/cas.15155
</cite> [<a href="https://doi.org/10.1111/cas.15155" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC8645748/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/34626053/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Kim%20MW%20et%20al%20(2021)%20Multi-miRNA%20panel%20of%20tumor-derived%20extracellular%20vesicles%20as%20promising%20diagnostic%20biomarkers%20of%20early-stage%20breast%20cancer.%20Cancer%20Sci%20112(12):5078%E2%80%935087.%2010.1111/cas.15155" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR127">
<cite>Kodahl AR et al (2014) Novel circulating microRNA signature as a potential non-invasive multi-marker test in ER-positive early-stage breast cancer: a case control study. Mol Oncol 8(5):874–883. 10.1016/j.molonc.2014.03.002
</cite> [<a href="https://doi.org/10.1016/j.molonc.2014.03.002" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC5528529/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/24694649/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Kodahl%20AR%20et%20al%20(2014)%20Novel%20circulating%20microRNA%20signature%20as%20a%20potential%20non-invasive%20multi-marker%20test%20in%20ER-positive%20early-stage%20breast%20cancer:%20a%20case%20control%20study.%20Mol%20Oncol%208(5):874%E2%80%93883.%2010.1016/j.molonc.2014.03.002" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR128">
<cite>Koprivčić I et al (2022) Serum leptin level in breast cancer. Acta Clin Croat 61(1):79–85. 10.20471/acc.2022.61.01.10
</cite> [<a href="https://doi.org/10.20471/acc.2022.61.01.10" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC9616027/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/36398078/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Kopriv%C4%8Di%C4%87%20I%20et%20al%20(2022)%20Serum%20leptin%20level%20in%20breast%20cancer.%20Acta%20Clin%20Croat%2061(1):79%E2%80%9385.%2010.20471/acc.2022.61.01.10" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR129">
<cite>Kostianets O, Shyyan M, Antoniuk SV, Filonenko V, Kiyamova R (2017) Panel of SEREX-defined antigens for breast cancer autoantibodies profile detection. Biomark Biochem Indic Expo Response Susceptibility Chem 22(2):149–156. 10.1080/1354750X.2016.1252952</cite> [<a href="https://doi.org/10.1080/1354750X.2016.1252952" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/27775439/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Kostianets%20O,%20Shyyan%20M,%20Antoniuk%20SV,%20Filonenko%20V,%20Kiyamova%20R%20(2017)%20Panel%20of%20SEREX-defined%20antigens%20for%20breast%20cancer%20autoantibodies%20profile%20detection.%20Biomark%20Biochem%20Indic%20Expo%20Response%20Susceptibility%20Chem%2022(2):149%E2%80%93156.%2010.1080/1354750X.2016.1252952" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR130">
<cite>Kothari C, Diorio C, Durocher F (2020) The importance of breast adipose tissue in breast cancer. Int J Mol Sci 21(16):5760. 10.3390/ijms21165760
</cite> [<a href="https://doi.org/10.3390/ijms21165760" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC7460846/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/32796696/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Kothari%20C,%20Diorio%20C,%20Durocher%20F%20(2020)%20The%20importance%20of%20breast%20adipose%20tissue%20in%20breast%20cancer.%20Int%20J%20Mol%20Sci%2021(16):5760.%2010.3390/ijms21165760" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR131">
<cite>Krystel-Whittemore M, Tan PH, Wen HY (2024) Predictive and prognostic biomarkers in breast tumours. Pathology (Phila) 56(2):186–191. 10.1016/j.pathol.2023.10.014</cite> [<a href="https://doi.org/10.1016/j.pathol.2023.10.014" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC10949537/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/38212230/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Krystel-Whittemore%20M,%20Tan%20PH,%20Wen%20HY%20(2024)%20Predictive%20and%20prognostic%20biomarkers%20in%20breast%20tumours.%20Pathology%20(Phila)%2056(2):186%E2%80%93191.%2010.1016/j.pathol.2023.10.014" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR132">
<cite>Lacombe J et al (2013) Identification and validation of new autoantibodies for the diagnosis of DCIS and node negative early-stage breast cancers. Int J Cancer 132(5):1105–1113. 10.1002/ijc.27766
</cite> [<a href="https://doi.org/10.1002/ijc.27766" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/22886747/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Lacombe%20J%20et%20al%20(2013)%20Identification%20and%20validation%20of%20new%20autoantibodies%20for%20the%20diagnosis%20of%20DCIS%20and%20node%20negative%20early-stage%20breast%20cancers.%20Int%20J%20Cancer%20132(5):1105%E2%80%931113.%2010.1002/ijc.27766" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR133">
<cite>Lee Y-C, Chen Y-J, Wu C-C, Lo S, Hou M-F, Yuan S-SF (2012) Resistin expression in breast cancer tissue as a marker of prognosis and hormone therapy stratification. Gynecol Oncol 125(3):742–750. 10.1016/j.ygyno.2012.02.032
</cite> [<a href="https://doi.org/10.1016/j.ygyno.2012.02.032" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/22370603/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Lee%20Y-C,%20Chen%20Y-J,%20Wu%20C-C,%20Lo%20S,%20Hou%20M-F,%20Yuan%20S-SF%20(2012)%20Resistin%20expression%20in%20breast%20cancer%20tissue%20as%20a%20marker%20of%20prognosis%20and%20hormone%20therapy%20stratification.%20Gynecol%20Oncol%20125(3):742%E2%80%93750.%2010.1016/j.ygyno.2012.02.032" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR134">
<cite>Lee OJ et al (2016) Resistin, a fat-derived secretory factor, promotes metastasis of MDA-MB-231 human breast cancer cells through ERM activation. Sci Rep 6:18923. 10.1038/srep18923
</cite> [<a href="https://doi.org/10.1038/srep18923" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC4700449/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/26729407/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Lee%20OJ%20et%20al%20(2016)%20Resistin,%20a%20fat-derived%20secretory%20factor,%20promotes%20metastasis%20of%20MDA-MB-231%20human%20breast%20cancer%20cells%20through%20ERM%20activation.%20Sci%20Rep%206:18923.%2010.1038/srep18923" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR135">
<cite>Lee A, Moon BI, Kim TH (2020) <em>BRCA1/BRCA2</em> pathogenic variant breast cancer: treatment and prevention strategies. Ann Lab Med 40(2):114–121. 10.3343/alm.2020.40.2.114
</cite> [<a href="https://doi.org/10.3343/alm.2020.40.2.114" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC6822003/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/31650727/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Lee%20A,%20Moon%20BI,%20Kim%20TH%20(2020)%20BRCA1/BRCA2%20pathogenic%20variant%20breast%20cancer:%20treatment%20and%20prevention%20strategies.%20Ann%20Lab%20Med%2040(2):114%E2%80%93121.%2010.3343/alm.2020.40.2.114" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR136">
<cite>Lee Y, Ni J, Beretov J, Wasinger VC, Graham P, Li Y (2023a) Recent advances of small extracellular vesicle biomarkers in breast cancer diagnosis and prognosis’. Mol Cancer 22(1):33. 10.1186/s12943-023-01741-x
</cite> [<a href="https://doi.org/10.1186/s12943-023-01741-x" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC9933347/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/36797736/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Lee%20Y,%20Ni%20J,%20Beretov%20J,%20Wasinger%20VC,%20Graham%20P,%20Li%20Y%20(2023a)%20Recent%20advances%20of%20small%20extracellular%20vesicle%20biomarkers%20in%20breast%20cancer%20diagnosis%20and%20prognosis%E2%80%99.%20Mol%20Cancer%2022(1):33.%2010.1186/s12943-023-01741-x" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR137">
<cite>Lee Y, Graham P, Li Y (2023b) Extracellular vesicles as a novel approach for breast cancer therapeutics. Cancer Lett 555:216036. 10.1016/j.canlet.2022.216036
</cite> [<a href="https://doi.org/10.1016/j.canlet.2022.216036" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/36521658/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Lee%20Y,%20Graham%20P,%20Li%20Y%20(2023b)%20Extracellular%20vesicles%20as%20a%20novel%20approach%20for%20breast%20cancer%20therapeutics.%20Cancer%20Lett%20555:216036.%2010.1016/j.canlet.2022.216036" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR138">
<cite>Lerévérend C et al (2025) Enhanced expression of galectin-9 in triple negative breast cancer cells following radiotherapy: implications for targeted therapy. Int J Cancer 156(1):229–242. 10.1002/ijc.35107
</cite> [<a href="https://doi.org/10.1002/ijc.35107" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/39077999/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Ler%C3%A9v%C3%A9rend%20C%20et%20al%20(2025)%20Enhanced%20expression%20of%20galectin-9%20in%20triple%20negative%20breast%20cancer%20cells%20following%20radiotherapy:%20implications%20for%20targeted%20therapy.%20Int%20J%20Cancer%20156(1):229%E2%80%93242.%2010.1002/ijc.35107" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR139">
<cite>Li J, Han X (2018) Adipocytokines and breast cancer. Curr Probl Cancer 42(2):208–214. 10.1016/j.currproblcancer.2018.01.004
</cite> [<a href="https://doi.org/10.1016/j.currproblcancer.2018.01.004" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/29433827/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Li%20J,%20Han%20X%20(2018)%20Adipocytokines%20and%20breast%20cancer.%20Curr%20Probl%20Cancer%2042(2):208%E2%80%93214.%2010.1016/j.currproblcancer.2018.01.004" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR140">
<cite>Li M et al (2019) A five-miRNA panel in plasma was identified for breast cancer diagnosis. Cancer Med 8(16):7006–7017. 10.1002/cam4.2572
</cite> [<a href="https://doi.org/10.1002/cam4.2572" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC6853814/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/31568692/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Li%20M%20et%20al%20(2019)%20A%20five-miRNA%20panel%20in%20plasma%20was%20identified%20for%20breast%20cancer%20diagnosis.%20Cancer%20Med%208(16):7006%E2%80%937017.%2010.1002/cam4.2572" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR141">
<cite>Li X et al (2020) Plasma-based microRNA signatures in early diagnosis of breast cancer. Mol Genet Genomic Med 8(5):e1092. 10.1002/mgg3.1092
</cite> [<a href="https://doi.org/10.1002/mgg3.1092" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC7216817/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/32124558/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Li%20X%20et%20al%20(2020)%20Plasma-based%20microRNA%20signatures%20in%20early%20diagnosis%20of%20breast%20cancer.%20Mol%20Genet%20Genomic%20Med%208(5):e1092.%2010.1002/mgg3.1092" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR142">
<cite>Li Z et al (2020a) Circular RNA hsa_circ_0001785 inhibits the proliferation, migration and invasion of breast cancer cells in vitro and in vivo by sponging miR-942 to upregulate SOCS3. Cell Cycle 19(21):2811–2825. 10.1080/15384101.2020.1824717
</cite> [<a href="https://doi.org/10.1080/15384101.2020.1824717" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC7714452/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/33054543/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Li%20Z%20et%20al%20(2020a)%20Circular%20RNA%20hsa_circ_0001785%20inhibits%20the%20proliferation,%20migration%20and%20invasion%20of%20breast%20cancer%20cells%20in%20vitro%20and%20in%20vivo%20by%20sponging%20miR-942%20to%20upregulate%20SOCS3.%20Cell%20Cycle%2019(21):2811%E2%80%932825.%2010.1080/15384101.2020.1824717" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR143">
<cite>Li X, Lu J, Zhang L, Luo Y, Zhao Z, Li M (2020b) Clinical implications of monitoring ESR1 mutations by circulating tumor DNA in estrogen receptor positive metastatic breast cancer: a pilot study. Transl Oncol 13(2):321–328. 10.1016/j.tranon.2019.11.007
</cite> [<a href="https://doi.org/10.1016/j.tranon.2019.11.007" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC6931202/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/31877464/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Li%20X,%20Lu%20J,%20Zhang%20L,%20Luo%20Y,%20Zhao%20Z,%20Li%20M%20(2020b)%20Clinical%20implications%20of%20monitoring%20ESR1%20mutations%20by%20circulating%20tumor%20DNA%20in%20estrogen%20receptor%20positive%20metastatic%20breast%20cancer:%20a%20pilot%20study.%20Transl%20Oncol%2013(2):321%E2%80%93328.%2010.1016/j.tranon.2019.11.007" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR144">
<cite>Li S et al (2024) Deciphering the role of LGALS2: insights into tertiary lymphoid structure-associated dendritic cell activation and immunotherapeutic potential in breast cancer patients. Mol Cancer 23(1):216. 10.1186/s12943-024-02126-4
</cite> [<a href="https://doi.org/10.1186/s12943-024-02126-4" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC11441145/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/39350165/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Li%20S%20et%20al%20(2024)%20Deciphering%20the%20role%20of%20LGALS2:%20insights%20into%20tertiary%20lymphoid%20structure-associated%20dendritic%20cell%20activation%20and%20immunotherapeutic%20potential%20in%20breast%20cancer%20patients.%20Mol%20Cancer%2023(1):216.%2010.1186/s12943-024-02126-4" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR145">
<cite>Lin D et al (2021) Circulating tumor cells: biology and clinical significance. Signal Transduct Target Ther 6(1):404. 10.1038/s41392-021-00817-8
</cite> [<a href="https://doi.org/10.1038/s41392-021-00817-8" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC8606574/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/34803167/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Lin%20D%20et%20al%20(2021)%20Circulating%20tumor%20cells:%20biology%20and%20clinical%20significance.%20Signal%20Transduct%20Target%20Ther%206(1):404.%2010.1038/s41392-021-00817-8" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR146">
<cite>Liu Z, Liu W (2018) Association of urinary and plasma DNA in early breast cancer patients and its links to disease relapse. Clin Transl Oncol 20(8):1053–1060. 10.1007/s12094-017-1825-9
</cite> [<a href="https://doi.org/10.1007/s12094-017-1825-9" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/29392540/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Liu%20Z,%20Liu%20W%20(2018)%20Association%20of%20urinary%20and%20plasma%20DNA%20in%20early%20breast%20cancer%20patients%20and%20its%20links%20to%20disease%20relapse.%20Clin%20Transl%20Oncol%2020(8):1053%E2%80%931060.%2010.1007/s12094-017-1825-9" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR147">
<cite>Liu L-Y et al (2013) The role of adiponectin in breast cancer: a meta-analysis. PLoS ONE 8(8):e73183. 10.1371/journal.pone.0073183
</cite> [<a href="https://doi.org/10.1371/journal.pone.0073183" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC3749999/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/23991180/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Liu%20L-Y%20et%20al%20(2013)%20The%20role%20of%20adiponectin%20in%20breast%20cancer:%20a%20meta-analysis.%20PLoS%20ONE%208(8):e73183.%2010.1371/journal.pone.0073183" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR148">
<cite>Liu W et al (2015) Detection of autoantibodies to multiple tumor-associated antigens (TAAs) in the immunodiagnosis of breast cancer. Tumour Biol J Int Soc Oncodevelopmental Biol Med 36(2):1307–1312. 10.1007/s13277-014-2756-5</cite> [<a href="https://doi.org/10.1007/s13277-014-2756-5" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/25355596/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Liu%20W%20et%20al%20(2015)%20Detection%20of%20autoantibodies%20to%20multiple%20tumor-associated%20antigens%20(TAAs)%20in%20the%20immunodiagnosis%20of%20breast%20cancer.%20Tumour%20Biol%20J%20Int%20Soc%20Oncodevelopmental%20Biol%20Med%2036(2):1307%E2%80%931312.%2010.1007/s13277-014-2756-5" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR149">
<cite>Liu Z et al (2017) Resistin confers resistance to doxorubicin-induced apoptosis in human breast cancer cells through autophagy induction. Am J Cancer Res 7(3):574–583
</cite> [<a href="/articles/PMC5385645/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/28401013/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Liu%20Z%20et%20al%20(2017)%20Resistin%20confers%20resistance%20to%20doxorubicin-induced%20apoptosis%20in%20human%20breast%20cancer%20cells%20through%20autophagy%20induction.%20Am%20J%20Cancer%20Res%207(3):574%E2%80%93583" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR150">
<cite>Liu C et al (2018) A panel containing PD-1, IL-2Rα, IL-10, and CA15-3 as a biomarker to discriminate breast cancer from benign breast disease. Cancer Manag Res 10:1749–1761. 10.2147/CMAR.S160452
</cite> [<a href="https://doi.org/10.2147/CMAR.S160452" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC6027692/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/29983594/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Liu%20C%20et%20al%20(2018)%20A%20panel%20containing%20PD-1,%20IL-2R%CE%B1,%20IL-10,%20and%20CA15-3%20as%20a%20biomarker%20to%20discriminate%20breast%20cancer%20from%20benign%20breast%20disease.%20Cancer%20Manag%20Res%2010:1749%E2%80%931761.%2010.2147/CMAR.S160452" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR151">
<cite>Liu T, Ye P, Ye Y, Lu S, Han B (2020) Circular RNA hsa_circRNA_002178 silencing retards breast cancer progression via microRNA-328-3p-mediated inhibition of COL1A1. J Cell Mol Med 24(3):2189–2201. 10.1111/jcmm.14875
</cite> [<a href="https://doi.org/10.1111/jcmm.14875" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC7011152/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/31957232/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Liu%20T,%20Ye%20P,%20Ye%20Y,%20Lu%20S,%20Han%20B%20(2020)%20Circular%20RNA%20hsa_circRNA_002178%20silencing%20retards%20breast%20cancer%20progression%20via%20microRNA-328-3p-mediated%20inhibition%20of%20COL1A1.%20J%20Cell%20Mol%20Med%2024(3):2189%E2%80%932201.%2010.1111/jcmm.14875" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR152">
<cite>Liu X et al (2022) Potential utility of miRNAs for liquid biopsy in breast cancer. Front Oncol 12:940314. 10.3389/fonc.2022.940314
</cite> [<a href="https://doi.org/10.3389/fonc.2022.940314" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC9386533/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/35992785/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Liu%20X%20et%20al%20(2022)%20Potential%20utility%20of%20miRNAs%20for%20liquid%20biopsy%20in%20breast%20cancer.%20Front%20Oncol%2012:940314.%2010.3389/fonc.2022.940314" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR153">
<cite>Lopes BC et al (2021) miR-210 and miR-152 as biomarkers by liquid biopsy in invasive ductal carcinoma. J Pers Med 11(1):31. 10.3390/jpm11010031
</cite> [<a href="https://doi.org/10.3390/jpm11010031" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC7825421/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/33419057/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Lopes%20BC%20et%20al%20(2021)%20miR-210%20and%20miR-152%20as%20biomarkers%20by%20liquid%20biopsy%20in%20invasive%20ductal%20carcinoma.%20J%20Pers%20Med%2011(1):31.%2010.3390/jpm11010031" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR154">
<cite>Lowry KP et al (2023) Variation in second breast cancer risk after primary invasive cancer by time since primary cancer diagnosis and estrogen receptor status. Cancer 129(8):1173–1182. 10.1002/cncr.34679
</cite> [<a href="https://doi.org/10.1002/cncr.34679" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC10409444/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/36789739/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Lowry%20KP%20et%20al%20(2023)%20Variation%20in%20second%20breast%20cancer%20risk%20after%20primary%20invasive%20cancer%20by%20time%20since%20primary%20cancer%20diagnosis%20and%20estrogen%20receptor%20status.%20Cancer%20129(8):1173%E2%80%931182.%2010.1002/cncr.34679" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR155">
<cite>Luo J et al (2014) A novel panel of microRNAs provides a sensitive and specific tool for the diagnosis of breast cancer. Mol Med Rep 10(2):785–791. 10.3892/mmr.2014.2274
</cite> [<a href="https://doi.org/10.3892/mmr.2014.2274" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/24866395/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Luo%20J%20et%20al%20(2014)%20A%20novel%20panel%20of%20microRNAs%20provides%20a%20sensitive%20and%20specific%20tool%20for%20the%20diagnosis%20of%20breast%20cancer.%20Mol%20Med%20Rep%2010(2):785%E2%80%93791.%2010.3892/mmr.2014.2274" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR156">
<cite>Luo J, Xiao J, Yang Y, Chen G, Hu D, Zeng J (2022) Strategies for five tumour markers in the screening and diagnosis of female breast cancer. Front Oncol 12:1055855. 10.3389/fonc.2022.1055855
</cite> [<a href="https://doi.org/10.3389/fonc.2022.1055855" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC9899879/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/36755860/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Luo%20J,%20Xiao%20J,%20Yang%20Y,%20Chen%20G,%20Hu%20D,%20Zeng%20J%20(2022)%20Strategies%20for%20five%20tumour%20markers%20in%20the%20screening%20and%20diagnosis%20of%20female%20breast%20cancer.%20Front%20Oncol%2012:1055855.%2010.3389/fonc.2022.1055855" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR157">
<cite>Maia J, Caja S, Strano Moraes MC, Couto N, Costa-Silva B (2018) Exosome-based cell-cell communication in the tumor microenvironment. Front Cell Dev Biol 6:18. 10.3389/fcell.2018.00018
</cite> [<a href="https://doi.org/10.3389/fcell.2018.00018" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC5826063/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/29515996/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Maia%20J,%20Caja%20S,%20Strano%20Moraes%20MC,%20Couto%20N,%20Costa-Silva%20B%20(2018)%20Exosome-based%20cell-cell%20communication%20in%20the%20tumor%20microenvironment.%20Front%20Cell%20Dev%20Biol%206:18.%2010.3389/fcell.2018.00018" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR158">
<cite>Mantzoros CS, Bolhke K, Moschos S, Cramer DW (1999) Leptin in relation to carcinoma in situ of the breast: a study of pre-menopausal cases and controls. Int J Cancer 80(4):523–526. 10.1002/(sici)1097-0215(19990209)80:4%3c523::aid-ijc7%3e3.0.co;2-c
</cite> [<a href="https://doi.org/10.1002/(sici)1097-0215(19990209)80:4&lt;523::aid-ijc7&gt;3.0.co;2-c" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/9935151/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Mantzoros%20CS,%20Bolhke%20K,%20Moschos%20S,%20Cramer%20DW%20(1999)%20Leptin%20in%20relation%20to%20carcinoma%20in%20situ%20of%20the%20breast:%20a%20study%20of%20pre-menopausal%20cases%20and%20controls.%20Int%20J%20Cancer%2080(4):523%E2%80%93526.%2010.1002/(sici)1097-0215(19990209)80:4%3c523::aid-ijc7%3e3.0.co;2-c" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR159">
<cite>Mao Y et al (2020) Circular RNA 000554 represses epithelial-mesenchymal transition in breast cancer by regulating microRNA-182/ZFP36 axis. FASEB J off Publ Fed Am Soc Exp Biol 34(9):11405–11420. 10.1096/fj.201903047R</cite> [<a href="https://doi.org/10.1096/fj.201903047R" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/32729957/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Mao%20Y%20et%20al%20(2020)%20Circular%20RNA%20000554%20represses%20epithelial-mesenchymal%20transition%20in%20breast%20cancer%20by%20regulating%20microRNA-182/ZFP36%20axis.%20FASEB%20J%20off%20Publ%20Fed%20Am%20Soc%20Exp%20Biol%2034(9):11405%E2%80%9311420.%2010.1096/fj.201903047R" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR160">
<cite>Markalunas EG et al (2024) Correlation analysis of genetic mutations and galectin levels in breast cancer patients. Genes 15(6):818. 10.3390/genes15060818
</cite> [<a href="https://doi.org/10.3390/genes15060818" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC11203217/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/38927753/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Markalunas%20EG%20et%20al%20(2024)%20Correlation%20analysis%20of%20genetic%20mutations%20and%20galectin%20levels%20in%20breast%20cancer%20patients.%20Genes%2015(6):818.%2010.3390/genes15060818" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR161">
<cite>Martínez-Sáez O, Prat A (2021) Current and future management of HER2-positive metastatic breast cancer. JCO Oncol Pract 17(10):594–604. 10.1200/OP.21.00172
</cite> [<a href="https://doi.org/10.1200/OP.21.00172" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/34077236/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Mart%C3%ADnez-S%C3%A1ez%20O,%20Prat%20A%20(2021)%20Current%20and%20future%20management%20of%20HER2-positive%20metastatic%20breast%20cancer.%20JCO%20Oncol%20Pract%2017(10):594%E2%80%93604.%2010.1200/OP.21.00172" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR162">
<cite>Marvalim C, Datta A, Lee SC (2023) Role of p53 in breast cancer progression: an insight into p53 targeted therapy. Theranostics 13(4):1421–1442. 10.7150/thno.81847
</cite> [<a href="https://doi.org/10.7150/thno.81847" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC10008729/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/36923534/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Marvalim%20C,%20Datta%20A,%20Lee%20SC%20(2023)%20Role%20of%20p53%20in%20breast%20cancer%20progression:%20an%20insight%20into%20p53%20targeted%20therapy.%20Theranostics%2013(4):1421%E2%80%931442.%2010.7150/thno.81847" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR163">
<cite>Matikas A et al (2022) Detection of circulating tumour cells before and following adjuvant chemotherapy and long-term prognosis of early breast cancer. Br J Cancer 126(11):1563–1569. 10.1038/s41416-022-01699-5
</cite> [<a href="https://doi.org/10.1038/s41416-022-01699-5" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC9130117/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/35145253/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Matikas%20A%20et%20al%20(2022)%20Detection%20of%20circulating%20tumour%20cells%20before%20and%20following%20adjuvant%20chemotherapy%20and%20long-term%20prognosis%20of%20early%20breast%20cancer.%20Br%20J%20Cancer%20126(11):1563%E2%80%931569.%2010.1038/s41416-022-01699-5" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR164">
<cite>Mauro L et al (2014) Evidences that estrogen receptor α interferes with adiponectin effects on breast cancer cell growth. Cell Cycle 13(4):553–564. 10.4161/cc.27455
</cite> [<a href="https://doi.org/10.4161/cc.27455" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/24335340/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Mauro%20L%20et%20al%20(2014)%20Evidences%20that%20estrogen%20receptor%20%CE%B1%20interferes%20with%20adiponectin%20effects%20on%20breast%20cancer%20cell%20growth.%20Cell%20Cycle%2013(4):553%E2%80%93564.%2010.4161/cc.27455" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR165">
<cite>Mauro L et al (2015) Estrogen receptor-α drives adiponectin effects on cyclin D1 expression in breast cancer cells. FASEB J off Publ Fed Am Soc Exp Biol 29(5):2150–2160. 10.1096/fj.14-262808</cite> [<a href="https://doi.org/10.1096/fj.14-262808" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/25657113/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Mauro%20L%20et%20al%20(2015)%20Estrogen%20receptor-%CE%B1%20drives%20adiponectin%20effects%20on%20cyclin%20D1%20expression%20in%20breast%20cancer%20cells.%20FASEB%20J%20off%20Publ%20Fed%20Am%20Soc%20Exp%20Biol%2029(5):2150%E2%80%932160.%2010.1096/fj.14-262808" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR166">
<cite>Mavaddat N et al (2012) Pathology of breast and ovarian cancers among BRCA1 and BRCA2 mutation carriers: results from the consortium of investigators of modifiers of BRCA1/2 (CIMBA). Cancer Epidemiol Biomark Prev Publ Am Assoc Cancer Res Cosponsored Am Soc Prev Oncol 21(1):134–147. 10.1158/1055-9965.EPI-11-0775</cite> [<a href="https://doi.org/10.1158/1055-9965.EPI-11-0775" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC3272407/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/22144499/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Mavaddat%20N%20et%20al%20(2012)%20Pathology%20of%20breast%20and%20ovarian%20cancers%20among%20BRCA1%20and%20BRCA2%20mutation%20carriers:%20results%20from%20the%20consortium%20of%20investigators%20of%20modifiers%20of%20BRCA1/2%20(CIMBA).%20Cancer%20Epidemiol%20Biomark%20Prev%20Publ%20Am%20Assoc%20Cancer%20Res%20Cosponsored%20Am%20Soc%20Prev%20Oncol%2021(1):134%E2%80%93147.%2010.1158/1055-9965.EPI-11-0775" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR167">
<cite>Maximus PS, Al Achkar Z, Hamid PF, Hasnain SS, Peralta CA (2020) Adipocytokines: Are they the theory of everything? Cytokine 133:155144. 10.1016/j.cyto.2020.155144
</cite> [<a href="https://doi.org/10.1016/j.cyto.2020.155144" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC7297161/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/32559663/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Maximus%20PS,%20Al%20Achkar%20Z,%20Hamid%20PF,%20Hasnain%20SS,%20Peralta%20CA%20(2020)%20Adipocytokines:%20Are%20they%20the%20theory%20of%20everything?%20Cytokine%20133:155144.%2010.1016/j.cyto.2020.155144" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR168">
<cite>McDermott AM et al (2014) Identification and validation of oncologic miRNA biomarkers for luminal A-like breast cancer. PLoS ONE 9(1):e87032. 10.1371/journal.pone.0087032
</cite> [<a href="https://doi.org/10.1371/journal.pone.0087032" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC3909065/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/24498016/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?McDermott%20AM%20et%20al%20(2014)%20Identification%20and%20validation%20of%20oncologic%20miRNA%20biomarkers%20for%20luminal%20A-like%20breast%20cancer.%20PLoS%20ONE%209(1):e87032.%2010.1371/journal.pone.0087032" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR169">
<cite>McGinn O, Riley D, Finlay-Schultz J, Paul KV, Kabos P, Sartorius CA (2022) Cytokeratins 5 and 17 maintain an aggressive epithelial state in basal-like breast cancer. Mol Cancer Res MCR 20(9):1443–1455. 10.1158/1541-7786.MCR-21-0866
</cite> [<a href="https://doi.org/10.1158/1541-7786.MCR-21-0866" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC9444965/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/35639459/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?McGinn%20O,%20Riley%20D,%20Finlay-Schultz%20J,%20Paul%20KV,%20Kabos%20P,%20Sartorius%20CA%20(2022)%20Cytokeratins%205%20and%2017%20maintain%20an%20aggressive%20epithelial%20state%20in%20basal-like%20breast%20cancer.%20Mol%20Cancer%20Res%20MCR%2020(9):1443%E2%80%931455.%2010.1158/1541-7786.MCR-21-0866" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR170">
<cite>McLean KE, Stone J (2018) Role of breast density measurement in screening for breast cancer. Climact J Int Menopause Soc 21(3):214–220. 10.1080/13697137.2018.1424816</cite> [<a href="https://doi.org/10.1080/13697137.2018.1424816" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/29447010/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?McLean%20KE,%20Stone%20J%20(2018)%20Role%20of%20breast%20density%20measurement%20in%20screening%20for%20breast%20cancer.%20Climact%20J%20Int%20Menopause%20Soc%2021(3):214%E2%80%93220.%2010.1080/13697137.2018.1424816" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR171">
<cite>Ménard S, Fortis S, Castiglioni F, Agresti R, Balsari A (2001) HER2 as a prognostic factor in breastcancer. Oncology 61 Suppl(2):67-72. 10.1159/000055404</cite> [<a href="https://doi.org/10.1159/000055404" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/11694790/" class="usa-link">PubMed</a>]</li>
<li id="CR172">
<cite>Mi Z, Zhongqiang C, Caiyun J, Yanan L, Jianhua W, Liang L (2022) Circular RNA detection methods: a minireview. Talanta 238(Pt 2):123066. 10.1016/j.talanta.2021.123066
</cite> [<a href="https://doi.org/10.1016/j.talanta.2021.123066" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/34808570/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Mi%20Z,%20Zhongqiang%20C,%20Caiyun%20J,%20Yanan%20L,%20Jianhua%20W,%20Liang%20L%20(2022)%20Circular%20RNA%20detection%20methods:%20a%20minireview.%20Talanta%20238(Pt%202):123066.%2010.1016/j.talanta.2021.123066" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR173">
<cite>Mirabelli P, Incoronato M (2013) Usefulness of traditional serum biomarkers for management of breast cancer patients. BioMed Res Int 2013:685641. 10.1155/2013/685641
</cite> [<a href="https://doi.org/10.1155/2013/685641" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC3856124/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/24350285/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Mirabelli%20P,%20Incoronato%20M%20(2013)%20Usefulness%20of%20traditional%20serum%20biomarkers%20for%20management%20of%20breast%20cancer%20patients.%20BioMed%20Res%20Int%202013:685641.%2010.1155/2013/685641" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR174">
<cite>Miyoshi Y et al (2003) Association of serum adiponectin levels with breast cancer risk. Clin Cancer Res off J Am Assoc Cancer Res 9(15):5699–5704</cite> [<a href="https://pubmed.ncbi.nlm.nih.gov/14654554/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Miyoshi%20Y%20et%20al%20(2003)%20Association%20of%20serum%20adiponectin%20levels%20with%20breast%20cancer%20risk.%20Clin%20Cancer%20Res%20off%20J%20Am%20Assoc%20Cancer%20Res%209(15):5699%E2%80%935704" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR175">
<cite>Moar K, Pant A, Saini V, Pandey M, Maurya PK (2023) Potential diagnostic and prognostic biomarkers for breast cancer: a compiled review. Pathol Res Pract 251:154893. 10.1016/j.prp.2023.154893
</cite> [<a href="https://doi.org/10.1016/j.prp.2023.154893" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/37918101/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Moar%20K,%20Pant%20A,%20Saini%20V,%20Pandey%20M,%20Maurya%20PK%20(2023)%20Potential%20diagnostic%20and%20prognostic%20biomarkers%20for%20breast%20cancer:%20a%20compiled%20review.%20Pathol%20Res%20Pract%20251:154893.%2010.1016/j.prp.2023.154893" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR176">
<cite>Moasser MM (2007) The oncogene HER2: its signaling and transforming functions and its role in human cancer pathogenesis. Oncogene 26(45):6469–6487. 10.1038/sj.onc.1210477
</cite> [<a href="https://doi.org/10.1038/sj.onc.1210477" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC3021475/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/17471238/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Moasser%20MM%20(2007)%20The%20oncogene%20HER2:%20its%20signaling%20and%20transforming%20functions%20and%20its%20role%20in%20human%20cancer%20pathogenesis.%20Oncogene%2026(45):6469%E2%80%936487.%2010.1038/sj.onc.1210477" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR177">
<cite>Molina R et al (1995) Use of serial carcinoembryonic antigen and CA 15.3 assays in detecting relapses in breast cancer patients. Breast Cancer Res Treat 36(1):41–48. 10.1007/BF00690183
</cite> [<a href="https://doi.org/10.1007/BF00690183" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/7579505/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Molina%20R%20et%20al%20(1995)%20Use%20of%20serial%20carcinoembryonic%20antigen%20and%20CA%2015.3%20assays%20in%20detecting%20relapses%20in%20breast%20cancer%20patients.%20Breast%20Cancer%20Res%20Treat%2036(1):41%E2%80%9348.%2010.1007/BF00690183" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR178">
<cite>Montero-Calle A, Garranzo-Asensio M, Moreno-Casbas MT, Campuzano S, Barderas R (2024) Autoantibodies in cancer: a systematic review of their clinical role in the most prevalent cancers. Front Immunol 15:1455602. 10.3389/fimmu.2024.1455602
</cite> [<a href="https://doi.org/10.3389/fimmu.2024.1455602" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC11371560/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/39234247/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Montero-Calle%20A,%20Garranzo-Asensio%20M,%20Moreno-Casbas%20MT,%20Campuzano%20S,%20Barderas%20R%20(2024)%20Autoantibodies%20in%20cancer:%20a%20systematic%20review%20of%20their%20clinical%20role%20in%20the%20most%20prevalent%20cancers.%20Front%20Immunol%2015:1455602.%2010.3389/fimmu.2024.1455602" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR179">
<cite>Mulrane L, McGee SF, Gallagher WM, O’Connor DP (2013) miRNA dysregulation in breast cancer. Cancer Res 73(22):6554–6562. 10.1158/0008-5472.CAN-13-1841
</cite> [<a href="https://doi.org/10.1158/0008-5472.CAN-13-1841" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/24204025/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Mulrane%20L,%20McGee%20SF,%20Gallagher%20WM,%20O%E2%80%99Connor%20DP%20(2013)%20miRNA%20dysregulation%20in%20breast%20cancer.%20Cancer%20Res%2073(22):6554%E2%80%936562.%2010.1158/0008-5472.CAN-13-1841" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR180">
<cite>Nagaraju GP et al (2016) The role of adiponectin in obesity-associated female-specific carcinogenesis. Cytokine Growth Factor Rev 31:37–48. 10.1016/j.cytogfr.2016.03.014
</cite> [<a href="https://doi.org/10.1016/j.cytogfr.2016.03.014" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/27079372/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Nagaraju%20GP%20et%20al%20(2016)%20The%20role%20of%20adiponectin%20in%20obesity-associated%20female-specific%20carcinogenesis.%20Cytokine%20Growth%20Factor%20Rev%2031:37%E2%80%9348.%2010.1016/j.cytogfr.2016.03.014" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR181">
<cite>Nehme R, Diab-Assaf M, Decombat C, Delort L, Caldefie-Chezet F (2022) Targeting adiponectin in breast cancer. Biomedicines 10(11):2958. 10.3390/biomedicines10112958
</cite> [<a href="https://doi.org/10.3390/biomedicines10112958" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC9687473/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/36428526/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Nehme%20R,%20Diab-Assaf%20M,%20Decombat%20C,%20Delort%20L,%20Caldefie-Chezet%20F%20(2022)%20Targeting%20adiponectin%20in%20breast%20cancer.%20Biomedicines%2010(11):2958.%2010.3390/biomedicines10112958" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR182">
<cite>Neves Rebello Alves L et al (2023) Biomarkers in breast cancer: an old story with a new end. Genes 14(7):1364. 10.3390/genes14071364
</cite> [<a href="https://doi.org/10.3390/genes14071364" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC10378988/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/37510269/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Neves%20Rebello%20Alves%20L%20et%20al%20(2023)%20Biomarkers%20in%20breast%20cancer:%20an%20old%20story%20with%20a%20new%20end.%20Genes%2014(7):1364.%2010.3390/genes14071364" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR183">
<cite>Nickson C, Mason KE, English DR, Kavanagh AM (2012) Mammographic screening and breast cancer mortality: a case-control study and meta-analysis. Cancer Epidemiol Biomark Prev Publ Am Assoc Cancer Res Cosponsored Am Soc Prev Oncol 21(9):1479–1488. 10.1158/1055-9965.EPI-12-0468</cite> [<a href="https://doi.org/10.1158/1055-9965.EPI-12-0468" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/22956730/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Nickson%20C,%20Mason%20KE,%20English%20DR,%20Kavanagh%20AM%20(2012)%20Mammographic%20screening%20and%20breast%20cancer%20mortality:%20a%20case-control%20study%20and%20meta-analysis.%20Cancer%20Epidemiol%20Biomark%20Prev%20Publ%20Am%20Assoc%20Cancer%20Res%20Cosponsored%20Am%20Soc%20Prev%20Oncol%2021(9):1479%E2%80%931488.%2010.1158/1055-9965.EPI-12-0468" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR184">
<cite>Nicolini A, Ferrari P, Rossi G (2015) Mucins and cytokeratins as serum tumor markers in breast cancer. Adv Exp Med Biol 867:197–225. 10.1007/978-94-017-7215-0_13
</cite> [<a href="https://doi.org/10.1007/978-94-017-7215-0_13" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/26530368/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Nicolini%20A,%20Ferrari%20P,%20Rossi%20G%20(2015)%20Mucins%20and%20cytokeratins%20as%20serum%20tumor%20markers%20in%20breast%20cancer.%20Adv%20Exp%20Med%20Biol%20867:197%E2%80%93225.%2010.1007/978-94-017-7215-0_13" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR185">
<cite>Nicolini A, Ferrari P, Duffy MJ (2018) Prognostic and predictive biomarkers in breast cancer: past, present and future. Semin Cancer Biol 52(Pt 1):56–73. 10.1016/j.semcancer.2017.08.010
</cite> [<a href="https://doi.org/10.1016/j.semcancer.2017.08.010" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/28882552/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Nicolini%20A,%20Ferrari%20P,%20Duffy%20MJ%20(2018)%20Prognostic%20and%20predictive%20biomarkers%20in%20breast%20cancer:%20past,%20present%20and%20future.%20Semin%20Cancer%20Biol%2052(Pt%201):56%E2%80%9373.%2010.1016/j.semcancer.2017.08.010" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR186">
<cite>Nielsen TO et al (2021) Assessment of Ki67 in breast cancer: updated recommendations from the International Ki67 in Breast Cancer Working Group. J Natl Cancer Inst 113(7):808–819. 10.1093/jnci/djaa201
</cite> [<a href="https://doi.org/10.1093/jnci/djaa201" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC8487652/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/33369635/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Nielsen%20TO%20et%20al%20(2021)%20Assessment%20of%20Ki67%20in%20breast%20cancer:%20updated%20recommendations%20from%20the%20International%20Ki67%20in%20Breast%20Cancer%20Working%20Group.%20J%20Natl%20Cancer%20Inst%20113(7):808%E2%80%93819.%2010.1093/jnci/djaa201" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR187">
<cite>Niu J, Jiang L, Guo W, Shao L, Liu Y, Wang L (2013) The association between leptin level and breast cancer: a meta-analysis. PLoS ONE 8(6):e67349. 10.1371/journal.pone.0067349
</cite> [<a href="https://doi.org/10.1371/journal.pone.0067349" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC3694967/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/23826274/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Niu%20J,%20Jiang%20L,%20Guo%20W,%20Shao%20L,%20Liu%20Y,%20Wang%20L%20(2013)%20The%20association%20between%20leptin%20level%20and%20breast%20cancer:%20a%20meta-analysis.%20PLoS%20ONE%208(6):e67349.%2010.1371/journal.pone.0067349" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR188">
<cite>Nordenskjöld A, Fohlin H, Fornander T, Löfdahl B, Skoog L, Stål O (2016) Progesterone receptor positivity is a predictor of long-term benefit from adjuvant tamoxifen treatment of estrogen receptor positive breast cancer. Breast Cancer Res Treat 160(2):313–322. 10.1007/s10549-016-4007-5
</cite> [<a href="https://doi.org/10.1007/s10549-016-4007-5" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC5065613/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/27722840/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Nordenskj%C3%B6ld%20A,%20Fohlin%20H,%20Fornander%20T,%20L%C3%B6fdahl%20B,%20Skoog%20L,%20St%C3%A5l%20O%20(2016)%20Progesterone%20receptor%20positivity%20is%20a%20predictor%20of%20long-term%20benefit%20from%20adjuvant%20tamoxifen%20treatment%20of%20estrogen%20receptor%20positive%20breast%20cancer.%20Breast%20Cancer%20Res%20Treat%20160(2):313%E2%80%93322.%2010.1007/s10549-016-4007-5" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR189">
<cite>Normann LS, Haugen MH, Aure MR, Kristensen VN, Mælandsmo GM, Sahlberg KK (2022) MiR-101-5p acts as a tumor suppressor in HER2-positive breast cancer cells and improves targeted therapy. Breast Cancer 14:25–39. 10.2147/BCTT.S338404
</cite> [<a href="https://doi.org/10.2147/BCTT.S338404" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC8898020/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/35256859/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Normann%20LS,%20Haugen%20MH,%20Aure%20MR,%20Kristensen%20VN,%20M%C3%A6landsmo%20GM,%20Sahlberg%20KK%20(2022)%20MiR-101-5p%20acts%20as%20a%20tumor%20suppressor%20in%20HER2-positive%20breast%20cancer%20cells%20and%20improves%20targeted%20therapy.%20Breast%20Cancer%2014:25%E2%80%9339.%2010.2147/BCTT.S338404" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR190">
<cite>Oh SW et al (2011) Adipokines, insulin resistance, metabolic syndrome, and breast cancer recurrence: a cohort study. Breast Cancer Res BCR 13(2):R34. 10.1186/bcr2856
</cite> [<a href="https://doi.org/10.1186/bcr2856" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC3219197/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/21450081/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Oh%20SW%20et%20al%20(2011)%20Adipokines,%20insulin%20resistance,%20metabolic%20syndrome,%20and%20breast%20cancer%20recurrence:%20a%20cohort%20study.%20Breast%20Cancer%20Res%20BCR%2013(2):R34.%2010.1186/bcr2856" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR191">
<cite>Orozco-Arguelles L et al (2021) Adiponectin and adiponectin receptor 1 expression proteins levels are modified in breast cancer in postmenopausal women with obesity. J Clin Pathol 74(9):571–576. 10.1136/jclinpath-2020-206471
</cite> [<a href="https://doi.org/10.1136/jclinpath-2020-206471" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/32848015/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Orozco-Arguelles%20L%20et%20al%20(2021)%20Adiponectin%20and%20adiponectin%20receptor%201%20expression%20proteins%20levels%20are%20modified%20in%20breast%20cancer%20in%20postmenopausal%20women%20with%20obesity.%20J%20Clin%20Pathol%2074(9):571%E2%80%93576.%2010.1136/jclinpath-2020-206471" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR192">
<cite>Ozawa PMM, Jucoski TS, Vieira E, Carvalho TM, Malheiros D, Ribeiro EMdeSF (2020) Liquid biopsy for breast cancer using extracellular vesicles and cell-free microRNAs as biomarkers. Transl Res J Lab Clin Med 223:40–60. 10.1016/j.trsl.2020.04.002</cite> [<a href="https://doi.org/10.1016/j.trsl.2020.04.002" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/32413499/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Ozawa%20PMM,%20Jucoski%20TS,%20Vieira%20E,%20Carvalho%20TM,%20Malheiros%20D,%20Ribeiro%20EMdeSF%20(2020)%20Liquid%20biopsy%20for%20breast%20cancer%20using%20extracellular%20vesicles%20and%20cell-free%20microRNAs%20as%20biomarkers.%20Transl%20Res%20J%20Lab%20Clin%20Med%20223:40%E2%80%9360.%2010.1016/j.trsl.2020.04.002" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR193">
<cite>Ozawa PMM et al (2020) Identification of miRNAs enriched in extracellular vesicles derived from serum samples of breast cancer patients. Biomolecules 10(1):150. 10.3390/biom10010150
</cite> [<a href="https://doi.org/10.3390/biom10010150" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC7022833/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/31963351/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Ozawa%20PMM%20et%20al%20(2020)%20Identification%20of%20miRNAs%20enriched%20in%20extracellular%20vesicles%20derived%20from%20serum%20samples%20of%20breast%20cancer%20patients.%20Biomolecules%2010(1):150.%2010.3390/biom10010150" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR194">
<cite>Pan H et al (2018) Association between serum leptin levels and breast cancer risk: an updated systematic review and meta-analysis. Medicine (Baltimore) 97(27):e11345. 10.1097/MD.0000000000011345
</cite> [<a href="https://doi.org/10.1097/MD.0000000000011345" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC6076146/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/29979411/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Pan%20H%20et%20al%20(2018)%20Association%20between%20serum%20leptin%20levels%20and%20breast%20cancer%20risk:%20an%20updated%20systematic%20review%20and%20meta-analysis.%20Medicine%20(Baltimore)%2097(27):e11345.%2010.1097/MD.0000000000011345" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR195">
<cite>Pan G, Mao A, Liu J, Lu J, Ding J, Liu W (2020) Circular RNA hsa_circ_0061825 (circ-TFF1) contributes to breast cancer progression through targeting miR-326/TFF1 signalling. Cell Prolif 53(2):e12720. 10.1111/cpr.12720
</cite> [<a href="https://doi.org/10.1111/cpr.12720" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC7048212/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/31961997/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Pan%20G,%20Mao%20A,%20Liu%20J,%20Lu%20J,%20Ding%20J,%20Liu%20W%20(2020)%20Circular%20RNA%20hsa_circ_0061825%20(circ-TFF1)%20contributes%20to%20breast%20cancer%20progression%20through%20targeting%20miR-326/TFF1%20signalling.%20Cell%20Prolif%2053(2):e12720.%2010.1111/cpr.12720" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR196">
<cite>Pan L et al (2024) HER2/PI3K/AKT pathway in HER2-positive breast cancer: a review. Med (Baltimore) 103(24):e38508. 10.1097/MD.0000000000038508</cite> [<a href="https://doi.org/10.1097/MD.0000000000038508" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC11175886/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/38875362/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Pan%20L%20et%20al%20(2024)%20HER2/PI3K/AKT%20pathway%20in%20HER2-positive%20breast%20cancer:%20a%20review.%20Med%20(Baltimore)%20103(24):e38508.%2010.1097/MD.0000000000038508" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR197">
<cite>Papakonstantinou A et al (2022) Prognostic value of ctDNA detection in patients with early breast cancer undergoing neoadjuvant therapy: a systematic review and meta-analysis. Cancer Treat Rev 104:102362. 10.1016/j.ctrv.2022.102362
</cite> [<a href="https://doi.org/10.1016/j.ctrv.2022.102362" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/35219090/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Papakonstantinou%20A%20et%20al%20(2022)%20Prognostic%20value%20of%20ctDNA%20detection%20in%20patients%20with%20early%20breast%20cancer%20undergoing%20neoadjuvant%20therapy:%20a%20systematic%20review%20and%20meta-analysis.%20Cancer%20Treat%20Rev%20104:102362.%2010.1016/j.ctrv.2022.102362" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR198">
<cite>Parums DV (2025) A review of circulating tumor DNA (ctDNA) and the liquid biopsy in cancer diagnosis, screening, and monitoring treatment response. Med Sci Monit Int Med J Exp Clin Res 31:e949300. 10.12659/MSM.949300</cite> [<a href="https://doi.org/10.12659/MSM.949300" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC12032849/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/40259565/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Parums%20DV%20(2025)%20A%20review%20of%20circulating%20tumor%20DNA%20(ctDNA)%20and%20the%20liquid%20biopsy%20in%20cancer%20diagnosis,%20screening,%20and%20monitoring%20treatment%20response.%20Med%20Sci%20Monit%20Int%20Med%20J%20Exp%20Clin%20Res%2031:e949300.%2010.12659/MSM.949300" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR199">
<cite>Penault-Llorca F, Radosevic-Robin N (2017) Ki67 assessment in breast cancer: an update. Pathology (Phila) 49(2):166–171. 10.1016/j.pathol.2016.11.006</cite> [<a href="https://doi.org/10.1016/j.pathol.2016.11.006" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/28065411/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Penault-Llorca%20F,%20Radosevic-Robin%20N%20(2017)%20Ki67%20assessment%20in%20breast%20cancer:%20an%20update.%20Pathology%20(Phila)%2049(2):166%E2%80%93171.%2010.1016/j.pathol.2016.11.006" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR200">
<cite>Perelmuter VM et al (2024) Characterization of EpCAM-positive and EpCAM-negative tumor cells in early-stage breast cancer. Int J Mol Sci 25(20):11109. 10.3390/ijms252011109
</cite> [<a href="https://doi.org/10.3390/ijms252011109" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC11508537/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/39456890/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Perelmuter%20VM%20et%20al%20(2024)%20Characterization%20of%20EpCAM-positive%20and%20EpCAM-negative%20tumor%20cells%20in%20early-stage%20breast%20cancer.%20Int%20J%20Mol%20Sci%2025(20):11109.%2010.3390/ijms252011109" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR201">
<cite>Pesapane F et al (2020) Will traditional biopsy be substituted by radiomics and liquid biopsy for breast cancer diagnosis and characterisation? Med Oncol Northwood Lond Engl 37(4):29. 10.1007/s12032-020-01353-1</cite> [<a href="https://doi.org/10.1007/s12032-020-01353-1" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/32180032/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Pesapane%20F%20et%20al%20(2020)%20Will%20traditional%20biopsy%20be%20substituted%20by%20radiomics%20and%20liquid%20biopsy%20for%20breast%20cancer%20diagnosis%20and%20characterisation?%20Med%20Oncol%20Northwood%20Lond%20Engl%2037(4):29.%2010.1007/s12032-020-01353-1" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR202">
<cite>Petrelli F, Viale G, Cabiddu M, Barni S (2015) Prognostic value of different cut-off levels of Ki-67 in breast cancer: a systematic review and meta-analysis of 64,196 patients. Breast Cancer Res Treat 153(3):477–491. 10.1007/s10549-015-3559-0
</cite> [<a href="https://doi.org/10.1007/s10549-015-3559-0" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/26341751/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Petrelli%20F,%20Viale%20G,%20Cabiddu%20M,%20Barni%20S%20(2015)%20Prognostic%20value%20of%20different%20cut-off%20levels%20of%20Ki-67%20in%20breast%20cancer:%20a%20systematic%20review%20and%20meta-analysis%20of%2064,196%20patients.%20Breast%20Cancer%20Res%20Treat%20153(3):477%E2%80%93491.%2010.1007/s10549-015-3559-0" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR203">
<cite>Petridou E, Papadiamantis Y, Markopoulos C, Spanos E, Dessypris N, Trichopoulos D (2000) Leptin and insulin growth factor I in relation to breast cancer (Greece). Cancer Causes Control 11(5):383–388. 10.1023/a:1008903727238
</cite> [<a href="https://doi.org/10.1023/a:1008903727238" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/10877331/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Petridou%20E,%20Papadiamantis%20Y,%20Markopoulos%20C,%20Spanos%20E,%20Dessypris%20N,%20Trichopoulos%20D%20(2000)%20Leptin%20and%20insulin%20growth%20factor%20I%20in%20relation%20to%20breast%20cancer%20(Greece).%20Cancer%20Causes%20Control%2011(5):383%E2%80%93388.%2010.1023/a:1008903727238" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR204">
<cite>Qiao P, Du H, Guo X, Yu M, Zhang C, Shi Y (2024) Serum exosomal miR-200c is a potential diagnostic biomarker for breast cancer. Biomark Biochem Indic Expo Response Susceptibility Chem 29(7):419–426. 10.1080/1354750X.2024.2406520</cite> [<a href="https://doi.org/10.1080/1354750X.2024.2406520" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/39317236/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Qiao%20P,%20Du%20H,%20Guo%20X,%20Yu%20M,%20Zhang%20C,%20Shi%20Y%20(2024)%20Serum%20exosomal%20miR-200c%20is%20a%20potential%20diagnostic%20biomarker%20for%20breast%20cancer.%20Biomark%20Biochem%20Indic%20Expo%20Response%20Susceptibility%20Chem%2029(7):419%E2%80%93426.%2010.1080/1354750X.2024.2406520" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR205">
<cite>Raheem AR, Abdul-Rasheed OF, Al-Naqqash MA (2019) The diagnostic power of circulating micro ribonucleic acid 34a in combination with cancer antigen 15–3 as a potential biomarker of breast cancer. Saudi Med J 40(12):1218–1226. 10.15537/smj.2019.12.24712
</cite> [<a href="https://doi.org/10.15537/smj.2019.12.24712" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC6969640/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/31828273/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Raheem%20AR,%20Abdul-Rasheed%20OF,%20Al-Naqqash%20MA%20(2019)%20The%20diagnostic%20power%20of%20circulating%20micro%20ribonucleic%20acid%2034a%20in%20combination%20with%20cancer%20antigen%2015%E2%80%933%20as%20a%20potential%20biomarker%20of%20breast%20cancer.%20Saudi%20Med%20J%2040(12):1218%E2%80%931226.%2010.15537/smj.2019.12.24712" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR206">
<cite>Rakha EA, Chmielik E, Schmitt FC, Tan PH, Quinn CM, Gallagy G (2022) Assessment of predictive biomarkers in breast cancer: challenges and updates. Pathobiol J Immunopathol Mol Cell Biol 89(5):263–277. 10.1159/000525092</cite> [<a href="https://doi.org/10.1159/000525092" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/35728576/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Rakha%20EA,%20Chmielik%20E,%20Schmitt%20FC,%20Tan%20PH,%20Quinn%20CM,%20Gallagy%20G%20(2022)%20Assessment%20of%20predictive%20biomarkers%20in%20breast%20cancer:%20challenges%20and%20updates.%20Pathobiol%20J%20Immunopathol%20Mol%20Cell%20Biol%2089(5):263%E2%80%93277.%2010.1159/000525092" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR207">
<cite>Ramos-Lobo AM, Donato J (2017) The role of leptin in health and disease. Temperature 4(3):258–291. 10.1080/23328940.2017.1327003</cite> [<a href="https://doi.org/10.1080/23328940.2017.1327003" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC5605162/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/28944270/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Ramos-Lobo%20AM,%20Donato%20J%20(2017)%20The%20role%20of%20leptin%20in%20health%20and%20disease.%20Temperature%204(3):258%E2%80%93291.%2010.1080/23328940.2017.1327003" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR208">
<cite>Rauf F, Anderson KS, LaBaer J (2020) Autoantibodies in early detection of breast cancer. Cancer Epidemiol Biomark Prev Publ Am Assoc Cancer Res Cosponsored Am Soc Prev Oncol. 29(12):2475–2485. 10.1158/1055-9965.EPI-20-0331</cite> [<a href="https://doi.org/10.1158/1055-9965.EPI-20-0331" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC7710604/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/32994341/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Rauf%20F,%20Anderson%20KS,%20LaBaer%20J%20(2020)%20Autoantibodies%20in%20early%20detection%20of%20breast%20cancer.%20Cancer%20Epidemiol%20Biomark%20Prev%20Publ%20Am%20Assoc%20Cancer%20Res%20Cosponsored%20Am%20Soc%20Prev%20Oncol.%2029(12):2475%E2%80%932485.%2010.1158/1055-9965.EPI-20-0331" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR209">
<cite>Rodriguez BJ et al (2019) Detection of TP53 and PIK3CA mutations in circulating tumor DNA using next-generation sequencing in the screening process for early breast cancer diagnosis. J Clin Med 8(8):1183. 10.3390/jcm8081183
</cite> [<a href="https://doi.org/10.3390/jcm8081183" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC6723048/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/31394872/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Rodriguez%20BJ%20et%20al%20(2019)%20Detection%20of%20TP53%20and%20PIK3CA%20mutations%20in%20circulating%20tumor%20DNA%20using%20next-generation%20sequencing%20in%20the%20screening%20process%20for%20early%20breast%20cancer%20diagnosis.%20J%20Clin%20Med%208(8):1183.%2010.3390/jcm8081183" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR210">
<cite>Rontogianni S et al (2019) Proteomic profiling of extracellular vesicles allows for human breast cancer subtyping. Commun Biol 2:325. 10.1038/s42003-019-0570-8
</cite> [<a href="https://doi.org/10.1038/s42003-019-0570-8" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC6722120/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/31508500/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Rontogianni%20S%20et%20al%20(2019)%20Proteomic%20profiling%20of%20extracellular%20vesicles%20allows%20for%20human%20breast%20cancer%20subtyping.%20Commun%20Biol%202:325.%2010.1038/s42003-019-0570-8" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR211">
<cite>Roy M, Fowler AM, Ulaner GA, Mahajan A (2023) Molecular classification of breast cancer. PET Clin 18(4):441–458. 10.1016/j.cpet.2023.04.002
</cite> [<a href="https://doi.org/10.1016/j.cpet.2023.04.002" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/37268505/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Roy%20M,%20Fowler%20AM,%20Ulaner%20GA,%20Mahajan%20A%20(2023)%20Molecular%20classification%20of%20breast%20cancer.%20PET%20Clin%2018(4):441%E2%80%93458.%2010.1016/j.cpet.2023.04.002" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR212">
<cite>Rzhevskiy AS et al (2025) A comprehensive review and meta-analysis of CTC isolation methods in breast cancer. Crit Rev Oncol Hematol 206:104579. 10.1016/j.critrevonc.2024.104579
</cite> [<a href="https://doi.org/10.1016/j.critrevonc.2024.104579" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/39615710/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Rzhevskiy%20AS%20et%20al%20(2025)%20A%20comprehensive%20review%20and%20meta-analysis%20of%20CTC%20isolation%20methods%20in%20breast%20cancer.%20Crit%20Rev%20Oncol%20Hematol%20206:104579.%2010.1016/j.critrevonc.2024.104579" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR213">
<cite>S. Lee J, Park S, M. Park J, H. Cho J, I. Kim S, Park B-W (2013) Elevated levels of preoperative CA 15–3 and CEA serum levels have independently poor prognostic significance in breast cancer. Ann Oncol off J Eur Soc Med Oncol 24(5):1225–1231. 10.1093/annonc/mds604</cite> [<a href="https://doi.org/10.1093/annonc/mds604" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/23230137/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?S.%20Lee%20J,%20Park%20S,%20M.%20Park%20J,%20H.%20Cho%20J,%20I.%20Kim%20S,%20Park%20B-W%20(2013)%20Elevated%20levels%20of%20preoperative%20CA%2015%E2%80%933%20and%20CEA%20serum%20levels%20have%20independently%20poor%20prognostic%20significance%20in%20breast%20cancer.%20Ann%20Oncol%20off%20J%20Eur%20Soc%20Med%20Oncol%2024(5):1225%E2%80%931231.%2010.1093/annonc/mds604" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR214">
<cite>Saliminejad K, Khorram Khorshid HR, Soleymani Fard S, Ghaffari SH (2019) An overview of microRNAs: biology, functions, therapeutics, and analysis methods. J Cell Physiol 234(5):5451–5465. 10.1002/jcp.27486
</cite> [<a href="https://doi.org/10.1002/jcp.27486" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/30471116/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Saliminejad%20K,%20Khorram%20Khorshid%20HR,%20Soleymani%20Fard%20S,%20Ghaffari%20SH%20(2019)%20An%20overview%20of%20microRNAs:%20biology,%20functions,%20therapeutics,%20and%20analysis%20methods.%20J%20Cell%20Physiol%20234(5):5451%E2%80%935465.%2010.1002/jcp.27486" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR215">
<cite>Samuel SM, Varghese E, Varghese S, Büsselberg D (2018) Challenges and perspectives in the treatment of diabetes associated breast cancer. Cancer Treat Rev 70:98–111. 10.1016/j.ctrv.2018.08.004
</cite> [<a href="https://doi.org/10.1016/j.ctrv.2018.08.004" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/30130687/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Samuel%20SM,%20Varghese%20E,%20Varghese%20S,%20B%C3%BCsselberg%20D%20(2018)%20Challenges%20and%20perspectives%20in%20the%20treatment%20of%20diabetes%20associated%20breast%20cancer.%20Cancer%20Treat%20Rev%2070:98%E2%80%93111.%2010.1016/j.ctrv.2018.08.004" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR216">
<cite>Samuels M, Cilibrasi C, Papanastasopoulos P, Giamas G (2022) Extracellular vesicles as mediators of therapy resistance in the breast cancer microenvironment. Biomolecules 12(1):132. 10.3390/biom12010132
</cite> [<a href="https://doi.org/10.3390/biom12010132" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC8773878/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/35053279/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Samuels%20M,%20Cilibrasi%20C,%20Papanastasopoulos%20P,%20Giamas%20G%20(2022)%20Extracellular%20vesicles%20as%20mediators%20of%20therapy%20resistance%20in%20the%20breast%20cancer%20microenvironment.%20Biomolecules%2012(1):132.%2010.3390/biom12010132" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR217">
<cite>Sant M, Bernat-Peguera A, Felip E, Margelí M (2022) Role of ctDNA in breast cancer. Cancers (Basel) 14(2):310. 10.3390/cancers14020310
</cite> [<a href="https://doi.org/10.3390/cancers14020310" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC8773730/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/35053474/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Sant%20M,%20Bernat-Peguera%20A,%20Felip%20E,%20Margel%C3%AD%20M%20(2022)%20Role%20of%20ctDNA%20in%20breast%20cancer.%20Cancers%20(Basel)%2014(2):310.%2010.3390/cancers14020310" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR218">
<cite>Saura C et al (2023) Early-stage breast cancer detection in breast milk. Cancer Discov 13(10):2180–2191. 10.1158/2159-8290.CD-22-1340
</cite> [<a href="https://doi.org/10.1158/2159-8290.CD-22-1340" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC10551665/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/37704212/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Saura%20C%20et%20al%20(2023)%20Early-stage%20breast%20cancer%20detection%20in%20breast%20milk.%20Cancer%20Discov%2013(10):2180%E2%80%932191.%2010.1158/2159-8290.CD-22-1340" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR219">
<cite>Sauter ER, Garofalo C, Hewett J, Hewett JE, Morelli C, Surmacz E (2004) Leptin expression in breast nipple aspirate fluid (NAF) and serum is influenced by body mass index (BMI) but not by the presence of breast cancer. Horm Metab Res Horm Stoffwechselforschung Horm Metab 36(5):336–340. 10.1055/s-2004-814490</cite> [<a href="https://doi.org/10.1055/s-2004-814490" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/15156414/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Sauter%20ER,%20Garofalo%20C,%20Hewett%20J,%20Hewett%20JE,%20Morelli%20C,%20Surmacz%20E%20(2004)%20Leptin%20expression%20in%20breast%20nipple%20aspirate%20fluid%20(NAF)%20and%20serum%20is%20influenced%20by%20body%20mass%20index%20(BMI)%20but%20not%20by%20the%20presence%20of%20breast%20cancer.%20Horm%20Metab%20Res%20Horm%20Stoffwechselforschung%20Horm%20Metab%2036(5):336%E2%80%93340.%2010.1055/s-2004-814490" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR220">
<cite>Schlüter C et al (1993) The cell proliferation-associated antigen of antibody Ki-67: a very large, ubiquitous nuclear protein with numerous repeated elements, representing a new kind of cell cycle-maintaining proteins. J Cell Biol 123(3):513–522. 10.1083/jcb.123.3.513
</cite> [<a href="https://doi.org/10.1083/jcb.123.3.513" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC2200129/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/8227122/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Schl%C3%BCter%20C%20et%20al%20(1993)%20The%20cell%20proliferation-associated%20antigen%20of%20antibody%20Ki-67:%20a%20very%20large,%20ubiquitous%20nuclear%20protein%20with%20numerous%20repeated%20elements,%20representing%20a%20new%20kind%20of%20cell%20cycle-maintaining%20proteins.%20J%20Cell%20Biol%20123(3):513%E2%80%93522.%2010.1083/jcb.123.3.513" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR221">
<cite>Seale KN, Tkaczuk KHR (2022) Circulating biomarkers in breast cancer. Clin Breast Cancer 22(3):e319–e331. 10.1016/j.clbc.2021.09.006
</cite> [<a href="https://doi.org/10.1016/j.clbc.2021.09.006" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/34756687/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Seale%20KN,%20Tkaczuk%20KHR%20(2022)%20Circulating%20biomarkers%20in%20breast%20cancer.%20Clin%20Breast%20Cancer%2022(3):e319%E2%80%93e331.%2010.1016/j.clbc.2021.09.006" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR222">
<cite>Shafiq A et al (2020) Elevated soluble galectin-3 as a marker of chemotherapy efficacy in breast cancer patients: a prospective study. Int J Breast Cancer 2020:4824813. 10.1155/2020/4824813
</cite> [<a href="https://doi.org/10.1155/2020/4824813" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC7097759/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/32231800/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Shafiq%20A%20et%20al%20(2020)%20Elevated%20soluble%20galectin-3%20as%20a%20marker%20of%20chemotherapy%20efficacy%20in%20breast%20cancer%20patients:%20a%20prospective%20study.%20Int%20J%20Breast%20Cancer%202020:4824813.%2010.1155/2020/4824813" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR223">
<cite>Shahbandi A, Nguyen HD, Jackson JG (2020) TP53 mutations and outcomes in breast cancer: reading beyond the headlines. Trends Cancer 6(2):98–110. 10.1016/j.trecan.2020.01.007
</cite> [<a href="https://doi.org/10.1016/j.trecan.2020.01.007" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC7931175/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/32061310/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Shahbandi%20A,%20Nguyen%20HD,%20Jackson%20JG%20(2020)%20TP53%20mutations%20and%20outcomes%20in%20breast%20cancer:%20reading%20beyond%20the%20headlines.%20Trends%20Cancer%206(2):98%E2%80%93110.%2010.1016/j.trecan.2020.01.007" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR224">
<cite>Shao Y, Sun X, He Y, Liu C, Liu H (2015) Elevated levels of serum tumor markers CEA and CA15-3 are prognostic parameters for different molecular subtypes of breast cancer. PLoS ONE 10(7):e0133830. 10.1371/journal.pone.0133830
</cite> [<a href="https://doi.org/10.1371/journal.pone.0133830" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC4514648/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/26207909/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Shao%20Y,%20Sun%20X,%20He%20Y,%20Liu%20C,%20Liu%20H%20(2015)%20Elevated%20levels%20of%20serum%20tumor%20markers%20CEA%20and%20CA15-3%20are%20prognostic%20parameters%20for%20different%20molecular%20subtypes%20of%20breast%20cancer.%20PLoS%20ONE%2010(7):e0133830.%2010.1371/journal.pone.0133830" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR225">
<cite>Sharifi Z, Talkhabi M, Taleahmad S (2022) Identification of potential microRNA diagnostic panels and uncovering regulatory mechanisms in breast cancer pathogenesis. Sci Rep 12(1):20135. 10.1038/s41598-022-24347-7
</cite> [<a href="https://doi.org/10.1038/s41598-022-24347-7" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC9684445/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/36418345/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Sharifi%20Z,%20Talkhabi%20M,%20Taleahmad%20S%20(2022)%20Identification%20of%20potential%20microRNA%20diagnostic%20panels%20and%20uncovering%20regulatory%20mechanisms%20in%20breast%20cancer%20pathogenesis.%20Sci%20Rep%2012(1):20135.%2010.1038/s41598-022-24347-7" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR226">
<cite>Shiino S et al (2022) Prognostic significance of receptor expression discordance between primary and recurrent breast cancers: a meta-analysis. Breast Cancer Res Treat 91(1):1–14. 10.1007/s10549-021-06390-6</cite> [<a href="https://doi.org/10.1007/s10549-021-06390-6" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC8758639/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/34613502/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Shiino%20S%20et%20al%20(2022)%20Prognostic%20significance%20of%20receptor%20expression%20discordance%20between%20primary%20and%20recurrent%20breast%20cancers:%20a%20meta-analysis.%20Breast%20Cancer%20Res%20Treat%2091(1):1%E2%80%9314.%2010.1007/s10549-021-06390-6" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR227">
<cite>Shimomura A et al (2016) Novel combination of serum microRNA for detecting breast cancer in the early stage. Cancer Sci 107(3):326–334. 10.1111/cas.12880
</cite> [<a href="https://doi.org/10.1111/cas.12880" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC4814263/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/26749252/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Shimomura%20A%20et%20al%20(2016)%20Novel%20combination%20of%20serum%20microRNA%20for%20detecting%20breast%20cancer%20in%20the%20early%20stage.%20Cancer%20Sci%20107(3):326%E2%80%93334.%2010.1111/cas.12880" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR228">
<cite>Siravegna G et al (2017) Genotyping tumour DNA in cerebrospinal fluid and plasma of a HER2-positive breast cancer patient with brain metastases. ESMO Open 2(4):e000253. 10.1136/esmoopen-2017-000253
</cite> [<a href="https://doi.org/10.1136/esmoopen-2017-000253" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC5640139/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/29067216/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Siravegna%20G%20et%20al%20(2017)%20Genotyping%20tumour%20DNA%20in%20cerebrospinal%20fluid%20and%20plasma%20of%20a%20HER2-positive%20breast%20cancer%20patient%20with%20brain%20metastases.%20ESMO%20Open%202(4):e000253.%2010.1136/esmoopen-2017-000253" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR229">
<cite>Skoracka K et al (2025) The role of leptin and ghrelin in the regulation of appetite in obesity. Peptides 186:171367. 10.1016/j.peptides.2025.171367
</cite> [<a href="https://doi.org/10.1016/j.peptides.2025.171367" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/39983918/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Skoracka%20K%20et%20al%20(2025)%20The%20role%20of%20leptin%20and%20ghrelin%20in%20the%20regulation%20of%20appetite%20in%20obesity.%20Peptides%20186:171367.%2010.1016/j.peptides.2025.171367" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR230">
<cite>Song L, Xiao Y (2018) Downregulation of hsa_circ_0007534 suppresses breast cancer cell proliferation and invasion by targeting miR-593/MUC19 signal pathway. Biochem Biophys Res Commun 503(4):2603–2610. 10.1016/j.bbrc.2018.08.007
</cite> [<a href="https://doi.org/10.1016/j.bbrc.2018.08.007" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/30139516/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Song%20L,%20Xiao%20Y%20(2018)%20Downregulation%20of%20hsa_circ_0007534%20suppresses%20breast%20cancer%20cell%20proliferation%20and%20invasion%20by%20targeting%20miR-593/MUC19%20signal%20pathway.%20Biochem%20Biophys%20Res%20Commun%20503(4):2603%E2%80%932610.%2010.1016/j.bbrc.2018.08.007" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR231">
<cite>Souza KCB et al (2019) Identification of cell-free circulating microRNAs for the detection of early breast cancer and molecular subtyping. J Oncol 2019:8393769. 10.1155/2019/8393769
</cite> [<a href="https://doi.org/10.1155/2019/8393769" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC6702831/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/31485228/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Souza%20KCB%20et%20al%20(2019)%20Identification%20of%20cell-free%20circulating%20microRNAs%20for%20the%20detection%20of%20early%20breast%20cancer%20and%20molecular%20subtyping.%20J%20Oncol%202019:8393769.%2010.1155/2019/8393769" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR232">
<cite>Stanowicka-Grada M, Senkus E (2023) Anti-HER2 drugs for the treatment of advanced HER2 positive breast cancer. Curr Treat Options Oncol 24(11):1633–1650. 10.1007/s11864-023-01137-5
</cite> [<a href="https://doi.org/10.1007/s11864-023-01137-5" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC10643304/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/37878202/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Stanowicka-Grada%20M,%20Senkus%20E%20(2023)%20Anti-HER2%20drugs%20for%20the%20treatment%20of%20advanced%20HER2%20positive%20breast%20cancer.%20Curr%20Treat%20Options%20Oncol%2024(11):1633%E2%80%931650.%2010.1007/s11864-023-01137-5" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR233">
<cite>Sudan SK et al (2020) Resistin: an inflammatory cytokine with multi-faceted roles in cancer. Biochimica Et Biophysica Acta (BBA) 1874(2):188419. 10.1016/j.bbcan.2020.188419</cite> [<a href="https://doi.org/10.1016/j.bbcan.2020.188419" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC8117252/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/32822824/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Sudan%20SK%20et%20al%20(2020)%20Resistin:%20an%20inflammatory%20cytokine%20with%20multi-faceted%20roles%20in%20cancer.%20Biochimica%20Et%20Biophysica%20Acta%20(BBA)%201874(2):188419.%2010.1016/j.bbcan.2020.188419" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR234">
<cite>Szostakowska M, Trębińska-Stryjewska A, Grzybowska EA, Fabisiewicz A (2019) Resistance to endocrine therapy in breast cancer: molecular mechanisms and future goals. Breast Cancer Res Treat 173(3):489–497. 10.1007/s10549-018-5023-4
</cite> [<a href="https://doi.org/10.1007/s10549-018-5023-4" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC6394602/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/30382472/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Szostakowska%20M,%20Tr%C4%99bi%C5%84ska-Stryjewska%20A,%20Grzybowska%20EA,%20Fabisiewicz%20A%20(2019)%20Resistance%20to%20endocrine%20therapy%20in%20breast%20cancer:%20molecular%20mechanisms%20and%20future%20goals.%20Breast%20Cancer%20Res%20Treat%20173(3):489%E2%80%93497.%2010.1007/s10549-018-5023-4" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR235">
<cite>Szostakowska-Rodzos M et al (2024) Longitudinal analysis of circulating tumor cell numbers improves tracking metastatic breast cancer progression. Sci Rep 14(1):12924. 10.1038/s41598-024-63679-4
</cite> [<a href="https://doi.org/10.1038/s41598-024-63679-4" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC11153567/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/38839863/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Szostakowska-Rodzos%20M%20et%20al%20(2024)%20Longitudinal%20analysis%20of%20circulating%20tumor%20cell%20numbers%20improves%20tracking%20metastatic%20breast%20cancer%20progression.%20Sci%20Rep%2014(1):12924.%2010.1038/s41598-024-63679-4" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR236">
<cite>Tang H et al (2019) CircKIF4A acts as a prognostic factor and mediator to regulate the progression of triple-negative breast cancer. Mol Cancer 18:23. 10.1186/s12943-019-0946-x
</cite> [<a href="https://doi.org/10.1186/s12943-019-0946-x" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC6369546/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/30744636/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Tang%20H%20et%20al%20(2019)%20CircKIF4A%20acts%20as%20a%20prognostic%20factor%20and%20mediator%20to%20regulate%20the%20progression%20of%20triple-negative%20breast%20cancer.%20Mol%20Cancer%2018:23.%2010.1186/s12943-019-0946-x" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR237">
<cite>Tarighati E, Keivan H, Mahani H (2023) A review of prognostic and predictive biomarkers in breast cancer. Clin Exp Med 23(1):1–16. 10.1007/s10238-021-00781-1
</cite> [<a href="https://doi.org/10.1007/s10238-021-00781-1" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/35031885/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Tarighati%20E,%20Keivan%20H,%20Mahani%20H%20(2023)%20A%20review%20of%20prognostic%20and%20predictive%20biomarkers%20in%20breast%20cancer.%20Clin%20Exp%20Med%2023(1):1%E2%80%9316.%2010.1007/s10238-021-00781-1" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR238">
<cite>Taucher S et al (2004) Prognostic markers in breast cancer: the reliability of HER2/neu status in core needle biopsy of 325 patients with primary breast cancer. Wien Klin Wochenschr 116(1–2):26–31. 10.1007/BF03040420
</cite> [<a href="https://doi.org/10.1007/BF03040420" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/15030120/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Taucher%20S%20et%20al%20(2004)%20Prognostic%20markers%20in%20breast%20cancer:%20the%20reliability%20of%20HER2/neu%20status%20in%20core%20needle%20biopsy%20of%20325%20patients%20with%20primary%20breast%20cancer.%20Wien%20Klin%20Wochenschr%20116(1%E2%80%932):26%E2%80%9331.%2010.1007/BF03040420" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR239">
<cite>Tfayli A, Temraz S, Abou Mrad R, Shamseddine A (2010) Breast cancer in low- and middle-income countries: an emerging and challenging epidemic. J Oncol 2010:490631. 10.1155/2010/490631
</cite> [<a href="https://doi.org/10.1155/2010/490631" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC3010663/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/21209708/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Tfayli%20A,%20Temraz%20S,%20Abou%20Mrad%20R,%20Shamseddine%20A%20(2010)%20Breast%20cancer%20in%20low-%20and%20middle-income%20countries:%20an%20emerging%20and%20challenging%20epidemic.%20J%20Oncol%202010:490631.%2010.1155/2010/490631" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR240">
<cite>Thakur S, Grover RK, Gupta S, Yadav AK, Das BC (2016) Identification of specific miRNA signature in paired sera and tissue samples of Indian women with triple negative breast cancer. PLoS ONE 11(7):e0158946. 10.1371/journal.pone.0158946
</cite> [<a href="https://doi.org/10.1371/journal.pone.0158946" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC4942139/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/27404381/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Thakur%20S,%20Grover%20RK,%20Gupta%20S,%20Yadav%20AK,%20Das%20BC%20(2016)%20Identification%20of%20specific%20miRNA%20signature%20in%20paired%20sera%20and%20tissue%20samples%20of%20Indian%20women%20with%20triple%20negative%20breast%20cancer.%20PLoS%20ONE%2011(7):e0158946.%2010.1371/journal.pone.0158946" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR241">
<cite>Thomas-Bonafos T, Pierga JY, Bidard F-C, Cabel L, Kiavue N (2024) Circulating tumor cells in breast cancer: clinical validity and utility. NPJ Breast Cancer 10(1):103. 10.1038/s41523-024-00706-7
</cite> [<a href="https://doi.org/10.1038/s41523-024-00706-7" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC11606964/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/39613809/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Thomas-Bonafos%20T,%20Pierga%20JY,%20Bidard%20F-C,%20Cabel%20L,%20Kiavue%20N%20(2024)%20Circulating%20tumor%20cells%20in%20breast%20cancer:%20clinical%20validity%20and%20utility.%20NPJ%20Breast%20Cancer%2010(1):103.%2010.1038/s41523-024-00706-7" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR242">
<cite>Topcu TO et al (2018) The clinical importance of serum galectin-3 levels in breast cancer patients with and without metastasis. J Cancer Res Ther 14:S583–S586. 10.4103/0973-1482.176425
</cite> [<a href="https://doi.org/10.4103/0973-1482.176425" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/30249872/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Topcu%20TO%20et%20al%20(2018)%20The%20clinical%20importance%20of%20serum%20galectin-3%20levels%20in%20breast%20cancer%20patients%20with%20and%20without%20metastasis.%20J%20Cancer%20Res%20Ther%2014:S583%E2%80%93S586.%2010.4103/0973-1482.176425" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR243">
<cite>Trebo A et al (2020) High galectin-7 and low galectin-8 expression and the combination of both are negative prognosticators for breast cancer patients. Cancers (Basel) 12(4):953. 10.3390/cancers12040953
</cite> [<a href="https://doi.org/10.3390/cancers12040953" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC7226378/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/32290551/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Trebo%20A%20et%20al%20(2020)%20High%20galectin-7%20and%20low%20galectin-8%20expression%20and%20the%20combination%20of%20both%20are%20negative%20prognosticators%20for%20breast%20cancer%20patients.%20Cancers%20(Basel)%2012(4):953.%2010.3390/cancers12040953" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR244">
<cite>Triantafyllou A et al (2022) Circulating miRNA expression profiling in breast cancer molecular subtypes: applying machine learning analysis in bioinformatics. Cancer Diagn Progn 2(6):739–749. 10.21873/cdp.10169
</cite> [<a href="https://doi.org/10.21873/cdp.10169" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC9628143/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/36340453/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Triantafyllou%20A%20et%20al%20(2022)%20Circulating%20miRNA%20expression%20profiling%20in%20breast%20cancer%20molecular%20subtypes:%20applying%20machine%20learning%20analysis%20in%20bioinformatics.%20Cancer%20Diagn%20Progn%202(6):739%E2%80%93749.%2010.21873/cdp.10169" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR245">
<cite>Turashvili G, Brogi E (2017) Tumor heterogeneity in breast cancer. Front Med 4:227. 10.3389/fmed.2017.00227</cite> [<a href="https://doi.org/10.3389/fmed.2017.00227" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC5727049/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/29276709/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Turashvili%20G,%20Brogi%20E%20(2017)%20Tumor%20heterogeneity%20in%20breast%20cancer.%20Front%20Med%204:227.%2010.3389/fmed.2017.00227" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR246">
<cite>Uehara M, Kinoshita T, Hojo T, Akashi-Tanaka S, Iwamoto E, Fukutomi T (2008) Long-term prognostic study of carcinoembryonic antigen (CEA) and carbohydrate antigen 15–3 (CA 15–3) in breast cancer. Int J Clin Oncol 13(5):447–451. 10.1007/s10147-008-0773-3
</cite> [<a href="https://doi.org/10.1007/s10147-008-0773-3" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/18946756/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Uehara%20M,%20Kinoshita%20T,%20Hojo%20T,%20Akashi-Tanaka%20S,%20Iwamoto%20E,%20Fukutomi%20T%20(2008)%20Long-term%20prognostic%20study%20of%20carcinoembryonic%20antigen%20(CEA)%20and%20carbohydrate%20antigen%2015%E2%80%933%20(CA%2015%E2%80%933)%20in%20breast%20cancer.%20Int%20J%20Clin%20Oncol%2013(5):447%E2%80%93451.%2010.1007/s10147-008-0773-3" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR247">
<cite>Urabe F, Kosaka N, Ito K, Kimura T, Egawa S, Ochiya T (2020) Extracellular vesicles as biomarkers and therapeutic targets for cancer. Am J Physiol Cell Physiol 318(1):C29–C39. 10.1152/ajpcell.00280.2019
</cite> [<a href="https://doi.org/10.1152/ajpcell.00280.2019" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/31693397/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Urabe%20F,%20Kosaka%20N,%20Ito%20K,%20Kimura%20T,%20Egawa%20S,%20Ochiya%20T%20(2020)%20Extracellular%20vesicles%20as%20biomarkers%20and%20therapeutic%20targets%20for%20cancer.%20Am%20J%20Physiol%20Cell%20Physiol%20318(1):C29%E2%80%93C39.%2010.1152/ajpcell.00280.2019" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR248">
<cite>van Gils CH, Otten JD, Verbeek AL, Hendriks JH, Holland R (1998) Effect of mammographic breast density on breast cancer screening performance: a study in Nijmegen, The Netherlands. J Epidemiol Community Health 52(4):267–271. 10.1136/jech.52.4.267
</cite> [<a href="https://doi.org/10.1136/jech.52.4.267" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC1756693/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/9616416/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?van%20Gils%20CH,%20Otten%20JD,%20Verbeek%20AL,%20Hendriks%20JH,%20Holland%20R%20(1998)%20Effect%20of%20mammographic%20breast%20density%20on%20breast%20cancer%20screening%20performance:%20a%20study%20in%20Nijmegen,%20The%20Netherlands.%20J%20Epidemiol%20Community%20Health%2052(4):267%E2%80%93271.%2010.1136/jech.52.4.267" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR249">
<cite>Vavoulis DV et al (2025) Multimodal cell-free DNA whole-genome TAPS is sensitive and reveals specific cancer signals. Nat Commun 16(1):430. 10.1038/s41467-024-55428-y
</cite> [<a href="https://doi.org/10.1038/s41467-024-55428-y" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC11711490/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/39779727/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Vavoulis%20DV%20et%20al%20(2025)%20Multimodal%20cell-free%20DNA%20whole-genome%20TAPS%20is%20sensitive%20and%20reveals%20specific%20cancer%20signals.%20Nat%20Commun%2016(1):430.%2010.1038/s41467-024-55428-y" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR250">
<cite>Venetis K et al (2023) <em>ESR1</em> mutations in HR+/HER2-metastatic breast cancer: enhancing the accuracy of ctDNA testing. Cancer Treat Rev 121:102642. 10.1016/j.ctrv.2023.102642
</cite> [<a href="https://doi.org/10.1016/j.ctrv.2023.102642" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/37864956/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Venetis%20K%20et%20al%20(2023)%20ESR1%20mutations%20in%20HR+/HER2-metastatic%20breast%20cancer:%20enhancing%20the%20accuracy%20of%20ctDNA%20testing.%20Cancer%20Treat%20Rev%20121:102642.%2010.1016/j.ctrv.2023.102642" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR251">
<cite>Wang L (2017) Early diagnosis of breast cancer. Sensors 17(7):1572. 10.3390/s17071572
</cite> [<a href="https://doi.org/10.3390/s17071572" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC5539491/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/28678153/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Wang%20L%20(2017)%20Early%20diagnosis%20of%20breast%20cancer.%20Sensors%2017(7):1572.%2010.3390/s17071572" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR252">
<cite>Wang G et al (2014) Nipple discharge of CA15-3, CA125, CEA and TSGF as a new biomarker panel for breast cancer. Int J Mol Sci 15(6):9546–9565. 10.3390/ijms15069546
</cite> [<a href="https://doi.org/10.3390/ijms15069546" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC4100109/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/24879526/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Wang%20G%20et%20al%20(2014)%20Nipple%20discharge%20of%20CA15-3,%20CA125,%20CEA%20and%20TSGF%20as%20a%20new%20biomarker%20panel%20for%20breast%20cancer.%20Int%20J%20Mol%20Sci%2015(6):9546%E2%80%939565.%2010.3390/ijms15069546" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR253">
<cite>Wang J et al (2015) Plasma autoantibodies associated with basal-like breast cancers. Cancer Epidemiol Biomark Prev Publ Am Assoc Cancer Res Cosponsored Am Soc Prev Oncol 24(9):1332–1340. 10.1158/1055-9965.EPI-15-0047</cite> [<a href="https://doi.org/10.1158/1055-9965.EPI-15-0047" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC4560641/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/26070530/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Wang%20J%20et%20al%20(2015)%20Plasma%20autoantibodies%20associated%20with%20basal-like%20breast%20cancers.%20Cancer%20Epidemiol%20Biomark%20Prev%20Publ%20Am%20Assoc%20Cancer%20Res%20Cosponsored%20Am%20Soc%20Prev%20Oncol%2024(9):1332%E2%80%931340.%2010.1158/1055-9965.EPI-15-0047" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR254">
<cite>Wang W et al (2017) The diagnostic value of serum tumor markers CEA, CA19-9, CA125, CA15-3, and TPS in metastatic breast cancer. Clin Chim Acta Int J Clin Chem 470:51–55. 10.1016/j.cca.2017.04.023</cite> [<a href="https://doi.org/10.1016/j.cca.2017.04.023" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/28457854/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Wang%20W%20et%20al%20(2017)%20The%20diagnostic%20value%20of%20serum%20tumor%20markers%20CEA,%20CA19-9,%20CA125,%20CA15-3,%20and%20TPS%20in%20metastatic%20breast%20cancer.%20Clin%20Chim%20Acta%20Int%20J%20Clin%20Chem%20470:51%E2%80%9355.%2010.1016/j.cca.2017.04.023" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR255">
<cite>Wang Y, Du L, Jing J, Zhao X, Wang X, Hou S (2023a) Leptin and leptin receptor expression as biomarkers for breast cancer: a retrospective study. BMC Cancer 23(1):260. 10.1186/s12885-023-10617-8
</cite> [<a href="https://doi.org/10.1186/s12885-023-10617-8" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC10029294/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/36941557/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Wang%20Y,%20Du%20L,%20Jing%20J,%20Zhao%20X,%20Wang%20X,%20Hou%20S%20(2023a)%20Leptin%20and%20leptin%20receptor%20expression%20as%20biomarkers%20for%20breast%20cancer:%20a%20retrospective%20study.%20BMC%20Cancer%2023(1):260.%2010.1186/s12885-023-10617-8" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR256">
<cite>Wang K, Wang X, Pan Q, Zhao B (2023b) Liquid biopsy techniques and pancreatic cancer: diagnosis, monitoring, and evaluation. Mol Cancer 22:167. 10.1186/s12943-023-01870-3
</cite> [<a href="https://doi.org/10.1186/s12943-023-01870-3" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC10557192/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/37803304/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Wang%20K,%20Wang%20X,%20Pan%20Q,%20Zhao%20B%20(2023b)%20Liquid%20biopsy%20techniques%20and%20pancreatic%20cancer:%20diagnosis,%20monitoring,%20and%20evaluation.%20Mol%20Cancer%2022:167.%2010.1186/s12943-023-01870-3" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR257">
<cite>Wilkinson L, Gathani T (2022) Understanding breast cancer as a global health concern. Br J Radiol 95(1130):20211033. 10.1259/bjr.20211033
</cite> [<a href="https://doi.org/10.1259/bjr.20211033" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC8822551/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/34905391/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Wilkinson%20L,%20Gathani%20T%20(2022)%20Understanding%20breast%20cancer%20as%20a%20global%20health%20concern.%20Br%20J%20Radiol%2095(1130):20211033.%2010.1259/bjr.20211033" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR258">
<cite>Wolff AC et al (2018) Human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists clinical practice guideline focused update. J Clin Oncol off J Am Soc Clin Oncol 36(20):2105–2122. 10.1200/JCO.2018.77.8738</cite> [<a href="https://doi.org/10.1200/JCO.2018.77.8738" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/29846122/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Wolff%20AC%20et%20al%20(2018)%20Human%20epidermal%20growth%20factor%20receptor%202%20testing%20in%20breast%20cancer:%20American%20Society%20of%20Clinical%20Oncology/College%20of%20American%20Pathologists%20clinical%20practice%20guideline%20focused%20update.%20J%20Clin%20Oncol%20off%20J%20Am%20Soc%20Clin%20Oncol%2036(20):2105%E2%80%932122.%2010.1200/JCO.2018.77.8738" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR259">
<cite>Wolff AC et al (2023) Human epidermal growth factor receptor 2 testing in breast cancer: ASCO-college of American pathologists guideline update. J Clin Oncol off J Am Soc Clin Oncol 41(22):3867–3872. 10.1200/JCO.22.02864</cite> [<a href="https://doi.org/10.1200/JCO.22.02864" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/37284804/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Wolff%20AC%20et%20al%20(2023)%20Human%20epidermal%20growth%20factor%20receptor%202%20testing%20in%20breast%20cancer:%20ASCO-college%20of%20American%20pathologists%20guideline%20update.%20J%20Clin%20Oncol%20off%20J%20Am%20Soc%20Clin%20Oncol%2041(22):3867%E2%80%933872.%2010.1200/JCO.22.02864" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR260">
<cite>Wu J-R, Zhao Y, Zhou X-P, Qin X (2020) Estrogen receptor 1 and progesterone receptor are distinct biomarkers and prognostic factors in estrogen receptor-positive breast cancer: evidence from a bioinformatic analysis. Biomed Pharmacother Biomedecine Pharmacother 121:109647. 10.1016/j.biopha.2019.109647</cite> [<a href="https://doi.org/10.1016/j.biopha.2019.109647" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/31733575/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Wu%20J-R,%20Zhao%20Y,%20Zhou%20X-P,%20Qin%20X%20(2020)%20Estrogen%20receptor%201%20and%20progesterone%20receptor%20are%20distinct%20biomarkers%20and%20prognostic%20factors%20in%20estrogen%20receptor-positive%20breast%20cancer:%20evidence%20from%20a%20bioinformatic%20analysis.%20Biomed%20Pharmacother%20Biomedecine%20Pharmacother%20121:109647.%2010.1016/j.biopha.2019.109647" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR261">
<cite>Wu D, Jia H, Zhang Z, Li S (2021) Circ_0000511 accelerates the proliferation, migration and invasion, and restrains the apoptosis of breast cancer cells through the miR-326/TAZ axis. Int J Oncol 58(4):1. 10.3892/ijo.2021.5181
</cite> [<a href="https://doi.org/10.3892/ijo.2021.5181" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC7891826/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/33649821/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Wu%20D,%20Jia%20H,%20Zhang%20Z,%20Li%20S%20(2021)%20Circ_0000511%20accelerates%20the%20proliferation,%20migration%20and%20invasion,%20and%20restrains%20the%20apoptosis%20of%20breast%20cancer%20cells%20through%20the%20miR-326/TAZ%20axis.%20Int%20J%20Oncol%2058(4):1.%2010.3892/ijo.2021.5181" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR262">
<cite>Xia S, Lin Q (2022) Estrogen receptor bio-activities determine clinical endocrine treatment options in estrogen receptor-positive breast cancer. Technol Cancer Res Treat 21:15330338221090352. 10.1177/15330338221090351
</cite> [<a href="https://doi.org/10.1177/15330338221090351" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC9036337/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/35450488/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Xia%20S,%20Lin%20Q%20(2022)%20Estrogen%20receptor%20bio-activities%20determine%20clinical%20endocrine%20treatment%20options%20in%20estrogen%20receptor-positive%20breast%20cancer.%20Technol%20Cancer%20Res%20Treat%2021:15330338221090352.%2010.1177/15330338221090351" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR263">
<cite>Xiao W et al (2019) Circahnak1 inhibits proliferation and metastasis of triple-negative breast cancer by modulating miR-421 and RASA1. Aging 11(24):12043–12056. 10.18632/aging.102539
</cite> [<a href="https://doi.org/10.18632/aging.102539" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC6949091/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/31857500/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Xiao%20W%20et%20al%20(2019)%20Circahnak1%20inhibits%20proliferation%20and%20metastasis%20of%20triple-negative%20breast%20cancer%20by%20modulating%20miR-421%20and%20RASA1.%20Aging%2011(24):12043%E2%80%9312056.%2010.18632/aging.102539" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR264">
<cite>Xu G et al (2020) CircNFIC suppresses breast cancer progression by sponging miR-658. J Cancer 11(14):4222–4229. 10.7150/jca.38830
</cite> [<a href="https://doi.org/10.7150/jca.38830" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC7196272/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/32368305/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Xu%20G%20et%20al%20(2020)%20CircNFIC%20suppresses%20breast%20cancer%20progression%20by%20sponging%20miR-658.%20J%20Cancer%2011(14):4222%E2%80%934229.%2010.7150/jca.38830" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR265">
<cite>Xu G et al (2024) Proteomic profiling of serum extracellular vesicles identifies diagnostic signatures and therapeutic targets in breast cancer. Cancer Res 84(19):3267–3285. 10.1158/0008-5472.CAN-23-3998
</cite> [<a href="https://doi.org/10.1158/0008-5472.CAN-23-3998" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC11443238/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/38900939/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Xu%20G%20et%20al%20(2024)%20Proteomic%20profiling%20of%20serum%20extracellular%20vesicles%20identifies%20diagnostic%20signatures%20and%20therapeutic%20targets%20in%20breast%20cancer.%20Cancer%20Res%2084(19):3267%E2%80%933285.%2010.1158/0008-5472.CAN-23-3998" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR266">
<cite>Yang R, Han Y, Yi W, Long Q (2022) Autoantibodies as biomarkers for breast cancer diagnosis and prognosis. Front Immunol 13:1035402. 10.3389/fimmu.2022.1035402
</cite> [<a href="https://doi.org/10.3389/fimmu.2022.1035402" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC9701846/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/36451832/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Yang%20R,%20Han%20Y,%20Yi%20W,%20Long%20Q%20(2022)%20Autoantibodies%20as%20biomarkers%20for%20breast%20cancer%20diagnosis%20and%20prognosis.%20Front%20Immunol%2013:1035402.%2010.3389/fimmu.2022.1035402" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR267">
<cite>Yarden Y (2001) Biology of HER2 and its importance in breast cancer. Oncology 61(Suppl 2):1–13. 10.1159/000055396
</cite> [<a href="https://doi.org/10.1159/000055396" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/11694782/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Yarden%20Y%20(2001)%20Biology%20of%20HER2%20and%20its%20importance%20in%20breast%20cancer.%20Oncology%2061(Suppl%202):1%E2%80%9313.%2010.1159/000055396" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR268">
<cite>Ye J et al (2014) Circulating adiponectin levels and the risk of breast cancer: a meta-analysis. Eur J Cancer Prev off J Eur Cancer Prev Organ ECP 23(3):158–165. 10.1097/CEJ.0b013e328364f293</cite> [<a href="https://doi.org/10.1097/CEJ.0b013e328364f293" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/23929213/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Ye%20J%20et%20al%20(2014)%20Circulating%20adiponectin%20levels%20and%20the%20risk%20of%20breast%20cancer:%20a%20meta-analysis.%20Eur%20J%20Cancer%20Prev%20off%20J%20Eur%20Cancer%20Prev%20Organ%20ECP%2023(3):158%E2%80%93165.%2010.1097/CEJ.0b013e328364f293" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR269">
<cite>Ye F et al (2019) circFBXW7 inhibits malignant progression by sponging miR-197-3p and encoding a 185-aa protein in triple-negative breast cancer. Mol Ther Nucleic Acids 18:88–98. 10.1016/j.omtn.2019.07.023
</cite> [<a href="https://doi.org/10.1016/j.omtn.2019.07.023" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC6796723/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/31536884/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Ye%20F%20et%20al%20(2019)%20circFBXW7%20inhibits%20malignant%20progression%20by%20sponging%20miR-197-3p%20and%20encoding%20a%20185-aa%20protein%20in%20triple-negative%20breast%20cancer.%20Mol%20Ther%20Nucleic%20Acids%2018:88%E2%80%9398.%2010.1016/j.omtn.2019.07.023" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR270">
<cite>Yi G, Wang D, Han J, Jia L, Liu X, He J (2022) Circklhl24 blocks breast cancer development by regulating the miR-1204/ALX4 network. Cancer Biother Radiopharm 37(8):684–696. 10.1089/cbr.2020.3992
</cite> [<a href="https://doi.org/10.1089/cbr.2020.3992" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/33781094/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Yi%20G,%20Wang%20D,%20Han%20J,%20Jia%20L,%20Liu%20X,%20He%20J%20(2022)%20Circklhl24%20blocks%20breast%20cancer%20development%20by%20regulating%20the%20miR-1204/ALX4%20network.%20Cancer%20Biother%20Radiopharm%2037(8):684%E2%80%93696.%2010.1089/cbr.2020.3992" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR271">
<cite>Yu X et al (2018) Identification and validation of circulating MicroRNA signatures for breast cancer early detection based on large scale tissue-derived data. J Breast Cancer 21(4):363–370. 10.4048/jbc.2018.21.e56
</cite> [<a href="https://doi.org/10.4048/jbc.2018.21.e56" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC6310725/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/30607157/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Yu%20X%20et%20al%20(2018)%20Identification%20and%20validation%20of%20circulating%20MicroRNA%20signatures%20for%20breast%20cancer%20early%20detection%20based%20on%20large%20scale%20tissue-derived%20data.%20J%20Breast%20Cancer%2021(4):363%E2%80%93370.%2010.4048/jbc.2018.21.e56" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR272">
<cite>Yu Z, Tang S, Ma H, Duan H, Zeng Y (2019) Association of serum adiponectin with breast cancer: a meta-analysis of 27 case-control studies. Medicine (Baltimore) 98(6):e14359. 10.1097/MD.0000000000014359
</cite> [<a href="https://doi.org/10.1097/MD.0000000000014359" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC6380750/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/30732167/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Yu%20Z,%20Tang%20S,%20Ma%20H,%20Duan%20H,%20Zeng%20Y%20(2019)%20Association%20of%20serum%20adiponectin%20with%20breast%20cancer:%20a%20meta-analysis%20of%2027%20case-control%20studies.%20Medicine%20(Baltimore)%2098(6):e14359.%2010.1097/MD.0000000000014359" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR273">
<cite>Zajkowska M, Lubowicka E, Fiedorowicz W, Szmitkowski M, Jamiołkowski J, Ławicki S (2019) Human plasma levels of VEGF-A, VEGF-C, VEGF-D, their soluble receptor—VEGFR-2 and applicability of these parameters as tumor markers in the diagnostics of breast cancer. Pathol Oncol Res POR 25(4):1477–1486. 10.1007/s12253-018-0527-0
</cite> [<a href="https://doi.org/10.1007/s12253-018-0527-0" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC6815280/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/30387014/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Zajkowska%20M,%20Lubowicka%20E,%20Fiedorowicz%20W,%20Szmitkowski%20M,%20Jamio%C5%82kowski%20J,%20%C5%81awicki%20S%20(2019)%20Human%20plasma%20levels%20of%20VEGF-A,%20VEGF-C,%20VEGF-D,%20their%20soluble%20receptor%E2%80%94VEGFR-2%20and%20applicability%20of%20these%20parameters%20as%20tumor%20markers%20in%20the%20diagnostics%20of%20breast%20cancer.%20Pathol%20Oncol%20Res%20POR%2025(4):1477%E2%80%931486.%2010.1007/s12253-018-0527-0" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR274">
<cite>Zaleski M et al (2018) Improved sensitivity for detection of breast cancer by combination of miR-34a and tumor markers CA 15–3 or CEA. Oncotarget 9(32):22523–22536. 10.18632/oncotarget.25077
</cite> [<a href="https://doi.org/10.18632/oncotarget.25077" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC5976482/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/29854296/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Zaleski%20M%20et%20al%20(2018)%20Improved%20sensitivity%20for%20detection%20of%20breast%20cancer%20by%20combination%20of%20miR-34a%20and%20tumor%20markers%20CA%2015%E2%80%933%20or%20CEA.%20Oncotarget%209(32):22523%E2%80%9322536.%2010.18632/oncotarget.25077" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR275">
<cite>Zhang XH-F, Giuliano M, Trivedi MV, Schiff R, Osborne CK (2013) Metastasis dormancy in estrogen receptor-positive breast cancer. Clin Cancer Res off J Am Assoc Cancer Res 19(23):6389–6397. 10.1158/1078-0432.CCR-13-0838</cite> [<a href="https://doi.org/10.1158/1078-0432.CCR-13-0838" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC3878717/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/24298069/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Zhang%20XH-F,%20Giuliano%20M,%20Trivedi%20MV,%20Schiff%20R,%20Osborne%20CK%20(2013)%20Metastasis%20dormancy%20in%20estrogen%20receptor-positive%20breast%20cancer.%20Clin%20Cancer%20Res%20off%20J%20Am%20Assoc%20Cancer%20Res%2019(23):6389%E2%80%936397.%2010.1158/1078-0432.CCR-13-0838" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR276">
<cite>Zhang L et al (2015) A circulating miRNA signature as a diagnostic biomarker for non-invasive early detection of breast cancer. Breast Cancer Res Treat 154(2):423–434. 10.1007/s10549-015-3591-0
</cite> [<a href="https://doi.org/10.1007/s10549-015-3591-0" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/26476723/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Zhang%20L%20et%20al%20(2015)%20A%20circulating%20miRNA%20signature%20as%20a%20diagnostic%20biomarker%20for%20non-invasive%20early%20detection%20of%20breast%20cancer.%20Breast%20Cancer%20Res%20Treat%20154(2):423%E2%80%93434.%2010.1007/s10549-015-3591-0" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR277">
<cite>Zhang X et al (2019) Parallel analyses of somatic mutations in plasma circulating tumor DNA (ctDNA) and matched tumor tissues in early-stage breast cancer. Clin Cancer Res off J Am Assoc Cancer Res. 25(21):6546–6553. 10.1158/1078-0432.CCR-18-4055</cite> [<a href="https://doi.org/10.1158/1078-0432.CCR-18-4055" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/31350313/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Zhang%20X%20et%20al%20(2019)%20Parallel%20analyses%20of%20somatic%20mutations%20in%20plasma%20circulating%20tumor%20DNA%20(ctDNA)%20and%20matched%20tumor%20tissues%20in%20early-stage%20breast%20cancer.%20Clin%20Cancer%20Res%20off%20J%20Am%20Assoc%20Cancer%20Res.%2025(21):6546%E2%80%936553.%2010.1158/1078-0432.CCR-18-4055" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR278">
<cite>Zhang K et al (2021) A two-miRNA signature of upregulated miR-185-5p and miR-362-5p as a blood biomarker for breast cancer. Pathol Res Pract 222:153458. 10.1016/j.prp.2021.153458
</cite> [<a href="https://doi.org/10.1016/j.prp.2021.153458" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/33962174/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Zhang%20K%20et%20al%20(2021)%20A%20two-miRNA%20signature%20of%20upregulated%20miR-185-5p%20and%20miR-362-5p%20as%20a%20blood%20biomarker%20for%20breast%20cancer.%20Pathol%20Res%20Pract%20222:153458.%2010.1016/j.prp.2021.153458" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR279">
<cite>Zhang A, Wang X, Fan C, Mao X (2021a) The role of Ki67 in evaluating neoadjuvant endocrine therapy of hormone receptor-positive breast cancer. Front Endocrinol 12:687244. 10.3389/fendo.2021.687244</cite> [<a href="https://doi.org/10.3389/fendo.2021.687244" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC8597938/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/34803903/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Zhang%20A,%20Wang%20X,%20Fan%20C,%20Mao%20X%20(2021a)%20The%20role%20of%20Ki67%20in%20evaluating%20neoadjuvant%20endocrine%20therapy%20of%20hormone%20receptor-positive%20breast%20cancer.%20Front%20Endocrinol%2012:687244.%2010.3389/fendo.2021.687244" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR280">
<cite>Zhang M, Bai X, Zeng X, Liu J, Liu F, Zhang Z (2021b) Circrna-mirna-mrna in breast cancer. Clin Chim Acta 523:120–130. 10.1016/j.cca.2021.09.013
</cite> [<a href="https://doi.org/10.1016/j.cca.2021.09.013" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/34537217/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Zhang%20M,%20Bai%20X,%20Zeng%20X,%20Liu%20J,%20Liu%20F,%20Zhang%20Z%20(2021b)%20Circrna-mirna-mrna%20in%20breast%20cancer.%20Clin%20Chim%20Acta%20523:120%E2%80%93130.%2010.1016/j.cca.2021.09.013" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR281">
<cite>Zhang H et al (2021c) Detection methods and clinical applications of circulating tumor cells in breast cancer. Front Oncol 11:652253. 10.3389/fonc.2021.652253
</cite> [<a href="https://doi.org/10.3389/fonc.2021.652253" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC8208079/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/34150621/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Zhang%20H%20et%20al%20(2021c)%20Detection%20methods%20and%20clinical%20applications%20of%20circulating%20tumor%20cells%20in%20breast%20cancer.%20Front%20Oncol%2011:652253.%2010.3389/fonc.2021.652253" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR282">
<cite>Zhang J, Wei Q, Dong D, Ren L (2021d) The role of TPsS, CA125, CA15-3 and CEA in prediction of distant metastasis of breast cancer. Clin Chim Acta 523:19–25. 10.1016/j.cca.2021.08.027
</cite> [<a href="https://doi.org/10.1016/j.cca.2021.08.027" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/34454906/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Zhang%20J,%20Wei%20Q,%20Dong%20D,%20Ren%20L%20(2021d)%20The%20role%20of%20TPsS,%20CA125,%20CA15-3%20and%20CEA%20in%20prediction%20of%20distant%20metastasis%20of%20breast%20cancer.%20Clin%20Chim%20Acta%20523:19%E2%80%9325.%2010.1016/j.cca.2021.08.027" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR283">
<cite>Zhang X, Xie P, Zhang K, Zhang W (2023) Circulating tumour cell isolation, analysis and clinical application. Cell Oncol Dordr Neth 46(3):533–544. 10.1007/s13402-023-00774-0</cite> [<a href="https://doi.org/10.1007/s13402-023-00774-0" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/36658417/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Zhang%20X,%20Xie%20P,%20Zhang%20K,%20Zhang%20W%20(2023)%20Circulating%20tumour%20cell%20isolation,%20analysis%20and%20clinical%20application.%20Cell%20Oncol%20Dordr%20Neth%2046(3):533%E2%80%93544.%2010.1007/s13402-023-00774-0" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR284">
<cite>Zhao J, Zou H, Han C, Ma J, Zhao J, Tang J (2018) Circlular RNA BARD1 (Hsa_circ_0001098) overexpression in breast cancer cells with TCDD treatment could promote cell apoptosis via miR-3942/BARD1 axis. Cell Cycle 17(24):2731–2744. 10.1080/15384101.2018.1556058
</cite> [<a href="https://doi.org/10.1080/15384101.2018.1556058" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC6343738/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/30521417/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Zhao%20J,%20Zou%20H,%20Han%20C,%20Ma%20J,%20Zhao%20J,%20Tang%20J%20(2018)%20Circlular%20RNA%20BARD1%20(Hsa_circ_0001098)%20overexpression%20in%20breast%20cancer%20cells%20with%20TCDD%20treatment%20could%20promote%20cell%20apoptosis%20via%20miR-3942/BARD1%20axis.%20Cell%20Cycle%2017(24):2731%E2%80%932744.%2010.1080/15384101.2018.1556058" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR285">
<cite>Zhong Y, Ding B, Qian L, Wu W, Wen Y (2022) Hormone receptor expression on endocrine therapy in patients with breast cancer: a meta-analysis. Am Surg 88(1):48–57. 10.1177/0003134820972327
</cite> [<a href="https://doi.org/10.1177/0003134820972327" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/33382340/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Zhong%20Y,%20Ding%20B,%20Qian%20L,%20Wu%20W,%20Wen%20Y%20(2022)%20Hormone%20receptor%20expression%20on%20endocrine%20therapy%20in%20patients%20with%20breast%20cancer:%20a%20meta-analysis.%20Am%20Surg%2088(1):48%E2%80%9357.%2010.1177/0003134820972327" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR286">
<cite>Zoroddu S, Di Lorenzo B, Paliogiannis P, Mangoni AA, Carru C, Zinellu A (2024) Resistin and omentin in breast cancer: a systematic review and meta-analysis. Clin Chim Acta Int J Clin Chem 562:119838. 10.1016/j.cca.2024.119838</cite> [<a href="https://doi.org/10.1016/j.cca.2024.119838" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/38972537/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Zoroddu%20S,%20Di%20Lorenzo%20B,%20Paliogiannis%20P,%20Mangoni%20AA,%20Carru%20C,%20Zinellu%20A%20(2024)%20Resistin%20and%20omentin%20in%20breast%20cancer:%20a%20systematic%20review%20and%20meta-analysis.%20Clin%20Chim%20Acta%20Int%20J%20Clin%20Chem%20562:119838.%2010.1016/j.cca.2024.119838" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR287">
<cite>Zou H, Liu S-H, Yang R, Wu X-J, Cao Y-P, Huang H-F (2022) Combination of neutrophil-to-lymphocyte ratio and red cell distribution width with serum tumor markers for the differential diagnosis of breast cancer and its association with pathological features and molecular types. Clin Breast Cancer 22(4):e526–e535. 10.1016/j.clbc.2021.11.014
</cite> [<a href="https://doi.org/10.1016/j.clbc.2021.11.014" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/34963613/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Zou%20H,%20Liu%20S-H,%20Yang%20R,%20Wu%20X-J,%20Cao%20Y-P,%20Huang%20H-F%20(2022)%20Combination%20of%20neutrophil-to-lymphocyte%20ratio%20and%20red%20cell%20distribution%20width%20with%20serum%20tumor%20markers%20for%20the%20differential%20diagnosis%20of%20breast%20cancer%20and%20its%20association%20with%20pathological%20features%20and%20molecular%20types.%20Clin%20Breast%20Cancer%2022(4):e526%E2%80%93e535.%2010.1016/j.clbc.2021.11.014" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR288">
<cite>Zubor P et al (2019) Why the gold standard approach by mammography demands extension by multiomics? Application of liquid biopsy miRNA profiles to breast cancer disease management. Int J Mol Sci 20(12):2878. 10.3390/ijms20122878
</cite> [<a href="https://doi.org/10.3390/ijms20122878" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC6627787/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/31200461/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Zubor%20P%20et%20al%20(2019)%20Why%20the%20gold%20standard%20approach%20by%20mammography%20demands%20extension%20by%20multiomics?%20Application%20of%20liquid%20biopsy%20miRNA%20profiles%20to%20breast%20cancer%20disease%20management.%20Int%20J%20Mol%20Sci%2020(12):2878.%2010.3390/ijms20122878" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR289">
<cite>Zuo X et al (2016) Identification of a panel of complex autoantigens (LGALS3, PHB2, MUC1, and GK2) in combination with CA15-3 for the diagnosis of early-stage breast cancer. Tumour Biol J Int Soc Oncodevelopmental Biol Med 37(1):1309–1317. 10.1007/s13277-015-3932-y</cite> [<a href="https://doi.org/10.1007/s13277-015-3932-y" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/26289852/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Zuo%20X%20et%20al%20(2016)%20Identification%20of%20a%20panel%20of%20complex%20autoantigens%20(LGALS3,%20PHB2,%20MUC1,%20and%20GK2)%20in%20combination%20with%20CA15-3%20for%20the%20diagnosis%20of%20early-stage%20breast%20cancer.%20Tumour%20Biol%20J%20Int%20Soc%20Oncodevelopmental%20Biol%20Med%2037(1):1309%E2%80%931317.%2010.1007/s13277-015-3932-y" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
</ol></section></section><section id="_ad93_" lang="en" class="associated-data"><h2 class="pmc_sec_title">Associated Data</h2>
<p class="font-secondary"><em>This section collects any data citations, data availability statements, or supplementary materials included in this article.</em></p>
<section id="_adda93_" lang="en" class="data-availability-statement"><h3 class="pmc_sec_title">Data Availability Statement</h3>
<p>No datasets were generated or analysed during the current study.</p></section></section></section><footer class="p courtesy-note font-secondary font-sm text-center"><hr class="headless">
<p>Articles from Journal of Cancer Research and Clinical Oncology are provided here courtesy of <strong>Springer</strong></p></footer></section></article>

                      

                    </main>
                </div>
            </div>
        </div>

        



<!-- Secondary navigation placeholder -->
<div class="pmc-sidenav desktop:grid-col-4 display-flex">
    <section class="pmc-sidenav__container" aria-label="Article resources and navigation">
        <button type="button" class="usa-button pmc-sidenav__container__close usa-button--unstyled">
            <img src="/static/img/usa-icons/close.svg" role="img" alt="Close" />
        </button>
    <div class="display-none desktop:display-block">
       <section class="margin-top-4 desktop:margin-top-0">
              <h2 class="margin-top-0">ACTIONS</h2>
           <ul class="usa-list usa-list--unstyled usa-list--actions">
               
               <li>
                     <a
                             href="https://doi.org/10.1007/s00432-025-06271-1"
                             class="usa-button usa-button--outline width-24 font-xs display-inline-flex flex-align-center flex-justify-start padding-left-1"
                             target="_blank"
                             rel="noreferrer noopener"
                             data-ga-category="actions"
                             data-ga-action="click"
                             data-ga-label="publisher_link_desktop"
                     >
                         <svg class="usa-icon width-3 height-3" aria-hidden="true" focusable="false" role="img" hidden>
                            <use xlink:href="/static/img/sprite.svg#launch"></use>
                         </svg>
                         <span class="display-inline-flex flex-justify-center flex-1 padding-right-2">View on publisher site</span>
                     </a>
               </li>
               
               
               <li>
                    <a
                            href="pdf/432_2025_Article_6271.pdf"
                            class="usa-button usa-button--outline width-24 display-inline-flex flex-align-center flex-justify-start padding-left-1"
                            data-ga-category="actions"
                            data-ga-action="click"
                            data-ga-label="pdf_download_desktop"
                    >
                         <svg class="usa-icon width-3 height-3" aria-hidden="true" focusable="false" role="img" hidden>
                            <use xlink:href="/static/img/sprite.svg#file_download"></use>
                        </svg>
                        <span class="display-inline-flex flex-justify-center flex-1">PDF (2.0 MB)</span>
                    </a>
               </li>
               
                
               <li>
                   <button role="button" class="usa-button width-24 citation-dialog-trigger display-inline-flex flex-align-center flex-justify-start padding-left-1"
                        aria-label="Open dialog with citation text in different styles"
                        data-ga-category="actions"
                        data-ga-action="open"
                        data-ga-label="cite_desktop"
                        data-all-citations-url="/resources/citations/12373631/"
                        data-citation-style="nlm"
                        data-download-format-link="/resources/citations/12373631/export/"
                    >
                        <svg class="usa-icon width-3 height-3" aria-hidden="true" focusable="false" role="img" hidden>
                            <use xlink:href="/static/img/sprite.svg#format_quote"></use>
                        </svg>
                       <span class="display-inline-flex flex-justify-center flex-1 button-label">Cite</span>
                    </button>
               </li>
                
               <li>

                        <button class="usa-button width-24 collections-dialog-trigger collections-button display-inline-flex flex-align-center flex-justify-start padding-left-1 collections-button-empty"
                              aria-label="Save article in MyNCBI collections."
                              data-ga-category="actions"
                              data-ga-action="click"
                              data-ga-label="collections_button_desktop"
                              data-collections-open-dialog-enabled="false"
                              data-collections-open-dialog-url="https://account.ncbi.nlm.nih.gov/?back_url=https%3A%2F%2Fpmc.ncbi.nlm.nih.gov%2Farticles%2FPMC12373631%2F%3Freport%3Dclassic%23open-collections-dialog"
                              data-in-collections="false">
                            <svg class="usa-icon width-3 height-3 usa-icon--bookmark-full" aria-hidden="true" focusable="false" role="img" hidden>
                                <use xlink:href="/static/img/action-bookmark-full.svg#icon"></use>
                            </svg>
                            <svg class="usa-icon width-3 height-3 usa-icon--bookmark-empty" aria-hidden="true" focusable="false" role="img" hidden>
                                <use xlink:href="/static/img/action-bookmark-empty.svg#icon"></use>
                            </svg>
                            <span class="display-inline-flex flex-justify-center flex-1">Collections</span>
                       </button>
               </li>
               <li class="pmc-permalink">
                    <button
                            type="button"
                            class="usa-button width-24 display-inline-flex flex-align-center flex-justify padding-left-1 shadow-none"
                            aria-label="Show article permalink"
                            aria-expanded="false"
                            aria-haspopup="true"
                            data-ga-category="actions"
                            data-ga-action="open"
                            data-ga-label="permalink_desktop"
                    >
                         <svg class="usa-icon width-3 height-3" aria-hidden="true" focusable="false" role="img" hidden>
                            <use xlink:href="/static/img/sprite.svg#share"></use>
                        </svg>
                        <span class="display-inline-flex flex-justify-center flex-1 button-label">Permalink</span>
                    </button>
                   

<div class="pmc-permalink__dropdown" hidden>
    <div class="pmc-permalink__dropdown__container">
          <h2 class="usa-modal__heading margin-top-0 margin-bottom-2 text-uppercase font-sans-xs">PERMALINK</h2>
          <div class="pmc-permalink__dropdown__content">
              <input type="text" class="usa-input" value="https://pmc.ncbi.nlm.nih.gov/articles/PMC12373631/" aria-label="Article permalink">
              <button class="usa-button display-inline-flex pmc-permalink__dropdown__copy__btn margin-right-0" title="Copy article permalink" data-ga-category="save_share" data-ga-action="link" data-ga-label="copy_link">
                  <svg class="usa-icon" aria-hidden="true" focusable="false" role="img">
                    <use xlink:href="/static/img/sprite.svg#content_copy"></use>
                  </svg>
                  <span class="margin-left-1">Copy</span>
              </button>
          </div>
    </div>
</div>
               </li>
           </ul>
       </section>
     </div>

        <section class="pmc-resources margin-top-6 desktop:margin-top-4" data-page-path="/articles/PMC12373631/">
            <h2 class="margin-top-0">RESOURCES</h2>
            
                <div class="usa-accordion usa-accordion--multiselectable" data-allow-multiple>
                    <h3 class="usa-accordion__heading">
                        <button
                        type="button"
                        class="usa-accordion__button"
                        aria-expanded="false"
                        aria-controls="resources-similar-articles"
                        data-ga-category="resources_accordion"
                        data-ga-action="open_similar_articles"
                        data-ga-label="/articles/PMC12373631/"
                        data-action-open="open_similar_articles"
                        data-action-close="close_similar_articles"
                        >
                            Similar articles
                        </button>
                    </h3>
                    <div
                            id="resources-similar-articles"
                            class="usa-accordion__content usa-prose"
                            
                                data-source-url="/resources/similar-article-links/40844552/"
                            
                    >
                        
                    </div>
                    <h3 class="usa-accordion__heading">
                        <button
                        type="button"
                        class="usa-accordion__button"
                        aria-expanded="false"
                        aria-controls="resources-cited-by-other-articles"
                        data-ga-category="resources_accordion"
                        data-ga-action="open_cited_by"
                        data-ga-label="/articles/PMC12373631/"
                        data-action-open="open_cited_by"
                        data-action-close="close_cited_by"
                        >
                             Cited by other articles
                        </button>
                    </h3>
                    <div
                            id="resources-cited-by-other-articles"
                            class="usa-accordion__content usa-prose"
                            
                                data-source-url="/resources/cited-by-links/40844552/"
                            
                    >
                          
                    </div>
                    
                        <h3 class="usa-accordion__heading">
                            <button
                            type="button"
                            class="usa-accordion__button"
                            aria-expanded="false"
                            aria-controls="resources-links-to-ncbi-databases"
                            data-ga-category="resources_accordion"
                            data-ga-action="open_NCBI_links"
                            data-ga-label="/articles/PMC12373631/"
                            data-action-open="open_NCBI_links"
                            data-action-close="close_NCBI_link"
                            >
                                 Links to NCBI Databases
                            </button>
                        </h3>
                        <div
                                id="resources-links-to-ncbi-databases"
                                class="usa-accordion__content usa-prose"
                                data-source-url="/resources/db-links/12373631/"
                        >
                        </div>
                    
                    
                </div>
            
        </section>


        <section
        class="usa-in-page-nav usa-in-page-nav--wide margin-top-6 desktop:margin-top-4"
        data-title-text="On this page"
        data-title-heading-level="h2"
        data-scroll-offset="0"
        data-root-margin="-10% 0px -80% 0px"
        data-main-content-selector="main"
        data-threshold="1"
        hidden
        ></section>
    </section>
</div>


        

<div class="overlay" role="dialog" aria-label="Citation Dialog" hidden>
    <div class="dialog citation-dialog" aria-hidden="true">
        <div class="display-inline-flex flex-align-center flex-justify width-full margin-bottom-2">
            <h2 class="usa-modal__heading margin-0">Cite</h2>
             <button type="button" class="usa-button usa-button--unstyled close-overlay text-black width-auto"  tabindex="1">
                <svg class="usa-icon width-3 height-3" aria-hidden="true" focusable="false" role="img">
                    <use xlink:href="/static/img/sprite.svg#close"></use>
                </svg>
             </button>
        </div>

        

<div class="citation-text-block">
  <div class="citation-text margin-bottom-2"></div>
  <ul class="usa-list usa-list--unstyled display-inline-flex flex-justify width-full flex-align-center">
      <li>
        <button
          class="usa-button usa-button--unstyled text-no-underline display-flex flex-align-center copy-button dialog-focus"
          data-ga-category="save_share"
          data-ga-action="cite"
          data-ga-label="copy"
          tabindex="2">
            <svg class="usa-icon width-3 height-3" aria-hidden="true" focusable="false" role="img">
                <use xlink:href="/static/img/sprite.svg#content_copy"></use>
            </svg>
            <span>Copy</span>
        </button>
      </li>
      <li>
          <a
              href="#"
              role="button"
              class="usa-button usa-button--unstyled text-no-underline display-flex flex-align-center export-button"
              data-ga-category="save_share"
              data-ga-action="cite"
              data-ga-label="download"
              title="Download a file for external citation management software"
              tabindex="3">
                <svg class="usa-icon width-3 height-3" aria-hidden="true" focusable="false" role="img">
                    <use xlink:href="/static/img/sprite.svg#file_download"></use>
                </svg>
                <span class="display-none mobile-lg:display-inline">Download .nbib</span>
                <span class="display-inline mobile-lg:display-none">.nbib</span>
            </a>
      </li>
      <li>
          

<div class="display-inline-flex flex-align-center">
  <label class="usa-label margin-top-0">Format:</label>
  <select aria-label="Format" class="usa-select citation-style-selector padding-1 margin-top-0 border-0 padding-right-4" tabindex="4" >
    
      <option data-style-url-name="ama"
              value="AMA"
              >
        AMA
      </option>
    
      <option data-style-url-name="apa"
              value="APA"
              >
        APA
      </option>
    
      <option data-style-url-name="mla"
              value="MLA"
              >
        MLA
      </option>
    
      <option data-style-url-name="nlm"
              value="NLM"
              selected="selected">
        NLM
      </option>
    
  </select>
</div>
      </li>
  </ul>
</div>
    </div>
</div>

        <div class="overlay" role="dialog" hidden>
  <div id="collections-action-dialog" class="dialog collections-dialog" aria-hidden="true">
   <div class="display-inline-flex flex-align-center flex-justify width-full margin-bottom-2">
        <h2 class="usa-modal__heading margin-0">Add to Collections</h2>
    </div>
    <div class="collections-action-panel action-panel">
      


<form id="collections-action-dialog-form"
      class="usa-form maxw-full collections-action-panel-form action-panel-content action-form action-panel-smaller-selectors"
      data-existing-collections-url="/list-existing-collections/"
      data-add-to-existing-collection-url="/add-to-existing-collection/"
      data-create-and-add-to-new-collection-url="/create-and-add-to-new-collection/"
      data-myncbi-max-collection-name-length="100"
      data-collections-root-url="https://www.ncbi.nlm.nih.gov/myncbi/collections/">

    <input type="hidden" name="csrfmiddlewaretoken" value="mUYf1NQZhnJ7UjL5NWzlsbee0Im4emZkbM0yQJwYRw6VGVGgf32IxbueYD5wPK4R">

    <fieldset class="usa-fieldset margin-bottom-2">
        <div class="usa-radio">
            <input type="radio"
            id="collections-action-dialog-new"
            class="usa-radio__input usa-radio__input--tile collections-new  margin-top-0"
            name="collections"
            value="new"
            data-ga-category="collections_button"
            data-ga-action="click"
            data-ga-label="collections_radio_new" />
            <label class="usa-radio__label" for="collections-action-dialog-new">Create a new collection</label>
        </div>
        <div class="usa-radio">
            <input type="radio"
            id="collections-action-dialog-existing"
            class="usa-radio__input usa-radio__input--tile collections-existing"
            name="collections"
            value="existing"
            checked="true"
            data-ga-category="collections_button"
            data-ga-action="click"
            data-ga-label="collections_radio_existing" />
            <label class="usa-radio__label" for="collections-action-dialog-existing">Add to an existing collection</label>
        </div>
    </fieldset>

    <fieldset class="usa-fieldset margin-bottom-2">
        <div class="action-panel-control-wrap new-collections-controls">
           <label for="collections-action-dialog-add-to-new" class="usa-label margin-top-0">
                Name your collection
               <abbr title="required" class="usa-hint usa-hint--required text-no-underline">*</abbr>
          </label>
          <input
            type="text"
            name="add-to-new-collection"
            id="collections-action-dialog-add-to-new"
            class="usa-input collections-action-add-to-new"
            pattern="[^&quot;&amp;=&lt;&gt;/]*" title="The following characters are not allowed in the Name field: &quot;&amp;=&lt;&gt;/"
            maxlength=""
            data-ga-category="collections_button"
            data-ga-action="create_collection"
            data-ga-label="non_favorties_collection"
            required
          />
        </div>
        <div class="action-panel-control-wrap existing-collections-controls">
             <label for="collections-action-dialog-add-to-existing" class="usa-label margin-top-0">
                Choose a collection
              </label>
              <select id="collections-action-dialog-add-to-existing"
                      class="usa-select collections-action-add-to-existing"
                      data-ga-category="collections_button"
                      data-ga-action="select_collection"
                      data-ga-label="($('.collections-action-add-to-existing').val() === 'Favorites') ? 'Favorites' : 'non_favorites_collection'">
              </select>
              <div class="collections-retry-load-on-error usa-input-error-message selection-validation-message">
                Unable to load your collection due to an error<br>
                <a href="#">Please try again</a>
              </div>
        </div>
    </fieldset>

    <div class="display-inline-flex">
        <button class="usa-button margin-top-0 action-panel-submit"
            type="submit"
            data-loading-label="Adding..."
            data-pinger-ignore
            data-ga-category="collections_button"
            data-ga-action="click"
            data-ga-label="add">
          Add
        </button>
        <button class="usa-button usa-button--outline margin-top-0 action-panel-cancel"
                aria-label="Close 'Add to Collections' panel"
                ref="linksrc=close_collections_panel"
                data-ga-category="collections_button"
                data-ga-action="click"
                data-ga-label="cancel">
          Cancel
        </button>
    </div>
</form>
    </div>
  </div>
</div>

        

      </div>
    </div>
  </div>



        
    
    

<footer class="ncbi-footer ncbi-dark-background " >
    
        <div class="ncbi-footer__icon-section">
            <div class="ncbi-footer__social-header">
                Follow NCBI
            </div>

            <div class="grid-container ncbi-footer__ncbi-social-icons-container">
                
                    <a href="https://twitter.com/ncbi"
                       class="ncbi-footer__social-icon ncbi-footer__social-icon--gray"
                       target="_blank"
                       rel="noreferrer noopener">
                        <svg width="40"
                             height="40"
                             viewBox="0 0 40 40"
                             fill="none"
                             xmlns="http://www.w3.org/2000/svg"
                             focusable="false"
                             aria-hidden="true">
                            <path d="m6.067 8 10.81 13.9L6 33.2h4.2l8.4-9.1 7.068 9.1H34L22.8 18.5 31.9 8h-3.5l-7.7 8.4L14.401 8H6.067Zm3.6 1.734h3.266l16.8 21.732H26.57L9.668 9.734Z">
                            </path>
                        </svg>
                        <span class="usa-sr-only">NCBI on X (formerly known as Twitter)</span>
                    </a>
                

                
                    <a href="https://www.facebook.com/ncbi.nlm"
                       class="ncbi-footer__social-icon ncbi-footer__social-icon--gray"
                       target="_blank"
                       rel="noreferrer noopener">
                        <svg width="16"
                             height="29"
                             focusable="false"
                             aria-hidden="true"
                             viewBox="0 0 16 29"
                             fill="none"
                             xmlns="http://www.w3.org/2000/svg">
                            <path d="M3.8809 21.4002C3.8809 19.0932 3.8809 16.7876 3.8809 14.478C3.8809 14.2117 3.80103 14.1452 3.54278 14.1492C2.53372 14.1638 1.52334 14.1492 0.514288 14.1598C0.302626 14.1598 0.248047 14.0972 0.248047 13.8936C0.256034 12.4585 0.256034 11.0239 0.248047 9.58978C0.248047 9.37013 0.302626 9.30224 0.528931 9.3049C1.53798 9.31688 2.54837 9.3049 3.55742 9.31555C3.80103 9.31555 3.8809 9.26097 3.87957 9.00272C3.87158 8.00565 3.85428 7.00592 3.90753 6.00884C3.97142 4.83339 4.31487 3.73115 5.04437 2.78467C5.93095 1.63318 7.15699 1.09005 8.56141 0.967577C10.5582 0.79319 12.555 0.982221 14.5518 0.927641C14.7102 0.927641 14.7462 0.99287 14.7449 1.13664C14.7449 2.581 14.7449 4.02668 14.7449 5.47104C14.7449 5.67604 14.6517 5.68669 14.4946 5.68669C13.4523 5.68669 12.4113 5.68669 11.3703 5.68669C10.3506 5.68669 9.92057 6.10868 9.90593 7.13904C9.89661 7.7647 9.91525 8.39303 9.89794 9.01869C9.88995 9.26364 9.96583 9.31822 10.2015 9.31688C11.7204 9.30623 13.2393 9.31688 14.7595 9.3049C15.0257 9.3049 15.0723 9.3728 15.0444 9.62439C14.89 10.9849 14.7515 12.3467 14.6144 13.7085C14.5691 14.1571 14.5785 14.1585 14.1458 14.1585C12.8386 14.1585 11.5313 14.1665 10.2254 14.1518C9.95119 14.1518 9.89794 14.2317 9.89794 14.4899C9.90593 19.0799 9.89794 23.6752 9.91125 28.2612C9.91125 28.5674 9.8407 28.646 9.53186 28.6433C7.77866 28.6273 6.02414 28.6366 4.27094 28.634C3.82499 28.634 3.87158 28.6992 3.87158 28.22C3.87602 25.9472 3.87913 23.6739 3.8809 21.4002Z">
                            </path>
                        </svg>
                        <span class="usa-sr-only">NCBI on Facebook</span>
                    </a>
                

                
                    <a href="https://www.linkedin.com/company/ncbinlm"
                       class="ncbi-footer__social-icon ncbi-footer__social-icon--gray"
                       target="_blank"
                       rel="noreferrer noopener">
                        <svg width="25"
                             height="23"
                             viewBox="0 0 26 24"
                             fill="none"
                             xmlns="http://www.w3.org/2000/svg"
                             focusable="false"
                             aria-hidden="true">
                            <path d="M14.6983 9.98423C15.6302 9.24808 16.5926 8.74754 17.6762 8.51991C19.673 8.09126 21.554 8.30824 23.1262 9.7526C24.2351 10.7723 24.7529 12.1115 25.0165 13.5612C25.1486 14.3363 25.2105 15.1218 25.2015 15.9081C25.2015 18.3043 25.2015 20.6898 25.2082 23.0806C25.2082 23.3468 25.1549 23.444 24.8621 23.4414C23.1297 23.4272 21.3992 23.4272 19.6704 23.4414C19.4041 23.4414 19.3429 23.3588 19.3442 23.1019C19.3535 20.5194 19.3442 17.9368 19.3442 15.3543C19.3442 14.0005 18.3258 12.9448 17.0266 12.9488C15.7273 12.9528 14.6983 14.0071 14.6983 15.361C14.6983 17.9328 14.6917 20.5047 14.6983 23.0753C14.6983 23.3708 14.6198 23.444 14.3296 23.4427C12.6185 23.4294 10.9079 23.4294 9.19779 23.4427C8.93155 23.4427 8.86099 23.3735 8.86232 23.1086C8.8783 19.7619 8.88628 16.4144 8.88628 13.066C8.88628 11.5688 8.87874 10.0708 8.86365 8.57182C8.86365 8.3575 8.90758 8.27896 9.14054 8.28029C10.9048 8.29094 12.6687 8.29094 14.4321 8.28029C14.6464 8.28029 14.6983 8.34818 14.6983 8.54653C14.6903 9.00047 14.6983 9.45441 14.6983 9.98423Z">
                            </path>
                            <path d="M6.55316 15.8443C6.55316 18.2564 6.55316 20.6699 6.55316 23.082C6.55316 23.3629 6.48127 23.4388 6.19906 23.4374C4.47737 23.4241 2.75568 23.4241 1.03399 23.4374C0.767751 23.4374 0.69986 23.3629 0.701191 23.1006C0.709178 18.2648 0.709178 13.4281 0.701191 8.59053C0.701191 8.34026 0.765089 8.27237 1.01669 8.2737C2.74991 8.28435 4.48048 8.28435 6.20838 8.2737C6.47462 8.2737 6.5465 8.33627 6.54517 8.6065C6.54783 11.0186 6.55316 13.4308 6.55316 15.8443Z">
                            </path>
                            <path d="M3.65878 0.243898C5.36804 0.243898 6.58743 1.45529 6.58743 3.1406C6.58743 4.75801 5.32145 5.95742 3.60819 5.96807C3.22177 5.97614 2.83768 5.90639 2.47877 5.76299C2.11985 5.61959 1.79344 5.40546 1.51897 5.13334C1.24449 4.86123 1.02755 4.53668 0.881058 4.17902C0.734563 3.82136 0.661505 3.43788 0.666231 3.05141C0.67555 1.42601 1.9362 0.242566 3.65878 0.243898Z">
                            </path>
                        </svg>
                        <span class="usa-sr-only">NCBI on LinkedIn</span>
                    </a>
                

                
                    <a href="https://github.com/ncbi"
                       class="ncbi-footer__social-icon ncbi-footer__social-icon--gray"
                       target="_blank"
                       rel="noreferrer noopener">
                        <svg width="28"
                             height="27"
                             viewBox="0 0 28 28"
                             fill="none"
                             xmlns="http://www.w3.org/2000/svg"
                             focusable="false"
                             aria-hidden="true">
                            <path d="M16.7228 20.6334C17.5057 20.5527 18.2786 20.3944 19.0301 20.1608C21.3108 19.4193 22.5822 17.8259 22.963 15.4909C23.1228 14.5112 23.1814 13.5287 22.9883 12.5437C22.8106 11.6423 22.4013 10.8028 21.8007 10.1076C21.7526 10.0605 21.7197 10 21.7064 9.934C21.6931 9.86799 21.7 9.79952 21.7262 9.73748C22.0856 8.6206 21.9711 7.51969 21.601 6.42677C21.582 6.3497 21.5345 6.2827 21.468 6.23923C21.4016 6.19577 21.3211 6.17906 21.2429 6.19248C20.7329 6.21649 20.2313 6.33051 19.7611 6.52928C19.1103 6.7908 18.4899 7.12198 17.9104 7.51703C17.84 7.56996 17.7581 7.60551 17.6713 7.62078C17.5846 7.63605 17.4954 7.6306 17.4112 7.60489C15.2596 7.05882 13.0054 7.06203 10.8554 7.61421C10.7806 7.63586 10.7018 7.63967 10.6253 7.62534C10.5487 7.611 10.4766 7.57892 10.4148 7.53167C9.64788 7.03247 8.85171 6.58918 7.96368 6.33359C7.65781 6.24338 7.34123 6.19458 7.02239 6.18849C6.94879 6.17986 6.87462 6.19893 6.81432 6.242C6.75402 6.28507 6.71191 6.34904 6.69621 6.42145C6.32342 7.51437 6.2209 8.61527 6.56307 9.73348C6.59635 9.84264 6.64694 9.93316 6.54177 10.0516C5.47666 11.2604 5.09988 12.6834 5.19574 14.2676C5.2663 15.4244 5.46201 16.5466 6.01454 17.5769C6.84399 19.1171 8.21664 19.9119 9.85158 20.3352C10.3938 20.4706 10.9444 20.5698 11.4998 20.632C11.5384 20.7492 11.4506 20.7798 11.408 20.8291C11.1734 21.1179 10.9894 21.4441 10.8634 21.7942C10.7622 22.0458 10.8315 22.4039 10.6065 22.5516C10.263 22.7766 9.83827 22.8485 9.42421 22.8871C8.17936 23.0056 7.26471 22.4877 6.6283 21.4348C6.25552 20.8184 5.76956 20.3325 5.08523 20.0663C4.76981 19.9325 4.42139 19.8967 4.08537 19.9638C3.7898 20.029 3.73788 20.1901 3.93891 20.4111C4.03639 20.5234 4.14989 20.6207 4.27575 20.6999C4.9796 21.1318 5.51717 21.7884 5.80152 22.5636C6.37002 23.9973 7.48039 24.5697 8.93825 24.6323C9.43741 24.6575 9.93768 24.615 10.4254 24.5058C10.5892 24.4672 10.6531 24.4872 10.6517 24.6762C10.6451 25.4936 10.6637 26.3123 10.6517 27.131C10.6517 27.6635 10.1684 27.9297 9.58663 27.7393C8.17396 27.2671 6.84977 26.5631 5.66838 25.656C2.59555 23.2891 0.720966 20.1861 0.217704 16.3376C-0.357453 11.9127 0.911353 8.00824 3.98551 4.73881C6.11909 2.42656 8.99932 0.939975 12.1203 0.540191C16.5351 -0.0601815 20.4347 1.14323 23.7232 4.16373C26.2449 6.47869 27.724 9.37672 28.1048 12.7726C28.5828 17.0325 27.3686 20.7945 24.4768 23.9827C22.9762 25.6323 21.0956 26.8908 18.9982 27.6488C18.8783 27.6927 18.7585 27.738 18.636 27.7726C18.0356 27.9404 17.6189 27.6395 17.6189 27.0098C17.6189 25.7452 17.6308 24.4806 17.6295 23.2159C17.6329 22.9506 17.6128 22.6856 17.5696 22.4238C17.4325 21.6664 17.3419 21.484 16.7228 20.6334Z">
                            </path>
                        </svg>
                        <span class="usa-sr-only">NCBI on GitHub</span>
                    </a>
                

                
                    <a href="https://ncbiinsights.ncbi.nlm.nih.gov/"
                       class="ncbi-footer__social-icon ncbi-footer__social-icon--gray"
                       target="_blank"
                       rel="noreferrer noopener">
                        <svg width="26"
                             height="26"
                             viewBox="0 0 27 27"
                             fill="none"
                             xmlns="http://www.w3.org/2000/svg"
                             focusable="false"
                             aria-hidden="true">
                            <path d="M23.7778 26.4574C23.1354 26.3913 22.0856 26.8024 21.636 26.3087C21.212 25.8444 21.4359 24.8111 21.324 24.0347C19.9933 14.8323 14.8727 8.80132 6.09057 5.85008C4.37689 5.28406 2.58381 4.99533 0.779072 4.99481C0.202773 4.99481 -0.0229751 4.83146 0.00455514 4.21479C0.0660406 3.08627 0.0660406 1.95525 0.00455514 0.826734C-0.0413285 0.0815827 0.259669 -0.0193618 0.896534 0.00266238C6.96236 0.222904 12.3693 2.24179 16.9889 6.16209C22.9794 11.2478 26.1271 17.7688 26.4372 25.648C26.4629 26.294 26.3179 26.5271 25.6609 26.4684C25.0827 26.417 24.4991 26.4574 23.7778 26.4574Z">
                            </path>
                            <path d="M14.8265 26.441C14.0924 26.441 13.2371 26.6795 12.6626 26.3786C12.0092 26.0372 12.3781 25.0644 12.246 24.378C11.1154 18.5324 6.6849 14.5497 0.74755 14.1001C0.217135 14.0615 -0.0104482 13.9422 0.0134113 13.3659C0.0519536 12.1454 0.0482829 10.9213 0.0134113 9.69524C-0.00127145 9.14464 0.196946 9.03268 0.703502 9.04736C9.21217 9.27128 16.5994 16.2511 17.2804 24.7231C17.418 26.4446 17.418 26.4446 15.6579 26.4446H14.832L14.8265 26.441Z">
                            </path>
                            <path d="M3.58928 26.4555C2.64447 26.4618 1.73584 26.0925 1.06329 25.4289C0.39073 24.7653 0.00933763 23.8617 0.0030097 22.9169C-0.00331824 21.9721 0.365937 21.0635 1.02954 20.3909C1.69315 19.7184 2.59675 19.337 3.54156 19.3306C4.48637 19.3243 5.39499 19.6936 6.06755 20.3572C6.7401 21.0208 7.1215 21.9244 7.12782 22.8692C7.13415 23.814 6.7649 24.7226 6.10129 25.3952C5.43768 26.0677 4.53409 26.4491 3.58928 26.4555Z">
                            </path>
                        </svg>
                        <span class="usa-sr-only">NCBI RSS feed</span>
                    </a>
                
            </div>
        </div>
    

    <div data-testid="gridContainer"
         class="grid-container ncbi-footer__container">
        <div class="grid-row ncbi-footer__main-content-container"
             data-testid="grid">
            
                <div class="ncbi-footer__column">
                    
                        <p class="ncbi-footer__circled-icons-heading">
                            Connect with NLM
                        </p>
                    

                    <div class="ncbi-footer__circled-icons-list">
                        
                            <a href=https://twitter.com/nlm_nih class="ncbi-footer__social-icon ncbi-footer__social-icon--circled" target="_blank" rel="noreferrer noopener">
                                <svg width="32"
                                     height="32"
                                     viewBox="0 0 40 40"
                                     fill="none"
                                     xmlns="http://www.w3.org/2000/svg"
                                     focusable="false"
                                     aria-hidden="true">
                                    <path d="m6.067 8 10.81 13.9L6 33.2h4.2l8.4-9.1 7.068 9.1H34L22.8 18.5 31.9 8h-3.5l-7.7 8.4L14.401 8H6.067Zm3.6 1.734h3.266l16.8 21.732H26.57L9.668 9.734Z">
                                    </path>
                                </svg>
                                <span class="usa-sr-only">NLM on X (formerly known as Twitter)</span>
                            </a>
                        

                        
                            <a href=https://www.facebook.com/nationallibraryofmedicine class="ncbi-footer__social-icon ncbi-footer__social-icon--circled" target="_blank" rel="noreferrer noopener">
                                <svg width="13"
                                     height="24"
                                     viewBox="0 0 13 24"
                                     fill="none"
                                     xmlns="http://www.w3.org/2000/svg"
                                     focusable="false"
                                     aria-hidden="true">
                                    <path d="M4.11371 23.1369C4.11371 23.082 4.11371 23.0294 4.11371 22.9745V12.9411H0.817305C0.6709 12.9411 0.670898 12.9411 0.670898 12.8016C0.670898 11.564 0.670898 10.3287 0.670898 9.09341C0.670898 8.97903 0.705213 8.95158 0.815017 8.95158C1.8673 8.95158 2.91959 8.95158 3.97417 8.95158H4.12057V8.83263C4.12057 7.8055 4.12057 6.7738 4.12057 5.74897C4.1264 4.92595 4.31387 4.11437 4.66959 3.37217C5.12916 2.38246 5.94651 1.60353 6.95717 1.1921C7.64827 0.905008 8.3913 0.764035 9.13953 0.778051C10.0019 0.791777 10.8644 0.830666 11.7268 0.860404C11.8869 0.860404 12.047 0.894717 12.2072 0.90158C12.2964 0.90158 12.3261 0.940469 12.3261 1.02968C12.3261 1.5421 12.3261 2.05452 12.3261 2.56465C12.3261 3.16857 12.3261 3.7725 12.3261 4.37642C12.3261 4.48165 12.2964 4.51367 12.1912 4.51138C11.5369 4.51138 10.8804 4.51138 10.2261 4.51138C9.92772 4.51814 9.63058 4.5526 9.33855 4.61433C9.08125 4.6617 8.84537 4.78881 8.66431 4.97766C8.48326 5.16652 8.3662 5.40755 8.32972 5.66661C8.28476 5.89271 8.26027 6.1224 8.25652 6.35289C8.25652 7.19014 8.25652 8.02969 8.25652 8.86923C8.25652 8.89439 8.25652 8.91955 8.25652 8.95615H12.0219C12.1797 8.95615 12.182 8.95616 12.1614 9.10714C12.0768 9.76596 11.9876 10.4248 11.9029 11.0813C11.8312 11.6319 11.7626 12.1824 11.697 12.733C11.6719 12.9434 11.6787 12.9434 11.4683 12.9434H8.26338V22.899C8.26338 22.979 8.26338 23.0591 8.26338 23.1392L4.11371 23.1369Z">
                                    </path>
                                </svg>
                                <span class="usa-sr-only">NLM on Facebook</span>
                            </a>
                        

                        
                            <a href=https://www.youtube.com/user/NLMNIH class="ncbi-footer__social-icon ncbi-footer__social-icon--circled" target="_blank" rel="noreferrer noopener">
                                <svg width="21"
                                     height="15"
                                     viewBox="0 0 21 15"
                                     fill="none"
                                     xmlns="http://www.w3.org/2000/svg"
                                     focusable="false"
                                     aria-hidden="true">
                                    <path d="M19.2561 1.47914C18.9016 1.15888 18.5699 0.957569 17.2271 0.834039C15.5503 0.678484 13.2787 0.655608 11.563 0.65332H9.43556C7.71987 0.65332 5.4483 0.678484 3.77151 0.834039C2.43098 0.957569 2.097 1.15888 1.74242 1.47914C0.813665 2.32097 0.619221 4.62685 0.598633 6.89384C0.598633 7.31781 0.598633 7.74101 0.598633 8.16345C0.626084 10.4121 0.827391 12.686 1.74242 13.521C2.097 13.8412 2.4287 14.0425 3.77151 14.1661C5.4483 14.3216 7.71987 14.3445 9.43556 14.3468H11.563C13.2787 14.3468 15.5503 14.3216 17.2271 14.1661C18.5676 14.0425 18.9016 13.8412 19.2561 13.521C20.1712 12.6929 20.3725 10.451 20.3999 8.22064C20.3999 7.74025 20.3999 7.25986 20.3999 6.77946C20.3725 4.54907 20.1689 2.30724 19.2561 1.47914ZM8.55942 10.5311V4.65201L13.5601 7.50005L8.55942 10.5311Z"
                                          fill="white" />
                                </svg>
                                <span class="usa-sr-only">NLM on YouTube</span>
                            </a>
                        
                    </div>
                </div>
            

            
                <address class="ncbi-footer__address ncbi-footer__column">
                    
        <p>
            <a class="usa-link usa-link--external"
            href="https://www.google.com/maps/place/8600+Rockville+Pike,+Bethesda,+MD+20894/%4038.9959508,
            -77.101021,17z/data%3D!3m1!4b1!4m5!3m4!1s0x89b7c95e25765ddb%3A0x19156f88b27635b8!8m2!3d38.9959508!
            4d-77.0988323"
            rel="noopener noreferrer" target="_blank">National Library of Medicine
            <br/> 8600 Rockville Pike<br/> Bethesda, MD 20894</a>
        </p>
    
                </address>
            

            
                <ul class="usa-list usa-list--unstyled ncbi-footer__vertical-list ncbi-footer__column">
                    
                        <li class="ncbi-footer__vertical-list-item">
                            









    <a href="https://www.nlm.nih.gov/web_policies.html" class="usa-link  usa-link--alt ncbi-footer__link"  >
        

        
            Web Policies
        

        
    </a>


                        </li>
                    
                        <li class="ncbi-footer__vertical-list-item">
                            









    <a href="https://www.nih.gov/institutes-nih/nih-office-director/office-communications-public-liaison/freedom-information-act-office" class="usa-link  usa-link--alt ncbi-footer__link"  >
        

        
            FOIA
        

        
    </a>


                        </li>
                    
                        <li class="ncbi-footer__vertical-list-item">
                            









    <a href="https://www.hhs.gov/vulnerability-disclosure-policy/index.html" class="usa-link usa-link--external usa-link--alt ncbi-footer__link" rel="noreferrer noopener" target='_blank' >
        

        
            HHS Vulnerability Disclosure
        

        
    </a>


                        </li>
                    
                </ul>
            

            
                <ul class="usa-list usa-list--unstyled ncbi-footer__vertical-list ncbi-footer__column">
                    
                        <li class="ncbi-footer__vertical-list-item">
                            









    <a href="https://support.nlm.nih.gov/" class="usa-link  usa-link--alt ncbi-footer__link"  >
        

        
            Help
        

        
    </a>


                        </li>
                    
                        <li class="ncbi-footer__vertical-list-item">
                            









    <a href="https://www.nlm.nih.gov/accessibility.html" class="usa-link  usa-link--alt ncbi-footer__link"  >
        

        
            Accessibility
        

        
    </a>


                        </li>
                    
                        <li class="ncbi-footer__vertical-list-item">
                            









    <a href="https://www.nlm.nih.gov/careers/careers.html" class="usa-link  usa-link--alt ncbi-footer__link"  >
        

        
            Careers
        

        
    </a>


                        </li>
                    
                </ul>
            
        </div>

        
            <div class="grid-row grid-col-12" data-testid="grid">
                <ul class="ncbi-footer__bottom-links-list">
                    
                        <li class="ncbi-footer__bottom-list-item">
                            









    <a href="https://www.nlm.nih.gov/" class="usa-link  usa-link--alt ncbi-footer__link"  >
        

        
            NLM
        

        
    </a>


                        </li>
                    
                        <li class="ncbi-footer__bottom-list-item">
                            









    <a href="https://www.nih.gov/" class="usa-link  usa-link--alt ncbi-footer__link"  >
        

        
            NIH
        

        
    </a>


                        </li>
                    
                        <li class="ncbi-footer__bottom-list-item">
                            









    <a href="https://www.hhs.gov/" class="usa-link usa-link--external usa-link--alt ncbi-footer__link" rel="noreferrer noopener" target='_blank' >
        

        
            HHS
        

        
    </a>


                        </li>
                    
                        <li class="ncbi-footer__bottom-list-item">
                            









    <a href="https://www.usa.gov/" class="usa-link usa-link--external usa-link--alt ncbi-footer__link" rel="noreferrer noopener" target='_blank' >
        

        
            USA.gov
        

        
    </a>


                        </li>
                    
                </ul>
            </div>
        
    </div>
</footer>

    


        
        
    
  <script  type="text/javascript" src="https://cdn.ncbi.nlm.nih.gov/core/pinger/pinger.js"> </script>


    
        

<button class="back-to-top" data-ga-category="pagination" data-ga-action="back_to_top">
    <label>Back to Top</label>
    <svg class="usa-icon order-0" aria-hidden="true" focusable="false" role="img">
        <use xlink:href="/static/img/sprite.svg#arrow_upward"></use>
    </svg>
</button>
    


        
    
    
    
        
    <script type="application/javascript">
    window.ncbi = window.ncbi || {};
    window.ncbi.pmc = window.ncbi.pmc || {};
    window.ncbi.pmc.options = {
        logLevel: 'INFO',
        
        staticEndpoint: '/static/',
        
        citeCookieName: 'pmc-cf',
    };
</script>
    <script type="module" crossorigin="" src="/static/assets/base-133c6271.js"></script>
    
    <script type="text/javascript" src="https://cdn.ncbi.nlm.nih.gov/core/jquery/jquery-3.6.0.min.js">&#xA0;</script>
    <script type="text/javascript">
        jQuery.getScript("https://cdn.ncbi.nlm.nih.gov/core/alerts/alerts.js", function () {
            galert(['div.nav_and_browser', 'div.header', '#universal_header', '.usa-banner', 'body > *:nth-child(1)'])
        });
    </script>


    <script type="text/javascript">var exports = {};</script>
     <script src="/static/CACHE/js/output.13b077bc3ffd.js"></script>

    <script type="module" crossorigin="" src="/static/assets/article-44d04358.js"></script>
    
    

    </body>
</html>
